=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehac237.pdf",
  "converted_date": "2026-01-31T14:49:47.666458",
  "file_size_bytes": 7216720,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehac237.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC/ERS GUIDELINES
EuropeanHeartJournal(2022)43,3618–3731
https://doi.org/10.1093/eurheartj/ehac237
2022 ESC/ERS Guidelines for the diagnosis and
treatment of pulmonary hypertension
Developed by the task force for the diagnosis and treatment of
pulmonary hypertension of the European Society of Cardiology
(ESC) and the European Respiratory Society (ERS).
Endorsed by the International Society for Heart and Lung
Transplantation (ISHLT) and the European Reference Network
on rare respiratory diseases (ERN-LUNG).
Authors/TaskForceMembers:MarcHumbert (France),GaborKovacs(Austria),
Marius M. Hoeper (Germany), Roberto Badagliacca (Italy), Rolf M.F. Berger
(Netherlands), Margarita Brida (Croatia), Jørn Carlsen (Denmark),
Andrew J.S. Coats (United Kingdom), Pilar Escribano-Subias (Spain),
Pisana Ferrari (Italy), Diogenes S. Ferreira (Brazil), Hossein Ardeschir Ghofrani
(Germany), George Giannakoulas (Greece), David G. Kiely (United Kingdom),
EckhardMayer(Germany),GergelyMeszaros(Hungary),BlinNagavci(Germany),
Karen M. Olsson (Germany), Joanna Pepke-Zaba (United Kingdom),
Jennifer K. Quint (United Kingdom), Göran Rådegran (Sweden),
Gerald Simonneau (France), Olivier Sitbon (France), Thomy Tonia (Switzerland),
Mark Toshner (United Kingdom), Jean-Luc Vachiery (Belgium),
AntonVonkNoordegraaf(Netherlands),MarionDelcroix
*†
(ERSChairperson)
(Belgium), Stephan Rosenkranz
*†
(ESC Chairperson) (Germany), and ESC/ERS
fi
Scienti c Document Group
*Correspondingauthors:StephanRosenkranz,ClinicIIIforInternalMedicine(DepartmentofCardiology,PulmonologyandIntensiveCareMedicine),andCologneCardiovascular
ResearchCenter(CCRC),HeartCenterattheUniversityHospitalCologne,KerpenerStr.62,50937Köln,Germany.Tel.:+49-221-478-32356.Email:stephan.rosenkranz@uk-
koeln.de;and
MarionDelcroix,ClinicalDepartmentofRespiratoryDiseases,CentreofPulmonaryVascularDiseases,UniversityHospitalsofLeuven,Herestraat49,3000Leuven,Belgium.Tel.:+3216
346813.Email:marion.delcroix@uzleuven.be
†Thetwochairpersonscontributedequallytothedocumentandarejointcorrespondingauthors.
Author/TaskForceMemberaffiliationsarelistedinauthorinformation.
1RepresentingtheAssociationforEuropeanPaediatricandCongenitalCardiology(AEPC)
ESCClinicalPracticeGuidelines(CPG)Committee:listedintheAppendix.
ESCsubspecialtycommunitieshavingparticipatedinthedevelopmentofthisdocument:
Associations:AssociationofCardiovascularNursing&AlliedProfessions(ACNAP),EuropeanAssociationofCardiovascularImaging(EACVI),andHeartFailureAssociation(HFA).
Councils:CouncilonCardiovascularGenomics.
WorkingGroups:AdultCongenitalHeartDisease,PulmonaryCirculationandRightVentricularFunction,Thrombosis.
PatientForum
ThecontentoftheseEuropeanSocietyofCardiology(ESC)/EuropeanRespiratorySociety(ERS)Guidelineshasbeenpublishedforpersonalandeducationaluseonly.Nocommercialuse
isauthorized.NopartoftheESC/ERSGuidelinesmaybetranslatedorreproducedinanyformwithoutwrittenpermissionfromtheESCandtheERS.Permissioncanbeobtainedupon
submissionofawrittenrequesttoOxfordUniversityPress,thepublisheroftheEuropeanHeartJournal,andthepartyauthorizedtohandlesuchpermissionsonbehalfoftheESC(journals.
permissions@oup.com).
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 2 ---
ESC/ERSGuidelines 3619
DocumentReviewers:MarkusSchwerzmann(ESCReviewCoordinator)(Switzerland),Anh-TuanDinh-Xuan
(ERSReviewCoordinator)(France),AndyBush(UnitedKingdom),MagdyAbdelhamid(Egypt),VictorAboyans
(France),EloisaArbustini(Italy),RiccardoAsteggiano(Italy),Joan-AlbertBarberà(Spain),MauriceBeghetti
(Switzerland),JelenaČelutkienė(Lithuania),MajaCikes(Croatia),RobinCondliffe(UnitedKingdom),
FrancesdeMan(Netherlands),VolkmarFalk(Germany),LaurentFauchier(France),SeanGaine(Ireland),
NazzarenoGalié(Italy),WendyGin-Sing(UnitedKingdom),JohnGranton(Canada),EkkehardGrünig
(Germany),PaulM.Hassoun(UnitedStatesofAmerica),MerelHellemons(Netherlands),TinyJaarsma
(Sweden),BarbroKjellström(Sweden),FrederikusA.Klok(Netherlands),AleksandraKonradi(Russian
Federation),KonstantinosC.Koskinas(Switzerland),DipakKotecha(UnitedKingdom),IreneLang(Austria),
BasilS.Lewis(Israel),AlesLinhart(CzechRepublic),GregoryY.H.Lip(UnitedKingdom),Maja-LisaLøchen
(Norway),AlexanderG.Mathioudakis(UnitedKingdom),RichardMindham(UnitedKingdom),
ShahinMoledina1(UnitedKingdom),RobertNaeije(Belgium),JensCosedisNielsen(Denmark),
HorstOlschewski(Austria),IsabelleOpitz(Switzerland),SteffenE.Petersen(UnitedKingdom),
EvaPrescott(Denmark),AminaRakisheva(Kazakhstan),AbilioReis(Portugal),ArsenD.Ristić(Serbia),
NicolasRoche(France),RitaRodrigues(Portugal),ChristineSelton-Suty(France),RogerioSouza(Brazil),
AndrewJ.Swift(UnitedKingdom),RhianM.Touyz(Canada/UnitedKingdom),SilviaUlrich(Switzerland),
MartinR.Wilkins(UnitedKingdom),andStephenJohnWort(UnitedKingdom)
Allexpertsinvolvedinthedevelopmentoftheseguidelineshavesubmitteddeclarationsofinterest.Thesehave
beencompiledinareportandsimultaneouslypublishedinasupplementarydocumenttotheguidelines.The
reportisalsoavailableontheESCwebsitewww.escardio.org/Guidelines
SeetheEuropeanHeartJournalonlineforsupplementarydatathatincludesbackgroundinformationand
detaileddiscussionofthedatathathaveprovidedthebasisoftheguidelines.
Keywords Guidelines (cid:129) Pulmonaryhypertension (cid:129) Pulmonaryarterialhypertension (cid:129) Chronicthrombo-embolicpulmonary
hypertension (cid:129) Leftheartdisease (cid:129) Congenitalheartdisease (cid:129) Lungdisease (cid:129) Connectivetissuedisease (cid:129) Endothelin
receptorantagonists (cid:129) Phosphodiesterasetype5inhibitors (cid:129) Solubleguanylatecyclasestimulators (cid:129) Prostacyclin
analogues (cid:129) Prostacyclinreceptoragonists (cid:129) Pulmonaryendarterectomy (cid:129) Balloonpulmonaryangioplasty (cid:129) Lung
transplantation
Table of contents 4.3.Group3,pulmonaryhypertensionassociatedwithlung
diseasesand/orhypoxia .............................................................................. 3640
1.Preamble............................................................................................................. 3624 4.4.Group4,pulmonaryhypertensionassociatedwithchronic
2.Introduction ...................................................................................................... 3625 pulmonaryarteryobstruction.................................................................. 3640
2.1.Whatisnew............................................................................................ 3625 4.5.Group5,pulmonaryhypertensionwithunclearand/or
2.2.Methods .................................................................................................... 3635 multifactorialmechanisms.......................................................................... 3640
3.Definitionsandclassifications .................................................................... 3636 5.Pulmonaryhypertensiondiagnosis.......................................................... 3640
3.1.Definitions ................................................................................................ 3636 5.1.Diagnosis................................................................................................... 3640
3.2.Classifications.......................................................................................... 3637 5.1.1.Clinicalpresentation..................................................................... 3640
4.Epidemiologyandriskfactors.................................................................... 3638 5.1.2.Electrocardiogram......................................................................... 3640
4.1.Group1,pulmonaryarterialhypertension................................ 3638 5.1.3.Chestradiography......................................................................... 3641
4.2.Group2,pulmonaryhypertensionassociatedwithleftheart 5.1.4.Pulmonaryfunctiontestsandarterialbloodgases ......... 3641
disease................................................................................................................. 3640 5.1.5.Echocardiography .......................................................................... 3642
Disclaimer:TheESC/ERSGuidelinesrepresenttheviewsoftheESCandtheERSandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidence
availableatthetimeoftheirpublication.TheESCandtheERSarenotresponsibleintheeventofanycontradiction,discrepancy,and/orambiguitybetweentheESC/ERSGuidelinesandany
otherofficialrecommendationsorguidelinesissuedbytherelevantpublichealthauthorities,particularlyinrelationtogooduseofhealthcareortherapeuticstrategies.Healthprofes-
sionalsareencouragedtotaketheESC/ERSGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgment,aswellasinthedeterminationandimplementationofpreventive,diag-
nostic,ortherapeuticmedicalstrategies;however,theESC/ERSGuidelinesdonotoverride,inanywaywhatsoever,theindividualresponsibilityofhealthprofessionalstomake
appropriateandaccuratedecisionsinconsiderationofeachpatient’shealthconditionandinconsultationwiththatpatientand,whereappropriateand/ornecessary,thepatient’scare-
giver.TheESC/ERSGuidelinesdonotexempthealthprofessionalsfromtakingintofullandcarefulconsiderationtherelevantofficialupdatedrecommendationsorguidelinesissuedbythe
competentpublichealthauthorities,inordertomanageeachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobligations.Itis
alsothehealthprofessional’sresponsibilitytoverifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription.
Thisarticlehasbeenco-publishedwithpermissionintheEuropeanHeartJournalandEuropeanRespiratoryJournal.©theEuropeanSocietyofCardiologyandtheEuropeanRespiratory
Society2022.Allrightsreserved.Thearticlesareidenticalexceptforminorstylisticandspellingdifferencesinkeepingwitheachjournal’sstyle.Eithercitationcanbeusedwhencitingthis
article.Forpermissionspleasee-mail:journals.permissions@oup.com.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 3 ---
3620 ESC/ERSGuidelines
5.1.6.Ventilation/perfusionlungscan................................................ 3643 6.3.3.3.Phosphodiesterase5inhibitorsandguanylatecyclase
5.1.7. Non-contrast and contrast-enhanced chest computed stimulators ............................................................................................... 3666
tomography examinations, and digital subtraction 6.3.3.3.1.Sildenafil............................................................................ 3667
angiography................................................................................................... 3644 6.3.3.3.2.Tadalafil............................................................................. 3667
5.1.8.Cardiacmagneticresonanceimaging.................................... 3645 6.3.3.3.3.Riociguat........................................................................... 3667
5.1.9.Bloodtestsandimmunology.................................................... 3646 6.3.3.4.Prostacyclinanaloguesandprostacyclinreceptor
5.1.10.Abdominalultrasound............................................................... 3646 agonists...................................................................................................... 3667
5.1.11.Cardiopulmonaryexercisetesting....................................... 3646 6.3.3.4.1.Epoprostenol.................................................................. 3667
5.1.12.Rightheartcatheterization,vasoreactivity,exercise,and 6.3.3.4.2.Iloprost.............................................................................. 3667
fluidchallenge .............................................................................................. 3646 6.3.3.4.3.Treprostinil...................................................................... 3667
5.1.12.1.Rightheartcatheterization............................................. 3646 6.3.3.4.4.Beraprost ......................................................................... 3667
5.1.12.2.Vasoreactivitytesting........................................................ 3647 6.3.3.4.5.Selexipag........................................................................... 3667
5.1.12.3.Exerciserightheartcatheterization ........................... 3647 6.3.4.Treatmentstrategiesforpatientswithidiopathic,
5.1.12.4.Fluidchallenge...................................................................... 3647 heritable,drug-associated,orconnectivetissuedisease-
5.1.13.Geneticcounsellingandtesting ............................................ 3648 associatedpulmonaryarterialhypertension .................................. 3667
5.2.Diagnosticalgorithm............................................................................ 3648 6.3.4.1.Initialtreatmentdecisioninpatientswithout
5.2.1Step1(suspicion) ........................................................................... 3648 cardiopulmonarycomorbidities...................................................... 3668
5.2.2.Step2(detection) ......................................................................... 3648 6.3.4.2.Treatmentdecisionsduringfollow-upinpatients
5.2.3.Step3(confirmation)................................................................... 3650 withoutcardiopulmonarycomorbidities.................................... 3669
5.3.Screeningandearlydetection.......................................................... 3652 6.3.4.3.Pulmonaryarterialhypertensionwith
5.3.1.Systemicsclerosis .......................................................................... 3653 cardiopulmonarycomorbidities...................................................... 3670
5.3.2.BMPR2mutationcarriers ........................................................... 3653 6.3.5.Druginteractions........................................................................... 3671
5.3.3.Portalhypertension ...................................................................... 3653 6.3.6.Interventionaltherapy ................................................................. 3671
5.3.4.Pulmonaryembolism ................................................................... 3653 6.3.6.1.BalloonatrialseptostomyandPottsshunt................ 3671
6.Pulmonaryarterialhypertension(group1)......................................... 3655 6.3.6.2.Pulmonaryarterydenervation ........................................ 3671
6.1.Clinicalcharacteristics ......................................................................... 3655 6.3.7.Advancedrightventricularfailure .......................................... 3672
6.2.Severityandriskassessment ............................................................ 3655 6.3.7.1.Intensivecareunitmanagement..................................... 3672
6.2.1.Clinicalparameters ....................................................................... 3655 6.3.7.2.Mechanicalcirculatorysupport....................................... 3672
6.2.2.Imaging................................................................................................ 3656 6.3.8.Lungandheart–lungtransplantation..................................... 3672
6.2.2.1.Echocardiography.................................................................. 3656 6.3.9.Evidence-basedtreatmentalgorithm .................................... 3673
6.2.2.2.Cardiacmagneticresonanceimaging ........................... 3656 6.3.10.Diagnosisandtreatmentofpulmonaryarterial
6.2.3.Haemodynamics............................................................................. 3656 hypertensioncomplications................................................................... 3673
6.2.4.Exercisecapacity............................................................................ 3657 6.3.10.1.Arrhythmias .......................................................................... 3673
6.2.5.Biochemicalmarkers .................................................................... 3658 6.3.10.2.Haemoptysis......................................................................... 3673
6.2.6.Patient-reportedoutcomemeasures ................................... 3658 6.3.10.3.Mechanicalcomplications................................................ 3673
6.2.7.Comprehensiveprognosticevaluation,riskassessment, 6.3.11.End-of-lifecareandethicalissues ........................................ 3674
andtreatmentgoals.................................................................................. 3659 6.3.12.Newdrugsinadvancedclinicaldevelopment(phase3
6.3.Therapy ..................................................................................................... 3660 studies) ........................................................................................................... 3674
6.3.1.Generalmeasures.......................................................................... 3660 7.Specificpulmonaryarterialhypertensionsubsets ............................ 3674
6.3.1.1.Physicalactivityandsupervisedrehabilitation .......... 3660 7.1.Pulmonaryarterialhypertensionassociatedwithdrugsand
6.3.1.2.Anticoagulation ...................................................................... 3660 toxins................................................................................................................... 3674
6.3.1.3.Diuretics.................................................................................... 3661 7.2.Pulmonaryarterialhypertensionassociatedwithconnective
6.3.1.4.Oxygen ...................................................................................... 3661 tissuedisease.................................................................................................... 3675
6.3.1.5.Cardiovasculardrugs ........................................................... 3661 7.2.1.Epidemiologyanddiagnosis....................................................... 3675
6.3.1.6.Anaemiaandironstatus .................................................... 3661 7.2.2.Therapy.............................................................................................. 3675
6.3.1.7.Vaccination............................................................................... 3661 7.3.Pulmonaryarterialhypertensionassociatedwithhuman
6.3.1.8.Psychosocialsupport........................................................... 3661 immunodeficiencyvirusinfection............................................................ 3676
6.3.1.9.Adherencetotreatments.................................................. 3661 7.3.1.Diagnosis ........................................................................................... 3676
6.3.2.Specialcircumstances................................................................... 3662 7.3.2.Therapy.............................................................................................. 3676
6.3.2.1.Pregnancyandbirthcontrol............................................. 3662 7.4.Pulmonaryarterialhypertensionassociatedwithportal
6.3.2.1.1.Pregnancy......................................................................... 3662 hypertension .................................................................................................... 3677
6.3.2.1.2.Contraception................................................................ 3662 7.4.1.Diagnosis ........................................................................................... 3677
6.3.2.2.Surgicalprocedures.............................................................. 3662 7.4.2.Therapy.............................................................................................. 3677
6.3.2.3.Travelandaltitude................................................................ 3662 7.4.2.1.Livertransplantation............................................................ 3677
6.3.3.Pulmonaryarterialhypertensiontherapies ........................ 3663 7.5.Pulmonaryarterialhypertensionassociatedwithadult
6.3.3.1.Calciumchannelblockers.................................................. 3663 congenitalheartdisease.............................................................................. 3678
6.3.3.2.Endothelinreceptorantagonists .................................... 3664 7.5.1.Diagnosisandriskassessment ................................................. 3678
6.3.3.2.1.Ambrisentan ................................................................... 3665 7.5.2.Therapy.............................................................................................. 3679
6.3.3.2.2.Bosentan........................................................................... 3665 7.6.Pulmonaryarterialhypertensionassociatedwith
6.3.3.2.3.Macitentan....................................................................... 3666 schistosomiasis ................................................................................................ 3680
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 4 ---
ESC/ERSGuidelines 3621
7.7.Pulmonaryarterialhypertensionwithsignsofvenous/ 12.Definitionofapulmonaryhypertensioncentre............................. 3701
capillaryinvolvement .................................................................................... 3680 12.1.Facilitiesandskillsrequiredforapulmonaryhypertension
7.7.1.Diagnosis ........................................................................................... 3681 centre.................................................................................................................. 3702
7.7.2.Therapy.............................................................................................. 3681 12.2.EuropeanReferenceNetwork ..................................................... 3702
7.8.Paediatricpulmonaryhypertension............................................... 3681 12.3.Patientassociationsandpatientempowerment................... 3702
7.8.1.Epidemiologyandclassification................................................ 3681 13.Keymessages ................................................................................................. 3703
7.8.2.Diagnosisandriskassessment ................................................. 3683 14.Gapsinevidence........................................................................................... 3703
7.8.3.Therapy.............................................................................................. 3683 14.1.Pulmonaryarterialhypertension(group1)............................. 3703
8.Pulmonaryhypertensionassociatedwithleftheartdisease 14.2.Pulmonaryhypertensionassociatedwithleftheartdisease
(group2).................................................................................................................. 3685 (group2)............................................................................................................ 3703
8.1.Definition,prognosis,andpathophysiology............................... 3685 14.3.Pulmonaryhypertensionassociatedwithlungdiseasesand/
8.2.Diagnosis................................................................................................... 3687 orhypoxia(group3).................................................................................... 3704
8.2.1.Diagnosisandcontroloftheunderlyingleft 14.4.Chronicthrombo-embolicpulmonaryhypertension
heartdisease ................................................................................................ 3687 (group4)............................................................................................................ 3704
8.2.2.Evaluationofpulmonaryhypertensionandpatient 14.5.Pulmonaryhypertensionwithunclearand/ormultifactorial
phenotyping.................................................................................................. 3687 mechanisms(group5) ................................................................................. 3704
8.2.3.Invasiveassessmentofhaemodynamics............................... 3687 15.‘Whattodo’and‘Whatnottodo’messagesfrom
8.3.Therapy ..................................................................................................... 3688 theGuidelines ....................................................................................................... 3704
8.3.1.Pulmonaryhypertensionassociatedwithleft-sidedheart 16.Qualityindicators......................................................................................... 3710
failure............................................................................................................... 3688 17.Supplementarydata..................................................................................... 3711
8.3.1.1.Heartfailurewithreducedejectionfraction............. 3688 18.Dataavailabilitystatement ....................................................................... 3711
8.3.1.2.Heartfailurewithpreservedejectionfraction......... 3688 19.Authorinformation..................................................................................... 3711
8.3.1.3.Interatrialshuntdevices ..................................................... 3689 20.Appendix.......................................................................................................... 3711
8.3.1.4.Remotepulmonaryarterialpressuremonitoringin 21.References....................................................................................................... 3712
heartfailure ............................................................................................. 3689
8.3.2.Pulmonaryhypertensionassociatedwithvalvularheart Tables of Recommendations
disease............................................................................................................. 3689
8.3.2.1.Mitralvalvedisease............................................................... 3689 RecommendationTable1—Recommendationsforrightheart
8.3.2.2.Aorticstenosis ....................................................................... 3689 catheterizationandvasoreactivitytesting ............................................ 3648
8.3.2.3.Tricuspidregurgitation........................................................ 3689 RecommendationTable2—Recommendationsfordiagnostic
8.3.3.Recommendationsontheuseofdrugsapprovedfor
strategy................................................................................................................ 3652
PAHinPH-LHD......................................................................................... 3689 RecommendationTable3—Recommendationsforscreening
9.Pulmonaryhypertensionassociatedwithlungdiseasesand/or
andimproveddetectionofpulmonaryarterialhypertensionand
hypoxia(group3) ................................................................................................ 3690
chronicthrombo-embolicpulmonaryhypertension ....................... 3654
9.1.Diagnosis................................................................................................... 3692 RecommendationTable4—Recommendationsforevaluating
9.2.Therapy ..................................................................................................... 3692
thediseaseseverityandriskofdeathinpatientswithpulmonary
9.2.1.Pulmonaryhypertensionassociatedwithchronic
arterialhypertension ..................................................................................... 3660
obstructivepulmonarydiseaseoremphysema ............................ 3692
RecommendationTable5—Recommendationsforgeneral
9.2.2.Pulmonaryhypertensionassociatedwithinterstitiallung
measuresandspecialcircumstances....................................................... 3662
disease............................................................................................................. 3692
RecommendationTable6—Recommendationsforwomenof
9.2.3.Recommendationsontheuseofdrugsapprovedfor
childbearingpotential .................................................................................... 3663
PAHinPHassociatedwithlungdisease.......................................... 3693
RecommendationTable7—Recommendationsforthe
10.Chronicthrombo-embolicpulmonaryhypertension(group4) 3693
treatmentofvasoreactivepatientswithidiopathic,heritable,or
10.1.Diagnosis ................................................................................................ 3694
drug-associatedpulmonaryarterialhypertension ............................ 3664
10.2.Therapy................................................................................................... 3695
RecommendationTable8—Recommendationsforthetreatment
10.2.1.Surgicaltreatment....................................................................... 3695
ofnon-vasoreactivepatientswithidiopathic,heritable,or
10.2.2.Medicaltherapy............................................................................ 3695
drug-associatedpulmonaryarterialhypertensionwhopresent
10.2.3.Interventionaltreatment.......................................................... 3696
withoutcardiopulmonarycomorbiditiesa ................................................... 3668
10.2.4.Multimodaltreatment............................................................... 3697
10.2.5.Follow-up........................................................................................ 3698
RecommendationTable9—Recommendationsforinitialoral
10.3.Chronicthrombo-embolicpulmonaryhypertensionteam drugcombinationtherapyforpatientswithidiopathic,heritable,
andexperiencecriteria................................................................................ 3698 ordrug-associatedpulmonaryarterialhypertensionwithout
11.Pulmonaryhypertensionwithunclearand/ormultifactorial cardiopulmonarycomorbidities................................................................ 3669
mechanisms(group5) ....................................................................................... 3699
RecommendationTable10—Recommendationsforsequential
11.1.Haematologicaldisorders................................................................ 3699 drugcombinationtherapyforpatientswithidiopathic,heritable,
11.2.Systemicdisorders ............................................................................. 3700 ordrug-associatedpulmonaryarterialhypertension ...................... 3670
11.3.Metabolicdisorders ........................................................................... 3700 RecommendationTable11—Recommendationsforthe
11.4.Chronickidneyfailure ...................................................................... 3700 treatmentofnon-vasoreactivepatientswithidiopathic,heritable,
11.5.Pulmonarytumourthromboticmicroangiopathy ................ 3700 ordrug-associatedpulmonaryarterialhypertensionwhopresent
11.6.Fibrosingmediastinitis....................................................................... 3700 withcardiopulmonarycomorbiditiesa.................................................... 3671
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 5 ---
3622 ESC/ERSGuidelines
RecommendationTable12—Recommendationsforintensive Table16Comprehensiveriskassessmentinpulmonaryarterial
caremanagementforpulmonaryarterialhypertension..................... 3672 hypertension(three-stratamodel).......................................................... 3657
RecommendationTable13—Recommendationsforlung Table17Suggestedassessmentandtimingforthefollow-upof
transplantation ................................................................................................. 3673 patientswithpulmonaryarterialhypertension.................................. 3658
RecommendationTable14—Recommendationsforpulmonary Table18Variablesusedtocalculatethesimplifiedfour-strata
arterialhypertensionassociatedwithdrugsortoxins ................... 3674 risk-assessmenttool....................................................................................... 3659
RecommendationTable15—Recommendationsforpulmonary Table19Dosingofpulmonaryarterialhypertensionmedication
arterialhypertensionassociatedwithconnectivetissuedisease 3675 inadults ............................................................................................................... 3664
RecommendationTable16—Recommendationsforpulmonary Table20Criteriaforlungtransplantationandlistinginpatients
arterialhypertensionassociatedwithhumanimmunodeficiency withpulmonaryarterialhypertension ................................................... 3672
virusinfection ................................................................................................... 3676 Table21Clinicalclassificationofpulmonaryarterialhypertension
RecommendationTable17—Recommendationsforpulmonary associatedwithcongenitalheartdisease .............................................. 3678
arterialhypertensionassociatedwithportalhypertension .......... 3677 Table22Useofpulmonaryarterialhypertensiontherapiesin
RecommendationTable18—Recommendationsforshunt children................................................................................................................ 3684
closureinpatientswithpulmonary–systemicflowratio.1.5:1 Table23Patientphenotypingandlikelihoodforleftheartdisease
basedoncalculatedpulmonaryvascularresistance......................... 3680 ascauseofpulmonaryhypertension...................................................... 3688
RecommendationTable19—Recommendationsforpulmonary Table24Pulmonaryhypertensionwithunclearand/or
arterialhypertensionassociatedwithadultcongenitalheartdisease 3680 multifactorialmechanisms........................................................................... 3699
RecommendationTable20—Recommendationsforpulmonary
fi
arterialhypertensionwithsignsofvenous/capillaryinvolvement 3681 List of gures
RecommendationTable21—Recommendationsforpaediatric
pulmonaryhypertension.............................................................................. 3685 Figure1Centralillustration........................................................................ 3639
RecommendationTable22—Recommendationsforpulmonary Figure2Symptomsinpatientswithpulmonaryhypertension ... 3641
hypertensionassociatedwithleftheartdisease................................ 3690 Figure3Clinicalsignsinpatientswithpulmonaryhypertension 3642
RecommendationTable23—Recommendationsforpulmonary Figure4Transthoracicechocardiographicparametersinthe
hypertensionassociatedwithlungdiseaseand/orhypoxia.......... 3693 assessmentofpulmonaryhypertension................................................ 3644
RecommendationTable24—Recommendationsforchronic Figure5Echocardiographicprobabilityofpulmonary
thrombo-embolicpulmonaryhypertensionandchronicthrombo- hypertensionandrecommendationsforfurtherassessment...... 3645
embolicpulmonarydiseasewithoutpulmonaryhypertension........ 3698 Figure6Diagnosticalgorithmofpatientswithunexplained
RecommendationTable25—Recommendationsforpulmonary dyspnoeaand/orsuspectedpulmonaryhypertension.................... 3650
hypertensioncentres..................................................................................... 3702 Figure7Pathophysiologyandcurrenttherapeutictargetsof
pulmonaryarterialhypertension(group1)......................................... 3655
List of tables Figure8Vasoreactivitytestingalgorithmofpatientswith
presumeddiagnosisofidiopathic,heritable,ordrug-associated
Table1StrengthoftherecommendationsaccordingtoGRADE 3635 pulmonaryarterialhypertension.............................................................. 3665
Table2Qualityofevidencegradesandtheirdefinitions.............. 3635 Figure9Evidence-basedpulmonaryarterialhypertension
Table3Classesofrecommendations.................................................... 3636 treatmentalgorithmforpatientswithidiopathic,heritable,
Table4Levelsofevidence.......................................................................... 3636 drug-associated,andconnectivetissuedisease-associated
Table5Haemodynamicdefinitionsofpulmonaryhypertension 3637 pulmonaryarterialhypertension.............................................................. 3666
Table6Clinicalclassificationofpulmonaryhypertension ............ 3638 Figure10Neonatalandpaediatricvs.adultpulmonary
Table7Drugsandtoxinsassociatedwithpulmonaryarterial hypertension ..................................................................................................... 3682
hypertension ..................................................................................................... 3640 Figure11Pathophysiologyofpulmonaryhypertensionassociated
Table8Electrocardiogramabnormalitiesinpatientswith withleftheartdisease(group2).............................................................. 3686
pulmonaryhypertension.............................................................................. 3643 Figure12Pathophysiologyofpulmonaryhypertensionassociated
Table9Radiographicsignsofpulmonaryhypertensionand withlungdisease(group3) ........................................................................ 3691
concomitantabnormalities ......................................................................... 3643 Figure13Diagnosticstrategyinchronicthrombo-embolic
Table10Additionalechocardiographicsignssuggestiveof pulmonaryhypertension.............................................................................. 3694
pulmonaryhypertension.............................................................................. 3645 Figure14Managementstrategyinchronicthrombo-embolic
Table11Haemodynamicmeasuresobtainedduringrightheart pulmonaryhypertension.............................................................................. 3696
catheterization.................................................................................................. 3646 Figure15Overlapintreatments/multimodalityapproachesin
Table12Routeofadministration,half-life,dosages,andduration chronicthrombo-embolicpulmonaryhypertension ....................... 3697
ofadministrationoftherecommendedtestcompoundsfor Figure16Pulmonaryhypertensioncentreschematic..................... 3701
vasoreactivitytestinginpulmonaryarterialhypertension............. 3647
Table13Phenotypicfeaturesassociatedwithpulmonaryarterial Abbreviations and acronyms
hypertensionmutations ............................................................................... 3649
Table14Characteristicdiagnosticfeaturesofpatientswith 6MWD 6-minutewalkingdistance
differentformsofpulmonaryhypertension........................................ 3651 6MWT 6-minutewalkingtest
Table15WorldHealthOrganizationclassificationoffunctional ABG Arterialbloodgasanalysis
statusofpatientswithpulmonaryhypertension............................... 3656 ACEi Angiotensin-convertingenzymeinhibitor
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 6 ---
ESC/ERSGuidelines 3623
ALAT Alanineaminotransferase HFpEF Heartfailurewithpreservedejectionfraction
ARB Angiotensinreceptorblocker HIV Humanimmunodeficiencyvirus
ARNI Angiotensinreceptor–neprilysininhibitor HPAH Heritablepulmonaryarterialhypertension
ASAT Aspartateaminotransferase HPS Hepatopulmonarysyndrome
ASIG AustralianSclerodermaInterestGroup HR Hazardratio
BNP Brainnatriureticpeptide HR-QoL Health-relatedqualityoflife
BPA Balloonpulmonaryangioplasty ICU Intensivecareunit
BPD Bronchopulmonarydysplasia IgG4 ImmunogolobulinG4
CAMPHOR CambridgePulmonaryHypertensionOutcome ILD Interstitiallungdisease
Review IPAH Idiopathicpulmonaryarterialhypertension
CCB Calciumchannelblocker IpcPH Isolatedpost-capillarypulmonaryhypertension
CDH Congenitaldiaphragmatichernia IPreceptor ProstacyclinI2receptor
cGMP Cyclicguanosinemonophosphate ISWT Incrementalshuttlewalkingtest
CHD Congenitalheartdisease i.v. Intravenous
CI Cardiacindex;Confidenceinterval LA Leftatrium/leftatrial
cMRI Cardiacmagneticresonanceimaging LAS Lungallocationscore
CO Cardiacoutput LHD Leftheartdisease
COMPERA Comparative,ProspectiveRegistryofNewly LTx Lungtransplantation
InitiatedTherapiesforPH LV Leftventricle/leftventricular
COPD Chronicobstructivepulmonarydisease LVAD Leftventricularassistdevice
CpcPH Combinedpost-andpre-capillarypulmonary mPAP Meanpulmonaryarterialpressure
hypertension MR Magneticresonance
CPET Cardiopulmonaryexercisetesting MRI Magneticresonanceimaging
CPFE Combinedpulmonaryfibrosisandemphysema NOAC Noveloralanticoagulant
CT Computedtomography NT-proBNP N-terminalpro-brainnatriureticpeptide
CTD Connectivetissuedisease OR Oddsratio
CTEPD Chronicthrombo-embolicpulmonarydisease PA Pulmonaryartery
CTEPH Chronicthrombo-embolicpulmonary PAC Pulmonaryarterialcompliance
hypertension PaCO Partialpressureofarterialcarbondioxide
2
CTPA Computedtomographypulmonaryangiography PADN Pulmonaryarterydenervation
DECT Dual-energycomputedtomography PAH Pulmonaryarterialhypertension
DLCO Lungdiffusioncapacityforcarbonmonoxide PAH-CTD Pulmonaryarterialhypertensionassociatedwith
DPAH Drug-ortoxin-associatedpulmonaryarterial connectivetissuedisease
hypertension PAH-SSc Pulmonaryarterialhypertensionassociatedwith
dPAP Diastolicpulmonaryarterialpressure systemicsclerosis
DPG Diastolicpressuregradient PAH-SYMPACT PulmonaryArterialHypertension-Symptoms
DSA Digitalsubtractionangiography andImpact
ECG Electrocardiogram PaO Partialpressureofarterialoxygen
2
ECMO Extracorporealmembraneoxygenation PAP Pulmonaryarterialpressure
EHJ EuropeanHeartJournal PAVM Pulmonaryarteriovenousmalformation
EMA EuropeanMedicinesAgency PAWP Pulmonaryarterialwedgepressure
EOV Exerciseoscillatoryventilation PCH Pulmonarycapillaryhaemangiomatosis
ERA Endothelinreceptorantagonist PDE5i Phosphodiesterase5inhibitor
ERJ EuropeanRespiratoryJournal PE Pulmonaryembolism
ERN EuropeanReferenceNetwork PEA Pulmonaryendarterectomy
ERN-LUNG EuropeanReferenceNetworkonrare PET Positronemissiontomography
respiratorydiseases P CO End-tidalpartialpressureofcarbondioxide
ET 2
ERS EuropeanRespiratorySociety PFT Pulmonaryfunctiontest
ESC EuropeanSocietyofCardiology PH Pulmonaryhypertension
EtD EvidencetoDecision PH-LHD Pulmonaryhypertensionassociatedwithleft
FPHR FrenchPulmonaryHypertensionRegistry heartdisease
FVC Forcedvitalcapacity PICO Population,Intervention,Comparator,Outcome
GRADE GradingofRecommendations,Assessment, PoPH Porto-pulmonaryhypertension
Development,andEvaluations PPHN Persistentpulmonaryhypertensionofthe
HAART Highlyactiveantiretroviraltherapy newborn
Hb Haemoglobin PROM Patient-reportedoutcomemeasure
HF Heartfailure PVD Pulmonaryvasculardisease
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 7 ---
3624 ESC/ERSGuidelines
PVOD Pulmonaryveno-occlusivedisease the most appropriate in the circumstances. These decisions are
PVR Pulmonaryvascularresistance madeinconsultationwiththepatientandcaregiverasappropriate.
PVRI Pulmonaryvascularresistanceindex Guidelinesareintendedforusebyhealthprofessionals.Toensurethat
QI Qualityindicator allphysicianshaveaccesstothemostrecentrecommendations,boththe
Qp/Qs Pulmonarybloodflow/systemicbloodflow EuropeanSocietyofCardiology(ESC)andEuropeanRespiratorySociety
RA Rightatrium/rightatrial (ERS)maketheirguidelinesfreelyavailableintheirownjournals.TheESC
RAP Rightatrialpressure andERSwarnnon-medicalreadersthatthetechnicallanguagemaybe
RCT Randomizedcontrolledtrial misinterpretedanddeclineanyresponsibilityinthisrespect.
REVEAL RegistrytoEvaluateEarlyandLong-TermPAH ManyGuidelineshavebeenissuedinrecentyearsbytheESCand
DiseaseManagement ERS.Becauseoftheirimpactonclinicalpractice,qualitycriteriafor
RHC Rightheartcatheterization the development of guidelines have been established in order to
RR Relativerisk makealldecisionstransparenttotheuser.TheERSandESCguid-
RV Rightventricle/rightventricular anceandproceduretoformulateandissueclinicalpracticerecom-
RVEF Rightventricularejectionfraction mendations can be found on the societies’ relevant website or
RV-FAC Rightventricularfractionalareachange journal (https://www.escardio.org/Guidelines and https://openres.
RVOTAT Rightventricularoutflowtractaccelerationtime ersjournals.com/content/8/1/00655-2021). The ESC and ERS
SaO Arterialoxygensaturation
GuidelinesrepresenttheofficialpositionoftheESCandERSonagi-
2
s.c. Subcutaneous ventopicandareregularlyupdated.
SCD Sicklecelldisease The panel of experts of these specific guidelines comprised an
sGC Solubleguanylatecyclase equalnumber ofERSandESC members,including representatives
SGLT-2i Sodium–glucosecotransporter-2inhibitor fromrelevantsubspecialtygroupsinvolvedinthemedicalcareofpa-
SLE Systemiclupuserythematosus tientswiththispathology.
SPAHR SwedishPulmonaryArterialHypertensionRegistry Theexpertsofthewritingandreviewingpanelsprovideddeclar-
sPAP Systolicpulmonaryarterialpressure ation of interest forms for all relationships that might be perceived
SPECT Single-photonemissioncomputedtomography
asrealorpotentialsourcesofconflictsofinterest.Theirdeclarations
SSc Systemicsclerosis ofinterestwerereviewedaccordingtotheESCdeclarationofinterest
SV Strokevolume rulesandcanbefoundontheESCwebsite(http://www.escardio.org/
SVI Strokevolumeindex Guidelines).Theyhavebeencompiledinareportandco-publishedina
SvO Mixedvenousoxygensaturation supplementary document of the guidelines. This process ensures
2
TAPSE Tricuspidannularplanesystolicexcursion transparencyandpreventspotentialbiasesinthedevelopmentandre-
TGF-β Transforminggrowthfactor-β viewprocesses.Anychangesindeclarationsofinterestthatarosedur-
TPR Totalpulmonaryresistance
ingthewritingperiodwerenotifiedtotheESCandupdated.TheTask
TR Tricuspidregurgitation
ForcereceiveditsentirefinancialsupportfromtheESCandERSwith-
TRPG Tricuspidregurgitationpressuregradient outanyinvolvementfromthehealthcareindustry.
TRV Tricuspidregurgitationvelocity TheESCClinicalPracticeGuidelines(CPG)CommitteeandtheERS
TSH Thyroid-stimulatinghormone Guidelines Director reporting to the ERS Science Council supervise
V/Q Ventilationperfusion andco-ordinatethepreparationofnewguidelines.TheseGuidelines
VE/VCO Ventilatoryequivalentforcarbondioxide underwent extensive review by the ESC CPG Committee, the ERS
2
VKA VitaminKantagonist Guidelines Working Group, and external experts. The guidelines
VO Oxygenuptake
weredevelopedaftercarefulconsiderationofthescientificandmedical
2
VO /HR Oxygenpulse knowledgeandtheevidenceavailableatthetimeofdrafting.Afterap-
2
VTE Venousthrombo-embolism propriaterevisions,theguidelinesweresignedoffbyalltheexpertsin
WHO-FC WorldHealthOrganizationfunctionalclass
theTaskForce.ThefinalizeddocumentwassignedoffbytheESCCPG
WSPH WorldSymposiumonPulmonaryHypertension Committee and endorsed by the ERS Executive Committee before
WU Woodunits being simultaneously published in the European Heart Journal (EHJ)
andtheEuropeanRespiratoryJournal(ERJ).Thedecisiontopublishthe
guidelinesinbothjournalswasmadetoensureadequatedissemination
1. Preamble oftherecommendationsinboththecardiologyandrespiratoryfields.
ThetaskofdevelopingtheESC/ERSGuidelinesalsoincludedcreat-
Guidelinessummarizeandevaluateavailableevidence,withtheaimof ingeducationaltoolsandimplementationprogrammesfortherecom-
assistinghealthprofessionalsinproposingthebestmanagementstrat- mendations,includingcondensedpocketguidelinesversions,summary
egiesforanindividualpatientwithagivencondition.Guidelinesand slides,alaysummary,andanelectronicversionfordigitalapplications
their recommendations should facilitate decision-making of health (smartphones,etc.).Theseversionsareabridgedandthus,formore
professionals in their daily practice. However, guidelines are not a detailedinformation,theusershouldalwaysaccessthefull-textversion
substituteforthepatient’srelationshipwiththeirpractitioner.Thefi- oftheguidelines,whichisfreelyavailableviatheESCandERSwebsites,
naldecisionsconcerninganindividualpatientmustbemadebythere- and hosted on the EHJ and ERJ websites. The National Cardiac
sponsiblehealthprofessional(s),basedonwhattheyconsidertobe Societies of the ESC are encouraged to endorse, adopt, translate,
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 8 ---
ESC/ERSGuidelines 3625
and implement all ESC Guidelines. Pulmonary national societies are the haemodynamic definition of PH.1 After careful evaluation, the
alsoencouragedtosharetheseguidelineswiththeirmembersandde- new definitions ofPHhavebeen endorsedandexpanded inthese
velop a summaryoreditorials intheirownlanguage, ifappropriate. guidelines,includingarevisedcut-offlevelforpulmonaryvascularre-
Implementationprogrammesareneededbecauseithasbeenshown sistance(PVR)andadefinitionofexercisePH.
thattheoutcomeofdiseasemaybefavourablyinfluencedbythethor- TheclassificationofPHhasbeenupdated,includingrepositioning
oughapplicationofclinicalrecommendations. ofvasoreactivepatientswithidiopathicpulmonaryarterialhyperten-
HealthprofessionalsareencouragedtotaketheESC/ERSGuidelines sion(IPAH)andarevisionofgroup5PH,includingrepositioningof
fullyintoaccountwhenexercisingtheirclinicaljudgement,aswellasin PHinlymphangioleiomyomatosisingroup3.
determining and implementing preventive, diagnostic, or therapeutic ConcerningthediagnosisofPH,anewalgorithmhasbeendevel-
medicalstrategies.However,theESC/ERSGuidelinesdonotoverride, opedaimingatearlierdetectionofPHinthecommunity.Inaddition,
inanyway,theindividualresponsibilityofhealthprofessionalstomake expedited referral is recommended for high-risk or complex pa-
appropriateandaccuratedecisionsinconsideringeachpatient’shealth tients.Screeningstrategiesarealsoproposed.
conditionandinconsultingwiththatpatientorthepatient’scaregiver Therisk-stratificationtablehasbeenexpandedtoincludeadditional
whereappropriateand/ornecessary.Itisalsothehealthprofessional’s echocardiographic and cardiac magnetic resonance imaging (cMRI)
responsibilitytoverifytherulesandregulationsapplicabletodrugsand prognosticindicators.Therecommendationsforinitialdrugtherapies
devicesatthetimeofprescriptionand,whereappropriate,torespect havebeensimplified,buildingonthisrevised,three-strata,multipara-
theethicalrulesoftheirprofessionineachcountry. metricriskmodeltoreplacefunctionalclassification.Atfollow-up,a
Off-labeluseofmedicationmaybepresentedintheseguidelinesif four-strata risk-assessment tool is now proposed based on refined
asufficientlevelofevidenceshowsthatitcanbeconsideredmedic- cut-off levels for World Health Organization functional class
ally appropriate to a given condition and if patients could benefit (WHO-FC), 6-minute walking distance (6MWD), and N-terminal
fromtherecommendedtherapy.However,thefinaldecisionscon- pro-brainnatriureticpeptide(NT-proBNP),categorizingpatientsas
cerninganindividualpatientmustbemadebytheresponsiblehealth low,intermediate–low,intermediate–high,orhighrisk.
professional,givingspecialconsiderationto: ThePAHtreatmentalgorithmhasbeenmodified,highlightingtheim-
portance of cardiopulmonary comorbidities, risk assessment both at
(cid:129) Thespecificsituationofthepatient.Inthisrespect,itisspecified
diagnosisandfollow-up,andtheimportanceofcombinationtherapies.
that, unless otherwise provided for by national regulations, off-
Treatmentstrategiesduringfollow-uphavebeen based on thefour-
label use of medication should be limited to situations where it
stratamodelintendedtofacilitatemoregranulardecision-making.
is in the patient’s interest to do so, with regards to the quality,
TherecommendationsformanagingPHassociatedwithleftheartdis-
safety,andefficacyofcare,andonlyafterthepatienthasbeenfully
ease(PH-LHD)andlungdiseasehavebeenupdated,includinganew
informedandprovidedconsent.
haemodynamicdefinitionofseverePHinpatientswithlungdisease.
(cid:129) Country-specific health regulations, indications by governmental
Ingroup4PH,thetermchronicthrombo-embolicpulmonarydis-
drugregulatoryagencies,andtheethicalrulestowhichhealthpro-
ease (CTEPD) with or without PH has been introduced, acknow-
fessionalsaresubject,whereapplicable.
ledging the presence of similar symptoms, perfusion defects, and
organized fibrotic obstructions in patients with or without PH at
2. Introduction
rest. Interventional treatment by balloon pulmonary angioplasty
(BPA) in combination with medical therapy has been upgraded in
Pulmonary hypertension (PH) is a pathophysiological disorder that thetherapeuticalgorithmofCTEPH.
mayinvolvemultipleclinicalconditionsandmaybeassociatedwitha NewstandardsforPHcentreshavebeenpresentedand,forthe
varietyofcardiovascularandrespiratorydiseases.Thecomplexityof firsttime,patientrepresentativeswereactivelyinvolvedindevelop-
managingPHrequiresamultifaceted,holistic,andmultidisciplinaryap- ingtheseguidelines.
proach, with active involvement of patients with PH in partnership Questionswithdirectconsequencesforclinicalpractitionersregard-
withclinicians.StreamliningthecareofpatientswithPHindailyclinical ingeachPHclassificationsubgroupwereselectedandaddressed,name-
practiceisachallengingbutessentialrequirementforeffectivelyman- lyguidanceon:initialtreatmentstrategyforgroup1PH(Population,
agingPH.Inrecentyears,substantialprogresshasbeenmadeindetect- Intervention,Control,Outcome[PICO]I);useoforalphosphodiester-
ingandmanagingPH,andnewevidencehasbeentimeouslyintegrated ase5inhibitors(PDE5is)forthetreatmentofgroup2PH(PICOII);use
inthisfourtheditionoftheESC/ERSGuidelinesforthediagnosisand oforalPDE5isforthetreatmentofgroup3PH(PICOIII);anduseofPH
treatmentofpulmonaryhypertension.Reflectingthemultidisciplinary
drugspriortoBPAforthetreatmentofgroup4PH(PICOIV).These
inputintomanagingpatientswithPHandinterpretingnewevidence, questionswereconsideredtobeimportantbecause:mostcontempor-
theTask Force included cardiologistsand pneumologists,a thoracic aryPHregistriesdescribevariableuseofinitialoralmonotherapyand
surgeon,methodologists,andpatients.Thesecomprehensiveclinical combination therapy; large case series show widespread use of
practiceguidelinescoverthewholespectrumofPH,withanemphasis PDE5isingroup2PH,despiteaclassIIIrecommendationinthe2015
ondiagnosingandtreatingpulmonaryarterialhypertension(PAH)and ESC/ERS Guidelines for the diagnosis and treatment of pulmonary
chronicthrombo-embolicpulmonaryhypertension(CTEPH). hypertension;largecaseseriesshowwidespreaduseofPDE5isingroup
3 PH, despite a class III recommendation in the 2015 ESC/ERS
2.1. What is new Guidelinesforthediagnosisandtreatmentofpulmonaryhypertension;
One of the most important proposals from the 6th World andthereisnoclearguidancefortherapywithPHdrugsinpatientswith
SymposiumonPulmonaryHypertension(WSPH)wastoreconsider inoperableCTEPHpriortoBPA.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 9 ---
3626 ESC/ERSGuidelines
Selectedrevisedrecommendations(R)andnewrecommendations(N)
Newor Recommendationin2015version Classa Recommendationin2022version Classa
revised
Rightheartcatheterizationandvasoreactivitytesting–RecommendationTable1
N ItisrecommendedthatRHCcomprisesacompletesetof
haemodynamicsandisperformedfollowingstandardized I
protocols
R Adenosineshouldbeconsideredforperforming Inhalednitricoxide,inhalediloprost,ori.v.epoprostenol
vasoreactivitytestingasanalternative arerecommendedforperformingvasoreactivitytesting
IIa I
Inhalediloprostmaybeconsideredforperforming
vasoreactivitytestingasanalternative
Diagnosticstrategy–RecommendationTable2
N Itisrecommendedtoassignanechocardiographic
probabilityofPH,basedonanabnormalTRVandthe
I
presenceofotherechocardiographicsignssuggestiveof
PH(seeTable10)
N Itisrecommendedtomaintainthecurrentthresholdfor
TRV(.2.8m/s)forechocardiographicprobabilityofPH I
accordingtotheupdatedhaemodynamicdefinition
N BasedontheprobabilityofPHbyechocardiography,
furthertestingshouldbeconsideredintheclinical
IIa
context(i.e.symptomsandriskfactorsorassociated
conditionsforPAH/CTEPH)
N Insymptomaticpatientswithintermediate
echocardiographicprobabilityofPH,CPETmaybe IIb
consideredtofurtherdeterminethelikelihoodofPH
Screeningandimproveddetectionofpulmonaryarterialhypertensionandchronicthrombo-embolicpulmonaryhypertension–
RecommendationTable3
N InpatientswithSSc,anannualevaluationoftheriskof
I
havingPAHisrecommended
R Restingechocardiographyisrecommendedasascreening InadultpatientswithSScof.3years’diseaseduration,
testinasymptomaticpatientswithSSc,followedbyannual anFVC≥40%,andaDLCO,60%,theDETECT
I I
screeningwithechocardiography,DLCO,andbiomarkers algorithmisrecommendedtoidentifyasymptomatic
patientswithPAH
N InpatientswithSSc,wherebreathlessnessremains
unexplainedfollowingnon-invasiveassessment,RHCis I
recommendedtoexcludePAH
N AssessingtheriskofhavingPAH,basedonanevaluation
ofbreathlessness,incombinationwithechocardiogram
IIa
orPFTsandBNP/NT-proBNP,shouldbeconsideredin
patientswithSSc
N PoliciestoevaluatetheriskofhavingPAHshouldbe
IIa
consideredinhospitalsmanagingpatientswithSSc
R RHCisrecommendedinallcasesofsuspectedPAH InsymptomaticpatientswithSSc,exercise
associatedwithCTD I echocardiographyorCPET,orCMRmaybeconsidered IIb
toaiddecisionstoperformRHC
N InpatientswithCTDwithoverlapfeaturesofSSc,an
IIb
annualevaluationoftheriskofPAHmaybeconsidered
R InPEsurvivorswithexercisedyspnoea,CTEPHshouldbe Inpatientswithpersistentornew-onsetdyspnoeaor
considered IIa exerciselimitationfollowingPE,furtherdiagnostic I
evaluationtoassessforCTEPH/CTEPDisrecommended
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 10 ---
ESC/ERSGuidelines 3627
N Forsymptomaticpatientswithmismatchedperfusion
lungdefectsbeyond3monthsofanticoagulationfor
acutePE,referraltoaPH/CTEPHcentreis I
recommendedafterconsideringtheresultsof
echocardiography,BNP/NT-proBNP,and/orCPET
N CounsellingregardingtheriskofPAH,andannual
screeningisrecommendedforindividualswhotest
I
positiveforPAH-causingmutationsandinfirst-degree
relativesofpatientswithHPAH
N Inpatientsreferredforlivertransplantation,
echocardiographyisrecommendedasascreeningtestfor I
PH
N Furthertests(echocardiography,BNP/NT-proBNP,
PFTs,and/orCPET)shouldbeconsideredinsymptomatic
IIa
patientswithCTD,portalhypertension,orHIVtoscreen
forPAH
Evaluatingthediseaseseverityandriskofdeathinpatientswithpulmonaryarterialhypertension–RecommendationTable4
N Forriskstratificationatthetimeofdiagnosis,theuseofa
three-stratamodel(low,intermediate,andhighrisk)is
I
recommended,takingintoaccountallavailabledata
includinghaemodynamics
N Forriskstratificationduringfollow-up,theuseofa
four-stratamodel(low,intermediate–low,intermediate–
high,andhighrisk)basedonWHO-FC,6MWD,and I
BNP/NT-proBNPisrecommended,withadditional
variablestakenintoaccountasnecessary
R Achievement/maintenanceofanintermediate-riskprofile InsomePAHaetiologiesandinpatientswith
shouldbeconsideredaninadequatetreatmentresponse comorbidities,optimizationoftherapyshouldbe
IIa IIa
formostpatientswithPAH consideredonanindividualbasiswhileacknowledging
thatalow-riskprofileisnotalwaysachievable
Generalmeasuresandspecialcircumstances–RecommendationTable5
R Supervisedexercisetrainingshouldbeconsideredin Supervisedexercisetrainingisrecommendedinpatients
physicallydeconditionedPAHpatientsundermedical IIa withPAHundermedicaltherapy I
therapy
R ImmunizationofPAHpatientsagainstinfluenzaand ImmunizationofpatientswithPAHagainstSARS-CoV-2,
I I
pneumococcalinfectionisrecommended influenza,andStreptococcuspneumoniaeisrecommended
R Correctionofanaemiaand/orironstatusmaybe Inthepresenceofiron-deficiencyanaemia,correctionof
IIb I
consideredinPAHpatients ironstatusisrecommendedinpatientswithPAH
N Intheabsenceofanaemia,ironrepletionmaybe
IIb
consideredinpatientswithPAHwithirondeficiency
R Oralanticoagulanttreatmentmaybeconsideredin Anticoagulationisnotgenerallyrecommendedinpatients
patientswithIPAH,HPAH,andPAHduetouseof IIb withPAHbutmaybeconsideredonanindividualbasis IIb
anorexigens
R Theuseofangiotensin-convertingenzymeinhibitors, TheuseofACEis,ARBs,ARNIs,SGLT-2is,beta-blockers,
angiotensin-2receptorantagonists,beta-blockers,and orivabradineisnotrecommendedinpatientswithPAH
ivabradineisnotrecommendedinpatientswithPAH III unlessrequiredbycomorbidities(i.e.highbloodpressure, III
unlessrequiredbycomorbidities(i.e.highbloodpressure, coronaryarterydisease,leftHF,orarrhythmias)
coronaryarterydisease,orleftHF)
R In-flightO administrationshouldbeconsideredfor In-flightO administrationisrecommendedforpatients
2 2
patientsinWHO-FCIIIandIVandthosewitharterial IIa usingoxygenorwhosearterialbloodoxygenpressureis I
bloodO pressureconsistently,8kPa(60mmHg) ,8kPa(60mmHg)atsealevel
2
R Inelectivesurgery,epiduralratherthangeneral Forinterventionsrequiringanaesthesia,multidisciplinary
anaesthesiashouldbepreferredwheneverpossible IIa consultationataPHcentretoassessriskandbenefit IIa
shouldbeconsidered
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 11 ---
3628 ESC/ERSGuidelines
Womenofchildbearingpotential–RecommendationTable6
R ItisrecommendedthatPAHpatientsavoidpregnancy Itisrecommendedthatwomenofchildbearingpotential
withPAHarecounselledatthetimeofdiagnosisabout
therisksanduncertaintiesassociatedwithbecoming
I I
pregnant;thisshouldincludeadviceagainstbecoming
pregnant,andreferralforpsychologicalsupportwhere
needed
N Itisrecommendedthatwomenofchildbearingpotential
withPAHbeprovidedwithclearcontraceptiveadvice,
consideringtheindividualneedsofthewomanbut I
recognizingthattheimplicationsofcontraceptivefailure
aresignificantinPAH
N ItisrecommendedthatwomenwithPAHwhoconsider
pregnancyorwhobecomepregnantreceiveprompt
counsellinginanexperiencedPHcentretofacilitate
I
geneticcounsellingandshareddecision-making,andto
providepsychologicalsupporttothepatientsandtheir
familieswhereneeded
N ForwomenwithPAHhavingterminationofpregnancy,it
isrecommendedthatthisbeperformedinPHcentres,
I
withpsychologicalsupportprovidedtothepatientand
herfamily
N ForwomenwithPAHwhodesiretohavechildren,where
available,adoptionandsurrogacywithpre-conception IIb
geneticcounsellingmaybeconsidered
N Asteratogenicpotentialhasbeenreportedinpreclinical
modelsforendothelinreceptorantagonistsandriociguat, III
thesedrugsarenotrecommendedduringpregnancy
Treatmentofvasoreactivepatientswithidiopathic,heritable,ordrug-associatedpulmonaryarterialhypertension–
RecommendationTable7
R ContinuationofhighdosesofCCBsisrecommendedin ContinuinghighdosesofCCBsisrecommendedin
patientswithIPAH,HPAH,andDPAHinWHO-FCIorII patientswithIPAH,HPAH,orDPAHinWHO-FCIorII
I I
withmarkedhaemodynamicimprovement(near withmarkedhaemodynamicimprovement(mPAP
normalization) ,30mmHgandPVR,4WU)
N Inpatientswithapositivevasoreactivitytestbut
insufficientlong-termresponsetoCCBswhorequire
IIa
additionalPAHtherapy,continuationofCCBtherapy
shouldbeconsidered
Treatmentofnon-vasoreactivepatientswithidiopathic,heritable,ordrug-associatedpulmonaryarterialhypertensionwhopresent
withoutcardiopulmonarycomorbiditiesb–RecommendationTable8
N InpatientswithIPAH/HPAH/DPAHwhopresentathigh
riskofdeath,initialcombinationtherapywithaPDE5i,an IIa
ERA,andi.v./s.c.prostacyclinanaloguesshouldbe
consideredc
N InpatientswithIPAH/HPAH/DPAHwhopresentat
intermediate–lowriskofdeathwhilereceivingERA/
IIa
PDE5itherapy,theadditionofselexipagshouldbe
considered
N InpatientswithIPAH/HPAH/DPAHwhopresentat
intermediate–highorhighriskofdeathwhilereceiving
ERA/PDE5itherapy,theadditionofi.v./s.c.prostacyclin IIa
analoguesandreferralforlungtransplantation(LTx)
evaluationshouldbeconsidered
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 12 ---
ESC/ERSGuidelines 3629
N InpatientswithIPAH/HPAH/DPAHwhopresentat
intermediate–lowriskofdeathwhilereceivingERA/
IIb
PDE5itherapy,switchingfromPDE5itoriociguatmaybe
considered
Initialoraldrugcombinationtherapyforpatientswithidiopathic,heritable,ordrug-associatedpulmonaryarterialhypertension
withoutcardiopulmonarycomorbidities–RecommendationTable9
R Ambrisentan+tadalafil Initialcombinationtherapywithambrisentanandtadalafil
I I
isrecommended
N Initialcombinationtherapywithmacitentanandtadalafil
I
isrecommended
R OtherERA+PDE-5i InitialcombinationtherapywithotherERAsandPDE5is
IIa IIa
shouldbeconsidered
N Initialcombinationtherapywithmacitentan,tadalafil,and
III
selexipagisnotrecommended
Sequentialdrugcombinationtherapyforpatientswithidiopathic,heritable,ordrug-associatedpulmonaryarterialhypertension–
RecommendationTable10
N Itisrecommendedtobasetreatmentescalationsonrisk
assessmentandgeneraltreatmentstrategies(see I
treatmentalgorithm)
R Macitentanaddedtosildenafil TheadditionofmacitentantoPDE5isororal/inhaled
I prostacyclinanaloguesisrecommendedtoreducethe I
riskofmorbidity/mortalityevents
N TheadditionoforaltreprostiniltoERAorPDE5i/
riociguatmonotherapyisrecommendedtoreducethe I
riskofmorbidity/mortalityevents
R Bosentanaddedtosildenafil Theadditionofbosentantosildenafilisnot
IIb recommendedtoreducetheriskofmorbidity/mortality III
events
R Riociguataddedtobosentan Theadditionofriociguattobosentanshouldbe
I IIa
consideredtoimproveexercisecapacity
Treatmentofnon-vasoreactivepatientswithidiopathic,heritable,ordrug-associatedpulmonaryarterialhypertensionwhopresent
withcardiopulmonarycomorbiditiesb–RecommendationTable11
N InpatientswithIPAH/HPAH/DPAHand
cardiopulmonarycomorbidities,initialmonotherapywith IIa
aPDE5ioranERAshouldbeconsidered
N InpatientswithIPAH/HPAH/DPAHwith
cardiopulmonarycomorbiditieswhopresentat
intermediateorhighriskofdeathwhilereceivingPDE5i IIb
orERAmonotherapy,additionalPAHmedicationmaybe
consideredonanindividualbasis
Efficacyofintensivecaremanagementforpulmonaryarterialhypertension–RecommendationTable12
N WhenmanagingpatientswithrightHFintheICU,itis
recommendedtoinvolvephysicianswithexpertise,treat
causativefactors,andusesupportivemeasuresincluding I
inotropesandvasopressors,fluidmanagement,andPAH
drugsasappropriate
N Mechanicalcirculatorysupportmaybeanoptionfor
selectedpatientsasabridgetotransplantationorto
IIa
recovery,andinterhospitaltransfershouldbeconsidered
ifsuchresourcesareunavailableonsite
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 13 ---
3630 ESC/ERSGuidelines
Lungtransplantation–RecommendationTable13
R Lungtransplantationisrecommendedsoonafter Itisrecommendedthatpotentiallyeligiblecandidatesare
inadequateclinicalresponseonmaximalmedicaltherapy referredforLTxevaluationwhentheyhavean
I inadequateresponsetooralcombinationtherapy, I
indicatedbyanintermediate–highorhighriskorbya
REVEALriskscore.7
N ItisrecommendedtolistpatientsforLTxwhopresent
withahighriskofdeathorwithaREVEALriskscore≥10
I
despitereceivingoptimizedmedicaltherapy,includings.c.
ori.v.prostacyclinanalogues
Pulmonaryarterialhypertensionassociatedwithdrugsortoxins–RecommendationTable14
N Itisrecommendedtomakeadiagnosisofdrug-or
toxin-associatedPAHinpatientswhohadrelevant
I
exposureandinwhomothercausesofPHhavebeen
excluded
N Inpatientswithsuspecteddrug-ortoxin-associatedPAH,
itisrecommendedtodiscontinuethecausativeagent I
immediatelywheneverpossible
N ImmediatePAHtherapyshouldbeconsideredinpatients
whopresentwithintermediate/high-riskPAHat IIa
diagnosis
N Patientswithlow-riskPAHshouldbere-evaluated3–4
monthsafterdiscontinuingthesuspecteddrugortoxin,
IIb
andPAHtherapymaybeconsideredwhenthe
haemodynamicshavenotnormalized
Pulmonaryarterialhypertensionassociatedwithconnectivetissuedisease–RecommendationTable15
N InpatientswithPAHassociatedwithCTD,treatmentof
theunderlyingconditionaccordingtocurrentguidelines I
isrecommended
Pulmonaryarterialhypertensionassociatedwithhumanimmunodeficiencyvirusinfection–RecommendationTable16
N InpatientswithPAHassociatedwithHIVinfection,
antiretroviraltreatmentaccordingtocurrentguidelinesis I
recommended
N InpatientswithPAHassociatedwithHIVinfection,initial
monotherapyshouldbeconsidered,followedby
IIa
sequentialcombinationifnecessary,takinginto
considerationcomorbiditiesanddrug–druginteractions
Pulmonaryarterialhypertensionassociatedwithportalhypertension–RecommendationTable17
R EchocardiographicassessmentforsignsofPHis Echocardiographyisrecommendedinpatientswithliver
recommendedinsymptomaticpatientswithliverdisease diseaseorportalhypertensionwithsignsorsymptoms
orportalhypertensionandinallcandidatesforliver I suggestiveofPH,andasascreeningtoolinpatients I
transplantation evaluatedforlivertransplantationortransjugular
portosystemicshunt
R Itisrecommendedthatthetreatmentalgorithmfor InpatientswithPAHassociatedwithportalhypertension,
patientswithotherformsofPAHshouldbeappliedto initialmonotherapyshouldbeconsidered,followedby
patientswithPAHassociatedwithportalhypertension, I sequentialcombinationifnecessary,takinginto IIa
takingintoaccounttheseverityofliverdisease considerationtheunderlyingliverdiseaseandindication
forlivertransplantation
R Livertransplantationmaybeconsideredinselected Livertransplantationshouldbeconsideredonan
patientsrespondingwelltoPAHtherapy individualbasisinpatientswithPAHassociatedwith
IIb IIa
portalhypertension,aslongasPVRisnormalornear
normalwithPAHtherapy
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 14 ---
ESC/ERSGuidelines 3631
N DrugsapprovedforPAHarenotrecommendedfor
patientswithportalhypertensionandunclassifiedPH(i.e. III
elevatedmPAP,highCO,andanormalPVR)
Shuntclosureinpatientswithpulmonary–systemicflowratio.1.5:1basedoncalculatedpulmonaryvascularresistance–
RecommendationTable18
N InpatientswithASD,VSD,orPDAandaPVR,3WU,
I
shuntclosureisrecommended
N InpatientswithASD,VSD,orPDAandaPVRof3–5
IIa
WU,shuntclosureshouldbeconsidered
N InpatientswithASDandaPVR.5WUthatdeclinesto
,5WUwithPAHtreatment,shuntclosuremaybe IIb
considered
N InpatientswithVSDorPDAandaPVR.5WU,shunt
closuremaybeconsideredaftercarefulevaluationin IIb
specializedcentres
N InpatientswithASDandaPVR.5WUdespitePAH
III
treatment,shuntclosureisnotrecommended
Pulmonaryarterialhypertensionassociatedwithadultcongenitalheartdisease–RecommendationTable19
N Riskassessmentisrecommendedforpatientswith
I
persistentPAHafterdefectclosure
N Riskassessmentshouldbeconsideredinpatientswith
IIa
Eisenmengersyndrome
R BosentanisrecommendedinWHO-FCIIIpatientswith Bosentanisrecommendedinsymptomaticpatientswith
I I
Eisenmengersyndrome Eisenmengersyndrometoimproveexercisecapacity
R Theuseofsupplementalirontreatmentmaybe Supplementalirontreatmentshouldbeconsideredin
IIb IIa
consideredinpatientswithlowferritinplasmalevels patientswithirondeficiency
R Combinationdrugtherapymaybeconsideredinpatients InpatientswithPAHaftercorrectedadultCHD,initial
withEisenmengersyndrome oralcombinationtherapywithdrugsapprovedforPAH
shouldbeconsideredforpatientsatlowandintermediate
IIb IIa
risk,whileinitialcombinationtherapyincludingi.v./s.c.
prostacyclinanaloguesshouldbeconsideredforpatients
athighrisk
R Combinationdrugtherapymaybeconsideredinpatients InpatientswithadultCHD,includingEisenmenger
withEisenmengersyndrome IIb syndrome,sequentialcombinationtherapyshouldbe IIa
consideredifpatientsdonotmeettreatmentgoals
N InwomenwithEisenmengersyndrome,pregnancyisnot
III
recommended
R Ifsymptomsofhyperviscosityarepresent,phlebotomy InpatientswithEisenmengersyndrome,routine
withisovolumicreplacementshouldbeconsidered,usually IIa phlebotomytolowerelevatedhaematocritisnot III
whenthehaematocritis.65% recommended
Pulmonaryarterialhypertensionwithsignsofvenous/capillaryinvolvement–RecommendationTable20
R Acombinationofclinicalfindings,physicalexamination, Acombinationofclinicalandradiologicalfindings,ABG,
bronchoscopy,andradiologicalfindingsisrecommended PFTs,andgenetictestingisrecommendedtodiagnose
I I
todiagnosePVOD/PCH PAHwithsignsofvenousand/orcapillaryinvolvement
(PVOD/PCH)
N InpatientswithPVOD/PCH,theuseofdrugsapproved
forPAHmaybeconsideredwithcarefulmonitoringof IIb
clinicalsymptomsandgasexchange
N Lungbiopsyisnotrecommendedtoconfirmadiagnosis
III
ofPVOD/PCH
Paediatricpulmonaryhypertension–RecommendationTable21
N Itisrecommendedtoperformthediagnosticwork-up,
includingRHCandacutevasoreactivitytesting,andtreat
I
childrenwithPHatcentreswithspecificexpertisein
paediatricPH
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 15 ---
3632 ESC/ERSGuidelines
R APHdiagnosticalgorithmwork-upisrecommendedfor InchildrenwithPH,acomprehensivework-upfor
diagnosisanddefinitionofthespecificaetiologygroupin confirmingdiagnosisandspecificaetiologyis
I I
paediatricPHpatients recommended(similartothatinadults,butadaptedfor
age)
N ForconfirmingPHdiagnosis,RHCisrecommended,
I
preferablybeforeinitiatinganyPAHtherapy
N InchildrenwithIPAH/HPAH,acutevasoreactivitytesting
isrecommendedtodetectthosewhomaybenefitfrom I
calciumchannelblockertherapy
N Itisrecommendedtodefineapositiveresponsetoacute
vasoreactivitytestinginchildrensimilartoadultsbya
reductionofmPAP≥10mmHgtoreachanabsolute I
valueofmPAP≤40mmHg,withanincreasedor
unchangedCO
R APAH-specifictherapeuticalgorithmisrecommendedin InchildrenwithPAH,atherapeuticstrategybasedonrisk
paediatricPHpatients I stratificationandtreatmentresponseisrecommended, I
extrapolatedfromthatinadultsbutadaptedforage
R Specificpaediatricdeterminantsofriskshouldbe Itisrecommendedtomonitorthetreatmentresponsein
considered childrenwithPAHbyseriallyassessingapanelofdata
IIa derivedfromclinicalassessment,echocardiographic I
evaluation,biochemicalmarkers,andexercisetolerance
tests
N Achievingandmaintainingalow-riskprofileshouldbe
consideredasanadequatetreatmentresponsefor IIa
childrenwithPAH
N Itisrecommendedtoscreeninfantswith
I
bronchopulmonarydysplasiaforPH
N Ininfantswith(oratriskof)bronchopulmonarydysplasia
andPH,treatinglungdisease,includinghypoxia,
aspiration,andstructuralairwaydisease,andoptimizing I
respiratorysupportisrecommendedbeforeinitiating
PAHtherapy
N Inneonatesandinfants,adiagnosticandtherapeutic
approachtoPHdistinctfromthatinolderchildrenand
adultsshouldbeconsidered,giventhefrequent IIa
associationwithdevelopmentalvascularandparenchymal
lungdisease
Pulmonaryhypertensionassociatedwithleftheartdisease–RecommendationTable22
N RHCisrecommendedforsuspectedPHinpatientswith I
LHD,ifitaidsmanagementdecisions
N RHCisrecommendedinpatientswithseveretricuspid
regurgitationwithorwithoutLHDpriortosurgicalor I
interventionalvalverepair
R PatientswithPH-LHDandaseverepre-capillary ForpatientswithLHDandsuspectedPHwithfeaturesof
componentasindicatedbyahighDPGand/orhighPVR aseverepre-capillarycomponentand/ormarkersofRV
IIa I
shouldbereferredtoanexpertPHcentreforacomplete dysfunction,referraltoaPHcentreforacomplete
diagnosticwork-upandanindividualtreatmentdecision diagnosticwork-upisrecommended
N InpatientswithLHDandCpcPHwithasevere
pre-capillarycomponent(e.g.PVR.5WU),an I
individualizedapproachtotreatmentisrecommended
N WhenpatientswithPHandmultipleriskfactorsforLHD,
whohaveanormalPAWPatrestbutanabnormal
I
responsetoexerciseorfluidchallenge,aretreatedwith
PAHdrugs,closemonitoringisrecommended
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 16 ---
ESC/ERSGuidelines 3633
N InpatientswithPHatRHC,aborderlinePAWP(13–
15mmHg)andfeaturesofHFpEF,additionaltestingwith
IIb
exerciseorfluidchallengemaybeconsideredtouncover
post-capillaryPH
Pulmonaryhypertensionassociatedwithlungdiseaseand/orhypoxia–RecommendationTable23
R Echocardiographyisrecommendedforthenon-invasive IfPHissuspectedinpatientswithlungdisease,itis
diagnosticassessmentofsuspectedPHinpatientswith recommendedthatechocardiographydbeperformed
I I
lungdisease andtheresultsinterpretedinconjunctionwithABG,
PFTsincludingDLCO,andCTimaging
R Optimaltreatmentoftheunderlyinglungdisease,including InpatientswithlungdiseaseandsuspectedPH,itis
long-termO therapyinpatientswithchronic recommendedtooptimizetreatmentoftheunderlying
2
hypoxaemia,isrecommendedinpatientswithPHdueto I lungdiseaseand,whereindicated,hypoxaemia, I
lungdiseases sleep-disorderedbreathing,and/oralveolar
hypoventilation
R Referraltoanexpertcentreisrecommendedinpatients InpatientswithlungdiseaseandsuspectedseverePH,or
withechocardiographicsignsofseverePHand/orsevere I wherethereisuncertaintyregardingthetreatmentofPH, I
rightventriculardysfunction referraltoaPHcentreisrecommendede
N InpatientswithlungdiseaseandseverePH,an
I
individualizedapproachtotreatmentisrecommended
N Itisrecommendedtorefereligiblepatientswithlung
I
diseaseandPHforLTxevaluation
R RHCisnotrecommendedforsuspectedPHinpatients InpatientswithlungdiseaseandsuspectedPH,RHCis
withlungdisease,unlesstherapeuticconsequencesareto recommendediftheresultsareexpectedtoaid
III I
beexpected(e.g.LTx,alternativediagnosessuchasPAH managementdecisions
orCTEPH,andpotentialenrolmentinaclinicaltrial)
N Inhaledtreprostinilmaybeconsideredinpatientswith
IIb
PHassociatedwithILD
N Theuseofambrisentanisnotrecommendedinpatients
III
withPHassociatedwithIPF
N Theuseofriociguatisnotrecommendedinpatientswith
III
PHassociatedwithIIP
Chronicthrombo-embolicpulmonaryhypertensionandchronicthrombo-embolicpulmonarydiseasewithoutpulmonary
hypertension–RecommendationTable24
R Lifelonganticoagulationisrecommendedinallpatients Lifelongtherapeuticdosesofanticoagulationare
I I
withCTEPH recommendedinallpatientswithCTEPH
N Antiphospholipidsyndrometestingisrecommendedin
I
patientswithCTEPH
N InpatientswithCTEPHandantiphospholipidsyndrome,
I
anticoagulationwithVKAsisrecommended
R ItisrecommendedthatallpatientswithCTEPHreceive ItisrecommendedthatallpatientswithCTEPHare
assessmentofoperabilityanddecisionsregardingother reviewedbyaCTEPHteamfortheassessmentof
I I
treatmentstrategiesmadebyamultidisciplinaryteamof multimodalitymanagement
experts
R SurgicalPEAindeephypothermiacirculatoryarrestis PEAisrecommendedasthetreatmentofchoicefor
recommendedforpatientswithCTEPH I patientswithCTEPHandfibroticobstructionswithin I
pulmonaryarteriesaccessiblebysurgery
R InterventionalBPAmaybeconsideredinpatientswhoare BPAisrecommendedinpatientswhoaretechnically
technicallyinoperableorcarryanunfavourablerisk:benefit IIb inoperableorhaveresidualPHafterPEAanddistal I
ratioforPEA obstructionsamenabletoBPA
R Riociguatisrecommendedinsymptomaticpatientswho Riociguatisrecommendedforsymptomaticpatientswith
havebeenclassifiedashavingpersistent/recurrentCTEPH inoperableCTEPHorpersistent/recurrentPHafterPEA
I I
aftersurgicaltreatmentorinoperableCTEPHbyaCTEPH
teamincludingatleastoneexperiencedPEAsurgeon
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 17 ---
3634 ESC/ERSGuidelines
N Long-termfollow-upisrecommendedafterPEAand
BPA,aswellasforpatientswithCTEPHestablishedon I
medicaltherapy
N Amultimodalityapproachshouldbeconsideredfor
patientswithpersistentPHafterPEAandforpatients IIa
withinoperableCTEPH
N InpatientswithCTEPDwithoutPH,long-term
anticoagulanttherapyshouldbeconsideredonan IIa
individualbasisf
N PEAorBPAshouldbeconsideredinselected
IIa
symptomaticpatientswithCTEPDwithoutPH
N Treprostinils.c.maybeconsideredinpatientsin
WHO-FCIII–IVwhohaveinoperableCTEPHor IIb
persistent/recurrentPHafterPEA
R Off-labeluseofdrugsapprovedforPAHmaybe Off-labeluseofdrugsapprovedforPAHmaybe
consideredinsymptomaticpatientswhohavebeen consideredinsymptomaticpatientswhohaveinoperable
IIb IIb
classifiedashavinginoperableCTEPHbyaCTEPHteam CTEPH
includingatleastoneexperiencedPEAsurgeon
N InpatientswithinoperableCTEPH,acombinationof
sGCstimulator/PDE5i,ERA,orparenteralprostacyclin IIb
analoguesmaybeconsidered
N BPAmaybeconsideredfortechnicallyoperablepatients
withahighproportionofdistaldiseaseandan IIb
unfavourablerisk:benefitratioforPEA
Pulmonaryhypertensioncentres–RecommendationTable25
N ItisrecommendedthatPHcentresmaintainapatient
I
registry
N ItisrecommendedthatPHcentrescollaboratewith
I
patientassociations
N AccreditationofthePHcentresshouldbeconsidered
IIa
(e.g.https://ec.europa.eu/health/ern/assessment_en)
R Itshouldbeconsideredthatareferralcentrefollowat PHcentresshouldfollow-upasufficientnumberof
least50patientswithPAHorCTEPHandshouldreceive patientstomaintainexpertise(atleast50patientswith
atleasttwonewreferralspermonthwithdocumented IIa PAHorCTEPHandatleasttwonewreferralspermonth IIa
PAHorCTEPH withdocumentedPAHorCTEPH)andconsider
establishingcollaborationswithhigh-volumecentres
6MWD,6-minutewalkingdistance;ABG,arterialbloodgasanalysis;ACEi,angiotensin-convertingenzymeinhibitor;ARB,angiotensinreceptorblocker;ARNI,angiotensinreceptor–
neprilysininhibitor;ASD,atrialseptaldefect;BNP,brainnatriureticpeptide;BPA,balloonpulmonaryangioplasty;CCB,calciumchannelblocker;CHD,congenitalheartdisease;CI,
cardiacindex;CMR,cardiacmagneticresonance;CO,cardiacoutput;CpcPH,combinedpost-andpre-capillarypulmonaryhypertension;CPET,cardiopulmonaryexercisetesting;
CT,computedtomography;CTD,connectivetissuedisease;CTEPD,chronicthrombo-embolicpulmonarydisease;CTEPH,chronicthrombo-embolicpulmonaryhypertension;
DLCO, Lung diffusion capacity for carbon monoxide; DPAH, drug-associated pulmonary arterial hypertension; DPG, diastolic pressure gradient; ERA, endothelin receptor
antagonist;FVC,forcedvitalcapacity;HF,heartfailure;HFpEF,heartfailurewithpreservedejectionfraction;HIV,humanimmunodeficiencyvirus;HPAH,heritablepulmonary
arterialhypertension;ICU,intensivecareunit;IIP,idiopathicinterstitialpneumonia;ILD,interstitiallungdisease;IPAH,idiopathicpulmonaryarterialhypertension;IPF,idiopathic
pulmonaryfibrosis;i.v.,intravenous;LHD,leftheartdisease;LTx,lungtransplantation;mPAP,meanpulmonaryarterialpressure;NT-proBNP,N-terminalpro-brainnatriuretic
peptide;PAH,pulmonaryarterialhypertension;PAP,pulmonaryarterialpressure;PAWP,pulmonaryarterialwedgepressure;PCH,pulmonarycapillaryhaemangiomatosis;PDA,
patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism; PEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary
hypertension;PH-LHD,pulmonaryhypertensionassociatedwithleftheartdisease;PVOD,pulmonaryveno-occlusivedisease;PVR,pulmonaryvascularresistance;RAP,meanright
atrialpressure;RHC,rightheartcatheterization;RV,rightventricle;SARS-CoV-2,severeacuterespiratorysyndromecoronavirus-2;s.c.,subcutaneous;sGC,solubleguanylate
cyclase;SGLT-2i,sodium–glucosecotransporter-2inhibitor;SSc,systemicsclerosis;SVI,strokevolumeindex;TRV,tricuspidregurgitationvelocity;VKA,vitaminKantagonist;VSD,
ventricularseptaldefect;VTE,venousthrombo-embolism;WHO-FC,WorldHealthOrganizationfunctionalclass;WU,Woodunits.
aClassofrecommendation.
bCardiopulmonarycomorbiditiesarepredominantlyencounteredinelderlypatientsandincluderiskfactorsforHFpEF,suchasobesity,diabetes,coronaryheartdisease,ahistoryof
hypertension,and/oralowDLCO.
cInitialtriple-combinationtherapyincludingi.v./s.c.prostacyclinanaloguesmayalsobeconsideredinpatientspresentingatintermediateriskbutseverehaemodynamicimpairment(e.g.
RAP≥20mmHg,CI,2.0L/min/m2,SVI,31mL/m2,and/orPVR≥12WU).
dAssessmentsshouldideallybemadewhenthepatientisclinicallystable,asexacerbationscansignificantlyraisePAP.
eThisrecommendationdoesnotapplytopatientswithend-stagelungdiseasewhoarenotconsideredcandidatesforLTx.
fLong-termanticoagulanttherapyisrecommendedwhentheriskofPErecurrenceisintermediateorhigh,orwhenthereisnohistoryofVTE.
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 18 ---
ESC/ERSGuidelines 3635
NewrecommendationsdevelopedwithGRADEEvidencetoDecisionframework
GRADE
Recommendations Qualityof Strengthof Classa Levelb
evidence recommendation
InpatientswithIPAH/HPAH/DPAHwhopresentatloworintermediateriskof Low Conditional
I B
death,initialcombinationtherapywithaPDE5iandanERAisrecommended
TheuseofPDE5iinpatientswithHFpEFandisolatedpost-capillaryPHisnot Low Conditional
III C
recommended
PDE5imaybeconsideredinpatientswithseverePHassociatedwithILD(individual Verylow Conditional
IIb C
decision-makinginPHcentres)
TheuseofPDE5iinpatientswithILDandnon-severePHisnotrecommended Verylow Conditional
III C
InpatientswithCTEPHwhoarecandidatesforBPA,medicaltherapyshouldbe Verylow Conditional
IIa B
consideredpriortotheintervention
BPA,balloonpulmonaryangioplasty;CTEPH,chronicthrombo-embolicpulmonaryhypertension;DPAH,drug-associatedpulmonaryarterialhypertension;ERA,endothelinreceptor
antagonist;HPAH,heritablepulmonaryarterialhypertension;HFpEF,heartfailurewithpreservedejectionfraction;ILD,interstitiallungdisease;IPAH,idiopathicpulmonaryarterial
hypertension;PDE5i,phosphodiesterase5inhibitor;PH,pulmonaryhypertension.
aClassofrecommendation.
bLevelofevidence.
2.2. Methods descriptionandsupportivematerial).Theresultingrecommen-
Three main methodological approaches were used in these dationswereratedasstrongorconditional,basedonfourpo-
guidelines,dependingonthetypeofquestionsaddressed: tential levels of evidence (high, moderate, low, or very low;
Tables1and2).AllTaskForcemembersapprovedtherecom-
(i) Fourquestionsthatwereconsideredhighlyimportantwerefor-
mendations.Inaddition,theserecommendationswerealsopre-
mulatedinthePICOformat,andassessedwithfullsystematic
sentedandvotedfollowingtheusualESCapproach.
reviews and application of the Grading of Recommendations,
(ii) Eightquestionsthatwereconsideredofkeyimportance(key
Assessment, Development, and Evaluations (GRADE) ap-
narrativequestions)wereassessedwithsystematicliterature
proach2 and the Evidence to Decision (EtD) framework3 (see searches and application of the EtD framework.6 The evi-
Supplementary Data, Section 2.1 for full methodology
dence grading was performed following the usual ESC
approach.
Table1 Strengthoftherecommendationsaccording (iii) Theremainingtopicsofinterestwereassessedusingtheprocess
toGRADE
commonly followed in ESC Guidelines. Structured literature
searches were undertaken and grading tables, as outlined in
Recommendation Rationale
Tables3and4,werecreatedtodescribelevelofconfidencein
strength
Strongrecommendation Thepaneliscertainthatthedesirable
for outweightheundesirableeffects Table 2 Quality of evidence grades and their
Conditional Thepanelislessconfidentthatthe definitions5
recommendationfor desirableoutweightheundesirable
Quality Definition
effects
Conditional Thepanelislessconfidentthatthe High Weareveryconfidentthatthetrueeffectliesclosetothat
recommendationagainst undesirableoutweighthedesirable oftheestimateoftheeffect
effects Moderate Wearemoderatelyconfidentintheeffectestimate:the
Strongrecommendation Thepaneliscertainthattheundesirable trueeffectislikelytobeclosetotheestimateoftheeffect,
against outweighthedesirableeffects butthereisapossibilitythatitissubstantiallydifferent
Norecommendation Theconfidenceintheresultsmightbe Low Ourconfidenceintheeffectestimateislimited:thetrue
verylowtomakearecommendation,or effectmaybesubstantiallydifferentfromtheestimateof
thetrade-offsbetweendesirableand theeffect
undesirableeffectsarefinelybalanced,or Verylow Wehaveverylittleconfidenceintheeffectestimate:the
nodataareavailable. trueeffectislikelytobesubstantiallydifferentfromthe
AdaptedfromtheERSHandbookforClinicalPracticeGuidelines.4 estimateofeffect
2202SRE/CSE©
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 19 ---
3636 ESC/ERSGuidelines
Table3 Classesofrecommendations
Definition Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered
favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
Table4 Levelsofevidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
therecommendationprovidedandthequalityofevidencesup- fi fi
3. De nitions and classi cations
porting the recommendation. The Task Force discussed each
draftrecommendationduringweb-basedconferencecallsdedi- 3.1. Definitions
catedtospecificsections,followedbyconsensusmodifications
ThedefinitionsforPHarebasedonhaemodynamicassessmentby
andanonlinevoteoneachrecommendation.Onlyrecommen- right heart catheterization (RHC). Although haemodynamics re-
dationsthatweresupportedbyatleast75%oftheTaskForce presentthecentralelementofcharacterizingPH,thefinaldiagnosis
memberswereincludedintheguidelines.Therecommendation andclassificationshouldreflectthewholeclinicalcontextandcon-
tableswerecolour-codedforeaseofinterpretation. sidertheresultsofallinvestigations.
snoitadnemmocer
fo
sessalC
2202
SRE/CSE©
2202
SRE/CSE©
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 20 ---
ESC/ERSGuidelines 3637
Pulmonaryhypertensionisdefinedbyameanpulmonaryarterial maycomprisebothpre-andpost-capillarycomponentscontributing
pressure (mPAP) .20mmHg at rest (Table 5). This is supported toPAPelevation.Inparticular,olderpatientsmaypresentwithsev-
by studies assessing the upper limit of normal pulmonary arterial eralconditionspredisposingthemtoPH.Theprimaryclassification
pressure (PAP) in healthy
subjects,7–9
and by studies investigating shouldbebasedonthepresumedpredominantcauseofthepulmon-
theprognostic relevance ofincreasedPAP (key narrative question arypressureincrease.
1,SupplementaryData,Section3.1).10–12 Post-capillary PH is haemodynamically defined as mPAP
ItisessentialtoincludePVRandpulmonaryarterialwedgepres- .20mmHgandPAWP.15mmHg.Pulmonaryvascularresistance
sure(PAWP)inthedefinitionofpre-capillaryPH,inordertodis- isusedtodifferentiatebetweenpatientswithpost-capillaryPHwho
criminate elevated PAP due to pulmonary vascular disease (PVD) have a significant pre-capillary component (PVR .2 WU—com-
fromthatduetoleftheartdisease(LHD),elevatedpulmonaryblood bined post- andpre-capillary PH [CpcPH])and thosewho do not
flow, or increased intrathoracic pressure (Table 5). Based on the (PVR≤2WU—isolatedpost-capillaryPH[IpcPH]).
availabledata,theupperlimitofnormalPVRandthelowestprognos- There are patients with elevated mPAP (.20mmHg) but low
tically relevant threshold of PVR is (cid:4)2 Wood units (WU).7,8,13,14 PVR(≤2WU)andlowPAWP(≤15mmHg).Thesepatientsarefre-
Pulmonary vascular resistance depends on body surface area and quently characterized by elevated pulmonary blood flow and, al-
age,withelderlyhealthysubjectshavinghighervalues.Theavailable though they have PH, they do not fulfil the criteria of pre- or
dataonthebestthresholdforPAWPdiscriminatingpre-andpost- post-capillaryPH.Thishaemodynamicconditionmaybedescribed
capillaryPHarecontradictory.Althoughtheupperlimitofnormal bytheterm‘unclassifiedPH’.PatientswithunclassifiedPHmaypre-
PAWP is considered to be 12mmHg,15 previous ESC/ERS sentwithcongenitalheartdisease(CHD),liverdisease,airwaydis-
GuidelinesforthediagnosisandtreatmentofPH,aswellasthere- ease, lung disease, or hyperthyroidism explaining their mPAP
cent consensus recommendation of the ESC Heart Failure elevation. Clinical follow-up of these patients is generally recom-
Association,16 suggest a higher threshold for the invasive diagnosis mended.Inthecaseofelevatedpulmonarybloodflow,itsaetiology
of heart failure (HF) with preserved ejection fraction (HFpEF) shouldbeexplored.
(PAWP ≥15mmHg). In addition, almost all therapeutic studies of AsthegroupsofPHaccordingtoclinicalclassificationrepresent
PAHhaveusedthePAWP≤15mmHgthreshold.Therefore,itisre- differentclinicalconditions,theremaybeadditionalclinicallyrelevant
commendedkeepingPAWP≤15mmHgasthethresholdforpre- haemodynamicthresholds(e.g.forPVR)fortheindividualPHgroups
capillaryPH,whileacknowledgingthatanyPAWPthresholdisarbi- besides the general thresholds of the haemodynamic definition of
traryandthatthepatientphenotype,riskfactors,andechocardio- PH,whicharediscussedinthecorrespondingsections.
graphic findings, including left atrial (LA) volume, need to be Exercise PH, defined by an mPAP/cardiac output (CO) slope
consideredwhendistinguishingpre-frompost-capillaryPH. .3mmHg/L/min between rest and exercise,17 has been re-
Patients with PAH are haemodynamically characterized by pre- introduced.ThemPAP/COslopeisstronglyagedependentandits
capillary PH in the absence of other causes of pre-capillary PH, upperlimitofnormalrangesfrom1.6–3.3mmHg/L/mininthesupine
suchasCTEPHandPHassociatedwithlungdiseases.AllPHgroups position.17AnmPAP/COslope.3mmHg/L/minisnotphysiological
insubjectsaged,60yearsandmayrarelybepresentinhealthysub-
jectsaged.60years.17Apathologicalincreaseinpulmonarypres-
sure during exercise is associated with impaired prognosis in
Table 5 Haemodynamic definitions of pulmonary patientswithexercisedyspnoea18andinseveralcardiovascularcon-
hypertension ditions.19–22AlthoughanincreasedmPAP/COslopedefinesanab-
Definition Haemodynamiccharacteristics normal haemodynamicresponse toexercise, itdoes notallowfor
differentiationbetweenpre-andpost-capillarycauses.ThePAWP/
PH mPAP.20mmHg COslopewithathreshold.2mmHg/L/minmaybestdifferentiate
Pre-capillaryPH mPAP.20mmHg betweenpre-andpost-capillarycausesofexercisePH.23,24
PAWP≤15mmHg
PVR.2WU
3.2. Classifications
IpcPH mPAP.20mmHg
The basic structure of the classification from the 2015 ESC/ERS
PAWP.15mmHg
Guidelines for the diagnosis and treatment of PH25,26 and the
PVR≤2WU
Proceedingsofthe6thWSPH1hasbeenkept(Table6).Thegeneral
CpcPH mPAP.20mmHg
purposeoftheclinicalclassificationofPHremainstocategorizeclin-
PAWP.15mmHg
ical conditions associated with PH, based on similar pathophysio-
PVR.2WU
logical mechanisms, clinical presentation, haemodynamic
ExercisePH mPAP/COslopebetweenrestandexercise
characteristics, and therapeutic management (Figure 1). The main
.3mmHg/L/min
changesareasfollows:
CO,cardiacoutput;CpcPH,combinedpost-andpre-capillarypulmonaryhypertension; (i) The subgroups ‘non-responders at vasoreactivity testing’ and
IpcPH,isolatedpost-capillarypulmonaryhypertension;mPAP,meanpulmonaryarterial
pressure;PAWP,pulmonaryarterialwedgepressure;PH,pulmonaryhypertension; ‘acute responders at vasoreactivity testing’ have been added
PVR,pulmonaryvascularresistance;WU,Woodunits. to IPAH as compared with the 2015 ESC/ERS Guidelines for
S loo wm Pe Ap Wati Pen (t ≤s 1p 5re mse mn Htw g)i ;th the isle hv aa et med om dyP nA amP i( c. c2 o0 ndm itm ioH ng m) ab yu bt elo dw esP cV riR be( d≤ b2 yW thU e) tea rn md thediagnosisandtreatmentofPH.25,26Inadditiontopatients
‘unclassifiedPH’(seetextforfurtherdetails). with IPAH, some patients with heritable PAH (HPAH) or
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 21 ---
3638 ESC/ERSGuidelines
Table 6 Clinical classification of pulmonary drug- or toxin-associated PAH (DPAH) might be acute
hypertension responders.
(ii) Thegroups‘PAHwithfeaturesofvenous/capillary(pulmonary
GROUP1Pulmonaryarterialhypertension(PAH)
veno-occlusivedisease/pulmonarycapillaryhaemangiomatosis
1.1Idiopathic
[PVOD/PCH]) involvement’ and ‘persistent PH of the new-
1.1.1Non-respondersatvasoreactivitytesting
born(PPHN)’havebeenincludedingroup1(PAH)ascom-
1.1.2Acuterespondersatvasoreactivitytesting
1.2Heritablea pared with the 2015 ESC/ERS Guidelines for the diagnosis
1.3Associatedwithdrugsandtoxinsa andtreatmentofPHandinlinewiththeProceedingsofthe
6thWSPH.1
1.4Associatedwith:
(iii) Instead of the general term ‘sleep-disordered breathing’, the
1.4.1Connectivetissuedisease
term‘hypoventilationsyndromes’shouldbeusedwithingroup
1.4.2HIVinfection
3todescribeconditionswithincreasedriskofPH.Solenoctur-
1.4.3Portalhypertension
nalobstructivesleepapnoeaisgenerallynotacauseofPH,but
1.4.4Congenitalheartdisease
PHisfrequentinpatientswithhypoventilationsyndromescaus-
1.4.5Schistosomiasis
ingdaytimehypercapnia.
1.5PAHwithfeaturesofvenous/capillary(PVOD/PCH)involvement
1.6PersistentPHofthenewborn
GROUP2PHassociatedwithleftheartdisease 4. Epidemiology and risk factors
2.1Heartfailure:
2.1.1withpreservedejectionfraction Pulmonaryhypertensionisamajorglobalhealthissue.Allagegroups
2.1.2withreducedormildlyreducedejectionfractionb areaffected.PresentestimatessuggestaPHprevalenceof(cid:4)1%of
2.2Valvularheartdisease theglobalpopulation.Duetothepresenceofcardiacandpulmonary
2.3Congenital/acquiredcardiovascularconditionsleadingto causesofPH,prevalenceishigherinindividualsaged.65years.29
post-capillaryPH Globally,LHDistheleadingcauseofPH.29Lungdisease,especially
GROUP3PHassociatedwithlungdiseasesand/orhypoxia chronic obstructive pulmonary disease (COPD), is the second
3.1Obstructivelungdiseaseoremphysema most common cause.29 In the UK, the observed PH prevalence
3.2Restrictivelungdisease hasdoubledinthelast10yearsandiscurrently125cases/millionin-
3.3Lungdiseasewithmixedrestrictive/obstructivepattern habitants.30Irrespectiveoftheunderlyingcondition,developingPH
3.4Hypoventilationsyndromes is associated with worsening symptoms and increased mortality.29
3.5Hypoxiawithoutlungdisease(e.g.highaltitude) Indevelopingcountries,CHD,someinfectiousdiseases(schistosom-
3.6Developmentallungdisorders iasis, human immunodeficiency virus [HIV]), and high altitude re-
GROUP4PHassociatedwithpulmonaryarteryobstructions presentimportantbutunder-studiedcausesofPH.29
4.1Chronicthrombo-embolicPH
4.2Otherpulmonaryarteryobstructionsc
4.1. Group 1, pulmonary arterial
GROUP5PHwithunclearand/ormultifactorialmechanisms
hypertension
5.1Haematologicaldisordersd
Recentregistrydatafromeconomicallydevelopedcountriesindicate
5.2Systemicdisorderse
a PAH incidence and prevalence of (cid:4)6 and 48–55 cases/million 5.3Metabolicdisordersf
adults, respectively.31 It has been thought to predominantly affect
5.4Chronicrenalfailurewithorwithouthaemodialysis
younger individuals, mostly females;32,33 this is currently true for
5.5Pulmonarytumourthromboticmicroangiopathy
HPAH,whichaffectstwiceasmanyfemalesasmales.However,re-
5.6Fibrosingmediastinitis
centdatafromtheUSAandEuropesuggestthatPAHisnowfre-
HF, heart failure; HIV, human immunodeficiency virus; PAH, pulmonary arterial quently diagnosed in older patients (i.e. those aged ≥65 years,
hypertension; PCH, pulmonary capillary haemangiomatosis; PH, pulmonary
whooftenpresentwithcardiovascularcomorbidities,resultingina
hypertension;PVOD,pulmonaryveno-occlusivedisease.
aPatientswithheritablePAHorPAHassociatedwithdrugsandtoxinsmightbeacute more equaldistributionbetween sexes).32 Inmost PAHregistries,
responders. IPAHwasthemostcommonsubtype(50–60%ofallcases),followed
bLeftventricularejectionfractionforHFwithreducedejectionfraction:≤40%;forHF
withmildlyreducedejectionfraction:41–49%. byPAHassociatedwithconnectivetissuedisease(CTD),CHD,and
cOther causes of pulmonary artery obstructions include: sarcomas (high or portalhypertension(porto-pulmonaryhypertension[PoPH]).32
intermediategradeorangiosarcoma),othermalignanttumours(e.g.renalcarcinoma, A number ofdrugs andtoxins are associated with thedevelop-
uterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (e.g.
ment of
PAH.1,34–45
The association between exposure to drugs
uterineleiomyoma),arteritiswithoutconnectivetissuedisease,congenitalpulmonary
arterialstenoses,andhydatidosis.
andtoxinsandPAHisclassifiedasdefiniteorpossible,asproposed
dIncluding inherited and acquired chronic haemolytic anaemia and chronic at the 6th WSPH (Table 7).1 There is a definite association with
myeloproliferativedisorders.
eIncludingsarcoidosis,pulmonaryLangerhans’scellhistiocytosis,andneurofibromatosis drugs,withavailabledatabasedonoutbreaks,epidemiologicalcase-
type1. controlstudies,orlargemulticentreseries.Apossibleassociationis
fIncludingglycogenstoragediseasesandGaucherdisease. suggestedbymultiplecaseseriesorcaseswithdrugswithsimilarme-
chanismsofaction.1
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 22 ---
ESC/ERSGuidelines 3639
PULMONARY HYPERTENSION
Prevalence
Global
11%%
population
Pulmonary congestion in Mortality Hazard Ratio Mortality Hazard Ratio
6 5
post-capillary PH 5 4 4 Right heart
3
3 failure
Pulmonary vascular disease / 2 2
obstruction in pre-capillary PH 1 1
0
10 20 30 40 50 60 0 1 2 3 4 5 6
mPAP (mmHg) PVR (Wood units)
CLINICAL CLASSIFICATION
PH associated with PH with unclear
Pulmonary arterial PH associated with PH associated with
pulmonary and/or multifactorial
hypertension (PAH) left heart disease lung disease arteryobstructions mechanisms
Idiopathic/heritable IpcPH Non-severe PH CTEPH Haematological
Associated CpcPH Severe PH Other pulmonary disorders
conditions obstructions Systemic disorders
PREVALENCE
Rare Very common Common Rare Rare
THERAPEUTIC STRATEGIES
Medical therapy IpcPH: PH-lung disease: Surgical therapy: Optimized
PAH drugs Treatment of LHDa Optimized care of PEA treatment of
CCB in underlying lung Interventional: underlying disease
responders CpcPH: disease BPA
Potentially:PAH
Lung Treatment of LHDa Severe PH: Medical therapy: drugs (trials)
transplantation Potentially:PAH Potentially:PAH PH drugs
drugs (trials) drugs (trials)
Figure1Centralillustration.BPA,balloonpulmonaryangioplasty;CCB,calciumchannelblocker;CTEPH,chronicthrombo-embolicpulmonaryhyper-
tension;CpCPH,combinedpost-andpre-capillarypulmonaryhypertension;IpcPH,isolatedpost-capillarypulmonaryhypertension;LHD,leftheartdis-
ease;PAH,pulmonaryarterialhypertension;PEA,pulmonaryendarterectomy;PH,pulmonaryhypertension.aTreatmentofheartfailureaccordingtothe
ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure.27Treatmentofleft-sidedvalvularheartdiseaseaccordingtothe2021
ESC/EACTSGuidelinesforthemanagementofvalvularheartdisease.28
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 23 ---
3640 ESC/ERSGuidelines
Table7 Drugsandtoxinsassociatedwithpulmonary 4.4. Group 4, pulmonary hypertension
arterialhypertension
associated with chronic pulmonary
Definite Possibleassociation artery obstruction
association ThenumberofpatientsdiagnosedwithCTEPHisincreasing,probably
duetoadeeperunderstandingofthediseaseandmoreactivescreening
Aminorex Alkylatingagents(cyclophosphamide,
for thiscondition in patients who remain dyspnoeic after pulmonary
Benfluorex mitomycinC)a
embolism (PE) or who have risk factors for developing CTEPH.
Dasatinib Amphetamines
RegistrydataindicateaCTEPHincidenceandprevalenceof2–6and
Dexfenfluramine Bosutinib 26–38 cases/million adults, respectively.31,54,55 Patients with chronic
Fenfluramine Cocaine
thrombo-embolic pulmonary disease (CTEPD) without PH still re-
Methamphetamines Diazoxide
presentasmallproportionofthepatientsreferredtoCTEPHcentres.56
Toxicrapeseedoil Direct-actingantiviralagentsagainsthepatitis
Cvirus(sofosbuvir) 4.5. Group 5, pulmonary hypertension
Indirubin(ChineseherbQing-Dai)
with unclear and/or multifactorial
Interferonalphaandbeta
Leflunomide mechanisms
L-tryptophan Group5PHconsistsofacomplexgroupofdisordersthatareasso-
Phenylpropanolamine ciatedwithPH.57Thecauseisoftenmultifactorialandcanbesecondary
Ponatinib toincreasedpre-andpost-capillarypressure,aswellasdirecteffectson
Selectiveproteasomeinhibitors(carfilzomib) pulmonaryvasculature.TheincidenceandprevalenceofPHinmostof
Solvents(trichloroethylene)a thesedisordersareunknown.However,high-qualityregistrieshavere-
StJohn’sWort centlyenabledestimationofPHprevalenceinadultpatientswithsar-
coidosis.58,59StudiessuggestthatPHcanbecommonanditspresence
aPulmonaryveno-occlusivedisease.
isoftenassociatedwithincreasedmorbidityandmortality.58,59
4.2. Group 2, pulmonary hypertension 5. Pulmonary hypertension
associated with left heart disease
diagnosis
In2013,theGlobalBurdenofDiseaseStudyreported61.7million
casesofHFworldwide,whichrepresentedalmostadoublingsince
5.1. Diagnosis
1990.46 In Europe and the USA, .80% of patients with HF are
ThediagnosticapproachtoPHismainlyfocusedontwotasks.The
aged ≥65 years. Post-capillary PH, either isolated or combined
primarygoalistoraiseearlysuspicionofPHandensurefast-track
with a pre-capillary component, is a frequent complication mainly
referral to PH centres in patients with a high likelihood of PAH,
inHFpEF,affectingatleast50%ofthesepatients.47,48Theprevalence
CTEPH, or other forms of severe PH. The second objective is to
ofPHincreaseswithseverityofleft-sidedvalvulardiseases,andPH
identify underlyingdiseases,especiallyLHD(group2PH)and lung
canbefoundin60–70%ofpatientswithsevereandsymptomaticmi-
disease(group3PH),aswellascomorbidities,toensureproperclas-
tralvalvedisease49andinupto50%ofthosewithsymptomaticaor-
sification,riskassessment,andtreatment.
ticstenosis.50
5.1.1.Clinicalpresentation
SymptomsofPHaremainlylinkedtorightventricle(RV)dysfunc-
4.3. Group 3, pulmonary hypertension
tion, and typically associated with exercise in the earlier course of
associated with lung diseases and/or
thedisease.25,26Thecardinalsymptomisdyspnoeaonprogressively
hypoxia minorexertion.Othercommonsymptomsarerelatedtothestages
MildPHiscommoninadvancedparenchymalandinterstitiallungdis-
andseverityofthedisease,andarelistedinFigure2.60–62Potential
ease.Studieshavereportedthat(cid:4)1–5%ofpatientswithadvanced clinical signs and physical findings are summarized in Figure 3.60,61
COPDwithchronicrespiratoryfailureorcandidatesforlungvolume Importantly,thephysicalexaminationmayalsobethekeytoidenti-
reductionsurgeryorlungtransplantation(LTx)haveanmPAP.35– fyingtheunderlyingcauseofPH(seeFigure3).
40mmHg.51,52 In idiopathic pulmonary fibrosis, an mPAP
≥25mmHg has been reported in 8–15% of patients upon initial 5.1.2.Electrocardiogram
work-up, with greater prevalence in advanced (30–50%) and end- Electrocardiogram(ECG)abnormalities(Table8)mayraisesuspicion
stage(.60%)disease.52Hypoxiaisapublichealthproblemforthe of PH, deliver prognostic information, and detect arrhythmias and
estimated 120 million people living at altitudes .2500m. Altitude signsofLHD.InadultswithclinicalsuspicionofPH(e.g.unexplained
dwellersareatriskofdevelopingPHandchronicmountainsickness. dyspnoeaonexertion),rightaxisdeviationhasahighpredictivevalue
However, it remains unclear to what extent PH and right HF are forPH.63AnormalECGdoesnotexcludethepresenceofPH,buta
publichealthproblemsinhigh-altitudecommunities;thisshouldbe normal ECG in combination with normal biomarkers (BNP/
addressed with updated methodology and large-scale population NT-proBNP)isassociatedwithalowlikelihoodofPHinpatientsre-
studies.53 ferredforsuspectedPHoratriskofPH(i.e.afteracutePE).64,65
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 24 ---
ESC/ERSGuidelines 3641
Symptoms
Early
Dyspnoea on exertion (WHO-FC)
Fatigue and rapid exhaustion
Dyspnoea when bending forward (bendopnoea)
Palpitations
Haemoptysis
Exercise-induced abdominal distension and nausea
Weight gain due to fluid retention
Syncope (during or shortly after physical exertion)
Rare symptoms due to pulmonary artery dilationa
Exertional chest pain:
dynamic compression of the left main coronary artery
Late Hoarseness (dysphonia):
compression of the left laryngeal recurrent nerve
(cardiovocal or Ortner´s syndrome)
Shortness of breath, wheezing, cough, lower respiratory
tract infection, atelectasis:
compression of the bronchi
Figure2Symptomsinpatientswithpulmonaryhypertension.WHO-FC,WorldHealthOrganizationfunctionalclass.aThoraciccompressionsyn-
dromes are found in a minority of patients with PAH with pronounced dilation of the pulmonary artery, and may occur at any disease stage and
eveninpatientswithotherwisemildfunctionalimpairment.
5.1.3.Chestradiography InpatientswithPAH,PFTsareusuallynormalormayshowmild
Chestradiographypresentsabnormalfindingsinmostpatientswith restrictive,obstructive,orcombinedabnormalities.71,72Moresevere
PH; however, a normal chest X-ray does not exclude PH.68 PFTabnormalitiesareoccasionallyfoundinpatientswithPAHasso-
Radiographic signs of PH include a characteristic configuration of ciatedwithCHD,73andthosewithgroup3PH.TheDLCOmaybe
the cardiac silhouette due to right heart (right atrium [RA]/RV) normalinpatientswithPAH,althoughitisusuallymildlyreduced.71A
andPAenlargement,sometimeswithpruningoftheperipheralves- severelyreducedDLCO(,45%ofthepredictedvalue)inthepres-
sels.Inaddition,signsoftheunderlyingcauseofPH,suchasLHDor enceofotherwisenormalPFTscanbefoundinPAHassociatedwith
lungdisease,maybefound(Table9).25,26,60,69,70 systemicsclerosis(SSc),PVOD,inPHgroup3—associatedwithem-
physema,interstitiallungdisease(ILD),orcombinedpulmonaryfi-
brosis and emphysema—and in some PAH phenotypes.74 A low
5.1.4.Pulmonaryfunctiontestsandarterialblood DLCO is associated with a poor prognosis in several forms of
gases PH.75–78
Pulmonary function tests (PFTs) and analysis of arterial blood gas PatientswithPAHusuallyhavenormalorslightlyreducedpartial
(ABG)orarterializedcapillarybloodarenecessarytodistinguishbe- pressureofarterialoxygen(PaO ).SeverereductionofPaO might
2 2
tweenPHgroups,assesscomorbiditiesandtheneedforsupplemen- raisesuspicionforpatentforamenovale,hepaticdisease,otherab-
taryoxygen,anddeterminediseaseseverity.Theinitialwork-upof normalities with right-to-left shunt (e.g. septal defect), or
patients with suspected PH should comprise forced spirometry, low-DLCO-associatedconditions.
bodyplethysmography,lungdiffusioncapacityforcarbonmonoxide Partial pressure of arterial carbon dioxide (PaCO ) is typically
2
(DLCO),andABG. lowerthannormalduetoalveolarhyperventilation.79LowPaCO
2
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 25 ---
3642 ESC/ERSGuidelines
Signs of PH SSiiggns of RV backward failure
Central, peripheral, or mixed cyanosis DDiisstended and pulsating jugular veins
Accentuated pulmonary component of tthhee AAbbdominal distension
second heart sound HHeepatomegaly
RV third heart sound AAssccites
Systolic murmur of tricuspid regurgitatioonn PPeerripheral oedema
Diastolic murmur of pulmonary regurgittaattiioonn
Signs pointing towards
SSigns of RV forward failure
underlying cause of PH
Digital clubbing: Cyanotic CHD, fibrotic lluunngg PPeerripheral cyanosis (blue lips and tips)
disease, bronchiectasis, PVOD, or liver ddiisseeaassee DDiizzziness
Differential clubbing/cyanosis: PPaalllor
PDA/Eisenmenger’s syndrome CCoool extremities
Auscultatory findings (crackles or wheeezziinngg,, PPrroolonged capillary refill
murmurs): lung or heart disease
Sequelae of DVT,venous insufficiency: CCTTEEPPHH
Telangiectasia: HHT or SSc
Sclerodactyly, Raynaud’s phenomenon, ddiiggiittaall
ulceration, GORD: SSc
Figure3Clinicalsignsinpatientswithpulmonaryhypertension.CHD,congenitalheartdisease;CTEPH,chronicthrombo-embolicpulmonaryhyper-
tension;DVT,deepvenousthrombosis;GORD,gastro-oesophagealrefluxdisease;HHT,hereditaryhaemorrhagictelangiectasia;PDA,patentductus
arteriosus;PH,pulmonaryhypertension;PVOD,pulmonaryveno-occlusivedisease;RV,rightventricle;SSc,systemicsclerosis.
atdiagnosisandfollow-upiscommoninPAHandassociatedwith tool with which to detect the cause of suspected or confirmed
unfavourable outcomes.80 Elevated PaCO is very unusual in PAH PH,particularlywithrespecttoPHassociatedwithLHDorCHD.
2
andreflectsalveolarhypoventilation,whichinitselfmaybeacause Yet, echocardiography alone is insufficient to confirm a diagnosis
of PH. Overnight oximetry or polysomnography should be per- ofPH,whichrequiresRHC.
formed if there is suspicion of sleep-disordered breathing or GiventheheterogeneousnatureofPHandthepeculiargeom-
hypoventilation.81 etry of the RV, there is no single echocardiographic parameter
that reliably informs about PH status and underlying aetiology.
5.1.5.Echocardiography Therefore,acomprehensiveechocardiographicevaluationforsus-
Independent of the underlying aetiology, PH leads to RV pressure pected PH includes estimating the systolic pulmonary arterial
overload and dysfunction, which can be detected by echocardiog- pressure (sPAP) and detecting additional signs suggestive of PH,
raphy.82–84Whenperformedaccurately,echocardiographyprovides aiming at assigning an echocardiographic level of probability of
comprehensiveinformationonrightandleftheartmorphology,RV PH. Echocardiographic findings of PH, including estimating pres-
and LV function, and valvular abnormalities, and gives estimates of sureandsignsofRVoverloadand/ordysfunction,aresummarized
haemodynamic parameters. Echocardiography is also a valuable in Figure 4.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 26 ---
ESC/ERSGuidelines 3643
Table8 Electrocardiogramabnormalitiesinpatients recommend using the peak TRV (and not the estimated sPAP) as
withpulmonaryhypertension the key variable for assigning the echocardiographic probability of
PH.ApeakTRV.2.8m/smaysuggestPH;however,thepresence
TypicalECGabnormalitiesinPH66
or absence of PH cannot be reliably determined by TRV alone.88
(cid:129) Ppulmonale(P.0.25mVinleadII) LoweringtheTRVthresholdinviewoftherevisedhaemodynamic
(cid:129) Rightorsagittalaxisdeviation(QRSaxis.90°orindeterminable) definition of PH is not supported by available data (key narrative
(cid:129) RVhypertrophy(R/S.1,withR.0.5mVinV1;RinV1+SinleadV5
question2,SupplementaryData,Section5.1).89–92Tricuspidregurgi-
.1mV) tation(TR)velocitymayunderestimate(e.g.inpatientswithsevere
(cid:129) Rightbundlebranchblock—completeorincomplete(qRorrSR TR)28oroverestimate(e.g.inpatientswithhighCOinliverdisease
patternsinV1)
orsicklecelldisease[SCD],93,94misinterpretationoftricuspidvalve
(cid:129) RVstrainpatterna(STdepression/T-waveinversionintheright closureartefactfortheTRjet,orincorrectassignmentofapeakTRV
pre-cordialV1–4andinferiorII,III,aVFleads) inthecaseofmaximumvelocityboundaryartefacts)pressuregradi-
(cid:129) ProlongedQTcinterval(unspecific)b ents.Hence,additionalvariablesrelatedtoRVmorphologyandfunc-
tion are used to define the echocardiographic probability of PH
ECG,electrocardiogram;PH,pulmonaryhypertension;QTc,correctedQTinterval; (Table10),82–84,95whichmaythenbedeterminedaslow,intermedi-
RV,rightventricular.
aPresentinadvancedPH. ate,orhigh.Wheninterpretedinaclinicalcontext,thisprobability
bPatientswithpulmonaryarterialhypertensioncanpresentwithaprolongedQTc can be used to decide the need for further investigation, including
interval (although non-specific), which may reflect RV dysfunction and delayed
cardiaccatheterizationinindividualpatients(Figure5). myocardialrepolarization,andisanindependentpredictorofmortality.67
EchocardiographicmeasuresofRVfunctionincludethetricuspid
annularplanesystolicexcursion(TAPSE),RVfractionalareachange
(RV-FAC), RV free-wall strain, and tricuspid annulus velocity (S′
wave)derivedfromtissueDopplerimaging,andpotentiallyRVejec-
tion fraction (RVEF) derived from 3D echocardiography.
Table9 Radiographicsignsofpulmonaryhyperten-
Furthermore, the TAPSE/sPAP ratio—representing a non-invasive
sionandconcomitantabnormalities
measure of RV–PA coupling96—may aid in diagnosing PH.90,97,98
SignsofPHand Signsofleftheart Signsoflung The pattern of RV outflowtract (RVOT) blood flow (mid-systolic
concomitant disease/ disease
‘notching’)maysuggestpre-capillaryPH.99,100
abnormalities pulmonary Toseparatebetweengroup2PHandotherformsofPH,andto
congestion assess the likelihoodof left ventricle (LV) diastolic dysfunction, LA
size and signs of LV hypertrophy should always be measured, and
Rightheart Centralairspace Flatteningof Dopplerechocardiographicsigns(e.g.E/Aratio,E/E′)shouldbeas-
enlargement opacification diaphragm(COPD/ sessedevenifthereliabilityofthelatterisconsideredlow.16Toiden-
emphysema)
tify CHD, 2D Doppler and contrast examinations are helpful, but
PAenlargement Interlobularseptal Hyperlucency
transoesophagealcontrastechocardiographyorotherimagingtech-
(includinganeurysmal thickening‘KerleyB’ (COPD/
niques (e.g. computer tomography [CT] angiography, cMRI) are
dilatation) lines emphysema)
neededinsomecasestodetectorexcludesinusvenosusatrialseptal
Pruningofthe Pleuraleffusions Lungvolumeloss defects,patentductusarteriosus,and/oranomalouspulmonaryven-
peripheralvessels (fibroticlung ous return.101 The clinical value of exercise Doppler echocardiog-
disease) raphy in identifying exercise PH remains uncertain because of the
‘Water-bottle’shape Leftatrial Reticular lack of validated criteria and prospective confirmatory data. In
ofcardiacsilhouettea enlargement opacification mostcases,increasesinsPAPduringexercisearecausedbydiastolic
(includingsplayed (fibroticlung LVdysfunction.16
carina) disease)
Leftventricular 5.1.6.Ventilation/perfusionlungscan
dilation A ventilation/perfusion (V/Q) lung scan (planar or single-photon
emission computed tomography[SPECT]) is recommendedin the
COPD,chronicobstructivepulmonarydisease;PA,pulmonaryartery;PH,pulmonary
hypertension. diagnosticwork-upofpatientswithsuspectedornewlydiagnosed
aMay be present in patients with PH with advanced right ventricular failure and PH, to rule out or detect signs of CTEPH.102,103 The V/Q SPECT
moderatepericardialeffusion.
issuperiortoplanarimagingandisthemethodologyofchoice;how-
ever,SPECThasbeenwidelyevaluatedinassessingPE,butnottothe
samedegreeinCTEPH.68 In theabsenceofparenchymallung dis-
EstimatesofsPAParebasedonthepeaktricuspidregurgitation ease,anormalperfusionscanexcludesCTEPHwithanegativepre-
velocity(TRV)andtheTRV-derivedtricuspidregurgitationpressure dicted value of 98%.104,105 In most patients with PAH, V/Q
gradient(TRPG)—afterexcludingpulmonarystenosis—takinginto scintigraphy is normal or shows a speckled pattern but no typical
accountnon-invasiveestimatesofRApressure(RAP).Considering perfusiondefectscharacteristicofPEorCTEPH,whereasmatched
theinaccuraciesinestimatingRAPandtheamplificationofmeasure- V/Qdefectsmaybe foundinpatientswith lungdisease (i.e.group
ment errors by using derived
variables,85–87
these guidelines 3 PH). Non-matched perfusion defects similar to those seen in
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 27 ---
3644 ESC/ERSGuidelines
A B C D
RV
RV LV
RV IVC
LV RA
Ao
LV RA
LA
Flattened interventricular septum
Dilated RV with basal RV/LV Distended inferior vena cava
Enlarged right ventricle; (arrows) leading to‘D-shaped’ LV;
ratio >1.0; with diminished inspiratory
parasternal long-axis view decreased LV eccentricity index;
four-chamber view collapsibility; subcostal view
parasternal short-axis view
E F G M-Mode H
RV S’
RV LV
RA
RA A’
TAPSE
E’
RVOT AT <105 ms <18 mm
‘notch’ Diastole Systole S’ <9.5 cm/s
RVOT acceleration time of Decreased peak systolic (S’)
Reduced right ventricular Decreased tricuspid annular
pulmonary ejection <105 ms velocity of tricuspid annulus
fractional area change (<35%); plane systolic excursion (TAPSE)
mid-systolic‘notch’ indicative of (<9.5 cm/s) measured with
four-chamber view measured with M-Mode (<18 mm)
pre-capillary PH tissue Doppler
I End-systolic J K Estimated RAP L
RV RV IVC RA RV RV
RV
LV
RA
IVC Collapsea eRAP
RA <2.1 cm >50% 3 (0-5)
>2.1 cm >50% 8 (5-10)
RA >18 cm2 PeakTRV PeakTRV >2.1 cm <50% 15 (10-20)
>2.8 m/s >2.8 m/s
Increased systolic peak tricuspid Estimation of systolic pulmonary Presence of pericardial effusion;
Enlarged right atrial area
regurgitation velocity (peakTRV); artery pressure (sPAP); four-chamber view;
(>18 cm2);
measured with continuous sPAP =TR pressure gradient + parasternal short-axis view;
four-chamber view
wave Doppler estimated RAP other views (e.g. subcostal view)
Figure4Transthoracicechocardiographicparametersintheassessmentofpulmonaryhypertension.Ao,aorta;IVC,inferiorvenacava;LA,leftatrium;
LV,leftventricle;PH,pulmonaryhypertension;RA,rightatrium;RAP,rightatrialpressure;RV,rightventricle;RVOTAT,rightventricularoutflowtract
accelerationtime;sPAP,systolicpulmonaryarterypressure;TAPSE,tricuspidannularplanesystolicexcursion;TR,tricuspidregurgitation;TRV,tricuspid
regurgitationvelocity.aReferstocollapseoninspiration.
CTEPHmaybepresentin7–10%ofpatientswithPVOD/PCHor features of parenchymal lung disease, and may also point towards
PAH.106,107Depositionoftheperfusionagentinextrapulmonaryor- thepresenceofPVOD/PCHbyshowingcentrilobularground-glass
gansmayhinttocardiacorpulmonaryright-to-leftshuntingandhas opacities (which may also be found in PAH), septal lines, and
beenreportedinCHD,hepato-pulmonarysyndrome,andpulmon- lymphadenopathy.68
aryarteriovenousmalformations(PAVMs).68 Computedtomographypulmonaryangiography(CTPA)ismainly
usedtodetectdirectorindirectsignsofCTEPH,suchasfillingde-
5.1.7.Non-contrastandcontrast-enhancedchest fects (including thrombus adhering to the vascular wall), webs or
computedtomographyexaminations,anddigital bandsinthePAs,PAretraction/dilatation,mosaicperfusion,anden-
subtractionangiography larged bronchial arteries. Importantly, the diagnostic accuracy of
Computedtomography(CT)imagingmayprovideimportantinfor- CTPAforCTEPHislimited(atthepatientlevel,sensitivityandspe-
mation for patients with unexplained dyspnoea or suspected/con- cificity are 76% and 96%, respectively),109 but was reported to be
firmedPH.TheCTsignssuggestingthepresenceofPHincludean higher when modern, high-quality multi-detector CT scanners
enlargedPAdiameter,aPA-to-aortaratio.0.9,andenlargedright were used and when interpreted by experienced readers.109,110
heartchambers.68Acombinationofthreeparameters(PAdiameter Computed tomography pulmonary angiography may also be used
≥30mm,RVOTwallthickness≥6mm,andseptaldeviation≥140° to detect other cardiovascularabnormalities, including intracardiac
[or RV:LV ratio ≥1]) is highly predictive of PH.108 Non-contrast shunts,abnormalpulmonaryvenousreturn,patentductusarterio-
chest CT can help determine the cause of PH when there are sus,andPAVMs.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 28 ---
ESC/ERSGuidelines 3645
Table 10 Additional echocardiographic signs sug- InpatientspresentingwithaclinicalpictureofacutePE,chestCT
gestiveofpulmonaryhypertension may be helpful in detecting signs of hitherto undetected CTEPH,
which may include the presence of the above CTEPH signs, and
A:Theventricles B:Pulmonary C:Inferiorvena RVhypertrophyasasignforchronicity.111,112Detecting‘acuteon
artery cavaandRA chronic’ PE is important, as it may impact the management of pa-
RV/LVbasaldiameter/ RVOTAT IVCdiameter tientswithpresumedacutePE.
arearatio.1.0 ,105msand/or .21mmwith Dual-energyCT(DECT)angiographyandiodinesubtractionmap-
mid-systolic decreasedinspiratory pingmayprovideadditionaldiagnosticinformationbycreatingiodine
notching collapse(,50%with maps,113whichreflectlungperfusion,therebypossiblyincreasingthe
asniffor,20%with diagnostic accuracy for CTEPH.114 Although increasingly used, the
quietinspiration) diagnostic value of DECT in the work-up of patients with PH has
notbeenestablished.
Flatteningofthe Earlydiastolic RAarea(end-systole)
interventricular pulmonary .18cm2
Digitalsubtractionangiography(DSA)ismainlyusedtoconfirm
septum(LVEI.1.1in regurgitation thediagnosisofCTEPHandtoassesstreatmentoptions(i.e.oper-
systoleand/ordiastole) velocity.2.2m/s ability or accessibility for BPA). Most centres use conventional
TAPSE/sPAPratio PAdiameter.AR two-orthree-planarDSA.However,C-armCTimagingmaypro-
,0.55mm/mmHg diameter vide a higher spatial resolution, potentially identifying more target
vesselsforBPAandprovidingproceduralguidance.115,116
PAdiameter
.25mm
5.1.8.Cardiacmagneticresonanceimaging
AR,aorticroot;IVC,inferiorvenacava;LV,leftventricle;LVEI,leftventricleeccentricity
index;PA,pulmonaryartery;RA,rightatrium;RV,rightventricle;RVOTAT,right Cardiacmagneticresonanceimagingaccuratelyandreproduciblyas-
ventricular outflow tract acceleration time; sPAP, systolic pulmonary arterial sesses atrial and ventricular size, morphology, and function.
pressure; TAPSE, tricuspid annular plane systolic excursion; TRV, tricuspid
AdditionalinformationonRV/LVmyocardialstraincanbeobtained
regurgitationvelocity.
aSignscontributingtoassessingtheprobabilityofPHinadditiontoTRV(seeFigure5). by applying tagging or by post-processing feature tracking. In add-
Signs from at least two categories (A/B/C) must be present to alter the level of ition, cMRI can be used to measure blood flow in the PA, aorta,
echocardiographicprobabilityofPH.
and vena cava, allowing for quantifying stroke volume (SV),
Peak tricuspid regurgitation velocity (m/s)
≤2.8a 2.9–3.4 >3.4
Presence of other echo PH signsb (seeTTTable 10)
Y Y YYYes/No
N N
PH PRRROBABILITY PH PRRROBABILITY PH PRRROBABILITY
LOW INTERMEDIAAATE HIGH
Risk factors or associated coonditionsfffor PPPAH or CTEPH
Y Y YYYes/No
N N
Further interventionc/
Alternative diagnosis Echofffollow-up
RHC (if indicatedd)
(Class IIa) (Class IIa)
(Class I)
Figure5Echocardiographicprobabilityofpulmonaryhypertensionandrecommendationsforfurtherassessment.CPET,cardiopulmonaryexercise
testing;CTEPH,chronicthrombo-embolicpulmonaryhypertension;echo,echocardiography;LHD,leftheartdisease;N,no;PAH,pulmonaryarterial
hypertension; PH, pulmonary hypertension; RHC, right heart catheterization; TRV, tricuspid regurgitation velocity; Y, yes. aOr unmeasurable. The
TRVthresholdof2.8m/swasnotchangedaccordingtotheupdatedhaemodynamicdefinitionofPH.bSignsfromatleasttwocategoriesinTable10
(A/B/C)mustbepresenttoalterthelevelofechocardiographicprobabilityofPH.cFurthertestingmaybenecessary(e.g.imaging,CPET).dRHCshould
beperformedifusefulinformation/atherapeuticconsequenceisanticipated(e.g.suspectedPAHorCTEPH),andmaynotbeindicatedinpatientswithout
riskfactorsorassociatedconditionsforPAHorCTEPH(e.g.whenmildPHandpredominantLHDorlungdiseasearepresent).
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 29 ---
3646 ESC/ERSGuidelines
intracardiacshunt,andretrogradeflow.Bycombiningcontrastmag- 5.1.12.Rightheartcatheterization,vasoreactivity,
neticresonance(MR)angiographyandpulmonaryperfusionimaging exercise,andfluidchallenge
with late gadolinium-enhancement imaging of the myocardium, a 5.1.12.1.Rightheartcatheterization
completepictureoftheheartandpulmonaryvasculaturecanbeob- Right heart catheterization is the gold standard for diagnosing and
tained(seeSupplementaryData,TableS2forcMRIindicesandnor- classifying PH. Performing RHC requires expertise and meticulous
malvalues).Alimitationisthatthereisnoestablishedmethodwith methodologyfollowingstandardizedprotocols.Inadditiontodiag-
whichtoestimatePAP.Eventhoughthecostandavailabilityofthe nosingandclassifyingPH,clinicalindicationsincludehaemodynamic
techniqueprecludesitsuseintheearlydiagnosisofPAH,itissensi- assessmentofheartorLTxcandidates124andevaluatingcongenital
tiveindetectingearlysignsofPHanddiagnosingCHD.117 cardiac shunts. Interpreting invasive haemodynamics should be
doneinthecontextoftheclinicalpictureandotherdiagnosticinves-
tigations.WhenperformedinPHcentres,thefrequenciesofserious
5.1.9.Bloodtestsandimmunology adverseevents(1.1%)andprocedure-relatedmortality(0.055%)are
The initial diagnostic assessment of patients with newly diagnosed low.125AknownthrombusortumourintheRVorRA,recentlyim-
PH/PAHaimstoidentifycomorbiditiesandpossiblecausesorcom- planted (,1 month) pacemaker, mechanical right heart valve,
plicationsofPH.Laboratoryteststhatshouldbeobtainedatthetime TriClip, and an acute infection are contraindications to RHC; the
ofPHdiagnosisinclude:bloodcounts(includinghaemoglobin[Hb]); risk:benefitratioshouldbeindividuallyassessedbeforeeachexamin-
serumelectrolytes(sodium,potassium);kidneyfunction(creatinine, ationanddiscussedwiththepatient.Themostfearedcomplication
calculation of estimated glomerular filtration rate, and urea); uric ofRHCisperforationofaPA.
acid; liver parameters (alanine aminotransferase, aspartate amino- Theadequatepreparationofpatients forRHCisofmajorrele-
transferase,andalkalinephosphatase,γ-glutamyltranspeptidase,bili- vance.Pre-existingmedicalconditionsshouldbeoptimallycontrolled
rubin); ironstatus (serumiron, transferrin saturation, andferritin); atthetimeoftheexamination(particularlybloodpressureandvol-
andBNPorNT-proBNP.Inaddition,serologicalstudiesshouldin- umecontrol).Inthesupineposition,themid-thoraciclevelisrecom-
cludetestingforhepatitisvirusesandHIV.Basicimmunologylabora- mendedasthezeroreferencelevel,whichisattheleveloftheLAin
tory work-up is recommended, including screening tests for mostpatients.126
anti-nuclear antibodies, anti-centromere antibodies, and anti-Ro. Foracompleteassessmentofcardiopulmonaryhaemodynamics,
Screeningforbiologicalmarkersofantiphospholipidsyndromeisre- all measures listed in Table 11 must be measured or calculated.
commended in patients with CTEPH. Additional thrombophilia
screeningisnotgenerallyrecommended,unlesstherapeuticconse-
quences are to be expected.118 Pulmonary arterial hypertension
andotherformsofseverePHcanbeassociatedwiththyroidfunc- Table11 Haemodynamicmeasuresobtainedduring
tion disorders; hence, laboratory screening should include at least rightheartcatheterization
thyroid-stimulatinghormone.
Measuredvariables Normalvalue
Rightatrialpressure,mean(RAP) 2–6mmHg
5.1.10.Abdominalultrasound
Pulmonaryarterypressure,systolic(sPAP) 15–30mmHg
Anabdominalultrasoundexaminationshouldbepartofthecompre-
Pulmonaryarterypressure,diastolic(dPAP) 4–12mmHg
hensive diagnostic work-up of patients with newly diagnosed PH,
Pulmonaryarterypressure,mean(mPAP) 8–20mmHg
particularlyifliverdiseaseissuspected.Amajorobjectiveistosearch
Pulmonaryarterialwedgepressure,mean(PAWP) ≤15mmHg
for liver disease and/or portal hypertension, or portocaval shunt
Cardiacoutput(CO) 4–8L/min
(Abernethy malformation). During the course of the disease, pa-
tientswithPHmaydevelopsecondaryorgandysfunctionmainlyaf- Mixedvenousoxygensaturation(SvO 2)a 65–80%
fecting the liver and kidneys.119 In these patients, abdominal Arterialoxygensaturation(SaO 2) 95–100%
ultrasoundisneededfordifferentialdiagnosticreasonsandtoassess Systemicbloodpressure 120/80mmHg
theextentoforgandamage. Calculatedparameters
Pulmonaryvascularresistance(PVR)b 0.3–2.0WU
Pulmonaryvascularresistanceindex(PVRI) 3–3.5WU·m2
5.1.11.Cardiopulmonaryexercisetesting
Totalpulmonaryresistance(TPR)c ,3WU
Cardiopulmonaryexercisetesting(CPET)isausefultooltoassess
Cardiacindex(CI) 2.5–4.0L/min·m2
theunderlyingpathophysiologicmechanismsleadingtoexercisein-
Strokevolume(SV) 60–100mL
tolerance.PatientswithPAHshowatypicalpattern,withalowend-
tidal partial pressure of carbon dioxide (P CO ), high ventilatory Strokevolumeindex(SVI) 33–47mL/m2
ET 2
equivalentforcarbondioxide(VE/VCO ),lowoxygenpulse(VO / Pulmonaryarterialcompliance(PAC)d .2.3mL/mmHg
2 2
HR),andlowpeakoxygenuptake(VO ).120Thesefindingsshould
2 WU,Woodunits.
prompt consideration of PVD. In patients with LHD or COPD, aDerived from blood sample taken from the pulmonary artery; compartmental
suchapatternmayindicateanadditionalpulmonaryvascularlimita-
oximetrytoexcludeanintracardiacshuntisrecommendedwhenSvO2.75%.
tion.121,122InpopulationsatriskofPAH,suchasthosewithSSc,a
bPVR,(mPAP−PAWP)/CO.
cTPR,mPAP/CO.
normalpeakVO 2seemstoexcludethediagnosisofPAH.123 dPAC,SV/(sPAP−dPAP).
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 30 ---
ESC/ERSGuidelines 3647
Incompleteassessments mustbe avoided,asthis maylead to mis- exercisePH.133ThemainreasontoperformexerciseRHCistoin-
diagnosis. As a minimum, mixed venous oxygen saturation (SvO ) vestigate patients with unexplained dyspnoea and normal resting
2
andarterialoxygensaturation(SaO )shouldbedetermined.Astep- haemodynamicsinordertodetectearlyPVDorleftheartdysfunc-
2
wise assessment of oxygen saturation should be performed in pa- tion. In addition, exercise haemodynamics may reveal important
tients with SvO .75% and whenever a left-to-right shunt is prognostic and functional information in patients at risk of PAH
2
suspected. Cardiac output (CO) should be assessed by the direct andCTEPH.22,134,135Tomaximizetheamountofinformation,exer-
Fickmethodorthermodilution(meanvaluesofatleastthreemea- ciseRHCmaybecombinedwithCPET.Accordingtotheavailable
surements).TheindirectFickmethodisconsideredtobelessreliable data and experience, exercise RHC is not associated with an add-
thanthermodilution;127however,thermodilutionshouldnotbeused itional risk of complications compared with resting RHC and
in the presence of shunts. Pulmonary vascular resistance CPET.133
([mPAP−PAWP]/CO) should be calculated for each patient. All Incrementalexercisetests(steporrampprotocol)withrepeated
pressuremeasurements,includingPAWP, shouldbe performedat haemodynamicmeasurementsprovidethemostclinicalinformation
end expiration (without breath-holding manoeuvre). In patients on pulmonary circulation. The minimally required haemodynamic
withlargeintrathoracicpressurechangesduringtherespiratorycy- variablesmeasuredateachexerciselevelincludemPAP,sPAP,dia-
cle(i.e.COPD,obesity,duringexercise),itisappropriatetoaverage stolicPAP(dPAP),PAWP,CO,heartrate,andsystemicbloodpres-
over at least three to four respiratory cycles.If no reliable PAWP sure.Inaddition,RAP,SvO ,andSaO shouldatleastbemeasuredat
2 2
curvecanbeobtained,orifthePAWPvaluesareimplausible,add- restandpeakexercise.Totalpulmonaryresistance(TPR),PVR,and
itionalmeasurementofLVend-diastolicpressureshouldbeconsid- cardiacindex(CI)shouldbecalculatedateachexerciselevel,aswell
eredtoavoidmisclassification.Saturationstakenwiththecatheterin asarteriovenousdifferenceinoxygenatpeakexercise.ThemPAP/
thewedgedpositioncanconfirmanaccuratePAWP.128 CO and PAWP/CO slopes should also be calculated.136,137 In pa-
tients with early PVD, PVR may be normal or mildly elevated at
5.1.12.2.Vasoreactivitytesting rest, but may change during exercise with a steep increase in
mPAP, reflected by an mPAP/CO slope .3mmHg/L/min, while
ThepurposeofvasoreactivitytestinginPAHistoidentifyacutevasor-
the PAWP/CO slope usually remains ,2mmHg/L/min. Patients
esponderswhomaybecandidatesfortreatmentwithhigh-dosecal-
withleftheartdysfunction,suchasthosewithHFpEF23and/ordy-
cium channel blockers (CCBs). Pulmonary vasoreactivity testing is
namic mitral regurgitation,138 and a normal PAWP at rest, usually
only recommended in patients with IPAH, HPAH, or DPAH.
Inhalednitricoxide129orinhalediloprost130,131aretherecommended show a steep increase in mPAP and PAWP (and mPAP/CO,
PAWP/COslope)duringexercise.
testcompoundsforvasoreactivitytesting(Table12).Thereissimilar
Accordingtorecentstudies,aPAWP/COslope.2mmHg/L/min
evidenceforintravenous(i.v.)epoprostenol,butduetoincremental
may be helpful in recognizing an abnormal PAWP increase and,
doseincreasesandrepetitivemeasurements,testingtakesmuchlong-
erandisthereforelessfeasible.129Adenosinei.v.isnolongerrecom- therefore, a cardiac exercise limitation, especially in patients with
mendedduetofrequentsideeffects.132Apositiveacuteresponseis PAWP 12–15mmHg at rest.23,24,139 A PAWP cut-off of
definedasareductioninmPAPby≥10mmHgtoreachanabsolute
.25mmHgduringsupineexercisehasbeenrecommendedfordiag-
value ≤40mmHg, with increased or unchanged CO.129 In patients nosingHFpEF.16Inpatientswithlungdisease,increasedintrathoracic
pressuremaycontributetomPAPelevation;thisisexaggerateddur-
withPH-LHD,vasoreactivitytestingisrestrictedtoevaluatingheart
ing exercise and can be recognized by a concomitant increase in
transplantation candidacy (see Section 8.1), and in patients with PH
RAP.140 Some exercise haemodynamics are age dependent, with
inthecontextofCHDwithinitialsystemic-to-pulmonaryshunting,va-
healthy elderly subjects presenting with steeper mPAP/CO and
soreactivitytestingcanbeperformedtoevaluatethepossibilityofde-
fectclosure(seeSection7.5).101
PAWP/COslopesthanhealthyyoungindividuals.9,141
5.1.12.3.Exerciserightheartcatheterization 5.1.12.4.Fluidchallenge
Rightheartcatheterizationisthegoldstandardmethodtoassesscar- FluidchallengemayrevealLVdiastolicdysfunctioninpatientswith
diopulmonary haemodynamics during exercise and to define PAWP ≤15mmHg, but a clinical phenotype suggestive of LHD.
Table12 Routeofadministration,half-life,dosages,anddurationofadministrationoftherecommendedtestcom-
poundsforvasoreactivitytestinginpulmonaryarterialhypertension
Compound Route Half-life Dosage Duration
Nitricoxide129 inh 15–30s 10–20p.p.m. 5–10mina
Iloprost130,131 inh 30min 5–10µgb 10–15minc
Epoprostenol129 i.v. 3min 2–12ng/kg/min 10mind
Inh,inhaled;i.v.,intravenous.
aMeasurementasasinglestepwithinthedoserange.
bAtmouthpiece.
cMeasurementasasinglestep,temporizefulleffect.
dIncrementalincreasein2ng/kg/minintervals,durationof10minateachstep.
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 31 ---
3648 ESC/ERSGuidelines
Most available data are derived from studies aiming to uncover screening recommendations herein specifically relate to patients
HFpEF(increaseinPAWP)ratherthanidentifygroup2PH(increase withanaprioridiagnosisofPAHandnot‘at-risk’populationsbeing
inPAP;seeSection8.1).Itisgenerallyacceptedthatrapidinfusion screenedforPAH(seeSection5.3).Allpatientswiththeseconditions
(over5–10min)of(cid:4)500mL(7–10mL/kg)ofsalinewouldbesuffi- shouldbeinformedaboutthepossibilityofageneticconditionand
cienttodetectanabnormalincreaseinPAWPto≥18mmHg(sug- thatfamilymemberscouldcarryamutationthatincreasestherisk
gestiveofHFpEF),142althoughvalidationandlong-termevaluationof ofPAH,allowingforscreeningandearlydiagnosis.33,148Evenifgen-
thesedataareneeded.143Thereareinsufficientdataonthehaemo- etictestingisnotperformed,familymembersshouldbemadeaware
dynamic response to fluid challenge in patients with PAH. Recent ofearlysignsandsymptoms,toensurethatatimelyandappropriate
datasuggestthatpassivelegraiseduringRHCmayalsohelptoun- diagnosisismade.148
coveroccultHFpEF.144 GeneticcounsellingbyappropriatelytrainedPAHprovidersorge-
neticistsshouldbeperformedpriortogenetictesting,toaddressthe
Recommendation Table 1 — Recommendations for complex questions related to penetrance, genetically at-risk family
rightheartcatheterizationandvasoreactivitytesting members,reproduction,geneticdiscrimination,andpsychosocialis-
sues.Carefulgeneticcounsellingwithgeneticcounsellorsormedical
Recommendations Classa Levelb geneticistsiscriticalpriortogenetictestingforasymptomaticfamily
members.148
Rightheartcatheterization
Ifthefamilialmutationisknownandanunaffectedfamilymember
ItisrecommendedthatRHCisperformedto testsnegativeforthatmutation,theriskofPAHforthatpersonisthe
confirmthediagnosisofPH(especiallyPAHor I B sameasforthegeneralpopulation.148
CTEPH)andtosupporttreatmentdecisions25,26
Manyofthelesscommonmutationsoutlinedhaveapotentialadd-
InpatientswithsuspectedorknownPH,itis itionalsetofsyndromicfeatures.ThesearesummarizedinTable13
recommendedthatRHCisperformedin I C where specific clinical history, examination, and investigations are
experiencedcentres125 suggested.Inparticular,cliniciansshouldundertakeathoroughhis-
ItisrecommendedthatRHCcomprisesa toryandexamination,assyndromicPAHdiagnosesmaybemissed
completesetofhaemodynamicsandisperformed I C if not interrogated. For example, in one of the largest studies to
followingstandardizedprotocols25,26,145 date,TBX4,ALK1,andENGmutationswererepresentedinthetop
Vasoreactivitytesting
sixmostcommongeneticfindingsinadultswithpreviouslydiagnosed
IPAH.149Thesefindingshavebeenconfirmedandextendedininter-
Vasoreactivitytestingisrecommendedinpatients
nationalgeneticsconsortiain4241patientswithPAH.150Itisthere-
withI/H/DPAHtodetectthosewhocanbe I B
foreapparentthatthereiseitherphenotypicheterogeneityofthese
treatedwithhighdosesofaCCB129,146
syndromesormisseddiagnosticfeatures.Asmoregenesassociated
Itisrecommendedthatvasoreactivitytestingis
I C withPAHarediscovered,itwillbecomeincreasinglydifficulttoindi-
performedatPHcentres
viduallytestforeach.Next-generationsequencinghasenabledthe
Itisrecommendedtoconsiderapositiveresponse
development of gene panels to simultaneously interrogate several
tovasoreactivitytestingbyareductioninmPAP
genes.151 It is, however, important to check the genes included in
≥10mmHgtoreachanabsolutevalueofmPAP I C
the panel at the time of testing, since the composition changes as
≤40mmHgwithanincreasedorunchanged
geneticdiscoveriesadvance.
COc129
Inhalednitricoxide,inhalediloprost,ori.v. 5.2. Diagnostic algorithm
epoprostenolarerecommendedforperforming I C
Amultistep,pragmaticapproachtodiagnosisshouldbeconsidered
vasoreactivitytesting129–132
inpatientswithunexplaineddyspnoeaorsymptoms/signsraisingsus-
Vasoreactivitytesting,foridentifyingcandidates
picion of PH. This strategy is depicted in detail in Figure 6 and
forCCBtherapy,isnotrecommendedinpatients
III C Table 14. The diagnostic algorithm does not address screening for
withPAHotherthanI/H/DPAH,andinPHgroups specificgroupsatriskofPH.
2,3,4,and5124,129
5.2.1Step1(suspicion)
CCB,calciumchannelblocker;CO,cardiacoutput;CTEPH,chronicthrombo-embolic
pulmonaryhypertension;I/H/DPAH,idiopathic,heritable,drug-associatedpulmonary PatientswithPHarelikelytobeseenbyfirst-linephysicians,mainly
arterial hypertension; i.v., intravenous; mPAP, mean pulmonary arterial pressure; general practitioners, for non-specific symptoms. Initial evaluation
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right
heartcatheterization. shouldincludeacomprehensivemedical(includingfamilial)history,
aClassofrecommendation. thorough physical examination (including measurement of blood
bLevelofevidence.
pressure,heartrate,andpulseoximetry),bloodtesttodetermine
cTestingshouldalsobeperformedinpatientswithabaselinemPAP≤40mmHg,in
whomthesamerespondercriteriaapply.
BNP/NT-proBNP,andrestingECG.Thisfirststepmayraiseasuspi-
cionofacardiacorrespiratorydisordercausingthesymptoms.
5.1.13.Geneticcounsellingandtesting 5.2.2.Step2(detection)
MutationsinPAHgeneshavebeenidentifiedinfamilialPAH,IPAH, Thesecondstepincludesclassical,non-invasivelungandcardiactest-
PVOD/PCH, and anorexigen-associated PAH (Table 13).148 The ing.Amongthosetests,echocardiographyisanimportantstepinthe
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 32 ---
ESC/ERSGuidelines 3649
2202SRE/CSE©
snoitatumnoisnetrepyhlairetrayranomluphtiwdetaicossaserutaefcipytonehP
31elbaT
ecnerefeR
snoitalupoP
snoitagitsevnI
gnihsiugnitsidlaitnetoP
ecnatirehnI
evitatuP
noisnetrepyhyranomluP
eneG
noitanimaxednalacinilc
nrettap
ralucelom
noitaicossacipytonehp
serutaef
msinahcem
251
tludadnacirtaideaP
debircsedsnoitagitsevnievitanimircsidoN
lacinilccitsongaidrocfiicepsoN
lamosotuA
ycneicfifusniolpaH
HAPcihtapoididnaelbatireH
2RPMB
debircsedserutaef
tnanimod
941
tludA
lamosotuA
nwonknU
3A31PTA
tnanimod
941
tludA
lamosotuA
nwonknU
1PQA
tnanimod
351
tludA
lamosotuA
ycneicfifusniolpaH
8CCBA
tnanimod
451
tludA
lamosotuA
ycneicfifusniolpaH
3KNCK
tnanimod
551
tludA
lamosotuA
ycneicfifusniolpaH
9DAMS
tnanimod
941
tludadnacirtaideaP
lamosotuA
nwonknU
HAPcihtapoididnaelbatireH
71xoS
tnanimod
esaesidtraehlatinegnoC
651
tludadnacirtaideaP
slevelnitpeldnaedirecylgirtgnitsaF
suoenatucbusfoycneicfieD
lamosotuA
;noitcnuffoniaG
HAPcihtapoididnaelbatireH
1VAC
eussitesopida
tnanimod
evitagentnanimod
yhportsydopiL
751,941
ssel(dnacirtaideaP
teefdna,seenk,sivlep:syar-XlatelekS
aisalparalletaP
lamosotuA
nwonknU
HAPcihtapoididnaelbatireH
4XBT
tluda)ylnommoc
esaesidgnullamyhcnerapesuffid:tsehcTC
,seitilamronbalatelekS
tnanimod
emordnysalletapllamS
dna,seenk,sivlepylralucitrap
)aisalpsydralletapoihcsi(
teef
esaesidgnullamyhcneraP
aisalpsydyranomlupohcnorB
yranomluptnetsisreP
etanoenehtfonoisnetrepyh
851
tludA
OCLDdecudeR
gnibbulclaegnalahplatsiD
lamosotuA
noitcnuffossoL
evisulcco-onevyranomluP
4KA2FIE
dnagninekcihtlatpesralubolretni:tsehcTC
evissecer
yrallipacyranomlup/esaesid
dna,yhtaponedahpmyllanitsaidem
sisotamoignameah
seiticaporaludonssalg-dnuorgralubolirtnec
951
tludatesno-redlO
OCLDdecuderelbissoP
lacinilccitsongaidrocfiicepsoN
lamosotuA
noitcnuffossoL
HAPcihtapoididnaelbatireH
RDK
debircsedserutaef
tnanimod
061
cirtaideapdnatludA
aimeanaycneicfied-norI
aisatceignaleT
lamosotuA
nwonknU
HAPcihtapoididnaelbatireH
GNE
,citapeh,yranomlupfognigaminoecneserP
lessevdoolblamronbA
tnanimod
cigahrromeahyratidereH
061
cirtaideapdnatludA
suonevoiretralanipsro,larberec
noitamrof
lamosotuA
ycneicfifusniolpaH
aisatceignalet
1LRVCA
snoitamroflam
suonevoiretralarecsiV
tnanimod
941
cirtaideapdnatludA
fotnemssessacipocsodneevisavnI
snoitamroflam
lamosotuA
ycneicfifusniolpaH
2FDG
aisatceignaletlanitsetniortsag
sisehtaidgnideelB
tnanimod
.noisnetrepyhlairetrayranomlup,HAP;edixonomnobracrofyticapacnoisuffidgnuL,OCLD;yhpargomotdetupmoc,TC
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on 22
January
2026
--- Страница 33 ---
3650 ESC/ERSGuidelines
Diagnostic algorithm of patients with unexplained exertional dyspnoea and/or suspected PH
GGeneralpractitioner Fast-track reffferral at
Medical history any time iin case of
Physical exam warningg signsa,
ECG or wheenPPPAH
BNP/NTTT-proBNP or CTTEPHe
O saturation are susspected
2
Suspected cause
Lung disease PH or cardiac disease
Lung assessmentb Hearrrt assessmentb
PFT Echocardiography
Rapid
ABG (see Figures 4–5,
cross-reffferral
Chest X-raaay TTTable 10)
as needed
Chest CTc CPET
CPET
Causes other than
Y Low PH probability
PHidentified
Intermediate/High
N
Refffer to PH centre
(Class I)
Comprehensive PH
work-up (TTTable 14
and ReCo TTTable 2)
Invasive assessment
Manage Further Risk factors fffor PPPAHd as needed
accordingly diagnostic work-up or CTEPHe (ReCo TTTable 2)
Figure6Diagnosticalgorithmofpatientswithunexplaineddyspnoeaand/orsuspectedpulmonaryhypertension.ABG,arterialbloodgasanalysis;BNP,
brainnatriureticpeptide;CPET,cardiopulmonaryexercisetesting;CT,computedtomography;CTEPH,chronicthrombo-embolicpulmonaryhyperten-
sion;ECG,electrocardiogram;HIV,humanimmunodeficiencyvirus;N,no;NT-proBNP,N-terminalpro-brainnatriureticpeptide;PAH,pulmonaryar-
terialhypertension;PE,pulmonaryembolism;PFT,pulmonaryfunctiontests;PH,pulmonaryhypertension;ReCo,recommendation;Y,yes.aWarning
signsincluderapidprogressionofsymptoms,severelyreducedexercisecapacity,pre-syncopeorsyncopeonmildexertion,signsofrightheartfailure.
bLungandheartassessmentbyspecialistasperlocalpractice.cAsindicated;CTpulmonaryangiographyrecommendedifPHsuspected.dIncludescon-
nectivetissuedisease(especiallysystemicsclerosis),portalhypertension,HIVinfection,andfamilyhistoryofPAH.eHistoryofPE,permanentintravascular
devices,inflammatoryboweldiseases,essentialthrombocythaemia,splenectomy,high-dosethyroidhormonereplacement,andmalignancy.
diagnosticalgorithm(Figure6),asitassignsalevelofprobabilityof PHisestablished;(2)inthepresenceofriskfactorsforPAH,orahis-
PH,irrespectiveofthecause.Inaddition,itisanimportantstepin toryofPE.Acomprehensivework-upshouldbeperformed,withthe
identifyingothercardiacdisorders.Basedonthisinitialassessment, goal ofestablishing thedifferential diagnoses anddistinguishing be-
ifcausesotherthanPHareidentifiedand/orincaseoflowprobabil- tweenthevariouscausesofPHaccordingtothecurrentclinicalclas-
ityofPH,patientsshouldbemanagedaccordingly. sification. The PH centre is responsible for performing an invasive
assessmentaccordingtotheclinicalscenario.
5.2.3.Step3(confirmation)
Atanytime,warningsignsmustberecognized,astheyareasso-
PatientsshouldbereferredtoaPHcentreforfurtherevaluationin ciated with worse outcomes and warrant immediate intervention.
thefollowingsituations:(1)whenanintermediate/highprobabilityof Such warning signs include: rapidly evolving or severe symptoms
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 34 ---
ESC/ERSGuidelines 3651
Table14 Characteristicdiagnosticfeaturesofpatientswithdifferentformsofpulmonaryhypertension
Diagnostictool Characteristic Group1(PAH) Group2(PH Group3(PH Group4(PH
findings/ associatedwithleft associatedwith associatedwith
features heartdisease) lungdisease) pulmonaryartery
obstructions)
5.1.1Clinical Clinicalfeatures Variableage,butyoung, Mostlyelderlypatients, Mostlyelderlypatients, Variableage,butelderly
presentation femalepatientsmaybe femalepredominancein malepredominance.161 maleandfemaleequally
predominantly caseofHFpEF.161 Historyandclinical affected.
affected.a161Clinical Historyandclinical findingssuggestiveof HistoryofVTE(CTEPH
presentationdependson findingssuggestiveof lungdisease.Smoking mayoccurinthe
associatedconditionsand LHD historycommon absenceofaVTE
phenotype history).
SeeSection5.1.1 RiskfactorsforCTEPH
SeeSection10.1
Oxygen Uncommon,exceptfor Uncommon Common,often Uncommon;common
requirementfor conditionswithlow profoundhypoxaemia inseverecaseswith
hypoxaemia DLCOorright-to-left inseverePH predominantlydistal
shunting pulmonaryartery
occlusions
5.1.3Chest RA/RV/PAsize↑ LA/LVsize↑ Signsofparenchymal RA/RV/PAsize↑
radiography Pruningofperipheral Cardiomegaly lungdisease Numberandsizeof
vessels Occasionalsignsof peripheralvessels↓
congestion(interstitial Occasionalsignsof
oedema/Kerleylines, pulmonaryinfarction
alveolaroedema,
pleuraleffusion)
5.1.4Pulmonary Spirometry/PFT Normalormildlyimpaired Normalormildly Abnormalas Normalormildly
functiontestsand impairment impaired determinedbythe impaired
ABG underlyinglungdisease
DLCO Normalor Normalor Oftenverylow(,45% Normalor
mild-to-moderately mild-to-moderately predicted) mild-to-moderately
reduced(lowDLCOin reduced,especiallyin reduced
SSc-PAH,PVOD,and HFpEF
someIPAHphenotypes)
Arterialbloodgas
PaO Normalorreduced Normalorreduced Reduced Normalorreduced 2
PaCO Reduced Usuallynormal Reduced,normal,or Normalorreduced
2
increased
5.1.5 SignsofPH(increased SignsofLHD(HFrEF, SignsofPH(increased SignsofPH(increased
Echocardiography sPAP,enlargedRA/RV) HFpEF,valvular)andPH sPAP,enlargedRA/RV) sPAP,enlargedRA/RV)
Congenitalheartdefects (increasedsPAP, SeeSection5.1.5 SeeSection5.1.5
maybepresent enlargedRA/RV)
SeeSection5.1.5 SeeSection8
5.1.6Lung Planar– Normalormatched Normalormatched Normalormatched Mismatchedperfusion
scintigraphy SPECTV/Q defect
5.1.7ChestCT SignsofPHorPVOD SignsofLHD Signsofparenchymal Intravascularfilling
SeeSection5.1.7 Pulmonaryoedema lungdisease defects,mosaic
SignsofPH SignsofPH perfusion,enlarged
bronchialarteries
SignsofPH
5.1.11 HighVE/VCO slope MildlyelevatedVE/ MildlyelevatedVE/ HighVE/VCO slope
2 2
Cardiopulmonary LowP CO ,decreasing VCO slope VCO slope LowP CO ,
ET 2 2 2 ET 2
exercisetesting duringexercise NormalP CO , NormalP CO, decreasingduring
ET 2 ET 2
NoEOV increasingduring
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 35 ---
3652 ESC/ERSGuidelines
exercise increasingduring exercise
EOV exercise NoEOV
5.1.12Rightheart Pre-capillaryPH Post-capillaryPH Pre-capillaryPH Pre-(orpost-)capillary
catheterization PH
ABG,arterialbloodgasanalysis;CT,computedtomography;CTEPH,chronicthrombo-embolicpulmonaryhypertension;DLCO,Lungdiffusioncapacityforcarbonmonoxide;EOV,
exerciseoscillatoryventilation;HFpEF,heartfailurewithpreservedejectionfraction;HFrEF,heartfailurewithreducedejectionfraction;IPAH,idiopathicpulmonaryarterialhypertension;
LA,leftatrium;LHD,leftheartdisease;LV,leftventricle;PA,pulmonaryartery;PaCO2,partialpressureofarterialcarbondioxide;PAH,pulmonaryarterialhypertension;PaO2,partial
pressureofarterialoxygen;PETCO2,end-tidalpartialpressureofcarbondioxide;PFT,pulmonaryfunctiontest;PH,pulmonaryhypertension;PVOD,pulmonaryveno-occlusivedisease;
RA,rightatrium;RV,rightventricle;sPAP,systolicpulmonaryarterialpressure;SPECT,single-photonemissioncomputedtomography;SSc-PAH,systemicsclerosis-associatedpulmonary
arterialhypertension;VE/VCO2,ventilatoryequivalentforcarbondioxide;V/Q,ventilationperfusionscintigraphy;VTE,venousthrombo-embolism.
↓,reduced;↑,increased.
aHowever,itmayaffectindividualsofallagesandsexes;diagnosisinmalesshouldnotbedelayed.
(WHO-FCIII/IV),clinicalsignsofRVfailure,syncope,signsoflowCO
Imaging
state, poorly tolerated arrhythmias, and compromised or deterio-
Ventilation/perfusionorperfusionlungscanis
rated haemodynamic status (hypotension, tachycardia). Such cases
recommendedinpatientswithunexplainedPHto I C mustbeimmediatelymanagedasinpatientsforinitialwork-upata
assessforCTEPH105
nearby hospital or PH centre. The presence of RV dysfunction by
CTpulmonaryangiographyisrecommendedin
echocardiography, elevated levels of cardiac biomarkers, and/or
thework-upofpatientswithsuspected I C
haemodynamicinstabilitymustpromptreferraltoaPHcentrefor
CTEPH104
immediateassessment.
This diagnostic process emphasizes the importance of sufficient Routinebiochemistry,haematology,immunology,
awarenessandcollaborationbetweenfirst-line,specializedmedicine HIVtesting,andthyroidfunctiontestsare
I C
andPHcentres.Effectiveandrapidcollaborationbetweeneachpart- recommendedinallpatientswithPAH,toidentify
ner permits earlier diagnosis and management, and improves associatedconditions
outcomes. Abdominalultrasoundisrecommendedforthe I C
screeningofportalhypertension164
ChestCTshouldbeconsideredinallpatients
IIa C
Recommendation Table 2 — Recommendations for withPH
diagnosticstrategy Digitalsubtractionangiographyshouldbe
consideredinthework-upofpatientswith IIa C
Recommendation Classa Levelb CTEPH
Echocardiography Otherdiagnostictests
Echocardiographyisrecommendedasthe PulmonaryfunctiontestswithDLCOare
first-line,non-invasive,diagnosticinvestigationin I B recommendedintheinitialevaluationofpatients I C
suspectedPH82,84,91 withPH78
Itisrecommendedtoassignanechocardiographic Openorthoracoscopiclungbiopsyisnot III C
probabilityofPH,basedonanabnormalTRVand recommendedinpatientswithPAH
I B
thepresenceofotherechocardiographicsigns CPET,cardiopulmonaryexercisetesting;CT,computedtomography;CTEPH,chronic
suggestiveofPH(seeTable10)91,92,162 thrombo-embolicpulmonaryhypertension;DLCO,Lungdiffusioncapacityforcarbon
monoxide;HIV,humanimmunodeficiencyvirus;PAH,pulmonaryarterialhypertension;
Itisrecommendedtomaintainthecurrent
PH,pulmonaryhypertension;TRV,tricuspidregurgitationvelocity.
thresholdforTRV(.2.8m/s)for
I C
aClassofrecommendation.
echocardiographicprobabilityofPHaccordingto bLevelofevidence.
theupdatedhaemodynamicdefinition88
BasedontheprobabilityofPHby 5.3. Screening and early detection
echocardiography,furthertestingshouldbe DespitetheadventofPAHtherapiesthatpreventclinicalworsen-
consideredintheclinicalcontext(i.e.symptoms IIa B ing166–168andeffectiveinterventionsforCTEPH,102thetimefrom
andriskfactorsorassociatedconditionsforPAH/ symptom onset to PH diagnosis remains at .2 years,169,170 with
CTEPH)92
most patients presenting with advanced disease. Decreasing the
Insymptomaticpatientswithintermediate timetodiagnosismayreduceemotionaluncertaintyinpatients,171
echocardiographicprobabilityofPH,CPETmay reduce the use of health care resources, and enable treatment at
IIb C
beconsideredtofurtherdeterminethelikelihood anearlierstagewhentherapiesmaybemoreeffective.172
ofPH123,163 Aproposedmultifacetedapproach172tofacilitateanearlierdiag-
Continued nosis includes: (1) screening asymptomatic, high-risk groups (with
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 36 ---
ESC/ERSGuidelines 3653
highprevalenceorwherethediagnosissignificantlyimpactsthepro- sex); and (2) the results of investigations (e.g. positive
posed intervention), including individuals with SSc (prevalence: 5– anti-centromere antibody profile, mild ILD, low DLCO, elevated
19%),173,174BMPR2mutationcarriers(14–42%),33first-degreerela- FVC/DLCO ratio, or elevated NT-proBNP).174,191 A recent
tivesofpatientswithHPAH,148andpatientsundergoingassessment meta-analysis showed that reduced digital capillary density, as as-
forlivertransplantation(2–9%);175(2)earlydetectionofsymptom- sessed by video-capillaroscopy, or progression to a severe active/
aticpatientsinat-riskgroupswithconditionssuchasportalhyperten- late pattern of vascular involvement is also a risk factor for
sion,176HIVinfection(0.5%),177andnon-SScCTD,wherethelower PAH.192InadditiontoidentifyingpatientsatincreasedriskofPAH,
prevalenceratesdonotsupportasymptomaticscreening;and(3)ap- a simple prediction model integrating symptoms, DLCO, and
plyingpopulation-basedstrategiesbydeployingearlydetectionap- NT-proBNP identified subjects at very low probability of PAH
proaches in PE follow-up clinics,178,179 breathlessness clinics,172 or who could potentially avoid further specific testing for PH.183
in at-risk patients identified from their health care behaviour and/ Furthermore, CPET may help to identify patients with SSc with a
orpreviousinvestigations.180 lowriskofhavingPAHandthustoavoidunnecessaryRHC.123
Screeningcanbedefinedasthesystematicapplicationofatestor TherecommendationsonscreeningforPAHinSSchavebeenes-
tests to identify at-risk, asymptomatic individuals. Screening ap- tablished based on key narrative question 3 (Supplementary Data,
proachescanalsobeextendedtoindividualswhowouldnotother- Section5.2).
wisehavesoughtmedicalattentiononaccountoftheirsymptoms,to
facilitateearlydetection.ToolsusedtoscreenforPHhaveprimarily
5.3.2.BMPR2mutationcarriers
been assessed, but not exclusively, in SSc,172,174 and include blood IntheevolvinglistofgenesknowntobeassociatedwithPAH,experi-
biomarkers(NT-proBNP),ECG,echocardiography(primarilyusing enceislargelyrestrictedtoBMPR2mutationcarrierswhocarryalife-
estimates of sPAP at rest, but also exercise studies),182 PFTs timeriskofdevelopingPAHof(cid:4)20%,withpenetrancehigherinfemale
(DLCOandforcedvitalcapacity[FVC]/DLCOratio),andexercise carriers (42%) compared with malecarriers (14%).33,148,193 There is
testing including CPET (which has been used in combination with currently no accepted screening strategy for evaluating PAH in
screeningalgorithmstoreducetheneedforRHC).123,163 BMPR2 mutation carriers. At present, based on expert consensus,
asymptomaticrelativeswhoscreenpositiveforPAH-causingmutations
5.3.1.Systemicsclerosis are often offered yearly screening echocardiography.25,26 The
InSSc,theprevalenceofPAHis5–19%,174withanannualincidence DELPHI-2study,whichprospectivelyscreenedcarriersandrelatives,
ofdevelopingPAHof0.7–1.5%.183–185Evidencefortheclinicalvalue recently demonstrated a 9.1% pick up over 47+27 months of
of detecting PAH early in SSc was provided by a screening pro- PAH, with 2/55 diagnosed at baseline and 3/55 at follow-up; this
gramme,186 which showed less severe haemodynamic impairment equates to an incidence of 2.3%/year.33 The screening schedule in-
andbettersurvival inscreened patients compared with a contem- cludedECG,NT-proBNP,DLCO,echocardiography,CPET,andop-
poraneous, non-screened cohort,187 providing a strong rationale tionalRHC;however,noneofthecaseswouldhavebeenpickedup
forscreeningforPAHinpatientswithSSc. by echocardiography alone. Screening programmes should adopt a
Thediagnosticaccuracyofechocardiographyorothertestsalonein multimodalapproach,althoughtheoptimalstrategyandscreeningper-
detectingPAHissuboptimal.173Severalscreeningalgorithmshavebeen iodremainsundefinedandwillrequiremultinational,multicentrestudy.
studiedusingacombinationofclinicalfeatures,echocardiography,PFTs,
and NT-proBNP to select patients with SSc for RHC (DETECT;173 5.3.3.Portalhypertension
AustralianSclerodermaInterestGroup[ASIG]188).Suchcombinedap- Anestimated1–2%ofpatientswithliverdiseaseandportalhyperten-
proacheshaveimproveddiagnosticaccuracycomparedwiththeuseof siondevelopPoPH,176,194whichisofparticularrelevanceinpatients
echocardiography,NT-proBNP,orPFTsalone,andareabletoprevent consideredfortransjugularportosystemicshuntingorlivertransplant-
unnecessaryRHCandidentifypatientswithmPAP21–24mmHg.189 ation.Insuchpatients,echocardiographyisrecommendedtoscreen
Therefore, a multimodal approach is warranted when screening pa- forPAH,evenintheabsenceofsymptoms.Byusingechocardiography,
tientswithSScforPAH;theechocardiographicassessmentshouldfol- sPAPcanbemeasuredin(cid:4)80%ofpatientswithportalhypertension,
lowthestrategydescribedinSection5.1.5. which aids decisions to perform RHC. In patients assessed for liver
Beyond initial screening, the frequency with which screening transplantation,onestudyshowedthatansPAPof.50mmHghad
shouldbeundertakeninasymptomaticsubjectswithSScisunclear. 97%sensitivityand77%specificityfordetectingmoderate-to-severe
AstudyfromtheAustralianSclerodermaStudyCohort,wherean- PAH.195OtherinvestigatorshaverecommendedRHCwhensPAPis
nual screening was recommended (some patients were screened .38mmHg.196WhenscreeningforPoPH,itisadvisedtoassessthe
up to 10 times), noted that most patients were diagnosed with echocardiographicprobabilityofPH(seeSection5.1.5).Inagreement
PAH at their first screening; however, those diagnosed on subse- withtheInternationalLiverTransplantSociety,forpatientsawaitingli-
quentscreeninghadalowermPAP,PVR,andWHO-FC,andbetter vertransplantation,itisrecommendedtoreassessforPAHannually,
survivalthanthosediagnosedatfirstscreening.190Basedoncurrent althoughtheoptimalintervalremainsunclear.175
evidence,annualscreeningforPAHinpatientswithSScissufficient.
Given the financial and emotional cost associated with regular 5.3.4.Pulmonaryembolism
screening,stratifyingsubjectswithSScintothoseathighestandlow- Chronicthrombo-embolicpulmonaryhypertensionisanuncommon
estriskofPAHwouldbedesirable.RiskfactorsforPAHinclude:(1) andunder-diagnosedcomplicationofacutePE.112Thereportedcu-
clinicalanddemographicfactors(i.e.breathlessness,longerdisease mulative incidence of CTEPH after acute, symptomatic PE ranges
duration, sicca symptoms, digital ulceration, older age, and male
0.1–11.8%,dependingonthecollectiveinvestigated.112,178,197–199A
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 37 ---
3654 ESC/ERSGuidelines
systematicreviewandmeta-analysisreportedaCTEPHincidenceof InadultpatientswithSScwith.3years’
0.6% in all patients with acute PE, 3.2% in survivors, and 2.8% in diseaseduration,anFVC≥40%,andaDLCO
I B
survivors without major comorbidities.178 A multicentre, observa- ,60%,theDETECTalgorithmisrecommended
tional, screening study reported a CTEPH incidence of 3.7/1000 toidentifyasymptomaticpatientswithPAH173,186
patient-yearsand a 2 year cumulative incidence of 0.79% following
InpatientswithSSc,wherebreathlessnessremains
acute PE.200 A recent prospective observational study (FOCUS, unexplainedfollowingnon-invasiveassessment, I C
Follow-upAfterAcutePulmonaryEmbolism)showeda cumulative RHCisrecommendedtoexcludePAH185–187
2yearincidenceof2.3%and16.0%forCTEPHandpost-PEimpair-
AssessingtheriskofhavingPAHbasedonan
ment,respectively,whichwerebothassociatedwithahigherriskof
evaluationofbreathlessness,incombinationwith
rehospitalizationanddeath.201Duetoinsufficientawareness,some
echocardiogramorPFTsandBNP/NT-proBNP, IIa B
patientsmayhaveadelayeddiagnosisofCTEPHbecausetheymay
shouldbeconsideredinpatientswith
initially be misclassified as acute PE.112 In this context, the current
SSc172,173,186,188,190
guidelinesdonotrecommendroutinefollow-upofpatientswithPE
PoliciestoevaluatetheriskofhavingPAH
byimagingmethodsofthepulmonaryvasculartree,butsuggestevalu-
shouldbeconsideredinhospitalsmanaging IIa C
ating the indeximaging test used todiagnose acute PEforsignsof
patientswithSSc
CTEPH. Echocardiography isthe preferred first-line diagnostictest
InsymptomaticpatientswithSSc,exercise
inpatientswithsuspectedCTEPH.103
echocardiographyorCPET,orCMRmaybe IIb C
Upto50%ofpatientshavepersistentperfusiondefectsafteran
acutePE;however,theclinicalrelevanceisunclear.202–204Allpatients consideredtoaiddecisionstoperformRHC
InpatientswithCTDwithoverlapfeaturesofSSc,
inwhomsymptomscanbeattributedtopost-thromboticdeposits
withinPAsareconsideredtohaveCTEPD,withorwithoutPH.54 anannualevaluationoftheriskofPAHmaybe IIb C
WhilepersistentdyspnoeaiscommonafteracutePE,205thepreva- considered
lenceofCTEPDwithoutPHisunknownandrequiresfurtherstudy CTEPH/CTEPD
(seeSection10.1).AstudyexploringscreeningforCTEPHfollowing Inpatientswithpersistentornew-onsetdyspnoea
acutePEidentified,usingechocardiography,alowyieldofadditional orexerciselimitationfollowingPE,further
I C
CTEPH diagnoses in asymptomatic patients.206 Current PE guide- diagnosticevaluationtoassessforCTEPH/
linesrecommendthatfurtherdiagnosticevaluationmaybeconsid- CTEPDisrecommended103
eredinasymptomaticpatientswithriskfactorsforCTEPHat3–6
Forsymptomaticpatientswithmismatched
months’follow-up.103,207ApproachestoearlydetectionofCTEPH
perfusionlungdefectsbeyond3monthsof
following acute PE are based on identifying patients at increased anticoagulationforacutePE,referraltoaPH/
I C
risk.208Inpatientswithpersistentornew-onsetdyspnoeaafterPE,
CTEPHcentreisrecommendedafterconsidering
non-invasive approaches use echocardiography to assess for PH theresultsofechocardiography,BNP/
andcross-sectionalimagingtoassessforpersistentperfusiondefects. NT-proBNP,and/orCPET203,206
LimiteddataexistonstrategiesusingDECT,CTlungsubtractioniod-
Other
inemapping,or3DMRperfusionimaging.Scoringsystems,including
CounsellingregardingtheriskofPAHandannual
theLeidenCTEPHrule-outcriteria206,209canbeusedtoinformdiag-
screeningarerecommendedinindividualswho
nostic strategies. Cardiopulmonary exercise testing may identify I B
testpositiveforPAH-causingmutationsandin
characteristicfeaturesofexerciselimitationduetoPVD,orsuggest
first-degreerelativesofpatientswithHPAH33
analternativediagnosis.Theoptimaltimingforassessingsymptoms
to aid early detection of CTEPH may be 3–6 months after acute Inpatientsreferredforlivertransplantation,
echocardiographyisrecommendedasascreening I C
PE,coincidingwiththeroutineevaluationofanticoagulanttreatment,
testforPH
but earlier assessment may be necessary in highly symptomatic or
deterioratingpatients.54,103 Furthertests(echocardiography,BNP/
NT-proBNP,PFTs,and/orCPET)shouldbe
IIa B
consideredinsymptomaticpatientswithCTD,
Recommendation Table 3 — Recommendations for
portalhypertension,orHIVtoscreenforPAH172
screening and improved detection of pulmonary ar-
terialhypertensionandchronicthrombo-embolicpul- BNP, brain natriuretic peptide; CMR, cardiac magnetic resonance; CPET,
monaryhypertension cardiopulmonaryexercisetesting;CTD,connective tissuedisease;CTEPD,chronic
thrombo-embolicpulmonarydisease;CTEPH,chronicthrombo-embolicpulmonary
Recommendations Classa Levelb hypertension;DLCO,Lungdiffusioncapacityforcarbonmonoxide;FVC,forcedvital
capacity; HIV, human immunodeficiency virus; HPAH, heritable pulmonary arterial
hypertension; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH,
Systemicsclerosis
pulmonaryarterialhypertension;PE,pulmonaryembolism;PFT,pulmonaryfunction
InpatientswithSSc,anannualevaluationofthe test; PH, pulmonary hypertension; RHC, right heart catheterization; SSc, systemic
I B
riskofhavingPAHisrecommended183,186 sclerosis.
aClassofrecommendation.
Continued bLevelofevidence.
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 38 ---
ESC/ERSGuidelines 3655
6. Pulmonary arterial 6.2. Severity and risk assessment
hypertension (group 1) 6.2.1.Clinicalparameters
ClinicalassessmentisakeypartofevaluatingpatientswithPAH,asit
6.1. Clinical characteristics providesvaluable informationfordeterminingdiseaseseverity,im-
ThesymptomsofPAHarenon-specificandmainlyrelatedtopro- provement, deterioration, or stability. At follow-up, changes in
WHO-FC(Table15),episodesofchestpain,arrhythmias,haemop-
gressiveRVdysfunction(seeSection5.1.1)asaconsequenceofpro-
tysis,syncope,andsignsofrightHFprovideimportantinformation.
gressivepulmonaryvasculopathy(Figure7).ThepresentationofPAH
maybemodifiedbydiseasesthatareassociatedwithPAH,aswellas Physicalexaminationshouldassessheartrate,rhythm,bloodpres-
sure,cyanosis,enlargedjugularveins,oedema,ascites,andpleuralef-
comorbidities.MoredetaileddescriptionsoftheindividualPAHsub-
fusions.TheWHO-FCisoneofthestrongestpredictorsofsurvival,
setsarereportedinSection7.
Pulmonary vasculopathy Right heart failure
Pulmonary Vascular
Intimal proliferation, fibrosis
artery obstruction
Vascular remodelling
Medial hypertrophy
Right ventricular
remodelling /
Thrombosis
dysfunction
Plexiform lesion
Vasoconstriction
Medial Intimal Plexiform
hyperplasia proliferation lesions
Current therapeutic targets
Endothelin pathway NO-sGC-cGMP pathway Prostacyclin pathway
Pro-endothelin-1 L-arginine Arachidonic acid
Endothelin-1 Nitric oxide Prostacyclin
(Vasoconstriction (Vasodilatation and (Vasodilatation and
and proliferation) antiproliferation) antiproliferation)
IP receptor
sGC PDE5
Endothelin Endothelin
receptorA receptor B
GTPP cGMMPP GGMPP cAMMPP
Figure7Pathophysiologyandcurrenttherapeutictargetsofpulmonaryarterialhypertension(group1).cAMP,cyclicadenosinemonophosphate;(c)
GMP,(cyclic)guanosine monophosphate; GTP,guanosine-5′-triphosphate; IP receptor, prostacyclin I2receptor; NO,nitric oxide; PDE5,phospho-
diesterase5;sGC,solubleguanylatecyclase.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 39 ---
3656 ESC/ERSGuidelines
Table15 WorldHealthOrganizationclassificationof pump failure.219–224 The rationale for the reported measure-
functional status of patients with pulmonary ments is strong, as RV systolic function metrics assess the adap-
hypertension
tation of RV contractility to increased afterload, and increased
right heart dimension and inferior vena cava dilation reflect
Class Descriptiona
failure of this mechanism, hence maladaptation.225 Pericardial
WHO-FCI PatientswithPHbutwithoutresultinglimitationof effusion and tricuspid regurgitation (TR) grading further explore
physicalactivity.Ordinaryphysicalactivitydoesnot RV overload and are of prognostic relevance in these pa-
causeunduedyspnoeaorfatigue,chestpain,ornear
tients.218,226–228
All of these variables are physiologically inter-
syncope dependent and their combination provides additional
WHO-FCII PatientswithPHresultinginslightlimitationofphysical prognostic information over single measurements.223
activity.Theyarecomfortableatrest.Ordinaryphysical Echocardiographyalsoenablescombinedparameterstobemea-
activitycausesunduedyspnoeaorfatigue,chestpain,or
sured,suchastheTAPSE/sPAPratio,whichistightlylinkedtoRV–
nearsyncope PAcouplingandpredictsoutcome.96,97Echocardiographicmeasure-
WHO-FCIII PatientswithPHresultinginmarkedlimitationof mentsofRVandRAsizescombinedwithLVeccentricityindexare
physicalactivity.Theyarecomfortableatrest.Lessthan crucialforassessingRVreverseremodellingasanemergingmarker
ordinaryactivitycausesunduedyspnoeaorfatigue, of treatment efficacy.220,229 Three-dimensional echocardiography
chestpain,ornearsyncope mayachievebetterestimationthanstandard2Dassessment,butun-
derestimationsofvolumesandejectionfractionhavebeenreported, WHO-FCIV PatientswithPHwithaninabilitytocarryoutany
andtechnicalissuesare,asyet,unresolved.230
physicalactivitywithoutsymptoms.Thesepatients
manifestsignsofrightHF.Dyspnoeaand/orfatiguemay
evenbepresentatrest.Discomfortisincreasedbyany 6.2.2.2.Cardiacmagneticresonanceimaging
physicalactivity TheroleofcMRIinevaluatingpatientswithPAHhasbeenaddressed
inseveralstudies,andRVvolumes,RVEF,andSVareessentialprog-
PH,pulmonaryhypertension;WHO-FC,WorldHealthOrganizationfunctionalclass.
aFunctional classification of PH modified after the New York Heart Association nostic determinants in PAH.225,231–236 In patients with PAH, initial
functionalclassificationaccordingtotheWorldHealthOrganization1998.147
cMRI measurements added prognostic value to current risk
scores.231,232Inaddition,riskassessmentat1yearoffollow-upbased
bothatdiagnosisandfollow-up,210–212andworseningWHO-FCis oncMRIwasatleastequaltoriskassessmentbasedonRHC.237The
one of the most alarming indicators of disease progression, which cMRIrisk-assessmentvariablesbasedonthecurrentliteraturearein-
shouldtriggerfurtherinvestigationstoidentifythecause(s)ofclinical
cludedinTable16.117,225,231–235,237Thestrokevolume
index(SVI)
deterioration.210,213,214 cut-off levels are based on the consensus of the literature;238 a
changeof10mLinSV(LVend-diastolicvolume−LVend-systolicvol-
ume)duringfollow-upisconsideredclinicallysignificant.239Thevalue
6.2.2.Imaging
ofcMRIinthefollow-upofpatientshasbeenshowninseveralstud-
Imagingoftheheartplays anessentialroleinthefollow-upofpa-
ies,andcMRIenablestreatmenteffectstobemonitoredandtreat-
tients with PAH. Several echocardiographic and cMRI parameters
mentstrategiesadaptedintimetopreventclinicalfailure.240–242
have been proposedto monitor RV functionduringthe courseof
PAH.TableS2providesalistofimagingparametersandrelativecut-
off values associated with increased and decreased risk of adverse 6.2.3.Haemodynamics
events. CardiopulmonaryhaemodynamicsassessedbyRHCprovideimport-
ant prognostic information, both at the time of diagnosis and at
6.2.2.1.Echocardiography follow-up.129,212,213,216,238,243–245,247,248 Currently available risk-
Echocardiographyisawidelyavailableimagingmodalityandisreadily stratificationtoolsincludehaemodynamicvariablesforprognostica-
performed at the patient’s bedside. It is crucial that a high-quality tion:RAPandPVRinREVEALriskscores,213,249,250andRAP,CI,and
echocardiographicassessmentbyPHspecialistsisundertakentore- SvO in the ESC/ERS risk-stratification table.25,26 The mPAP pro-
2
duceintraobserverandinterobservervariability.Ofnote,estimated vides little prognostic information, except in acute vasodilator re-
sPAPatrestisnotprognosticandirrelevanttotherapeuticdecision- sponders.129 A recent study from France, which combined clinical
making.212,215,216 An increase in sPAP does not necessarily reflect and haemodynamic parameters, found that WHO-FC, 6MWD,
diseaseprogressionandadecreaseinsPAPdoesnotnecessarilyre- RAP,andSVI(butnotSVandSvO )wereindependentpredictors
2
flectimprovement. ofoutcome.238
Despite the complex geometry ofthe right heart, echocardio- To refine the risk-stratification table (Table 16), SVI criteria are
graphic surrogates of the true right heart dimensions, which in- nowaddedwiththecut-offvaluesof.38mL/m2and,31mL/m2
clude a description of RV and RA areas, and the LV eccentricity todeterminelow-riskandhigh-riskstatus,respectively.238
index,provideusefulclinicalinformationinPAH.217,218Rightven- Theoptimaltimingoffollow-upRHChasnotbeendetermined.
tricular dysfunction can be evaluated measuring fractional area While some centres regularly perform invasive follow-up assess-
change,TAPSE,tissueDoppler,and2Dspeckletrackingmyocar- ments,othersperformthemasclinicallyindicated,andthereisno
dialstrainrecordingofRVfree-wallmotion,allofwhichrepresent evidencethatanyofthesestrategiesisassociatedwithbetterout-
isovolumetric and ejection-phase indices of load-induced RV comes(Table17).
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 40 ---
ESC/ERSGuidelines 3657
Table16 Comprehensiveriskassessmentinpulmonaryarterialhypertension(three-stratamodel)
Determinantsofprognosis(estimated Lowrisk Intermediaterisk Highrisk
1-yearmortality) (,5%) (5–20%) (.20%)
Clinicalobservationsandmodifiablevariables
SignsofrightHF Absent Absent Present
Progressionofsymptomsandclinical
No Slow Rapid
manifestations
Syncope No Occasionalsyncopea Repeatedsyncopeb
WHO-FC I,II III IV
6MWDc .440m 165–440m ,165m
CPET PeakVO .15mL/min/kg PeakVO 11–15mL/min/kg PeakVO ,11mL/min/kg
2 2 2
(.65%pred.) (35–65%pred.) (,35%pred.)
VE/VCO slope,36 VE/VCO slope36–44 VE/VCO slope.44
2 2 2
Biomarkers:BNPorNT-proBNPd BNP,50ng/L BNP50–800ng/L BNP.800ng/L
NT-proBNP,300ng/L NT-proBNP300–1100ng/L NT-proBNP.1100ng/L
Echocardiography RAarea18–26cm2 RAarea.26cm2
RAarea,18cm2
TAPSE/sPAP0.19–0.32mm/ TAPSE/sPAP,0.19mm/mmHg
TAPSE/sPAP.0.32mm/mmHg
mmHg Moderateorlargepericardial
Nopericardialeffusion
Minimalpericardialeffusion effusion
cMRIe RVEF37–54%
RVEF.54% RVEF,37%
SVI26–40mL/m2
SVI.40mL/m2 SVI,26mL/m2
RVESVI
RVESVI,42mL/m2 RVESVI.54mL/m2
42–54mL/m2
Haemodynamics RAP,8mmHg RAP8–14mmHg RAP.14mmHg
CI≥2.5L/min/m2 CI2.0–2.4L/min/m2 CI,2.0L/min/m2
SVI.38mL/m2 SVI31–38mL/m2 SVI,31mL/m2
SvO .65% SvO 60–65% SvO ,60%
2 2 2
6MWD,6-minutewalkingdistance;BNP,brainnatriureticpeptide;CI,cardiacindex;cMRI,cardiacmagneticresonanceimaging;CPET,cardiopulmonaryexercisetesting;HF,heartfailure;
NT-proBNP,N-terminalpro-brainnatriureticpeptide;PAH,pulmonaryarterialhypertension;pred.,predicted;RA,rightatrium;RAP,rightatrialpressure;sPAP,systolicpulmonary
arterialpressure;SvO2,mixedvenousoxygensaturation;RVESVI,rightventricularend-systolicvolumeindex;RVEF,rightventricularejectionfraction;SVI,strokevolumeindex;
TAPSE,tricuspidannularplanesystolicexcursion;VE/VCO2,ventilatoryequivalentsforcarbondioxide;VO2,oxygenuptake;WHO-FC,WorldHealthOrganizationfunctionalclass.
aOccasionalsyncopeduringheavyexerciseoroccasionalorthostaticsyncopeinastablepatient.
bRepeatedepisodesofsyncopeevenwithlittleorregularphysicalactivity.
cObservethat6MWDisdependentuponage,height,andburdenofcomorbidities.
dToharmonizewiththefour-stratamodelshowninTable18,theBNPandNT-proBNPcut-offlevelshavebeenupdatedfromthe2015versionbasedondatafromtheREVEALregistry,
acknowledgingthattheEuropeanvalidationstudieshaveusedtheoriginalcut-offlevels.274,292,293,295,296,302
ecMRIparametersadaptedfromSection6.2.2.2.
6.2.4.Exercisecapacity valuethandeteriorationonkeyclinicaloutcomes(mortalityandsur-
The6-minutewalkingtest(6MWT)isthemostwidelyusedmeasure vival).250,252,253Theseresultsareconsistentwithobservationsfrom
ofexercisecapacityinPHcentres.The6MWTiseasytoperform, clinicaltrialsandregistries;254,255however,thereisnosinglethresh-
inexpensive, and widely accepted by patients, health professionals, old thatwould apply toall patients.256 Some studieshavealso sug-
and medicines agencies as an important and validated variable in gestedthataddingSaO measuredbypulseoximetryandheartrate
2
PH.AswithallPHassessments,6MWTresultsmustalwaysbeinter- responsesmayimproveprognosticrelevance.246,257Hypoxaemiaob-
preted in the clinical context. The 6MWD isinfluenced by factors servedduringthe6MWTisassociatedwithworsesurvival,butthese
such as sex, age, height, weight, comorbidities, need for oxygen, findingsstillawaitconfirmationinlargemulticentrestudies.
learningcurve,andmotivation.Testresultsareusuallygiveninabso- Theincrementalshuttlewalkingtest(ISWT)isanalternativemax-
lutedistance(metres)ratherthanthe percentageofpredictedva- imaltestforassessingpatientswithPAH.TheISWThasapotential
lues. Change in 6MWD is one of the most commonly used advantageoverthe6MWTinthatitdoesnothaveaceilingeffect;
parametersinPAHclinicaltrialsasaprimaryendpoint,keysecond- furthermore, it keeps the simplicity of a simple-to-perform field
aryendpoint,orcomponentofclinicalworsening.251Arecentinves- test,incontrasttoCPET.However,theISWTexperienceinPAH
tigationshowedthatthebest absolute-thresholdvaluesfor1year iscurrentlylimited.258
mortalityand1yearsurvival,respectively,were165mand440m, Cardiopulmonaryexercisetestingisanon-invasivemethodforas-
respectively.252 Improvements in 6MWD have had less predictive sessing functional capacity and exercise limitation. It is usually
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 41 ---
3658 ESC/ERSGuidelines
Table17 Suggestedassessmentandtimingforthefollow-upofpatientswithpulmonaryarterialhypertension
At 3–6monthsafterchangesin Every3–6monthsinstable Incaseofclinical
baseline therapya patientsa worsening
Medicalassessment(including
WHO-FC)
6MWT
Bloodtest(including
NT-proBNP)b,c
ECG
EchocardiographyorcMRI
ABGorpulseoximetryd
Disease-specificHR-QoL
CPET
RHC
6MWT,6-minutewalkingtest;ABG,arterialbloodgasanalysis;ALAT,alanineaminotransferase;ASAT,aspartateaminotransferase;BNP,brainnatriureticpeptide;cMRI,cardiacmagnetic
resonanceimaging;CPET,cardiopulmonaryexercisetesting;ECG,electrocardiogram;HR-QoL,health-relatedqualityoflife;INR,internationalnormalizedratio;NT-proBNP,N-terminal
pro-brainnatriureticpeptide;PAH,pulmonaryarterialhypertension;RHC,rightheartcatheterization;TSH,thyroid-stimulatinghormone;WHO-FC,WorldHealthOrganization
functionalclass.
Green:isindicated;yellow:shouldbeconsidered;orange:maybeconsidered.
aIntervalstobeadjustedaccordingtopatientneeds,PAHaetiology,riskcategory,demographics,andcomorbidities.
bBasiclaboratorytestsincludebloodcount,INR(inpatientsreceivingvitaminKantagonists),serumcreatinine,sodium,potassium,ASAT/ALAT,bilirubin,andBNP/NT-proBNP.
cExtendedlaboratorytests(e.g.TSH,troponin,uricacid,ironstatus,etc.)accordingtoclinicalcircumstances.
dABGshouldbeperformedatbaselinebutmaybereplacedbypulseoximetryinstablepatientsatfollow-up.
performed as a maximal exercise test, and is safe even in patients .300ng/L) and NT-proBNP (,300, 300–1400, and .1400ng/L)
withsevereexerciselimitation.259,260MostPHcentresuseanincre- for low, intermediate, and high risk, respectively, in the ESC/ERS
mentalrampprotocol,althoughthetesthasnotyetbeenstandar- risk-assessmentmodelatbaselineandduringfollow-upareprognos-
dized for this patient population. Robust prognostic evidence for ticforlong-termoutcomesandcanbeusedtopredictresponseto
peakVO andVE/VCO hasbeenfoundinthreestudies,allpowered treatment.266 Refined cut-off values for BNP (,50, 50–199, 200–
2 2
for multivariable analysis.261–263 When associated with SVI, peak 800, and .800ng/L) and NT-pro-BNP (,300, 300–649, 650–
VO provided useful information to further stratify patients with 1100, and .1100ng/L) for low, intermediate–low, intermediate–
2
PAH at intermediate risk.264 However, the added value of CPET high, and high risk, respectively, have recently been introduced as
on top of common clinical and haemodynamic variables remains partofafour-stratarisk-assessmentstrategy(seeSection6.2.7).280
largelyunexplored.
6.2.6.Patient-reportedoutcomemeasures
6.2.5.Biochemicalmarkers Apatient-reportedoutcomemeasure(PROM)isatermforhealth
Considerableeffortshavebeenmadetoidentifyadditionalbiomar- outcomesthatare‘self-reported’bythepatient.Itisthepatient’sex-
kers of PVD, addressing
prognosis,265–272
diagnosis, and differenti- perience of living with PH and its impact on them and their care-
ation of PH
subtypes,270,273–276
as well as PAH treatment givers, including symptomatic, intellectual, psychosocial, spiritual,
response.266EmergingproteinsrelatedtoPAHandvascularremod- and goal-orientated dimensions of the disease and its treatment.
ellingincludebonemorphogeneticproteins9and10andtranslation- Despitetreatmentadvances improving survival,patients with PAH
allycontrolledtumourprotein.270,277,278Proteome-widescreening presentwitharangeofnon-specificyetdebilitatingsymptoms,which
inIPAHandHPAHidentifiedamultimarkerpanelwithprognostic affecthealth-relatedqualityoflife(HR-QoL).281,282
informationinadditiontotheREVEALriskscore.271Anotherstudy Patient-reported outcome measures remain an underused out-
foundthatearlydevelopmentofSSc-associatedPAH(PAH-SSc)was come measure. Tools validated in patients with PAH should be
predictedbyhighcirculatinglevelsofC-X-Cmotifchemokine4in used to assess HR-QoL282,283 in individual patients. There has
patients with SSc.276 However, none of these biomarkers have beenarelianceongenericPROMs,whichhavebeenstudiedinpa-
beenintroducedinclinicalpractice. tients with PAH but may lack sensitivity to detect changes in
Thus,BNPandNT-proBNPremaintheonlybiomarkersroutinely PAH.284,285Toaddressthis,anumberofPH-specificHR-QoLinstru-
used in clinical practice at PH centres, correlating with myocardial ments have been developed and validated (e.g. Cambridge
stress and providing prognostic information.279 Brain natriuretic Pulmonary Hypertension Outcome Review [CAMPHOR],286
peptideandNT-proBNParenotspecificforPH,astheycanbeele- emPHasis-10,282,287 Living with Pulmonary Hypertension,288 and
vatedinotherformsofheartdisease,exhibitinggreatvariability.The Pulmonary Arterial Hypertension-Symptoms and Impact
previously proposed cut-off levels of BNP (,50, 50–300, and [PAH-SYMPACT]).289 These disease-specific PROMs track
2202SRE/CSE© Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 42 ---
ESC/ERSGuidelines 3659
Table18 Variablesusedtocalculatethesimplifiedfour-stratarisk-assessmenttool
Determinantsofprognosis Lowrisk Intermediate–lowrisk Intermediate–highrisk Highrisk
Pointsassigned 1 2 3 4
WHO-FC IorIIa - III IV
6MWD,m .440 320–440 165–319 ,165
BNPor ,50 50–199 200–800 .800
NT-proBNP,ang/L ,300 300–649 650–1100 .1100
6MWD,6-minutewalkingdistance;BNP,brainnatriureticpeptide;NT-proBNP,N-terminalpro-brainnatriureticpeptide;WHO-FC,WorldHealthOrganizationfunctionalclass.
Riskiscalculatedbydividingthesumofallgradesbythenumberofvariablesandroundingtothenextinteger.
aWHO-FCIandIIareassigned1pointasbothareassociatedwithgoodlong-termsurvival.
functionalstatus,clinicaldeterioration,andprognosisinPAH,andare 6MWD,andNT-proBNP(Table18).280,308Patientswerecategorized
more sensitive to the differences in the risk status than generic aslow,intermediate–low,intermediate–high,orhighrisk.Together,
PROMs.290,291 In addition, HR-QoL scores provide independent these studies included .4000 patients with PAHandshowedthat
prognosticinformation.287 thefour-stratamodelperformedatleastaswellasthethree-strata
modelinpredictingmortality.Thefour-stratamodelpredictedsur-
6.2.7.Comprehensiveprognosticevaluation,risk vival in patients with IPAH, HPAH, DPAH, and PAH associated
assessment,andtreatmentgoals withCTD(includingtheSScsubgroup),andinpatientswithPoPH.
Inthe2015ESC/ERSGuidelinesforthediagnosisandtreatmentof
Theobserved1-yearmortalityratesinthefourriskstratawere0–
PH,riskassessmentwasbasedonamultiparametricapproachusing 3%, 2–7%, 9–19%, and .20%, respectively. Compared with the
athree-stratamodeltoclassifypatientsatlow,intermediate,orhigh three-strata model, the four-strata model was more sensitive to
riskofdeath.Originally,thesestratawerebasedonestimated1year changesinriskfrombaselinetofollow-up,andthesechangeswere
mortalityratesof,5%,5–10%,and.10%,respectively.25,26Since associatedwithchangesinthelong-termmortalityrisk.Themainad-
then,registrydatahaveshownthatobserved1yearmortalityrates vantageofthefour-stratamodeloverthethree-stratamodelisbetter
in the intermediate- and high-risk groups were sometimes higher discriminationwithintheintermediate-riskgroup,whichhelpsguide
than predicted (i.e. up to 20% in the intermediate-risk group and therapeutic decision-making (see Section 6.3.4). For these reasons,
.20%inthehigh-riskgroup).Thesenumbershavebeenupdatedac- thefour-stratamodelisincludedintheupdatedtreatmentalgorithm
cordinglyintherevisedthree-stratariskmodel(Table16).292–294 (seeFigure9).However,thethree-stratamodelismaintainedforini-
Several abbreviated approaches of the 2015 ESC/ERS risk- tialassessment,whichshouldbecomprehensiveandincludeechocar-
stratificationtoolhavebeenintroducedandindependentlyvalidated diographicandhaemodynamicvariables,forwhichcut-offvaluesfor
using the Swedish Pulmonary Arterial Hypertension Registry thefour-stratamodelhaveyettobeestablished.
(SPAHR),292 the Comparative, Prospective Registry of Newly Several studies have identified WHO-FC, 6MWD, and BNP/
Initiated Therapies for PH (COMPERA),293 and the French PH NT-proBNPasthestrongestprognosticpredictors.293,295,296With
Registry(FPHR).295Otherrisk-stratificationtoolshavebeendevel- theabbreviatedrisk-assessmenttools,missingvaluesbecomeanim-
opedfromtheUSREVEAL,includingtheREVEAL2.0riskscorecal- portantlimitation.REVEALLite2providesaccuratepredictionwhen
culator,andanabridgedversion(REVEALLite2).249,296Inallthese one key variable (WHO-FC, 6MWD, or BNP/NT-proBNP) is un-
studies,WHO-FC,6MWD,andBNP/NT-proBNPemergedasthe available,butisnolongeraccuratewhentwoofthesevariablesare
variableswiththehighestpredictivevalue. missing.293,296 The original three-strata SPAHR/COMPERA risk
The main limitation of the 2015 ESC/ERS three-strata, tool was developed with at least two variables available, while the
risk-assessmenttoolisthat60–70%ofthepatientsareclassifiedas four-strata model was developed and validated in patients for
intermediaterisk.292–295,297–303Aninitialattempttosubstratifythe whomallthreevariableswereavailable.Itisthereforerecommended
intermediate-riskgrouphasbeenproposed,usingamodifiedmean touseatleastthesethreevariablesforriskstratification.However,
score in the SPAHR equation (with low–intermediate, 1.5–1.99 twocomponentsmaybeusedwhenvariablesaremissing,especially
andhigh–intermediate,2.0–2.49ascut-offs),wherethehigh–inter- whenafunctionalcriterion(WHO-FCor6MWD)iscombinedwith
mediate group was associated with worse survival.302 There have BNPorNT-proBNP.296
alsobeenattemptstofurtherimproveriskstratificationbyexploring Collectively, the available studies support a risk-based,
theadditionalvalueofnewbiomarkers,304orbymeasuringRVstruc- goal-orientated treatment approach in patients with PAH, where
ture and function by echocardiography and cMRI.231,305,306 Other achievingand/ormaintainingalow-riskstatusisfavourableandre-
strategieshaveincludedincorporatingrenalfunction307orcombin- commended (key narrative question 4, Supplementary Data,
ing6MWDwithTAPSE/sPAPratio;96,97however,allofthesestrat- Section 6.1).298,300,303,309,310 For risk stratification at diagnosis, use
egieshavetobefurthervalidated. of the three-strata model is recommended taking into account as
Two recent registry studies have evaluated a four-strata, manyfactorsaspossible(Table16),withastrongemphasisondisease
risk-assessment tool based on refined cut-off levels for WHO-FC, type, WHO-FC, 6MWD, BNP/NT-proBNP, and haemodynamics.
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 43 ---
3660 ESC/ERSGuidelines
At follow-up, the four-strata model (Table 18) is recommended PAH,forinstancepatientswithSScorfamilymembersofpatients
as a basic risk-stratification tool, but additional variables should with HPAH, should be referred to a PH centre for individual
be considered as needed, especially right heart imaging and decision-making.
haemodynamics. At any stage, individual factors such as age,
sex, disease type, comorbidities, and kidney function should also
6.3.1.Generalmeasures
beconsidered.
Managing patients with PAH requires a comprehensive treatment
strategyandmultidisciplinarycare.InadditiontoapplyingPAHdrugs,
Recommendation Table 4 — Recommendations for general measures and care in special situations represent integral
evaluatingthediseaseseverityandriskofdeathinpa-
componentsofoptimizedpatientcare.Inthiscontext,thesystemic
tientswithpulmonaryarterialhypertension
consequences ofPHand right-sidedHF, often contributing to dis-
Recommendations Classa Levelb
easeburden,shouldbeappropriatelymanaged.119
Itisrecommendedtoevaluatediseaseseverityin
6.3.1.1.Physicalactivityandsupervisedrehabilitation
patientswithPAHwithapanelofdataderived
fromclinicalassessment,exercisetests, The2015ESC/ERSGuidelinesforthediagnosisandtreatmentofPH
I B
biochemicalmarkers,echocardiography,and suggestedthatpatientswithPAHshouldbeencouragedtobeactive
haemodynamic
withinsymptomlimits.25,26Sincethen,additionalstudieshaveshown
evaluations212,213,216,249,292,293,295,296,302,307 the beneficial impact of exercise training on exercise capacity
Achievingandmaintainingalow-riskprofileon (6MWD) and quality of
life.312–316
A large, randomized controlled
trial (RCT) in 11 centres across 10 European countries, including
optimizedmedicaltherapyisrecommendedasa
I B 116patientswithPAH/CTEPHonPAHdrugs,showedasignificant
treatmentgoalinpatientswith
PAH210,212,213,216,298,300,303,309,310
improvementin6MWDof34.1+8.3m,qualityoflife,WHO-FC,
Forriskstratificationatthetimeofdiagnosis,the and peak VO 2 compared with standard of care.315 Since most of
thestudiesincludedpatientswhowerestableonmedicaltreatment,
useofathree-stratamodel(low,intermediate,
andhighrisk)isrecommended,takinginto I B patients with PAH should be treated with the best standard of
pharmacologicaltreatmentandbeinastableclinicalconditionbefore
accountallavailabledata,including
haemodynamics292,293,295 embarking on a supervised rehabilitation programme. Establishing
specialized rehabilitation programmes for patients with PH would
Forriskstratificationduringfollow-up,theuseofa
furtherenhancepatientaccesstothisintervention.317
four-stratamodel(low,intermediate–low,
intermediate–high,andhighrisk)basedon
I B
WHO-FC,6MWD,andBNP/NT-proBNPis 6.3.1.2.Anticoagulation
recommended,withadditionalvariablestaken Thereareseveralreasonstoconsideranticoagulationinpatientswith
intoaccountasnecessary280,308 PAH. Histopathological specimens from PAH patients’ lungs have
InsomePAHaetiologiesandpatientswith shown insitu thrombosis of pulmonary vessels. Patients withCHD
comorbidities,optimizationoftherapyshouldbe or PA aneurysms may develop thrombosis of the central PAs.
consideredonanindividualbasis,while IIa B Abnormalities inthe coagulation and fibrinolyticsystemindicating a
acknowledgingthatalow-riskprofileisnotalways pro-coagulantstatehavebeenreportedinpatientswithPAH.318
achievable293,294,299,311
DatafromRCTsonanticoagulationinPAHarelacking,andregis-
trydatahaveyieldedconflictingresults.Thelargestregistryanalysis
6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP,
N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension;
sofarsuggestedapotentialsurvivalbenefitassociatedwithanticoa-
WHO-FC,WorldHealthOrganizationfunctionalclass. gulationinpatientswithIPAH,319butthisfindingwasnotconfirmed
aClassofrecommendation.
bLevelofevidence. by others.320 Two recent meta-analyses also concluded that using
anticoagulants may improve survival in patients with IPAH;321,322
however, none of the included studies were methodologically ro-
bust.Despitethelackofevidence,registrydataobtainedbetween
6.3. Therapy 2007and2016showedthatanticoagulationwasusedin43%ofpa-
Accordingtotherevisedhaemodynamicdefinition,PAHmaybedi- tientswith IPAH.293 InPAH associatedwith SSc, registrydata and
agnosedinpatientswithmPAP.20mmHgandPVR.2WU.Yet, meta-analysesuniformlyindicatedthatanticoagulationmaybeharm-
theefficacyofdrugsapprovedforPAHhasonlybeendemonstrated ful.320–322InCHD,therearealsonoRCTsonanticoagulation.There
in patients with mPAP ≥25mmHg and PVR .3 WU (see isalsonoconsensusabouttheuseofanticoagulantsinpatientswho
SupplementaryData,TableS1).Nodataareavailablefortheefficacy havepermanenti.v.linesfortherapywithprostacyclinanalogues;this
ofdrugsapprovedforPAHinpatientswhosemPAPis,25mmHg islefttolocalcentrepractice.
andwhosePVRis,3WU.Hence,forsuchpatients,theefficacyof As anticoagulation is associated with an increased bleeding risk,
drugsapprovedforPAHhasnotbeenestablished.Thesameistrue andintheabsenceofrobustdata,nogeneralrecommendationhas
for patients with exercise PH, who, by definition, do not fulfil the beenmadefororagainsttheuseofanticoagulantsinpatientswith
diagnostic criteria for PAH. Patients at high risk of developing PAH.;therefore,individualdecision-makingisrequired.
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 44 ---
ESC/ERSGuidelines 3661
6.3.1.3.Diuretics transferrin saturation ,20%.329 The underlying pathological me-
RightHF is associated with systemicfluidretention, reduced renal chanismsarecomplex.330–333InpatientswithPAH,irondeficiency
bloodflow,andactivationoftherenin–angiotensin–aldosteronesys- is associated with impaired myocardial function, aggravated symp-
tem.Increasedright-sidedfillingpressuresaretransmittedtothere- toms,andincreasedmortalityrisk.333,334Basedonthesedata,regular
nal veins, increasing interstitial and tubular hydrostatic pressure monitoringofironstatus(serumiron,ferritin,transferrinsaturation,
withintheencapsulatedkidney,whichdecreasesnetglomerularfil- solubletransferrinreceptors)isrecommendedinpatientswithPAH.
trationrateandoxygendelivery.119 Inpatientswithsevereirondeficiencyanaemia(Hb,7–8g/dL),
Avoidingfluidretentionisoneofthekeyobjectivesinmanagingpa- i.v.supplementationisrecommended.335–337Oralironformulations
tientswithPH.Oncethesepatientsdevelopsignsofright-sidedHFand
containingferrous(Fe2+
)sulfate,ferrousgluconate,andferrousfu-
oedema, restricting fluid intake and using diuretics is recommended. marateareoftenpoorlytolerated,anddrugefficacymaybeimpaired
Thethreemainclassesofdiuretics—loopdiuretics,thiazides,andmin- inpatientswithPAH.330,331Ferricmaltolisanew,orallyavailablefor-
eralocorticoid receptor antagonists—are used as monotherapyor in mulationofferric(Fe3+ )ironandmaltol.Onesmall,open-labelstudy
combination, as determined by the patient’s clinical need and kidney suggestedgood tolerabilityandefficacyinpatientswith severePH
function.Patientsrequiringdiuretictherapyshouldbeadvisedtoregu- withmild-to-moderateirondeficiencyandanaemia.338Incontrast,
larlymonitortheirbodyweightandtoseekmedicaladviceincaseof twosmall,12week,randomized,cross-overtrialsstudyingironsup-
weightgain.Closecollaborationbetweenpatients,PHcentres,especial- plementationinPAHpatientswithoutanaemiaprovidednosignifi-
lyPHnurses,andprimarycarephysiciansplaysavitalrole.Kidneyfunc- cant clinical benefit.339 Randomized controlled trials comparing
tion and serum electrolytes should be regularly monitored, and oralandi.v.ironsupplementationinpatientswithPAHarelacking.
intravascularvolumedepletionmustbeavoidedasitmaycauseafur-
ther decline in CO and systemic blood pressure. Physicians should 6.3.1.7.Vaccination
bearinmindthatfluidretentionandoedemamaynotnecessarilysignal Asageneralhealthcaremeasure,itisrecommendedthatpatients
right-sidedHF,butmayalsobeasideeffectofPAHtherapy.323 withPAHbevaccinatedatleastagainstinfluenza,Streptococcuspneu-
moniae,andSARS-CoV-2.
6.3.1.4.Oxygen
6.3.1.8.Psychosocialsupport
AlthoughoxygenadministrationreducesPVRandimprovesexercise
ReceivingadiagnosisofPH—oftenafterasubstantialdelay—andex-
toleranceinpatientswithPAH,therearenodatatosuggestthatlong-
termoxygentherapyhassustainedbenefitsonthecourseofthedis- periencingthephysicallimitationshaveasubstantialimpactonpsy-
chological, emotional, and social aspects of patients and their
ease. Most patients with PAH, except those with CHD and
families.Symptomsofdepressionandanxiety,aswellasadjustment
pulmonary-to-systemicshunts,haveminordegreesofarterialhypox-
disorders,haveahighprevalenceinpatientswithPAH.Pulmonary
aemiaatrest,unlesstheyhaveapatentforamenovale.Datashowthat
arterial hypertension also has grave repercussions on ability to
nocturnaloxygentherapydoesnotmodifythenaturalhistoryofad-
vancedEisenmengersyndrome.324Intheabsenceofrobustdataon
workandincome.281,340–344
Empathic and hopeful communication is essential for physicians
theuseofoxygeninpatientswithPAH,guidanceisbasedonevidence
inpatientswithCOPD;325whenPaO is,8kPa(60mmHg;alterna- caringforpatientswithPAH.Awarenessandknowledgeaboutthe
2
tively,SaO ,92%)onatleasttwooccasions,patientsareadvisedto disease and its treatment options empower patients to engage in
2
takeoxygentoachieveaPaO .8kPa.Ambulatoryoxygenmaybe shared decision-making. Adequate diagnostic screening tools are
2 consideredwhenthereisevidenceofsymptomaticbenefitandcor- thekeytoidentifyingpatientsinneedofreferralforpsychological/
rectable desaturation on exercise.326,327 Nocturnal oxygen therapy
psychiatricsupport,includingpsychopharmacologicalmedication,345
shouldbeconsideredincaseofsleep-relateddesaturation.328 orsocialassistance.Patientsupportgroupsmayplayanimportant
role,andpatientsshouldbeadvisedtojoinsuchgroups.Giventhe
life-limitingcharacterofPAH,advancedcareplanningwithreferral
6.3.1.5.Cardiovasculardrugs
tospecialistpalliativecareservicesshouldbesupportedattheright
Nodatafromrigorousclinicaltrialsareavailableontheusefulness time.346
andsafetyofdrugsthatareeffectiveinsystemichypertensionorleft-
sided HF, such as angiotensin-converting enzyme inhibitors, angio-
6.3.1.9.Adherencetotreatments
tensinreceptorblockers(ARBs),angiotensinreceptor–neprilysinin-
AdheringtomedicaltherapyiskeytosuccessfullymanagingPAH.In
hibitors (ARNIs), sodium–glucose cotransporter-2 inhibitors
general,factorsthataffectadherencearepatientrelated(e.g.demo-
(SGLT-2is), beta-blockers, or ivabradine in patients with PAH. In
graphics, cognitive impairment, polypharmacy, adverse reactions/
thisgroupofpatients,thesedrugsmayleadtopotentiallydangerous
sideeffects,psychologicalhealth,healthliteracy,patientunderstand-
dropsinbloodpressure,heartrate,orboth.Likewise,theefficacyof
ingofthetreatmentrationale,andcomorbidities),physicianrelated
digoxin/digitoxinhasnotbeendocumentedinPAH,althoughthese
(expertise, awareness of guidelines, and multidisciplinary team ap-
drugsmaybeadministeredtoslowventricularrateinpatientswith
proach), and health care system related (work setting, access to
PAHwhodevelopatrialtachyarrhythmias. treatments,andcost).347
Recentstudieshaveindicatedthatadherencetodrugtherapyin
6.3.1.6.Anaemiaandironstatus patientswithPAHmaybesuboptimal.348,349Giventhecomplexity
IrondeficiencyiscommoninpatientswithPAHandisdefinedbyser- of PAH treatment, potential side effects, and risks associated with
um ferritin ,100µg/L, or serum ferritin 100–299µg/L and treatment interruptions, adherence should be periodically
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 45 ---
3662 ESC/ERSGuidelines
monitored by a member of the multidisciplinary team, to identify hormonal contraceptives should be carefully considered.361 Using
non-adherenceandanychangestothetreatmentregimenspontan- hormonalimplantsoranintrauterinedevicearealternativeoptions
eouslytriggeredbypatientsornon-expertphysicians.Topromote withlowfailurerates.Surgicalsterilizationmaybeconsideredbutis
adherence, it is important to ensure that patients are involved in associatedwithperi-operativerisks.Emergencypost-coitalhormo-
caredecisionsandappropriatelyinformedabouttreatmentoptions nalcontraceptionissafeinPH.
andrationale,expectations,sideeffects,andpotentialconsequences
of non-adherence. Patients should be advised that any changes in 6.3.2.2.Surgicalprocedures
treatmentshouldbemadeincooperationwiththePHcentre. SurgicalproceduresinpatientswithPHareassociatedwithanele-
vatedriskofrightHFanddeath.Inaprospective,multinationalregis-
6.3.2.Specialcircumstances tryincluding114patientswithPAHwhounderwentnon-cardiacand
6.3.2.1.Pregnancyandbirthcontrol non-obstetric surgery, the peri-operative mortality rate was 2% in
6.3.2.1.1. Pregnancy. Historically,pregnancyinwomenwithPAH electiveproceduresand15%inemergencyprocedures.362Themor-
and other forms of severe PH has been associated with maternal talityriskwasassociatedwiththeseverityofPH.Thedecisiontoper-
mortalityratesofupto56%andneonatalmortalityratesofupto formsurgeryshouldbemadebyamultidisciplinaryteaminvolvinga
13%.350WithimprovedtreatmentofPAHandnewapproachesto PHphysician,andmustbebasedonanindividualrisk:benefitassess-
managingwomenduringpregnancyandtheperi-partumperiod,ma- ment considering various factors, including indication, urgency, PH
ternalmortalityhasdeclinedbutremainshigh,ranging11–25%.351–355 severity, and patient preferences. Risk scores to predict the peri-
Forthesereasons,previousESC/ERSGuidelinesforthediagnosisand operativemortalityriskhavebeendevelopedbutrequirefurtherval-
treatmentofPHhaverecommendedthatpatientswithPAHshould
idation.363Generalrecommendationscannotbemade.Thesameis
avoidpregnancy.25,26However,therearereportsoffavourablepreg- trueregardingthepreferredmodeofanaesthesia.Pre-operativeop-
nancyoutcomesinwomenwithPH,including,butnotlimitedto,wo- timizationofPAHtherapyshouldbeattemptedwheneverpossible
men with IPAH who respond to CCB therapy.353,354,356,357 (see also the 2022 ESC Guidelines on cardiovascular assessment
Nonetheless,pregnancyremainsassociatedwithunforeseeablerisks,
andmanagementofpatientsundergoingnon-cardiacsurgery).364
andmayacceleratePHprogression.358WomenwithPHcandeteri-
orate at any time during or after pregnancy. Therefore, physicians 6.3.2.3.Travelandaltitude
havearesponsibilitytoinformpatientsabouttherisksofpregnancy, Hypobarichypoxiamayinducearterialhypoxaemia,additionalhyp-
sothatwomenandtheirfamiliescanmakeinformeddecisions. oxic pulmonary vasoconstriction, and increased RV load in
Women with poorly controlled disease, indicated by an PAH.365,366 Cabin aircraft pressures are equivalent to altitudes up
intermediate- or high-risk profile and signs of RV dysfunction, are to 2438m,367 at which the PaO decreases to that of an inspired
2
at high risk of adverse outcomes; in the event of pregnancy, they O fraction of 15.1% at sea level.365 However, evidence suggests
2
shouldbecarefullycounselledandearlyterminationshouldbead- that short-term (less than 1 day) normobaric hypoxia is generally
vised. For patients with well-controlled disease, a low-risk profile, well tolerated in clinically stable patients with PAH.365,368–372
and normal or near-normal resting haemodynamics who consider In-flightoxygenadministration isadvised forpatients using oxygen
becoming pregnant, individual counselling and shared decision- at sea level and for those with PaO ,8kPa (60mmHg) or SaO
2 2
makingarerecommended.Insuchcases,alternativessuchasadop- ,92%.25,26,325,369,372 An oxygen flow rate of 2 L/min will raise in-
tion and surrogacy may also be explored. Pre-conception genetic spiredoxygenpressuretovaluesasatsealevel,andpatientsalready
counsellingshouldalsobeconsideredinHPAH. using oxygen at sea level should increase their oxygen flow
WomenwithPHwhobecomepregnantorpresentduringpreg- rate.25,26,373
nancywithnewlydiagnosedPAHshouldbetreated,wheneverpos- Astheeffectsofmoderatetolong-term(hours–days)hypoxiaex-
sible, in centres with a multidisciplinary team experienced in posure in PAH remain largely unexplored,374,375 patients should
managingPHinpregnancy.Ifpregnancyiscontinued,PAHtherapy avoid altitudes .1500m without supplemental oxygen.25,26,369
mayhavetobeadjusted.Itisrecommendedtostopendothelinre- However,patientswithPAHwhoarenothypoxaemicatsealevel
ceptorantagonists(ERAs),riociguat,andselexipagbecauseofpoten- have tolerated day trips to 2500m reasonably well.376 Patients
tialorunknownteratogenicity.359Despitelimitedevidence,CCBs, shouldtravelwithwritteninformationabouttheirdisease,including
PDE5is, and inhaled/i.v./subcutaneous (s.c.) prostacyclin analogues a medication list,bring extra dosesoftheir medication,and be in-
areconsideredsafeduringpregnancy.356,360 formedaboutlocalPHcentresneartheirtraveldestination.25,26
Pregnancy in PH is a very sensitive topic and requires empathic
communication.Psychologicalsupportshouldbeofferedwhenever Recommendation Table 5 — Recommendations for
needed. generalmeasuresandspecialcircumstances
Recommendations Classa Levelb
6.3.2.1.2.Contraception. WomenwithPHofchildbearingpoten-
tialshouldbeprovidedwithclearcontraceptiveadvice,considering Generalmeasures
theindividualneedsofthewomanbutrecognizingthattheimplica- Supervisedexercisetrainingisrecommendedin
tionsofcontraceptivefailurearesignificantinPH.Withappropriate patientswithPAHundermedical I A
use,manyformsofcontraception,includingoralcontraceptives,are therapy314,315,317
highlyeffective.Inpatientstreatedwithbosentan,reducedefficacyof
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 46 ---
ESC/ERSGuidelines 3663
Psychosocialsupportisrecommendedinpatients Itisrecommendedtoprovidewomenof
I C
withPAH childbearingpotentialwithPAHwithclear
ImmunizationofpatientswithPAHagainst contraceptiveadvice,consideringtheindividualneeds I C
SARS-CoV-2,influenza,andStreptococcus I C ofthewomanbutrecognizingthattheimplicationsof
pneumoniaeisrecommended contraceptivefailurearesignificantinPAH
Diuretictreatmentisrecommendedinpatients ItisrecommendedthatwomenwithPAHwho
withPAHwithsignsofRVfailureandfluid I C considerpregnancyorwhobecomepregnant
retention receivepromptcounsellinginanexperiencedPH
Long-termoxygentherapyisrecommendedin centre,tofacilitategeneticcounsellingandshared I C
patientswithPAHwhosearterialbloodoxygen I C decision-making,andtoprovidepsychological
pressureis,8kPa(60mmHg)c supporttothepatientsandtheirfamilieswhere
Inthepresenceofiron-deficiencyanaemia, needed
correctionofironstatusisrecommendedin I C ForwomenwithPAHhavingaterminationof
patientswithPAH pregnancy,itisrecommendedthatthisbe I C
performedinPHcentres,withpsychological
Intheabsenceofanaemia,ironrepletionmaybe
consideredinpatientswithPAHwithiron IIb C supportprovidedtothepatientsandtheirfamilies
deficiency ForwomenwithPAHwhodesiretohavechildren,
whereavailable,adoptionandsurrogacywithpre- IIb C
Anticoagulationisnotgenerallyrecommendedin
patientswithPAHbutmaybeconsideredonan IIb C conceptiongeneticcounsellingmaybeconsidered
individualbasis Asteratogenicpotentialhasbeenreportedin
pre-clinicalmodelsforendothelinreceptor
TheuseofACEis,ARBs,ARNIs,SGLT-2is, III B
antagonistsandriociguat,thesedrugsarenot
beta-blockers,orivabradineisnotrecommended
inpatientswithPAHunlessrequiredby III C
recommendedduringpregnancy359,377
comorbidities(i.e.highbloodpressure,coronary PAH,pulmonaryarterialhypertension;PH,pulmonaryhypertension.
arterydisease,leftHF,orarrhythmias) aClassofrecommendation.
bLevelofevidence.
Specialcircumstances
In-flightoxygenadministrationisrecommended
forpatientsusingoxygenorwhosearterialblood I C
6.3.3.Pulmonaryarterialhypertensiontherapies
oxygenpressureis,8kPa(60mmHg)atsealevel
6.3.3.1.Calciumchannelblockers
Forinterventionsrequiringanaesthesia,
Patients with PAH who respond favourably to acute vasoreactivity
multidisciplinaryconsultationataPHcentreto IIa C
testing (Figure 8) may respond favourably to treatment with
assessriskandbenefitshouldbeconsidered
CCBs.129,146Lessthan10%ofpatientswithIPAH,HPAH,orDPAH
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; areresponders,whileanacutevasodilatorresponsedoesnotpredict
ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; PAH, pulmonary afavourablelong-termresponsetoCCBsinpatientswithotherforms
arterialhypertension;PH,pulmonaryhypertension;RV,rightventricle;SARS-CoV-2, of PAH.129,146,378 The CCBs that have predominantly been used in
severe acute respiratory syndrome coronavirus-2; SGLT-2i, sodium–glucose
cotransporter-2inhibitor.
PAHarenifedipine,diltiazem,andamlodipine.129,146Amlodipineand
aClassofrecommendation. felodipineareincreasinglybeingusedinclinicalpracticeduetotheir
bLevelofevidence.
longhalf-lifeandgoodtolerability.Thedailydosesthathaveshownef-
cMeasuredonatleasttwooccasions.
ficacyinPAHarerelativelyhighandtheymustbereachedprogressive-
ly (Table 19). The most common adverse events are systemic
hypotensionandperipheraloedema.
Patientswhomeetthecriteriaforapositiveacutevasodilatorre-
Recommendation Table 6 — Recommendations for sponseandtreatedwithCCBsshouldbecloselyfollowedforsafety
womenofchildbearingpotential andefficacy,withacompletereassessmentafter3–6monthsofther-
apy,includingRHC.Additionalacutevasoreactivitytestingshouldbe
Recommendations Classa Levelb
performed at re-evaluation to detect persistent vasodilator re-
Itisrecommendedthatwomenofchildbearing sponse,supportingpossibleincreasesinCCBdosage.Patientswith
potentialwithPAHarecounselledatthetimeof a satisfactory chronic response present with WHO-FC I/II and
diagnosisabouttherisksanduncertainties marked haemodynamic improvement (ideally, mPAP ,30mmHg
I C
associatedwithbecomingpregnant;thisshould andPVR,4WU)whileonCCBtherapy.Intheabsenceofasatis-
includeadviceagainstbecomingpregnant,and factory response, additional PAH therapy should be instituted. In
referralforpsychologicalsupportwhereneeded somecases,acombinationofCCBswithapprovedPAHdrugsisre-
Continued quired because of clinical deterioration with CCB withdrawal
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 47 ---
3664 ESC/ERSGuidelines
attempts.Patientswhohavenotundergoneavasoreactivitystudyor Nifedipine 10mgt.i.d. 20–60mgb.i.d.ort.i.d.
thosewithanegativetestshouldnotbestartedonCCBsbecauseof
Endothelinreceptorantagonists(oraladministration)
potentiallyseveresideeffects(e.g.severehypotension,syncope,and
Ambrisentan 5mgo.d. 10mgo.d.
RV failure), unless prescribed at standard doses for other
indications.379 Bosentan 62.5mgb.i.d. 125mgb.i.d.
Macitentan 10mgo.d. 10mgo.d.
Phosphodiesterase5inhibitors(oraladministration)
Recommendation Table 7 — Recommendations for
Sildenafil 20mgt.i.d. 20mgt.i.d.c
thetreatmentofvasoreactivepatientswithidiopath-
ic, heritable, or drug-associated pulmonary arterial Tadalafil 20or40mg 40mgo.d.
hypertension o.d.
Prostacyclinanalogues(oraladministration)
Recommendations Classa Levelb
Beraprostsodium 20µgt.i.d. Maximumtolerateddoseupto
HighdosesofCCBsarerecommendedinpatients 40µgt.i.d.
withIPAH,HPAH,orDPAHwhoareresponders I C Beraprost 60µgb.i.d. Maximumtolerateddoseupto
toacutevasoreactivitytesting extendedrelease 180µgb.i.d.
Closefollow-upwithcompletereassessment Treprostinil 0.25mgb.i.d. Maximumtolerateddose
after3–4monthsoftherapy(includingRHC)is
I C or
recommendedinpatientswithIPAH,HPAH,or 0.125mgt.i.d.
DPAHtreatedwithhighdosesofCCBs
Prostacyclinreceptoragonist(oraladministration)
ContinuinghighdosesofCCBsisrecommended
Selexipag 200µgb.i.d. Maximumtolerateddoseupto
inpatientswithIPAH,HPAH,orDPAHin
1600µgb.i.d.
WHO-FCIorIIwithmarkedhaemodynamic I C
improvement(mPAP,30mmHgandPVR,4 Solubleguanylatecyclasestimulator(oraladministration)
WU) Riociguatd 1mgt.i.d. 2.5mgt.i.d.
InitiatingPAHtherapyisrecommendedinpatients Prostacyclinanalogues(inhaledadministration)
whoremaininWHO-FCIIIorIVorthosewithout I C Iloproste 2.5µg6–9 5.0µg6–9timesperday
markedhaemodynamicimprovementafterhigh
timesperday
dosesofCCBs Treprostinile 18µg4times 54–72µg4timesperday
Inpatientswithapositivevasoreactivitytestbut
perday
insufficientlong-termresponsetoCCBswho
IIa C Prostacyclinanalogues(i.v.ors.c.administration)
requireadditionalPAHtherapy,continuationof
Epoprostenoli.v. 2ng/kg/min Determinedbytolerabilityand
CCBtherapyshouldbeconsidered
effectiveness;typicaldoserange
CCBsarenotrecommendedinpatientswithouta
at1yearis16–30ng/kg/min,
vasoreactivitystudyornon-responders,unless
III C
prescribedforotherindications(e.g.Raynaud’s withwideindividualvariability
Treprostinils.c.or 1.25ng/kg/ Determinedbytolerabilityand phenomenon)
i.v. min effectiveness;typicaldoserange
CCB,calciumchannelblocker;DPAH,drug-associatedpulmonaryarterialhypertension; at1yearis25–60ng/kg/min,
HPAH,heritablepulmonaryarterialhypertension;IPAH,idiopathicpulmonaryarterial
withwideindividualvariability
hypertension; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial
hypertension;PVR,pulmonaryvascularresistance;RHC,rightheartcatheterization;
b.i.d.,twicedaily;i.v.,intravenous;o.d.,oncedaily;s.c.,subcutaneous;t.i.d.,threetimes
WHO-FC,WorldHealthOrganizationfunctionalclass;WU,Woodunits.
aClassofrecommendation. daily.
bLevelofevidence. Dosagesarethosecommonlyusedinclinicalpractice.Thisdoesnotexcludetheuseof
alternativedosages.
aThedailydosagesofamlodipineandfelodipinecanbeadministeredinasingledoseor
dividedintotwodoses.
bThere are different release formulations of diltiazem, some of which should be
Table19 Dosingofpulmonaryarterialhypertension
administeredo.d.ort.i.d.
medicationinadults cSildenafilisapprovedatadoseof20mgt.i.d.butdosesusedinpracticevarywidelyand
aresometimeshigher.
Starting Targetdose dInpatientsatriskofsystemichypotension,riociguatmaybestartedat0.5mgt.i.d.
dose
eDosesprovidedarefornebulizersandmaydifferwiththeuseofotherformulations
andotherinhalationdevices.
Calciumchannelblockers
Amlodipine 5mgo.d. 15–30mgo.d.a 6.3.3.2.Endothelinreceptorantagonists
Diltiazem 60mgb.i.d.b 120–360mgb.i.d.b Binding of endothelin-1 to endothelin receptors A and B on PA
Felodipine 5mgo.d. 15–30mgo.d.a smooth-muscle cells promotes vasoconstriction and proliferation
Continued (Figure 7).380 Endothelin B receptors are mostly expressed on
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 48 ---
ESC/ERSGuidelines 3665
VVVasoreactivity testing algorithm in patients with presumed diagnosis of I/H/D-PPPAH and treatment of responders
Reffferto PHcentre
Right heart catheterization
with pulmonary vasoreactivity testinga
(Class I)
≥10 mmHg mPPPAP drop from baseline
N
to ≤40 mmHg with increased or unchanged cardiac output
Y
Initiatetherapppy with calcium channel blockkkers
and titrate to optimized individual doseb
(Class I)
Reassess after 3–6 months
WHO-FC I/II, BNP <50 ng/L or NTTT-proBNP <300 ng/L, Treat according
N
normal or near-normalresting haemodynamicsc to Figure 9
YY
Continue therapppy andreassessevery 6–12 months
Figure8Vasoreactivitytestingalgorithmofpatientswithpresumeddiagnosisofidiopathic,heritable,ordrug-associatedpulmonaryarterialhyperten-
sion.BNP,brainnatriureticpeptide;I/H/D-PAH,idiopathic,heritable,drug-associatedpulmonaryarterialhypertension;mPAP,meanpulmonaryarterial
pressure;N,no;NT-proBNP,N-terminalpro-brainnatriureticpeptide;PH,pulmonaryhypertension;PVR,pulmonaryvascularresistance;WHO-FC,
WorldHealthOrganizationfunctionalclass;WU,Woodunits;Y,yes.aInhalednitricoxideandinhalediloprostarerecommended;intravenousepopros-
tenolcanbeusedifinhalednitricoxideorinhalediloprostareunavailable.bSeetextfordetails.cmPAP≤30mmHgandPVR≤4WU.
pulmonaryendothelialcells,promotingvasodilationthroughacceler- peripheraloedemawasreportedwithambrisentanuse,whilethere
ated production of prostacyclin and nitric oxide, and clearance of wasnoincreasedincidenceofabnormalliverfunction.
endothelin-1.380Nevertheless,selectiveblockingofendothelinAre-
ceptorsaloneornon-selectiveblockingofbothAandBreceptors
6.3.3.2.2. Bosentan. Bosentanisanoral, dualERAthat improves
hasshownsimilareffectivenessinPAH.380Endothelialreceptoran-
exercise capacity, WHO-FC, haemodynamics, and time to clinical
tagonists have teratogenic effects and should not be used during
worsening in patients with PAH.383 The approved target dose in
pregnancy.381
adults is 125mg b.i.d. Dose-dependent increases in liver transami-
nasescanoccurin(cid:4)10%oftreatedpatients(reversibleafterdose
6.3.3.2.1.Ambrisentan. AmbrisentanisanoralERAthatpreferen- reductionordiscontinuation).384Thus,liverfunctiontestingshould
tially blocks the endothelin A receptors. The approved dosages in be performed monthly in patients receiving bosentan.384 Due to
adultsare5mgand10mgo.d.InpatientswithPAH,ithasdemon- pharmacokineticinteractions,bosentanmayrenderhormonalcon-
strated efficacy for symptoms, exercise capacity, haemodynamics, traceptivesunreliableandlowerserumlevelsofwarfarin,sildenafil,
and time to clinical worsening.382 An increased incidence of andtadalafil.361,385–387
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 49 ---
3666 ESC/ERSGuidelines
TTTreatment of patients with I/H/D-PPPAH or PPPAH-CTD
Diagnosis confirmed at PH centre,, vasoreactivity testing negative
General measures throughout
the course of the disease
(ReCoTTTable 5)
(Class I)
Patient without Patient with
cardiopulmonary comorbiditiesa cardiopulmonary comorbiditiesa
All risk categories
Risk (3 strata)
(TTTable 16)
Low or intermediate High
InitialERRRA InitialERA + PDE5i Initial oral monotherapppy
+PDE5itherapppy andi.vvv./s.c.. PCAb with PDE5i or ERRRA
(ClassI) (Class IIa) (ClassIIa)
Regularfffollow-up assessment Regular fffollow-up assessment
(TTTable 17) and individualizedtherapppy
Risk (4 strata)
(TTTable 18)
Intermediate-high
Low Intermediate-low
or high
Switch from Addi.vvv.. orr s.c.. PCA and/or
Continueinitialtherapppy Add PRRRA
OR PDE5ito sGCs evaluaaateffforlung transplantaation
(Class I) (Class IIa) (ClassIIb) (Class IIa)
Figure9Evidence-basedpulmonaryarterialhypertensiontreatmentalgorithmforpatientswithidiopathic,heritable,drug-associated,andconnective
tissuedisease-associatedpulmonaryarterialhypertension.DLCO,Lungdiffusioncapacityforcarbonmonoxide;ERA,endothelinreceptorantagonist;I/
H/D-PAH,idiopathic,heritable,ordrug-associatedpulmonaryarterialhypertension;i.v.,intravenous;PAH-CTD,PAHassociatedwithconnectivetissue
disease;PCA,prostacyclinanalogue;PDE5i,phosphodiesterase5inhibitor;PH,pulmonaryhypertension;PRA,prostacyclinreceptoragonist;ReCo,rec-
ommendation;s.c.,subcutaneous;sGCs,solubleguanylatecyclasestimulator.aCardiopulmonarycomorbiditiesareconditionsassociatedwithanin-
creased risk of left ventricular diastolic dysfunction, and include obesity, hypertension, diabetes mellitus, and coronary heart disease; pulmonary
comorbidities may include signs of mild parenchymal lung disease and are often associated with a low DLCO (,45% of the predicted value).
bIntravenousepoprostenolori.v./s.c.treprostinil.
6.3.3.2.3. Macitentan. Macitentan is an oral, dual ERA that has 6.3.3.3.Phosphodiesterase5inhibitorsandguanylatecyclase
been found to increase exercise capacity and reduce a composite stimulators
endpointofclinicalworseninginpatientswithPAH.167Whilenoliver Stimulatingsolubleguanylatecyclase(sGC)bynitricoxideresultsin
toxicityhasbeenshown,areductioninHbto≤8g/dLwasobserved production of the intracellular second messenger cyclic guanosine
in4.3%ofpatientsreceiving10mgofmacitentan.167 monophosphate(cGMP)(Figure7).Thispathwayiscontrolledbya
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 50 ---
ESC/ERSGuidelines 3667
negative feedback loop through degradation of cGMP via different RCT,inwhichsixtoninerepetitiveiloprostinhalationswerecom-
phosphodiesterases,among which subtype 5 (PDE5) isabundantly pared with placebo in treatment-naïve patients with PAH or
expressedinthepulmonaryvasculature.388Phosphodiesterase5in- CTEPH.407Thestudyshowedanincreaseinexercisecapacityand
hibitorsandsGCstimulatorsmustnotbecombinedwitheachother improvementinsymptoms,PVR,andclinicaleventsintheiloprost
andwithnitrates,asthiscanresultinsystemichypotension.389 groupcomparedwiththeplacebogroup.
6.3.3.3.1.Sildenafil. Sildenafilisanorallyactive,potent,andselect- 6.3.3.4.3. Treprostinil. Treprostinilisavailablefors.c.,i.v.,inhaled,
ive inhibitor of PDE5. Several RCTs of patients with PAH treated andoraladministration.Treprostinils.c.improvedexercisecapacity,
withsildenafil(withorwithoutbackgroundtherapy)haveconfirmed haemodynamics,andsymptomsinPAH.408Infusion-sitepainwasthe
favourable results on exercise capacity, symptoms, and/or haemo- most common adverse effect, which led to treatment discontinu-
dynamics.390–392 The approved dose of sildenafil is 20mg t.i.d. ationin8%ofcases.408Basedonitschemicalstability,i.v.treprostinil
Mostsideeffectsofsildenafilaremildtomoderateandmainlyrelated mayalsobeadministeredviaimplantablepumps,improvingconveni-
tovasodilation(headache,flushing,andepistaxis). enceandlikelydecreasingtheoccurrenceoflineinfections.409,410
Inhaledtreprostinilimprovedthe6MWD,NT-proBNP,andqual-
6.3.3.3.2.Tadalafil. Tadalafilisaonce-dailyadministeredPDE5i.An ityoflifemeasuresinpatientswithPAHonbackgroundtherapywith
RCTof406patientswithPAH(53%onbackgroundbosentanther- eitherbosentanorsildenafil.411Inhaledtreprostinilisnotapproved
apy)treatedwithtadalafilatdosesupto40mgo.d.showedfavour- inEurope.
able results on exercise capacity, symptoms, haemodynamics, and OraltreprostinilhasbeenevaluatedintwoRCTsofpatientswith
timeto clinicalworsening.393Thesideeffectprofile wassimilarto PAHonbackgroundtherapywithbosentanand/orsildenafil.Inboth
thatofsildenafil. trials,theprimaryendpoint—6MWD—didnotreachstatisticalsig-
nificance.412,413AnadditionalRCTintreatment-naïvepatientswith
6.3.3.3.3.Riociguat. WhilePDE5isaugmentthenitricoxide–cGMP PAH showed improved 6MWD.414 An event-driven RCT that en-
pathway by slowing cGMP degradation, sGC stimulators enhance rolled690patientswithPAHdemonstratedthatoraltreprostinilre-
cGMP production by directly stimulating the enzyme, both in the duced the risk of clinical worsening events in patients who were
presence and absence of endogenous nitric oxide.394 An RCT of receivingoralmonotherapywithERAsorPDE5is.415Oraltreprosti-
443patients with PAH (44% and6% on background therapy with nilisnotapprovedinEurope.
ERAsorprostacyclinanalogues,respectively)treatedwithriociguat
up to 2.5mg t.i.d. showed favourable results on exercise capacity, 6.3.3.4.4.Beraprost. Beraprostisachemicallystableandorallyac-
haemodynamics, WHO-FC, and time to clinical worsening.395 The tiveprostacyclinanalogue.TwoRCTshaveshownamodest,short-
sideeffectprofilewassimilartothatofPDE5is. termimprovementinexercisecapacityinpatientswithPAH;416,417
however,therewerenohaemodynamicimprovementsorlong-term
6.3.3.4.Prostacyclinanaloguesandprostacyclinreceptoragonists outcomebenefits.BeraprostisnotapprovedinEurope.
Theprostacyclinmetabolicpathway(Figure7)isdysregulatedinpa-
tients with PAH, with less prostacyclin synthase expressed in PAs 6.3.3.4.5.Selexipag. Selexipagisanorallyavailable,selective,pros-
andreducedprostacyclinurinarymetabolites.396Prostacyclinanalo- tacyclinreceptoragonistthatischemicallydistinctfromprostacyclin,
guesandprostacyclinreceptoragonistsinducepotentvasodilation, withdifferentpharmacology.InapilotRCTinpatientswithPAH(re-
inhibit platelet aggregation, and also have both cytoprotective and ceiving stable ERA and/or PDE5i therapy), selexipag reduced PVR
anti-proliferativeactivities.397Themostcommonadverseeventsob- after 17 weeks.418 An event-driven, phase 3 RCT that enrolled
servedwith thesecompounds arerelated to systemicvasodilation 1156 patients419 showed that selexipag alone or on top of mono
andincludeheadache,flushing,jawpain,anddiarrhoea. ordoubletherapywithanERAand/oraPDE5ireducedtherelative
riskofcompositemorbidity/mortalityeventsby40%.Themostcom-
6.3.3.4.1. Epoprostenol. Epoprostenol has a short half-life (3– monsideeffectswereheadache,diarrhoea,nausea,andjawpain.
5min) and needs continuous i.v. administration via an infusion
pumpandapermanenttunnelledcatheter.Athermo-stableformu- 6.3.4.Treatmentstrategiesforpatientswith
lationisavailabletomaintainstabilityupto48h.398Itsefficacyhas idiopathic,heritable,drug-associated,or
beendemonstratedinthreeunblindedRCTsinpatientswithIPAH connectivetissuedisease-associatedpulmonary
(WHO-FC III and IV)399,400 and SSc-associated PAH.401 arterialhypertension
Epoprostenolimprovedsymptoms,exercisecapacity,haemodynam- Pulmonaryarterialhypertensionisarareandlife-threateningdisease
ics, and mortality.399 Long-term, persistent efficacy has also been andshouldbemanaged,wherepossible,atPHcentresinclosecol-
shown in IPAH,212,245 as well as in other associated PAH condi- laborationwiththepatient’slocalphysicians.
tions.402–404Seriousadverseeventsrelatedtothedeliverysystemin-
This section describes drug treatment and is focused on non-
clude pump malfunction, local site infection, catheter obstruction, vasoreactive patients with IPAH/HPAH/DPAH and on patients
and sepsis. Recommendations for preventing central venous cath- with PAH associated with connective tissue disease (PAH-CTD).
eterbloodstreaminfectionshavebeenproposed.405,406 Information on the dosing of PAH medication is summarized in
Table19.ForotherformsofPAH,treatmentstrategieshavetobe
6.3.3.4.2.Iloprost. Iloprostisaprostacyclinanalogueapprovedfor modified (see Section 7). The approach to vasoreactive patients
inhaled administration. Inhaled iloprost has been evaluated in one withIPAH/HPAH/DPAHisdescribedinSection6.3.3.1.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 51 ---
3668 ESC/ERSGuidelines
Inadditiontotargeteddrugtreatment,thecomprehensiveman- obtained with initial ERA/PDE5i combination therapy. Further
agementofpatientswithPAHincludesgeneralmeasuresthatmay studiesareneededtodeterminewhetheroraltriple-combination
includesupplementaryoxygen,diureticstooptimizevolumestatus, therapyimpactslong-termoutcomes.
psychosocial support, and standardized exercise training (Section Based on the evidence generated by these and other stud-
6.3.1).315 Prior to the treatment decisions, patients and their next ies,303,422–424 initial dual-combination therapy with an ERA and a
ofkinshouldbeprovidedwithappropriateandtimelyinformation PDE5iisrecommendedfornewlydiagnosedpatientswhopresent
about the risks and benefits of the treatment options so they can at low or intermediate risk. Initial oral triple-combination therapy
make the final, informed, and joint decision about the treatment isnotrecommended,giventhecurrentlackofevidencesupporting
withthemedicalteam.TreatmentdecisionsinpatientswithIPAH/ this strategy. In patients presenting at high risk, initial triple-
HPAH/DPAH or PAH-CTD should be stratified according to the combination therapy including an i.v./s.c. prostacyclin analogue
presence or absence of cardiopulmonary comorbidities (Section shouldbeconsidered.426,427Whileitisacknowledgedthattheevi-
6.3.4.3)andaccordingtodiseaseseverityassessedbyriskstratifica- denceforthisapproachislimitedtocaseseries,thereisconsensus
tion(Section6.2.7). thatthisstrategyhasthehighestlikelihoodofsuccess,especiallyin
view of registry data from France showing that initial triple-
6.3.4.1.Initialtreatmentdecisioninpatientswithout combinationtherapyincludingani.v./s.c.prostacyclinanaloguewas
cardiopulmonarycomorbidities associatedwithbetterlong-termsurvivalthanmonotherapyordual-
TheinitialtreatmentofpatientswithPAHshouldbebasedonacom- combinationtherapy.428Initialtriple-combinationtherapyincluding
prehensive, multiparameter risk assessment, considering disease ani.v./s.c.prostacyclinanalogueshouldalsobeconsideredinpatients
typeandseverity,comorbidities,accesstotherapies,economicas- at intermediate risk presenting with severe haemodynamic impair-
pects,andpatientpreference. ment (e.g. RAP ≥20 mmHg, CI ,2.0L/min/m2, SVI ,31mL/m2,
Thefollowingconsiderationspredominantlyapplytopatientswith and/orPVR≥12WU).238,426
IPAH/HPAH/DPAH or PAH-CTD without cardiopulmonary co- Therecommendationsforinitialoraldouble-combinationtherapy
morbidities,aspatientswithcomorbiditieswereunder-represented are based on PICO question I (Supplementary Data, Section 6.2).
in the clinical studies addressing treatment strategies and combin- Althoughthequalityofevidenceislow,initialoralcombinationther-
ationtherapyinpatientswithPAH.Treatmentconsiderationsforpa- apywithanERAandaPDE5iachievesimportanttargetsinsymptom
tientswithPAHandcardiopulmonarycomorbiditiesaresummarized improvement (functional class), exercise capacity, cardiac biomar-
inSection6.3.4.3. kers,andreductionofhospitalizations.
Forpatientspresentingatloworintermediaterisk,initialcombin-
ationtherapywithanERAandaPDE5iisrecommended.Thisap-
Recommendation Table 8 — Recommendations for
proach was assessed in the AMBITION study, which compared
the treatment of non-vasoreactive patients with idio-
initial combination therapy using ambrisentan at a target dose of pathic,heritable,ordrug-associatedpulmonaryarterial
10mg o.d. and tadalafil at a target dose of 40mg o.d. with initial hypertension who present without cardiopulmonary
monotherapy with either drug.166 AMBITION predominantly in- comorbiditiesa
cludedpatientswithIPAH/HPAH/DPAHorPAH-CTD.Theprimary
RecommendationTable8A
endpointwasthetimetofirstclinicalfailureevent(acompositeof
death, hospitalization for worsening PAH, disease progression, or Recommendations Classb Levelc
unsatisfactory long-term clinical response). The hazard ratio (HR)
fortheprimaryendpointinthecombination-therapygroupvs.the Recommendationsforinitialtherapy
pooled monotherapy group was 0.50 (95% confidence interval InpatientswithIPAH/HPAH/DPAHwhopresent
[CI],0.35–0.72;P,0.001)andthereweresignificantimprovements
athighriskofdeath,initialcombinationtherapy
IIa C
in6MWDandNT-proBNPwithinitialcombinationtherapy.Atthe withaPDE5i,anERA,andi.v./s.c.prostacyclin
endofthestudy,10%ofthepatientsassignedtoinitialcombination analoguesshouldbeconsideredd
therapyhaddiedcomparedwith14%ofthepatientsassignedtoini-
Recommendationsfortreatmentdecisionsduringfollow-up
tialmonotherapy(HR0.67;95%CI,0.42–1.08).420
InpatientswithIPAH/HPAH/DPAHwhopresent
IntheTRITONstudy,treatment-naïvepatientswithPAHwere
atintermediate–lowriskofdeathwhilereceiving
assignedtoinitialdual-combinationtherapywithmacitentanand IIa B
ERA/PDE5itherapy,theadditionofselexipag
tadalafil, or initial triple-combination therapy with macitentan
shouldbeconsidered419
10mgo.d.,tadalafil ata targetdoseof40mgo.d.,andselexipag
InpatientswithIPAH/HPAH/DPAHwhopresent
up to 1600 µg o.d.421 TRITON predominantly included patients
atintermediate–highorhighriskofdeathwhile
withIPAH/HPAH/DPAHorPAH-CTD.Atweek26,PVRwasre-
receivingERA/PDE5itherapy,theadditionofi.v./ IIa C
ducedby52%and54%,withdouble-ortriple-combinationther-
s.c.prostacyclinanaloguesandreferralforLTx
apy, respectively, and 6MWD had increased by 55 m and 56 m,
evaluationshouldbeconsidered
respectively. The geometric means of the NT-proBNP ratio
InpatientswithIPAH/HPAH/DPAHwhopresent from baseline to week 26 were 0.25 and 0.26, respectively.
Hence, TRITON did not show a benefit of oral triple- vs. oral
atintermediate–lowriskofdeathwhilereceiving
IIb B
double-combination therapy but confirmed that substantial im- ERA/PDE5itherapy,switchingfromPDE5ito
riociguatmaybeconsidered429
provements in haemodynamics and exercise capacity can be
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 52 ---
ESC/ERSGuidelines 3669
Patients who achieve a low-risk status have a much superior
RecommendationTable8B
long-term survival compared with patients with intermediate-
or high-risk status.292,295,296 Achieving and maintaining a low-
GRADE
risk profile is therefore a key objective in managing patients
with PAH.
Recommendations Quality Strengthof Classa Levelb
Several clinical trials have assessed the safety and efficacy of se-
of recommendation
quentialcombinationtherapyinpatientswithPAH.SERAPHINen-
evidence
rolled742patientswithPAH,mostlywithIPAH/HPAH/DPAHand
Recommendationsforinitialtherapy PAH-CTD,ofwhom63.7%werereceivingotherPAHmedication
InpatientswithIPAH/ Low Conditional atthetimeofenrolment,mostlysildenafil.167Inthesubgroupofpa-
HPAH/DPAHwho
tientswithbackgroundPAHtherapy,macitentanatadailydoseof
presentatlowor
10mgreducedtheriskofclinicalworseningeventscomparedwith
intermediateriskof
death,initial I B
placebo(HR0.62;95%CI,0.43–0.89).167
combinationtherapy GRIPHONassessedthesafetyandefficacyofselexipag.419This
withaPDE5iandan study enrolled 1156 patients with PAH, also mostly with IPAH/
ERAis
HPAH/DPAHorPAH-CTD,whoweretreatmentnaïveorreceiv-
recommended166
ingbackgroundtherapywithanERA,PDE5i,oracombinationof
CI, cardiac index; DLCO, Lung diffusion capacity for carbon monoxide; DPAH, both. Selexipag at a dose of up to 1600µg b.i.d. was associated
drug-associated pulmonary arterial hypertension; ERA, endothelin receptor with a reduced risk of clinical worsening events independent of
antagonist; HFpEF, heart failure with preserved ejection fraction; HPAH, heritable
thebackgroundmedication.InpatientsreceivingERA/PDE5icom-
pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension;
binationtherapy(n=376),theriskofclinicalworseningeventswas
i.v., intravenous; LTx, lung transplantation; PAH, pulmonary arterial hypertension;
PDE5i,phosphodiesterase5inhibitor;PVR,pulmonaryvascularresistance;RAP,right lower with selexipag than with placebo (HR 0.63; 95% CI, 0.44–
atrialpressure;s.c.,subcutaneous;SVI,strokevolumeindex;WU,Woodunits. 0.90).431
aCardiopulmonarycomorbiditiesarepredominantlyencounteredinelderlypatients The effects ofcombination therapyon long-term survivalin pa-
andincluderiskfactorsforHFpEFsuchasobesity,diabetes,coronaryheartdisease,a
tientswithPAHremainunclear.A2016meta-analysisdemonstrated
historyofhypertension,and/oralowDLCO.
thatcombinationtherapy(initialandsequential)wasassociatedwith
bClassofrecommendation.
cLevelofevidence. a significantrisk reduction for clinical worsening(relative risk [RR]
dInitialtriple-combinationtherapyincludingi.v./s.c.prostacyclinanaloguesmayalsobe 0.65;95%CI,0.58–0.72;P,0.0001);432however,all-causemortality
considered in patients presenting at intermediate risk but severe haemodynamic wasnotimproved(RR0.86;95%CI,0.72–1.03;P=0.09)andasub-
impairment(e.g.RAP≥20mmHg,CI,2.0L/min/m2,SVI,31mL/m2,and/orPVR
stantialproportionofpatientshadclinicalworseningeventsordied
≥12WU).
despite receiving combination therapy. In addition, registry data
showedthattheuseofcombination therapyincreasedsince2015
Recommendation Table 9 — Recommendations for
but there was no clear improvement in overall survival
initial oral drug combination therapy for patients
rates.428,433,434 Thesedatawere corroborated bya study showing
withidiopathic,heritable,ordrug-associatedpulmon-
ary arterial hypertension without cardiopulmonary that less than half of patients receiving initial combination therapy
comorbidities with an ERA and a PDE5i achieved and maintained a low-risk
profile.422
Recommendations Classa Levelb SwitchingfromPDE5istoriociguathasalsobeeninvestigatedas
a treatment-escalation strategy.429,435 REPLACE was a rando-
Initialcombinationtherapywithambrisentanand
I B
tadalafilisrecommended166,420,423 mized, controlled, open-label study that enrolled patients on a
PDE5i-based therapy who were in WHO-FC III and had a
Initialcombinationtherapywithmacitentanand
tadalafilisrecommended421,430 I B 6MWD of 165–440m.429 The study predominantly included pa-
tients with IPAH/HPAH/DPAH or PAH-CTD who were rando-
InitialcombinationtherapywithotherERAsand
IIa B mized to continue their PDE5i or to switch from a PDE5i to
PDE5isshouldbeconsidered430
riociguat up to 2.5mg t.i.d. The study met its primary endpoint,
Initialcombinationtherapywithmacitentan,
III B termed ‘clinical improvement’, which was a composite of pre-
tadalafil,andselexipagisnotrecommended421
specified improvements in 6MWD, WHO-FC, and NT-proBNP
ERA,endothelinreceptorantagonist;PDE5i,phosphodiesterase5inhibitor. atweek24.Clinicalimprovementatweek24wasdemonstrated
aClassofrecommendation.
in 41% of the patients who switched to riociguat and in 20% of
bLevelofevidence.
the patients who maintained their PDE5i (odds ratio [OR] 2.78;
95%CI,1.53–5.06;P=0.0007).Inaddition,fewerpatientsinthe
6.3.4.2.Treatmentdecisionsduringfollow-upinpatientswithout riociguatgroupexperiencedaclinicalworseningevent(OR0.10;
cardiopulmonarycomorbidities 95%CI,0.01–0.73;P=0.0047).
PatientswithPAHrequireregularfollow-up,includingriskstrati- Basedontheevidencesummarizedabove,thefollowingrecom-
fication and an assessment of patient concordance with therapy. mendationsfortreatmentdecisionsduringfollow-upare:
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 53 ---
3670 ESC/ERSGuidelines
(i) Inpatientswhoachievealow-riskstatuswiththeirinitialPAH Theadditionoftadalafiltobosentanmaybe
IIb C
therapy,continuationoftreatmentisrecommended. consideredtoimproveexercisecapacity393
(ii) Inpatients who areatintermediate–low riskdespite receiving
Theadditionofinhalediloprosttobosentanmay
IIb B
ERA/PDE5i therapy, adding selexipag should be considered to beconsideredtoimproveexercisecapacity441,442
reducetheriskofclinicalworsening.Inthesepatients,switching Theadditionofambrisentantosildenafilmaybe
fromPDE5itoriociguatmayalsobeconsidered. IIb C
consideredtoimproveexercisecapacity443
(iii) Inpatientswhoareatintermediate–highorhighriskwhilere-
Theadditionofbosentantosildenafilmaybe
ceiving oral therapies, the addition of i.v. epoprostenol or i.v./ IIb C
consideredtoimproveexercisecapacity419,444
s.c.treprostinilandreferralforLTxevaluationshouldbeconsid-
Theadditionofsildenafiltobosentanmaybe
ered.309,436Ifaddingi.v./s.c.prostacyclinanaloguesisunfeasible, IIb C
consideredtoimproveexercisecapacity444–446
adding selexipagor switchingfrom PDE5i to riociguat may be
Othersequentialdouble-ortriple-combination
considered.
therapiesmaybeconsideredtoimproveexercise IIb C
RecommendationTable10—Recommendationsfor capacityand/oralleviatePHsymptoms
sequentialdrugcombinationtherapyforpatientswith Evidencefromstudieswithsafetyofcombinationtherapyas
idiopathic, heritable, or drug-associated pulmonary
theprimaryoutcomemeasure
arterialhypertension
CombiningriociguatandPDE5isisnot
III B
Recommendations Classa Levelb recommendedd389
Generalrecommendationforsequentialcombination 6MWD, 6-minute walking distance; ERA, endothelin receptor antagonist; PDE5i,
phosphodiesterase5inhibitor;PH,pulmonaryhypertension.
therapy
aClassofrecommendation.
Itisrecommendedtobasetreatmentescalations bLevelofevidence.
onriskassessmentandgeneraltreatment I C
cERAsusedintheGRIPHONstudywerebosentanandambrisentan.
dThe PATENT plus study investigated the combination of sildenafil and riociguat;
strategies(seeFigure9) however,combiningriociguatwithanyPDE5iiscontraindicated.
Evidencefromstudieswithacompositemorbidity/mortality
endpointastheprimaryoutcomemeasure
TheadditionofmacitentantoPDE5isororal/
inhaledprostacyclinanaloguesisrecommendedto 6.3.4.3.Pulmonaryarterialhypertensionwithcardiopulmonary
I B
reducetheriskofmorbidity/mortality comorbidities
events167,168,437 Overthepastdecade,thedemographicsandcharacteristicsofpa-
TheadditionofselexipagtoERAscand/orPDE5is tients with IPAH have changed, especially in industrialized coun-
isrecommendedtoreducetheriskofmorbidity/ I B tries.447 In several contemporary registries, the average age of
mortalityevents418,419 patientsdiagnosedwithIPAHis(cid:4)60yearsorolder.161,295,299,447,448
TheadditionoforaltreprostiniltoERAorPDE5i/ Manyelderlypatientshavecardiopulmonarycomorbidities,mak-
riociguatmonotherapyisrecommendedto ing the distinction from group 2 and group 3 PH challenging.
I B
reducetheriskofmorbidity/mortality AmongelderlypatientsdiagnosedwithIPAH,twomaindisease
events412,413,415 phenotypes have emerged. One phenotype (herein called the
Theadditionofbosentantosildenafilisnot leftheartphenotype)consistsofelderly,mostlyfemalepatients
recommendedtoreducetheriskofmorbidity/ III B withriskfactorsforHFpEF(e.g.hypertension,obesity,diabetes,
mortalityevents419a orcoronaryheartdisease)butpre-capillaryPHratherthanpost-
capillaryPH;449,450(cid:4)30%ofthesepatientshaveahistoryofatrial
Evidencefromstudieswithchangein6MWDastheprimary
fibrillation.161Theotherphenotype(calledthecardiopulmonary
outcomemeasure
phenotype)consistsofelderly,predominantlymalepatientswho
Theadditionofsildenafiltoepoprostenolis
I B
havealowDLCO(,45%ofthepredictedvalue),areoftenhy-
recommendedtoimproveexercisecapacity392,438 poxaemic, have a significant smoking history, and have risk fac-
Theadditionofinhaledtreprostiniltosildenafilor tors for LHD.77,78,161,451 In a cluster analysis of 841 newly
bosentanmonotherapyshouldbeconsideredto IIa B diagnosed patients with IPAH from the COMPERA registry,
improveexercisecapacity411,439
12.6%hadaclassicphenotypeofyoung,mostlyfemalepatients
Theadditionofriociguattobosentanshouldbe withoutcardiopulmonarycomorbidities,while35.8%presented
IIa B
consideredtoimproveexercisecapacity395,440 with a left heart phenotype and 51.6% with a cardiopulmonary
Continued phenotype.161
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 54 ---
ESC/ERSGuidelines 3671
There are no evidence-based rules for determining a RecommendationTable11—Recommendationsfor
patient’s phenotype. The AMBITION study used the presence thetreatmentofnon-vasoreactivepatientswithidio-
pathic,heritable,ordrug-associatedpulmonaryarter-
of more than three risk factors for LHD together with
ial hypertension who present with cardiopulmonary
certain haemodynamic criteria to exclude patients from the comorbiditiesa
primary analysis.166 However, the COMPERA cluster analysis
mentioned above found that the presence of a single risk Recommendations Classb Levelc
factor may change the phenotype.161 Pending further data, it is
the overall profile that should be used to determine a patient’s Recommendationsforinitialtherapy
phenotype. InpatientswithIPAH/HPAH/DPAHand
Comparedwithpatientswithoutcardiopulmonarycomorbidities, cardiopulmonarycomorbidities,initial
IIa C
patients with cardiopulmonary comorbidities respond less well to monotherapywithaPDE5ioranERAshouldbe
PAH medication, are more likely to discontinue this medication considered
duetoefficacyfailureorlackoftolerability,arelesslikelytoreach
Recommendationsfortreatmentdecisionsduringfollow-up
a low-risk status, and have a higher mortality risk. While the
InpatientswithIPAH/HPAH/DPAHwith
age-adjusted mortality of patients with the left heart phenotype
cardiopulmonarycomorbiditieswhopresentat
seemstobesimilartothatofpatientswithclassicalPAH,patients
intermediateorhighriskofdeathwhilereceiving withacardiopulmonaryphenotypeandalowDLCOhaveaparticu- IIb C
PDE5iorERAmonotherapy,additionalPAH
larlyhighmortalityrisk.77,78,161,450,451
medicationmaybeconsideredonanindividual
As patients with cardiopulmonary comorbidities were under-
basis
represented in or excluded from PAH trials, no evidence-based
treatmentrecommendationscanbemadeforthispatientpopula- DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor
antagonist; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic
tion.RegistrydatasuggestthatmostphysiciansusePDE5isaspri-
pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PDE5i,
mary treatment for these patients. Endothelin receptor phosphodiesterase5inhibitor.
antagonists or PDE5i/ERA combinations are occasionally used, aCardiopulmonarycomorbiditiesarepredominantlyencounteredinelderlypatients
andincluderiskfactorsforHFpEFsuchasobesity,diabetes,coronaryheartdisease,a
but the drug discontinuation rate is higher than in patients with
historyofhypertension,and/oralowDLCO.
classicalPAH.447,450AsubgroupanalysisfromAMBITION,which bClassofrecommendation.
assessedtheresponsetoPAHtherapyin105patientswhowere cLevelofevidence.
excluded from the primary analysis set because of a left heart
phenotype, found that these patients—compared with patients
in the primary analysis set—had less clinical improvement and a 6.3.5.Druginteractions
higherlikelihoodofdrugdiscontinuationsduetosafetyandtoler- Among PAH drugs, clinically relevantpharmacokinetic interactions
abilitywithbothmonotherapyandinitialcombinationtherapy.449 are observed between bosentan and sildenafil (reduced sildenafil
Data from the ASPIRE registry demonstrated that patients with plasma concentration385), bosentan and hormonal contraceptives
IPAH and a cardiopulmonary phenotype had less improvement
(reducedcontraceptionefficacy361),andbosentanandvitaminKan-
inexercisecapacityandPROMscomparedwithpatientswithclas- tagonists (VKAs) (potential need for VKA dose adjustment386).
sicalIPAH.451 Additional pharmacokinetic interactions of potential clinical rele-
In patients with a left heart phenotype, ERA therapy is vancearelistedinSupplementaryData,TableS4.
associated with an elevated risk of fluid retention.449 Moreover,
in patients with a cardiopulmonary phenotype, PAH medication 6.3.6.Interventionaltherapy
may cause a decline in the peripheral oxygen saturation.452 6.3.6.1.BalloonatrialseptostomyandPottsshunt
Thereislittlepublishedexperienceontheuseofprostacyclinana- Balloonatrialseptostomy,454,455bycreatinganinteratrialshunt,and
logues or prostacyclin receptor agonists in this patient
Pottsshunt,456–459byconnectingtheleftPAanddescendingaorta,
population.453 aim to decompress the right heart and increase systemic blood
ThelackofsolidevidencefortreatingelderlypatientswithPAH flow,therebyimprovingsystemicoxygentransportdespitearterial
andcardiopulmonarycomorbiditiesmakestreatmentrecommen- oxygen desaturation. As these procedures are complex and asso-
dationschallenging,andpatientsshouldbecounselledaccordingly. ciatedwithhighrisk,includingsubstantialprocedure-relatedmortal-
Intheabsenceofevidenceontreatmentstrategiesinthesepatients, ity,theyarerarelyperformedinpatientswithPAHandmayonlybe
risk stratification is of limited usefulness in guiding therapeutic consideredincentreswithexperienceinthetechniques.
decision-making. Initial monotherapy (see Supplementary Data,
Table S3) is recommended for most of these patients, with 6.3.6.2.Pulmonaryarterydenervation
PDE5isbeingthemostwidelyusedcompoundsaccordingtoregis- TherationaleforperformingaPAdenervation(PADN)isbasedon
trydata.161Furthertreatmentdecisionsshouldbemadeonanin- theincreasedsympatheticoverdrivecharacterizingPAH,whichisas-
dividual basis in collaboration with the PH centre and local sociatedwithpooroutcome.460,461Althoughthecontributionofthis
physicians. mechanismtodevelopingPAHisnotcompletelyunderstood,itisas-
The treatment algorithm for patients with PAH is shown in sociated with vasoconstriction and vascular remodelling through a
Figure 9 and the accompanying section describing the treatment baroreflexmediatedbystretchreceptorslocatedatthebifurcation
algorithm. ofthePAs.462,463Applyingradiofrequencyatthelatteracutelyand
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 55 ---
3672 ESC/ERSGuidelines
chronically improves haemodynamic variables.464 However, there is analogoustoleftventricularassistdevices(LVADs)isnotyetavailable
little evidence yet from multicentre RCTs demonstrating a benefit forpatientswithPHandend-stagerightHF.
ofPADNinpatientsalreadyreceivingrecommendedmedicaltherapy.
AsmallmulticentrestudytestedthefeasibilityofPADNusinganintra-
vascularultrasoundcatheterinpatientsreceivingdualortripletherapy
RecommendationTable12—Recommendationsfor
intensive care management for pulmonary arterial
forPAH;465theprocedurewassafeandassociatedwithareductionin
hypertension
PVR,andincreasesin6MWDanddailyactivity.Althoughpotentially
promising,PADNshouldbeconsideredexperimental. Recommendations Classa Levelb
WhenmanagingpatientswithrightHFintheICU,
6.3.7.Advancedrightventricularfailure
itisrecommendedtoinvolvephysicianswith
6.3.7.1.Intensivecareunitmanagement
expertise,treatcausativefactors,anduse
PatientswithPHmayrequireintensivecaretreatmentforrightHF, I C
supportivemeasures,includinginotropesand
comorbidities(includingmajorsurgery),orboth.Themortalityriskis
vasopressors,fluidmanagement,andPAHdrugs,
high in such patients,466,467 and specialized centres should be in-
asappropriate
volved whenever possible. In addition to basic intensive care unit
Mechanicalcirculatorysupportmaybeanoption
(ICU) standards, RV function in these patients should be carefully
monitored. Non-specific clinical signs of right HFwith low CO in- forselectedpatientsasabridgetotransplantation
orrecovery,andinterhospitaltransfershouldbe IIa C
clude pale skin with peripheral cyanosis, hypotension, tachycardia,
consideredifsuchresourcesareunavailableon
declining urine output, and increasing lactate levels. Non-invasive
site
monitoring shouldinclude biomarkers(NT-proBNPandtroponin)
andechocardiography.Minimuminvasivemonitoringconsistsofan HF,heartfailure;ICU,intensivecareunit;PAH,pulmonaryarterialhypertension.
upperbodycentralvenouscathetertomeasurecentralvenouspres- aClassofrecommendation.
sureandcentralvenousoxygensaturation,thelatterreflecting CO.
bLevelofevidence.
Right heart catheterization or other forms of advanced haemo-
dynamicassessmentshouldbeconsideredinpatientswithadvanced 6.3.8.Lungandheart–lungtransplantation
rightHForincomplexsituations.468
Lungtransplantationremainsanimportanttreatmentoptionforpa-
TreatingrightHFshouldfocusontreatabletriggerssuchasinfec- tientswithPAHrefractorytooptimizedmedicaltherapy.Inpatients
tion, arrhythmia, anaemia, and other comorbidities. Fluid manage- with PAH, referral to an LTx centre should be considered early
ment is of utmost importance in these patients, most of whom (Table20):
requireanegativefluidbalancetoreduceRVpre-load,therebyim-
provingRVgeometryandfunction.468PatientswithalowCOmay
benefit from treatment with inotropes; dobutamine and milrinone Table20 Criteriaforlungtransplantationandlisting
arethemostfrequentlyusedsubstancesinthissetting.Maintaining inpatientswithpulmonaryarterialhypertension
the mean systemic blood pressure .60mmHg is a key objective
Referral
when treating right HF, and patients with persistent hypotension
PotentiallyeligiblepatientsforwhomLTxmightbeanoptionincaseof
may require vasopressors such as norepinephrine or vasopressin.
treatmentfailure
Intubation and invasive mechanical ventilation should be avoided
ESC/ERSintermediate–highorhighriskorREVEALriskscore.7on
wheneverpossibleinpatientswithadvancedRVfailurebecauseof
appropriatePAHmedication
a high risk of further haemodynamic deterioration and death.
ProgressivediseaseorrecenthospitalizationforworseningPAH
Pulmonary arterial hypertension medication should be considered
Needfori.v.ors.c.prostacyclintherapy
on an individual basis, taking into account underlying disease, co-
morbidities, and existing medication. In patients with newly diag- Knownorsuspectedhigh-riskvariants,suchasPVODorPCH,systemic
nosed PAH presenting with low CO, combination therapy sclerosis,orlargeandprogressivepulmonaryarteryaneurysms
includingi.v./s.c.prostacyclinanaloguesshouldbeconsidered.426 SignsofsecondaryliverorkidneydysfunctionduetoPAHorother
potentiallylife-threateningcomplications,suchasrecurrenthaemoptysis
6.3.7.2.Mechanicalcirculatorysupport Listing
Inspecialistcentres,variousformsofmechanicalcirculatorysupport Patienthasbeenfullyevaluatedandpreparedfortransplantation
areavailableformanagingRVfailure,withveno-arterialextracorpor- ESC/ERShighriskorREVEALriskscore.10onappropriatePAH
ealmembraneoxygenation(ECMO)beingthemostwidelyusedap- medication,usuallyincludingi.v.ors.c.prostacyclinanalogues
proach. Mechanical circulatory support has become an established
Progressivehypoxaemia,especiallyinpatientswithPVODorPCH
bridgingtooltotransplantationinpatientswithirreversiblerightHF,
Progressive,butnotend-stageliverofkidneydysfunctionduetoPAH,or
butisoccasionallyusedasabridgetorecoveryinpatientswithtreat-
life-threateninghaemoptysis
ablecausesandpotentiallyreversibleRVfailure.468Nogeneralrecom-
mendations can be made regarding the indication for mechanical ERS, European Respiratory Society; ESC, European Society of Cardiology; i.v.,
intravenous;LTx,lungtransplantation;PAH,pulmonaryarterialhypertension;PCH,
circulatorysupport,whichneedstobeindividualized,consideringpa-
pulmonary capillary haemangiomatosis; PVOD, pulmonary veno-occlusive disease;
tientfactorsandlocalresources.469,470Long-termmechanicalsupport
s.c.,subcutaneous.
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 56 ---
ESC/ERSGuidelines 3673
(1) when they present with an inadequate response to treatment frequencyofventriculararrhythmiasandbradyarrhythmiasappears
despite optimized combination therapy; (2) when they present to be considerably
lower.477–479
Of note, age is an independent
withanintermediate–highorhighriskofdeath(i.e.1-yearmortality riskfactorforatrialarrhythmias.Inprospectivestudies,theincidence
.10% when estimated with established risk-stratification tools)471 ofatrialarrhythmiaswas3–25%overanobservationtimeof5years
(see Section 6.2.7), which exceeds the current mortality rate after
incohortsprimarilycontainingpatientswithIPAH.479–481
LTx;472(3)whenpatientshaveadiseasevariantthatpoorlyresponds IntheabsenceofspecificevidenceforPAH,managinganticoagula-
tomedicaltherapy,suchasPVODorPCH. tioninpatientswithPAHandatrialarrhythmiashouldfollowthere-
Bothheart–lungandbilateralLTxhavebeenperformedforPAH. commendationsforpatientswithothercardiacconditions.477
Currently, most patients receive bilateral LTx, while combined PatientswithPAHareespeciallysensitivetohaemodynamicstress
heart–lung transplantation is reserved for patients who have add- duringatrialarrhythmiasduetotachycardiaandlossofatrioventricular
itionalnon-correctablecardiacconditions.473Withtheintroduction synchrony.Maintainingsinusrhythmisanimportanttreatmentobject-
ofthelungallocationscore(LAS),waitinglistmortalityhasdecreased iveinthesepatients.New-onsetarrhythmiasfrequentlyleadtoclinical
andtheoddsofreceivingadonororganhaveincreased.474Insome deterioration and are associated with increased mortality.481
countries,an‘exceptionalLAS’canbeobtainedforpatientswithse- Observational studies have shown that a variety of rhythm control
verePH.SomeothercountriesnotusingtheLAShavesuccessfully strategies are feasible, including pharmacological cardioversion with
implemented high-priority programmes for these patients.475 The anti-arrhythmic drugs, electricalcardioversion, and invasivecatheter
patientandtheirnextofkinshouldbefullyengagedinthetransplant ablation procedures. To achieve or maintain a stable sinus rhythm,
assessmentprocessandinformedoftherisksandbenefits,andthe prophylaxiswithanti-arrhythmicdrugswithoutnegativeinotropicef-
finaldecisionshouldbejointlymadebetweenthepatientandmedical fects,suchasoralamiodarone,shouldbeconsidered,evenifspecific
team (seeSection 6.3.1.8). For patients with PAHwho survivethe data regarding their efficacy are lacking. Low-dose beta-blockers
earlypost-transplantperiod,long-termoutcomesaregood.Astudy and/ordigoxinmaybeusedonanindividualpatientbasis.
foundthatforprimarytransplantpatientswithIPAHwhosurvived Catheterablationisthepreferredapproachinmanagingatrialflut-
to1year,conditionalmediansurvivalwas10.0years.476 terandsomeotheratrialtachycardias,althoughcatheterablationin
patientswithPAHisoftenmoretechnicallychallengingthaninpa-
RecommendationTable13—Recommendationsfor tientswithastructurallynormalrightheartchamber.482Thesafety
lungtransplantation and efficacy of ablation techniques for atrial fibrillation specifically
inthePAHpopulationareuncertain,anditispossiblethat,dueto
Recommendations Classa Levelb
remodelling of the RA, non-pulmonary vein triggers may play a
Itisrecommendedthatpotentiallyeligible moreimportantrolethaninpatientswithoutPAH.483
candidatesarereferredforLTxevaluationwhen
theyhaveaninadequateresponsetooral I C 6.3.10.2.Haemoptysis
combinationtherapy,indicatedbyanintermediate– Haemoptysis,rangingfrommildtolife-threatening,mayoccurinall
highorhighriskorbyaREVEALriskscore.7 forms of PH but is particularly common in HPAH and PAH asso-
ItisrecommendedtolistpatientsforLTxwho ciatedwithCHD.Pulmonarybleedingfrequentlyoriginatesfromen-
presentwithahighriskofdeathorwithaREVEAL
largedbronchialarteries;484–486hence,thediagnosticevaluationof
riskscore≥10despitereceivingoptimized I C patients with PAH and haemoptysis should include a
medicaltherapyincludings.c.ori.v.prostacyclin contrast-enhancedCTscanwithanarterialphase.Evenifthesource
analogues of bleeding cannot be determined, embolization of enlarged bron-
chial arteries is recommended in patients who present with
i.v., intravenous;LTx,lungtransplantation;s.c.,subcutaneous.
aClassofrecommendation. moderate-to-severe haemoptysis or recurrent episodes of mild
bLevelofevidence. haemoptysis.Lungtransplantshouldbeconsideredinpatientswith
recurrentandseverehaemoptysisdespiteoptimizedtreatment.
6.3.9.Evidence-basedtreatmentalgorithm
A treatment algorithm for patients with IPAH/HPAH/DPAH or
6.3.10.3.Mechanicalcomplications
PAH-CTDisshowninFigure9.Theevidencesupportingthisalgo-
Mechanical complications in patients with PAH usually arise from
rithm has mainly been generated in patients with IPAH/HPAH/
progressivedilatationofthePAandincludePAaneurysms,rupture,
DPAH or PAH-CTD who present without cardiopulmonary co-
anddissection,andcompressionofadjacentstructuressuchasthe
morbidities.PatientswithHIV-associatedPAH,PoPH,andPAHas-
leftmaincoronaryartery,pulmonaryveins,mainbronchi,andrecur-
sociated with congenital heart disease were not enrolled or rentlaryngealnerves.487–492
under-represented in most PAH therapy trials. Treatment recom-
Pulmonary artery aneurysm was independently related to an in-
mendationsforthesepatientsareprovidedinSection7.
creasedriskofsuddencardiacdeathinonestudy.492Symptomsand
signs are non-specific; in most cases, patients are asymptomatic and
6.3.10.Diagnosisandtreatmentofpulmonary thesecomplicationsareincidentallydiagnosed.Pulmonaryarteryaneur-
arterialhypertensioncomplications ysmsareusuallydetectedduringechocardiographyandbestvisualized
6.3.10.1.Arrhythmias bycontrast-enhancedCTorMRI.Treatmentoptionsforasymptomatic
ThemostcommontypesofarrhythmiasobservedinPAHaresupra- PAaneurysmorPAdissectionarenotwelldefined.LTxhastobecon-
ventricular, mainly atrial fibrillation and atrial flutter, while the sideredonanindividualbasis.490,493
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 57 ---
3674 ESC/ERSGuidelines
For patients with left main coronary artery compression syn- rapeseedoilwerethemostprominentexamples,whereasmetham-
drome,percutaneouscoronarystentingisaneffectiveandsafetreat- phetamines, interferons, and some tyrosine kinase inhibitors are
ment.62 For patients with asymptomatic left main coronary artery morecommoncausesnowadays(Table7).Pulmonaryarterialhyper-
compressionornon-severecompromiseofitsanatomy,evaluation tensionisararecomplicationinpatientsexposedtothesedrugs,and
with intravascular ultrasound or coronary pressure wire may help manyofthesedrugshavealsobeenlinkedtootherpulmonarycom-
toavoidunnecessaryinterventions.494 plications such as parenchymal lung disease or pleural effusions.
Thesepulmonarycomplicationsmayoccurconcurrently.
6.3.11.End-of-lifecareandethicalissues
Methamphetamine-associated PAH has mainly been reported
TheclinicalcourseofPAHmaybecharacterizedbyprogressivede- fromtheUSA,wheresomecentreshavefoundthat20–29%oftheir
terioration and occasional episodes of acute decompensation. Life
otherwise idiopathic cases of PAH were associated with metham-
expectancyisdifficulttopredict,aspatientsmayeitherdieslowlybe-
phetamine use.497,498 Compared with patients with IPAH, those
causeofprogressiverightHForexperiencesuddendeath.
with methamphetamine-associated PAH had more severe haemo-
Patient-orientatedcareisessentialinmanagingPAH.Information dynamicimpairmentandahighermortalityrisk.498Alphaandbeta
aboutdiseaseseverityandpossibleprognosisshouldbeprovidedat
interferonshavealsobeenassociatedwithdevelopingPAH.499The
initialdiagnosisbutempathicandhopefulcommunication,aswellas
sameistrueofsometyrosinekinaseinhibitors,especiallydasatinib,
yielding hope, is essential, in line with Section 6.3.1.8. At the right
butalsobosutinibandponatinib.40,500
time,openandsensitivecommunicationwillenableadvancedplan-
Drug-ortoxin-inducedPAHshouldalwaysbeconsideredinpa-
ning and discussion of a patient’s fears, concerns, and wishes, and
tients presenting with unexplained exertional dyspnoea or other
willultimatelycontributetomakingthefinal,well-informed,andjoint
warning signs. The diagnostic approach should be the same as in
decisionabouttreatmentwiththemedicalteam.
other forms of PH, and the diagnosis is usually made by excluding
Patients approaching end of life require frequent assessment of
otherformsofPHinpatientswhohavebeenexposedtodrugsas-
theirfullneedsbyamultidisciplinaryteam.Inadvancedstages,recog-
sociatedwithdevelopingPAH.
nizingthatcardiopulmonaryresuscitationinseverePAHhasapoor
TreatmentofDPAHfollowsthesamebasicprinciplesastreating
outcomemayenableadonotresuscitateorder;thismayfacilitate
otherformsofPAH.Importantly,partialorfullreversalofPAHhas
patients being in their preferred place of care at end of life.
beenreportedafterdiscontinuingthecausativeagent,atleastforin-
Attentionshouldbegiventocontrollingdistressingsymptomsand
terferonsanddasatinib.499,500Hence,multidisciplinarymanagement
prescribingappropriatedrugswhilewithdrawingmedicationthatis
ofthepatientshouldincludediscontinuingthepresumedcausative
no longer needed, which may include PAH medication.
agents once PAH is diagnosed (also see the 2022 ESC Guidelines
Well-informedpsychological,social,andspiritualsupportisalsovital.
onCardio-Oncology).501InpatientswithmildPHandalow-riskpro-
Specialist palliative care should be consulted for patients whose file,discontinuingthetriggeralonemaybesufficient,anditisrecom-
needsarebeyondtheexpertiseofthePHteam.346
mended that these patients be observed over 3–4 months before
consideringPAHtherapy.Pulmonaryarterialhypertensiontherapy
6.3.12.Newdrugsinadvancedclinicaldevelopment
shouldbeinitiatedinpatientswhodonotnormalizetheirhaemo-
(phase3studies)
dynamicsafterwithdrawingorinpatientspresentingwithmoread-
Pulmonaryarterialhypertensionremainsanincurableconditionwith
vancedPAHatdiagnosis.UnlikeinotherformsofPAH,de-escalation
ahighmortalityrate,despiteuseofPAHdrugsmainlytargetingim-
ofPAHtherapyisoftenpossibleduringthecourseofthedisease.500
balance of vasoactive factors. Novel agents, which are currently in
Physicians should bear in mind that DPAH may have features of
phase 3 development, are ralinepag and sotatercept. Ralinepag is
PVOD/PCH, especially in patients treated with alkylating agents
an orally available prostacyclin receptor agonist, which, in a phase
such as mitomycin C or cyclophosphamide. Health professional
2RCTthatincluded61patientswithPAH,improvedPVRcompared
with placebo after 22 weeks of therapy.495 Sotatercept—a fusion awarenessisessentialinidentifyingcasesofDPAHandreportingad-
verseeffectsofpharmaceuticalproducts.
proteincomprisingtheextracellulardomainofthehumanactivinre-
ceptortypeIIAlinkedtotheFcdomainofhumanimmunoglobulin
G1—actsasaligandtrapformembersofthetransforminggrowth
RecommendationTable14—Recommendationsfor
factor(TGF)-βsuperfamily,thusrestoringbalancebetweengrowth-
pulmonary arterial hypertension associated with
promotingandgrowth-inhibitingpathways.496Inaphase2RCTthat
drugsortoxins
included106patientswithPAHtreatedover24weeks,s.c.sotater-
ceptreducedPVRinpatientsreceivingbackgroundPAHtherapy;496 Recommendations Classa Levelb
improvementswerealsoobservedin6MWDandNT-proBNP.496
Itisrecommendedtomakeadiagnosisofdrug-or
fi toxin-associatedPAHinpatientswhohad
7. Speci c pulmonary arterial I C
relevantexposureandinwhomothercausesof
hypertension subsets
PHhavebeenexcluded
Inpatientswithsuspecteddrug-or
7.1. Pulmonary arterial hypertension
toxin-associatedPAH,itisrecommendedto
I C
associated with drugs and toxins immediatelydiscontinuethecausativeagent
Several drugs and toxins are associated with developing PAH or wheneverpossible
PVOD/PCH. Historically, certain appetite suppressants and toxic Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 58 ---
ESC/ERSGuidelines 3675
Resting echocardiography combined with other tests is recom-
ImmediatePAHtherapyshouldbeconsideredin
patientswhopresentwithintermediate-/high-risk IIa C mendedasascreeningtestinasymptomaticpatientswithSSc,fol-
lowedbyannualassessments.Screening/earlydetectionisdiscussed
PAHatdiagnosis
inSection5.3.1.InotherCTDs,PHscreeningintheabsenceofsug-
Patientswithlow-riskPAHshouldbere-evaluated
3–4monthsafterdiscontinuingthesuspected gestive symptoms is not recommended, while echocardiography
drugortoxin,andPAHtherapymaybe IIb C shouldbeperformedinthepresenceofsymptoms.Asinotherforms
ofPAH,RHCisrecommendedinallcasesofsuspectedPAH-CTDto
consideredwhenthehaemodynamicshavenot
confirmdiagnosis,determineseverity,andruleoutLHD.504
normalized
PAH,pulmonaryarterialhypertension;PH,pulmonaryhypertension.
aClassofrecommendation. 7.2.2.Therapy
bLevelofevidence. DrugsforPAHshouldbeprescribedinPAH-CTDaccordingtothe
same treatment algorithm as in IPAH (Figure 9). Patients with
PAH-CTDhavebeenincludedinmostofthemajorRCTsforregu-
latory approval of PAH therapy.518 Some aspects of PAH-CTD
7.2. Pulmonary arterial hypertension treatment differ according to the associated CTD.506
associatedwithconnectivetissuedisease Immunosuppressive therapy combining glucocorticosteroids and
Pulmonaryarterialhypertensionisawell-knownpulmonaryvascular cyclophosphamide may result in clinical improvement in patients
complication of
SSc,173,502–504
systemic lupus erythematosus
withSLE-ormixedCTD-associatedPAH,506whileitisnotrecom-
(SLE),505–507 mixed CTD,506 and, rarely, dermatomyositis508 and mendedinPAH-SSc.519PatientswithSScandotherCTDsmayhave
Sjögren’ssyndrome.509Conversely,therelationshipbetweenrheuma- ILD and/or HFpEF, which needs to be considered when initiating
toidarthritisandPAHisnotestablished.510AfterIPAH,PAH-CTDis PAHtherapy.504,515InSSc,thelong-termrisk/benefitratiooforalan-
thesecondmostprevalenttypeofPAHinwesterncountries.511 ticoagulationisunfavourablebecauseofanincreasedriskofbleeding,
Systemicsclerosis,particularlyinitslimitedvariant,representsthe whileVKAs arerecommended inPAH-CTDwitha thrombophilic
main cause of PAH-CTD inEuropeand the USA (SLE being more
predisposition(e.g.antiphospholipidsyndrome).319
commoninAsia).173,502,506Theprevalenceofpre-capillaryPHinlarge SubgroupanalysesofpatientswithPAH-SScenrolledinRCTsper-
cohortsofpatientswithSScis5–19%.173,502Inthesepatients,PHmay formedwithmonotherapyorcombinationtherapyofERAs,PDE5is,
occurinassociationwithILD504,512orasaresultofPAH,173,502–504,506 sGCstimulators,prostacyclinreceptoragonists,epoprostenol,and
sometimes with features of venous/capillary involvement.504,513 prostacyclin analogues have shown positive effects vs. pla-
Moreover,group2PH-LHDisalsocommonduetomyocardialSSc
cebo.301,401,519,520Insomeofthesetrials,themagnitudeofthere-
involvement.504,514 Of note, patients with SLE may also present sponse in the PAH-CTD subgroup was lower than in the IPAH
withPAH,LHD,ILD,andCTEPH(mostlyinthesettingofantipho-
subgroup.519,520Continuousi.v.epoprostenoltherapyimprovedex-
spholipid syndrome). It istherefore essential tocarefully determine ercisecapacity,symptoms,andhaemodynamicsina3-monthRCTin
whichmechanismisoperativeinagivenpatient,sincethiswilldictate
PAH-SSc.401However,aretrospectiveanalysisshowedabetteref-
treatmentinthecontextofamultifaceteddisease. fect of i.v. epoprostenol on survival in IPAH compared with
Cluster analysis performed in patients with SSc has shown that
PAH-SSc.521ThechoiceofPAHtherapyinthecontextofSScand
pre-capillaryPHcanbecharacterizedintodistinctclustersthatdiffer its systemic manifestations may consider other vascular damage
inprognosis.503Onecluster,characterizedbythepresenceofexten- suchasdigitalulcers.522
siveILD,andanotherbyseverelyimpairedhaemodynamicscarrieda Connectivetissuediseaseshouldnotbeconsideredasanapriori
dismalprognosis,whilethetwoothersshowedeithertheabsenceof
contraindicationforLTx.523ThishasbeenextensivelystudiedinSSc,
ILDorthepresenceoflimitedILD,withmild-to-moderateriskPAH whereamultidisciplinaryapproachoptimizingSScmanagementbe-
andarelativelyfavourableoverallprognosis.503 fore,during, and after surgery isrecommended.523 Indications and
contraindicationsfortransplantationhavetobeadaptedtothespe-
cificities of CTD, with a special focus on digestive (gastro-
7.2.1.Epidemiologyanddiagnosis oesophageal reflux disease and intestinal disease), cardiac, renal,
ThereisastrongfemalepredominanceinPAH-CTD(female/male andcutaneousinvolvement.523
ratio4:1),andmeanageatdiagnosisiscommonly.50years,espe-
ciallyinSSc.173,502–511,513,515,516InthesettingofaCTD,patientsmay
presentwithconcomitantdisorderssuchasILD,andhaveshorter
RecommendationTable15—Recommendationsfor
survivalcomparedwithpatientswithIPAH.503Theunadjustedrisk pulmonaryarterialhypertensionassociatedwithcon-
nectivetissuedisease
ofdeathforPAH-SSccomparedwithIPAHis2.9,andthepredictors
ofoutcomearebroadlysimilartothoseforIPAH.516,517Symptoms
Recommendations Classa Levelb
andclinicalpresentationarealsosimilartoIPAH,andsomepatients
thoughttohaveIPAHcanbeidentifiedashavinganassociatedCTD InpatientswithPAHassociatedwithCTD,
by careful clinical examination and immunological screening tests. treatmentoftheunderlyingconditionaccording
I A
ChestCTisrecommendedforevaluatingthepresenceofassociated tocurrentguidelinesis
ILD or PVOD/PCH.504,513,515 An isolated reduction of DLCO is recommended166,167,419,524
commoninPAH-CTD.173,502–504
Continued
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 59 ---
3676 ESC/ERSGuidelines
InpatientswithPAHassociatedwithCTD,the 7.3.2.Therapy
sametreatmentalgorithmasforpatientswith I C CurrentrecommendationsforthetreatmentofPAH-HIVarelargely
IPAHisrecommended
basedondatafromIPAH.25,26
TreatmentofPAH-HIVwithHAARThasimprovedfunctionalsta-
PAH-CTD,pulmonaryarterialhypertensionassociatedwithconnectivetissuedisease; tusandsurvivalinsomeretrospectivestudies.525,526,531Theuseof
IPAH,idiopathicpulmonaryarterialhypertension.
aClassofrecommendation. HAARTinPAH-HIVisthereforerecommended,irrespectiveofviral
bLevelofevidence. loadandCD4+cellcount.
Anticoagulationisnotrecommendedbecauseofanincreasedrisk
ofbleedinganddruginteractions.319,527PatientswithPAH-HIVare
7.3. Pulmonary arterial hypertension
usuallynon-responderstoacutevasoreactivitytestingandtherefore
associated with human shouldnotreceiveCCBs.378
immunodeficiency virus infection Theprospective,open-label,BREATHE-4studyshowedthatbo-
sentan markedly improved WHO-FC, exercise capacity, quality of
The use of highly active antiretroviral therapy (HAART), and ad-
life, and haemodynamics after 16 weeks in patients with
vancesinmanagingopportunisticinfectionshavecontributedtoin-
creased life expectancy in patients with HIV.525,526 Consequently,
PAH-HIV.532Inalong-term,retrospectiveseries,bosentantherapy
was associated with haemodynamic normalization in 10/59 pa-
thespectrumofcomplicationshasshiftedtowardsotherlong-term
conditions, including PAH.Clinical andhistopathological findings in tients.533 Bosentan potentially interacts with antiretroviral drugs,
and close monitoring is required when combined with HAART.
PAHassociatedwithHIVinfection(PAH-HIV)sharemanysimilar-
itieswithIPAH.1,527WiththeavailabilityofHAARTgivenincombin- VeryfewpatientswithPAH-HIVhavebeenincludedinRCTswith
ambrisentan and macitentan, and no definite conclusion can be
ationwithPAHtherapies,theprognosisofPAH-HIVhasmarkedly
improved in recent years.526,528 In addition, the incidence of drawnfromthosestudies.
PositiveeffectsofsildenafilandtadalafilinPAH-HIVhavebeenes-
PAH-HIV has declined in parallel with the increasing availability of
HAART.528Takentogether,theseeffectsonsurvivalandincidence
tablishedincasestudies.534,535Interactionshavebeenreportedbe-
tweenPDE5isandproteaseinhibitors, resultinginmajorincreases
haveresultedinastablePAHprevalenceinpatientswithHIVover
in PDE5iconcentrations; these drugs should be introduced at low
recentdecades.AFrenchpopulationstudyindicatedthatthepreva-
dosages with careful monitoring of potential side effects, including
lenceofPAHinindividualswithHIVinfectionwas0.46%,whichis
verysimilartotheprevalencebeforetheHAARTera.177
hypotension.536,537TherearenodataontheuseofthesGCstimu-
latorriociguatinPAH-HIV.
ThepathogenesisofPAH-HIVremainsunclear.Thereisnoevidence
Treatmentwithi.v.epoprostenolresultedinsignificantimprove-
ofadirectroleofHIVinthepathogenesisofPAHand,althoughpresent
ininflammatorycellsinthelungs,thevirusitselfhasneverbeenfoundin mentinWHO-FC,exercisecapacity,haemodynamics,andsurvival
pulmonaryvascularlesionsofpatientswithPAH-HIV.529Thissuggests in selected patients with PAH-HIV.403,538 There are very few data
thatanindirectactionofviralinfectiononinflammationandgrowthfac- on the use of i.v. or s.c. treprostinil or inhaled iloprost in
PAH-HIV.539,540
torsmayactasatriggerinapredisposedpatient.
Therearenoclinicaltrialdataontheuseofcombinationtherapy
for PAH-HIV. Given the lack of supporting evidence and potential
7.3.1.Diagnosis safety concerns when PAH drugs are co-administered with anti-
PulmonaryarterialhypertensionassociatedwithHIVsharesaclinical retroviraldrugs,initialmonotherapywithPAHmedicationisrecom-
presentationwithIPAH.BeforetheavailabilityofHAARTmostpa- mended,followedbyanindividualizeduseofcombinationtherapyin
tientswereinWHO-FCIIIorIVatdiagnosis.Nowadays,patientsare patientswhodonotreachalow-riskprofile.
diagnosed with much less severe symptoms and haemodynamics.
PatientsmaypresentwithotherriskfactorsforPAHsuchasliverdis-
ease(chronicviralhepatitisBorC)orexposuretodrugsortoxins. RecommendationTable16—Recommendationsfor
PatientswithPAH-HIVaremorelikelytobemaleandi.v.drugabu- pulmonary arterial hypertension associated with hu-
sers.403,526ThereisnocorrelationbetweentheseverityofPAHand
manimmunodeficiencyvirusinfection
thestageofHIVinfectionorthedegreeofimmunodeficiency.403,530
Recommendations Classa Levelb
Because of its low prevalence, asymptomatic patients with HIV
should not be screened for PAH. However, echocardiography InpatientswithPAHassociatedwithHIV
shouldbeperformedinpatientswithunexplaineddyspnoeatode- infection,antiretroviraltreatmentaccordingto I A
tect HIV-related cardiovascular complications such as myocarditis, currentguidelinesisrecommended541,542
cardiomyopathy,orPAH.Rightheartcatheterizationismandatory InpatientswithPAHassociatedwithHIV
toconfirmthediagnosisofPAH-HIVandtoruleoutLHD.527
infection,initialmonotherapyshouldbe
Pulmonaryarterialhypertensionisanindependentriskfactorfor considered,followedbysequentialcombinationif IIa C
death in patients with HIV. In the 1990s, before the availability of necessary,takingintoconsiderationcomorbidities
HAART,patientswithPAH-HIVhadpooroutcomes,witha3year anddrug–druginteractions
survivalof,50%.403Theoverallsurvivalhasnowimprovedandpa-
HIV,Humanimmunodeficiencyvirus;PAH,pulmonaryarterialhypertension.
tientswithPAH-HIVhaveabetterprognosisthanmostpatientswith aClassofrecommendation.
otherformsofPAH.526 bLevelofevidence.
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 60 ---
ESC/ERSGuidelines 3677
7.4. Pulmonary arterial hypertension nodifferencesbetweenthetwotreatmentgroupsinsecondaryout-
associated with portal hypertension comemeasures,includingWHO-FC,6MWD,andNT-proBNP.
Pulmonary arterial hypertension associated with portal hyperten-
sion,commonlyreferredtoasPoPH,developsin2–6%ofpatients 7.4.2.1.Livertransplantation
withportalhypertension,withorwithoutliverdisease.InPAHregis- Porto-pulmonary hypertension is not per se an indication for liver
tries, PoPH represents 5–15%of the patients.543–545 Rarely, some transplantation.Pulmonaryarterialhypertensionposesamajorthreat
patientswithPoPHhaveportosystemicshuntsintheabsenceofpor- topatientswhoundergolivertransplantationwhenindicatedforthe
tal hypertension (congenital extrahepatic cavoportal shunts).546 severityofliverdisease.InahistoricalseriesfromtheMayoClinic,se-
However, PoPH is distinct from hepatopulmonary syndrome verePAHwithmPAP≥50mmHgwasassociatedwitha100%peri-
(HPS),whichischaracterizedbyintrapulmonaryvasculardilatations operative mortality rate. In patients with mPAP 35–50mmHg and
andhypoxaemia.Ofnote,HPSandPoPHcanoccursequentiallyor PVR.3.0WU,mortalitywasstill50%.550Inlivertransplantationcan-
concurrentlyinpatientswithportalhypertension.547 didates with PAH, targeted medical therapy successfully improves
haemodynamics and establishes eligibility for
transplantation.545,551–
554 However, haemodynamic criteria for successful liver transplant-
7.4.1.Diagnosis
ation have not been firmly established. The International Liver
ThediagnosisofPoPHisbasedonthepresenceofotherwiseunex-
Transplant Society proposed haemodynamic targets of mPAP
plainedpre-capillaryPHinpatientswithportalhypertensionorapor-
,35mmHgandPVR,5WU,ormPAP≥35mmHgandPVR,3
tosystemic shunt. The diagnostic approach is the same as in other
WU in patients receiving PAH therapy, while acknowledging that
patientswithsuspectedornewlydetectedPH.Transthoracicechocar-
thesecriterianeedtobefurthervalidated.175AnmPAP≥45mmHg
diographyisusuallythefirstnon-invasiveassessmentinpatientswith
isregardedasanabsolutecontraindicationtolivertransplantation.175
suspectedPH,andechocardiographyisalsorecommendedasascreen-
In patients with PoPH who successfully underwent liver trans-
ingtoolinpatientsevaluatedforlivertransplantation.Aspatientswith
plantation,de-escalationordiscontinuationofPAHmedicationisof-
liver diseaseoften havean elevatedCO, TRV tends to overestimate
tenfeasible,butthishastobeperformedonanindividualbasis.551,554
PAPinthesepatients.Hence,RHCwithcomprehensivehaemodynamic
assessmentisessentialtoconfirmthediagnosisofPHandtodistinguish
RecommendationTable17—Recommendationsfor
PAH(withelevatedPVR)fromunclassifiedPH(withanormalPVR).
pulmonaryarterialhypertensionassociatedwithpor-
talhypertension
7.4.2.Therapy
PatientswithunclassifiedPH(i.e.mPAP.20mmHg,elevatedCO, Recommendations Classa Levelb
and PVR ≤2.0 WU) should be regularly followed-up but should Echocardiographyisrecommendedinpatients
notbetreatedwithdrugsapprovedforPAH. withliverdiseaseorportalhypertensionwith
In patients with an established diagnosis of PoPH, treatment signsorsymptomssuggestiveofPH,andasa
I C
shouldfollowthesamegeneralprinciplesasinotherpatientswith screeningtoolinpatientsevaluatedforliver
PAH, taking into account the severity of underlying liver disease, transplantationortransjugularportosystemic
the indication for liver transplantation, and the potential effects of shunt
PAHmedicationongasexchange,whichmaydeterioratewithvaso- ItisrecommendedthatpatientswithPAH
dilatorsinpatientswithPoPH.548,549AlldrugsapprovedforPAHcan
associatedwithportalhypertensionarereferred
I C
principallybeusedtotreatpatientswithPoPH,bearinginmindthat tocentreswithexpertiseinmanagingboth
these patients are usually excluded from registration studies. conditions
Nevertheless, various case series support the use of approved
InpatientswithPAHassociatedwithportal
PAHmedicationinpatientswithPoPH.Thelargestseriespublished hypertension,initialmonotherapyshouldbe
sofarreportedon574patientswithPoPHtreatedwithvariousPAH
considered,followedbysequentialcombinationif
drugs,mostlyPDE5isorERAs,aloneandincombination.545Mostpa- IIa C
necessary,takingintoconsiderationthe
tients(56.8%)wereinChild–PughclassAatthetimeofPAHdiag-
underlyingliverdiseaseandindicationforliver
nosis. At the first follow-up, which took place 4.5 months after
transplantation
starting treatment, improvements were seen in haemodynamics,
Livertransplantationshouldbeconsideredonan
WHO-FC, 6MWD, and BNP/NT-proBNP; survival at 5 years was
individualbasisinpatientswithPAHassociated
IIa C
51%.Inpatientspresentingwithmildliverdisease,themaincauses
withportalhypertension,aslongasPVRisnormal
ofdeathwerePAHprogressionandmalignancy,whereascomplica-
ornearnormalwithPAHtherapy
tionsofliverdiseasewerethemostcommoncausesofdeathinpa-
DrugsapprovedforPAHarenotrecommended
tientswithadvancedliverdisease.The5yearsurvivalofpatientswho
forpatientswithportalhypertensionand
underwentlivertransplantation(n=63)was81%. III C
unclassifiedPH(i.e.elevatedmPAP,highCO,and
TheonlyRCTdedicatedtothetreatmentofPoPHwasPORTICO,
anormalPVR)
a12weekstudythatrandomized85patientstomacitentan(n=43)
orplacebo(n=42).168PORTICOmetitsprimaryendpoint,demon- mPAP,meanpulmonaryarterialpressure;CO,cardiacoutput;PAH,pulmonaryarterial
stratingasignificantreductioninPVRfrombaseline(ratioofgeomet- hypertension;PH,pulmonaryhypertension;PVR,pulmonaryvascularresistance.
aClassofrecommendation.
ricmean0.65;95%CI,0.59–0.72;P,0.0001).Therewere,however, bLevelofevidence.
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 61 ---
3678 ESC/ERSGuidelines
7.5. Pulmonary arterial hypertension mostfrequentcondition,butothercomplexCHDsmayalsoleadto
associated with adult congenital heart segmentalPH.
Approximately3–7%ofpatientswithadultCHDwilleventually
disease
develop PAH; it is more frequently encountered in females, and
ThepresenceofPHinadultswithCHDhasanegativeimpactonthe
theincidencedependsontheunderlying lesionandincreaseswith
natural course of CHD, and worsens clinical status and overall out- ageandageatdefectclosure.556TheestimatedprevalenceofPAH
come.555PulmonaryarterialhypertensionassociatedwithadultCHD
inpatientsaftercorrectingasimplecardiacdefectis3%.557Theepi-
isincludedingroup1ofthePHclinicalclassification(Table6)andrepre-
demiologyofPAHassociatedwithadultCHDisexpectedtochange
sents a heterogeneous patient population. Post-capillary PH in adult
duetoadvancesindiagnosticandtherapeuticpaediatriccardiology,
CHD(e.g.systolicordiastolic,systemic,ventriculardysfunctionincom-
resultinginfewerpatientswithsimpleadultCHDandmorepatients
binationwithshuntlesionsorcomplexadultCHD,andsystemicatrio-
with complex lesions and/or closed defects who develop PAH in
ventricularvalvedysfunction)shouldbeexcludedtodeterminefurther adulthood.558
management.Aspecificclinicalclassification(Table21)isprovidedto
The clinical presentation of Eisenmenger syndrome, an advanced
bettercharacterizePAHassociatedwithadultCHD.Somecomplex
formofadultCHD-associatedPAH,ischaracterizedbythemultiorgan
CHDsareassociatedwithcongenitalabnormalitiesofthepulmonary
effectsofchronichypoxaemia,includingcyanosis,andhaematological
vasculartreeleadingtosegmentalPH.InsegmentalPH,oneormore,
changes, including secondary erythrocytosis and thrombocytopenia;
butnotall,segmentsofthelung(s)arehypertensiveandeachhyperten-
themainsymptomsaredyspnoea,fatigue,andsyncope.Eisenmenger
siveareamaypresentwithPHofdifferentseverity,whileotherpartsof
syndromemayalsopresentwithhaemoptysis,chestpain,cerebrovas-
thelungvasculaturemaybehypoplastic.Pulmonaryatresiawithven-
cularaccidents,brainabscesses,coagulationabnormalities,andsudden
tricular septal defect and systemic-to-pulmonary collaterals is the
death. Patients with adult CHD and Down syndrome are at an in-
creasedriskofdevelopingEisenmengersyndrome.
Table21 Clinicalclassificationofpulmonaryarterial
hypertensionassociatedwithcongenitalheartdisease 7.5.1.Diagnosisandriskassessment
Thediagnosticwork-upofPAHassociatedwithadultCHDshould
(1) Eisenmengersyndrome
bebasedonthepresenceof symptomsandincludesmedicalhis-
Includesalllargeintra-andextracardiacdefectsthatbeginas
tory,physicalexamination,PFTs,ABG,imaging(especiallyechocar-
systemic-to-pulmonaryshuntsandprogresstoseverelyelevated
diography),andexerciseandlaboratorytesting.Ofnote,standard
PVRandtoreverse(pulmonary-to-systemic)orbidirectional
echocardiographiccriteriafordetectingPHmaynotbeapplicable
shunting.Cyanosis,secondaryerythrocytosis,andmultipleorgan
in complex adult CHD.559 Right heart catheterization with com-
involvementareusuallypresent.Closingthedefectsis
partmentaloximetryforcalculatingpulmonarybloodflow/system-
contraindicated.
ic blood flow (Qp/Qs) is required to confirm PAH diagnosis and
(2) PAHassociatedwithprevalentsystemic-to-pulmonaryshunts
(cid:129) Correctablea guidetherapeuticinterventions.Thermodilutionshouldbeavoided
(cid:129) Non-correctable inthepresenceofintracardiacshunts,anddirectFickisthemost
accuratemethod.Pulmonaryvascularresistancemaybeoveresti-
Includemoderate-to-largedefects.PVRismildlytomoderately
mated due to erythrocytosis.560 Interpreting invasive haemo-
increasedandsystemic-to-pulmonaryshuntingisstillprevalent,
dynamics (see Section 5.1.12) should be made in the context of
whereascyanosisatrestisnotafeature.
(3) PAHwithsmall/coincidentalbdefects multiparametricassessmentof exercise capacity, laboratorytest-
ing,andimaging.
MarkedlyelevatedPVRinthepresenceofcardiacdefectsconsidered
haemodynamicallynon-significant(usuallyventricularseptaldefects Predictors of worse outcomes in adult CHD-associated PAH are
,1cmandatrialseptaldefects,2cmofeffectivediameter WHO-FC III–IV, exercise intolerance assessed by 6MWD or peak
VO ,historyofhospitalizationforrightHF,biomarkers(NT-proBNP
assessedbyechocardiography),whichthemselvesdonotaccount 2
.500pg/mL,C-reactiveprotein.10mg/mL, high serumcreatinine,
forthedevelopmentofelevatedPVR.Theclinicalpictureisvery
andlowalbuminlevels),irondeficiency,andechocardiographicindices
similartoIPAH.Closingthedefectsiscontraindicated.
ofRVdysfunction.559,561WhencomparedwithpatientswithIPAH,pa-
(4) PAHafterdefectcorrection
tientswithEisenmengersyndromemayhavearelativelystablelong-
Congenitalheartdiseaseisrepaired,butPAHeitherpersists
termclinicalcourse.Therightventricleisunloadedbytheright-to-left
immediatelyaftercorrectionorrecurs/developsmonthsoryears
aftercorrectionintheabsenceofsignificant,post-operative, shunt, sustaining CO at the expense of hypoxaemia and cyanosis.
However,duetoimmortaltimebias,prognosisofEisenmengersyn-
haemodynamiclesions.
dromeisnotasfavourableaspreviouslythought.562
IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial As in other forms of PAH, risk assessment is important to guide
hypertension;PVR,pulmonaryvascularresistance.
aWithsurgeryorintravascularpercutaneousprocedure,seealsotheRecommendation
therapy,andspecificriskfactorshavebeendescribedinEisenmenger
Table18forshuntclosure. syndrome.Alargemulticentrestudyshowedthatmortalityinadults
bThesizeappliestoadultpatients.However,alsoinadults,thesimplediametermaybe
with Eisenmenger syndrome was predicted bythepresence of pre-
insufficientfordefiningthehaemodynamicrelevanceofthedefect,andalsothepressure
gradient,theshuntsizeanddirection,andthepulmonary-to-systemicflowsratioshould tricuspidshunt,advancingage,lowrestoxygensaturation,absenceof
beconsidered. sinusrhythm,andpresenceofpericardialeffusion.563
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 62 ---
ESC/ERSGuidelines 3679
7.5.2.Therapy emboli during administration.571 Supplemental oxygen therapy has
Outcomes in adult CHD-associated PAH have improved with the notbeenshowntoimpactsurvival.
availability of new PAH therapies, advances in surgical and peri- OralanticoagulanttreatmentwithVKAsmaybeconsideredinpa-
operative management, and a team-based, multidisciplinary ap- tients with large PA aneurysms with thrombus, atrial arrhythmias,
proachinPHcentres.Thesepatientsshouldbemanagedbyspecia- and previous thrombo-embolic events, but with low bleeding risk.
lized health professionals. Patient education, behavioural In patients with very high Hb levels (.20mg/dL), standard inter-
modifications,andsocialandpsychologicalsupportareallimportant national normalized ratio measures are less accurate, and
aspectsofmanagement. citrate-adjustedbloodbottlesmustbeused.Regardingusingnovel
Shunt closure (surgical or interventional)mayonly be consid- oral anticoagulants (NOACs), a large, nationwide, German, adult
ered in patients with prevalent systemic-to-pulmonary shunting CHD database (including 106 NOAC-treated patients with
without significantly increased PVR. Criteria for defect closure Eisenmengersyndrome)showedthatNOACusershadhigherlong-
based on Qp/Qs ratio and (baseline and/or after targeted PAH termriskofbleeding,majoradversecardiovascularevents,andmor-
treatment) PVR have been proposed by the 2020 ESC tality compared with those on VKAs, suggesting that initiating
Guidelines for the management of adult congenital heart dis- NOACs should be reserved for experienced adult CHD centres,
ease.101 Decisions on shunt closure should not be made on carefullyweighingpotentialbenefitsandrisks.572,573
haemodynamic numbers alone, and a multiparametric strategy Comparedwithothergroup1subgroups,limiteddataexistonthe
should be followed. For instance, shunt closure is not indicated useofdrugsapprovedforPAHinpatientswithadultCHD-associated
in the case of desaturation during exercise in the 6MWT or PAH.Bosentanimproved6MWDanddecreasedPVRinpatientswith
CPET,orwhenthereissecondaryerythrocytosissuggestingdy- EisenmengersyndromeinWHO-FCIII.574Patientswithmorecom-
namic reversal of shunt. There is no evidence for a long-term plexlesionswerelesslikelytorespondtoPAHtherapiescompared
benefit of a treat-and-repair approach in patients with adult withpatientswithsimplelesions.AnRCTinvestigatingtheefficacyof
CHD-associated PAH with prevalent systemic-to-pulmonary macitentanfoundnoeffecton6MWDinamixedcohortofpatients
shunts; therefore, there is a need for future prospective stud- with Eisenmenger syndrome (6MWD improved in both treatment
ies.564 Defect closure is contraindicated in all patients with and placebo arms), although decreases in NT-proBNP and PVR
Eisenmenger syndrome, and may also adversely affect patients werenotedinthemacitentanarm.575
with small/coincidental defects that behave similarly to IPAH.565 ExperienceswithotherERAsandPDE5ishaveshownfavourable
Therearenoprospectivedataavailableontheusefulnessofvasor- functionalandhaemodynamicresultsinEisenmengersyndrome.576
eactivitytesting,balloonclosuretesting,orlungbiopsyforasses- In a small, single-centre, pilot study, adding nebulized iloprost to a
singoperabilityandnormalizationofPVRafterclosure.566 background of oral PAH therapy failed to improve 6MWD in
PatientswithadultCHD-associatedPAHmaypresentwithclinical Eisenmengersyndrome.577Incasesymptomspersistorinclinicalde-
deteriorationindifferentcircumstances,suchasarrhythmia,during terioration,asequentialandsymptom-orientatedtreatmentstrategy
non-cardiac surgery requiring general anaesthesia, dehydration or is recommended in Eisenmenger syndrome, starting with an oral
bleeding, thrombo-embolism, and lung infections. Surgeries should ERA (or PDE5i) and escalating therapy. Should symptoms not ad-
belimitedtothosedeemedessential,andperformedinspecialized equatelyimprovewithoraltherapies,i.v./s.c.optionsshouldbepro-
centres with anaesthetists experienced in adult CHD and PAH. actively considered.578 There is a theoretical risk of paradoxical
Endocarditisshouldbesuspectedinpatientswithsepsis,whereasa embolisminright-to-leftshuntlesionswiththepresenceofacentral
cerebral abscess should be excluded in those with neurological venouscatheterfori.v.therapy;therefore,s.c.prostacyclinanalogue
symptomsornewheadache,especiallyinthosewithlowoxygensa- infusionmaybeconsidered.
turations and complex anatomies. It is recommended to avoid The effect of PAH therapies in patients with prevalent
strenuous exercise, but mild and moderate activities seem to be systemic-to-pulmonaryshuntsislesswellestablished.Patientswith
beneficial.567Patientsshouldreceiveallrecommendedvaccinations small/coincidental defects should be treated with PAH medica-
andendocarditisprophylaxisinthepresenceofcyanosis.Although tion.557ThisisalsothecaseforpatientswithPAHafterdefectcor-
pregnantpatientswithleft-to-rightshuntsandstable,well-controlled rection who have increased mortality compared with those with
PAH have tolerated pregnancy well under specialized care, preg- Eisenmenger syndrome.579 These patients were included in major
nancyisstillassociatedwithbothhighmaternalmortalityandfoetal RCTswithPAHtherapiesandshouldbeevaluatedbasedoncom-
complicationsinEisenmengersyndromeandshouldbediscouraged prehensiveriskassessment(Table16).580TheeffectofPAHtherap-
inthissetting;568,569hence,effectivecontraceptionishighlyrecom- iesinpatientswithsegmentalPHremainsamatterofdebate.101,581
mended. Levonorgestrel-based, long-acting, reversible contracep- Whilesomeserieshavereportedpromisingresults,therehavebeen
tion implants or intrauterine devices have been recommended for cases where therapies were not tolerated.581 Similarly, using PAH
thesepatients.570 therapiesinFontancirculationhasyieldedconflictingresults,andre-
Secondaryerythrocytosisisbeneficialforadequateoxygentrans- sultsoffurtherstudiesareawaited.582–584
portanddelivery,androutinephlebotomyshouldbeavoidedwhen- Heart–lungtransplantationorLTxwithheartsurgeryisanoption
ever possible. Symptoms of hyperviscosity in the presence of inhighlyselectedcasesnotresponsivetomedicaltreatment;how-
haematocrit.65%shouldbeapproachedwithappropriatehydra- ever, it is limited by organ availability and lesion complexity.
tion.Irondeficiencyshouldbecorrected.Wheni.v.ironsupplemen- Mortality is high during the first year after surgery, especially after
tation is administered, special care should be taken to avoid air heart–lungtransplantation,butremainsrelativelylowthereafter.585
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 63 ---
3680 ESC/ERSGuidelines
RecommendationTable18—Recommendationsfor
InpatientswithPAHaftercorrectedadultCHD,
shunt closure in patients with pulmonary–systemic
initialoralcombinationtherapywithdrugs
flowratio.1.5:1basedoncalculatedpulmonaryvas-
approvedforPAHshouldbeconsideredfor
cularresistance
patientsatlowandintermediaterisk,whileinitial IIa Cc
Recommendations Classa Levelb combinationtherapyincludingi.v./s.c.prostacyclin
analoguesshouldbeconsideredforpatientsat
InpatientswithanASD,VSD,orPDAandaPVR
I C highrisk
,3WU,shuntclosureisrecommended
InpatientswithadultCHD,includingEisenmenger
InpatientswithanASD,VSD,orPDAandaPVR
IIa C syndrome,sequentialcombinationtherapyshould
of3–5WU,shuntclosureshouldbeconsidered IIa C
beconsideredifpatientsdonotmeettreatment
InpatientswithanASDandaPVR.5WUthat
goals
declinesto,5WUwithPAHtreatment,shunt IIb C
Intheabsenceofsignificanthaemoptysis,oral
closuremaybeconsidered
anticoagulanttreatmentmaybeconsideredin
InpatientswithaVSDorPDAandaPVR.5WU, IIb C
patientswithEisenmengersyndromewith
shuntclosuremaybeconsideredaftercareful IIb C
pulmonaryarterythrombosis
evaluationinspecializedcentres
InwomenwithEisenmengersyndrome,
InpatientswithanASDandaPVR.5WU III C
pregnancyisnotrecommended
despitePAHtreatment,shuntclosureisnot III C
InpatientswithEisenmengersyndrome,routine
recommended
phlebotomytolowerelevatedhaematocritisnot III C
ASD,atrialseptaldefect;PAH,pulmonaryarterialhypertension;PDA,patentductus recommended
arteriosus;PVR,pulmonaryvascularresistance;VSD,ventricularseptaldefect;WU,
Woodunits. CHD,congenitalheartdisease;ERA,endothelinreceptorantagonist;i.v.,intravenous;
Decisionsonshuntclosureshouldnotbemadeonhaemodynamicnumbersalone;a PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; s.c.,
multiparametricstrategyshouldbefollowed(seeSection7.5.2). subcutaneous.
aClassofrecommendation. aClassofrecommendation.
bLevelofevidence. bLevelofevidence.
cLevelofevidencediffersfromthe2020ESCGuidelinesforthemanagementofadult
congenitalheartdiseasebecausethenumberofpatientswithadultCHDincludedin
theAMBITIONstudywasverylow.
RecommendationTable19—Recommendationsfor
pulmonary arterial hypertension associated with adult
7.6. Pulmonary arterial hypertension
congenitalheartdisease
associated with schistosomiasis
Recommendations Classa Levelb Schistosomiasisisoneofthemostcommonchronicinfectiousdis-
eases worldwide, affecting around 200 million people.586,587
Riskassessment
Schistosomiasis-associated PAH is present in 5% of patients with
Riskassessmentisrecommendedforpatients I C the hepatosplenicform of the disease.586 It is thusa leading cause
withpersistentPAHafterdefectclosure
of PAH, especially in some regions of South America, Africa, and
Riskassessmentshouldbeconsideredinpatients IIa C Asia. Compared with patients with IPAH, patients with
withEisenmengersyndrome schistosomiasis-associatedPAHpresentwithhigherCOandlower
Treatment PVR,andhaveabettersurvival.587Registrydatasuggestthatsurvival
Bosentanisrecommendedinsymptomatic inschistosomiasis-associatedPAHhasimprovedinrecentyearswith
patientswithEisenmengersyndrometoimprove I B theuseofPAHdrugs.588
exercisecapacity574
7.7. Pulmonary arterial hypertension
InpatientswithEisenmengersyndrome,theuseof
supplementaloxygentherapyshouldbe with signs of venous/capillary
IIa C
consideredincaseswhereitconsistentlyincreases involvement
arterialoxygensaturationandreducessymptoms
The common risk factors, identical genetic substrate, and indistin-
Supplementalirontreatmentshouldbe IIa C guishableclinicalpresentationsofPCHandPVODnecessitatetheir
consideredinpatientswithirondeficiency
considerationasasinglediseasebelongingtothegroup1PHspec-
InpatientswithadultCHD,includingEisenmenger trum of diseases (PAH with signs of venous/capillary involve-
syndrome,otherERAs,PDE5is,riociguat,
IIa C
ment).1,425,589InPVOD/PCH,post-capillarylesionsaffectingseptal
prostacyclinanalogues,andprostacyclinreceptor veins and pre-septal venules consist of loose, fibrous remodelling
agonistsshouldbeconsidered oftheintimathat maytotally occludethe lumen.1,425,589,590These
Continued changes are frequently associated with PCH consisting of capillary
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 64 ---
ESC/ERSGuidelines 3681
ectasia and proliferation, with doubling and tripling of the alveolar RecommendationTable20—Recommendationsfor
septalcapillarylayersthatmaybefocallydistributedwithinthealveo- pulmonaryarterialhypertensionwithsignsofvenous/
larinterstitium.425,590 capillaryinvolvement
TheproportionofpatientswithIPAHthatfulfilthecriteriafor
Recommendations Classa Levelb
PVOD/PCHis(cid:4)10%,resultinginalowestestimateofPVOD/PCH
incidence and prevalence of ,1 case/million.425 In contrast to Acombinationofclinicalandradiologicalfindings,
IPAH,thereisamalepredominanceinPVOD/PCHanditsprogno- ABG,PFTs,andgenetictestingisrecommended
I A
sisisworse.425,589,591FamilialPVOD/PCHtypicallyoccursinthe todiagnosePAHwithsignsofvenousand/or
youngsiblingsofonegeneration,withunaffectedandsometimes capillaryinvolvement(PVOD/PCH)591
consanguineousparents,indicatingthatthediseasesegregatesas IdentificationofbiallelicEIF2AK4mutationsis
arecessivetrait.158,425,591BiallelicmutationsintheEIF2AK4gene recommendedtoconfirmadiagnosisofheritable I A
causeheritablePVOD/PCH.158Inaddition,PVOD/PCHcancom- PVOD/PCH158,591
plicatethecourseofassociatedconditions,suchasSSc,425orbe
ReferralofeligiblepatientswithPVOD/PCHtoa
associatedwithexposuretoenvironmentaltriggers,suchasalkyl- transplantcentreforevaluationisrecommended I C
ating agents (cyclophosphamide, mitomycin C)34 and solvents assoonasthediagnosisisestablished
(trichloroethylene).38
InpatientswithPVOD/PCH,theuseofdrugs
approvedforPAHmaybeconsideredwithcareful IIb C
7.7.1.Diagnosis monitoringofclinicalsymptomsandgasexchange
Mostpatientscomplainofnon-specificdyspnoeaonexertionandfa- Lungbiopsyisnotrecommendedtoconfirma
III C
tigue.590Physicalexaminationmayrevealdigitalclubbingandbibasal diagnosisofPVOD/PCH
crackles on lung auscultation.590 Pulmonary arterial hypertension
ABG, arterial blood gas analysis; PAH, pulmonary arterial hypertension; PCH,
and PVOD/PCH share the same haemodynamic profile as pre- pulmonary capillary haemangiomatosis; PFT, pulmonary function test; PVOD,
capillaryPH.590,591ThePAWPisnotelevatedbecausethepulmon- pulmonaryveno-occlusivedisease.
aClassofrecommendation.
aryvascularchangesoccurinsmallvenulaeandcapillaries,whilethe bLevelofevidence.
LAfillingpressureremainsnormal.590,591AdiagnosisofPVOD/PCH
isbasedontheresultsoftestssuggestingvenouspost-capillaryin-
volvement, chronic interstitial pulmonary oedema, and capillary 7.8. Paediatric pulmonary hypertension
proliferation.1,590,591 These tests include PFTs (decreased DLCO, Pulmonaryhypertensionmaypresentatallages,includingininfants
frequently ,50% theoretical values), ABG (hypoxaemia), and and children. Pulmonary hypertension in childhood shares many
non-contrastchestCT(subpleuralthickenedseptallines,centrilob- commonfeatureswithPHinadulthood;however,therearealsoim-
ular ground-glass opacities, and mediastinal lymphadenop- portantdifferences,whichconcernepidemiology,aetiology,genetic
athy).1,425,589,591,592 Importantly, these patients are at risk of background, age-dependent diagnostic and treatment approaches,
drug-inducedpulmonaryoedemawithPAHtherapy,afindingsug- and disease monitoring. An important and conceptually distinctive
gestiveofPVOD/PCH.425,591DetectingbiallelicEIF2AK4mutations featureofpaediatricPHisinjurytodevelopingfoetal,neonatal,or
is sufficient to confirm a diagnosis of heritable PVOD/ paediatriclungcirculation.
PCH.158,591,592 Lung biopsy is hazardous in PH and is not recom-
mendedfordiagnosingPVOD/PCH.1,425
7.8.1.Epidemiologyandclassification
ThereportedannualincidentrateforpaediatricPHis64/millionchil-
7.7.2.Therapy dren.594 The distribution of the various aetiologies of PH in child-
There is no established medical therapy for PVOD/PCH.425 hood differs from PH in adulthood.594–596 Pulmonary arterial
ComparedwithIPAH,PVOD/PCHhasapoorprognosisandlimited hypertensionisthemostfrequenttypeofPHinchildren,withthe
responsetoPAHtherapy,withariskofpulmonaryoedemadueto vast majority (82%) of cases being infants with transient PAH (i.e.
pulmonaryvenousobstruction.425,591However,therearereportsof PPHNorrepairablecardiacshuntdefects).Oftheremainingchildren
incompleteandtransientclinicalimprovementinindividualpatients with PAH, most have either IPAH, HPAH, or irreversible
with PVOD/PCH treated with PAH therapy, which should be CHD-associated PAH. The reported incidences of IPAH/HPAH
used with great caution in this setting.425,591 Diuretics, oxygen and (non-transient) CHD-associated PAH are 0.7 and 2.2/million
therapy,andslowtitrationofPAHtherapycanbeusedonanin- children,respectively,withaprevalenceof4.4and15.6/millionchil-
dividual basis.425 Therefore, therapy for PVOD/PCH should be dren, respectively.594 Other conditions associated with PAH
undertaken at centres with extensive experience in managing (Table6)dooccurinchildrenbutarerare.
PH, and patients should be fully informed about the risks.425 Another significant proportion (34–49%) of children with non-
Anecdotalreportssuggestapotentialbenefitofimmunomodula- transientPHareneonatesandinfantswithPHassociatedwithre-
tory treatments, but this approach requires further study.593 spiratory disease, especially developmental lung diseases, including
TheonlycurativetherapyforPVOD/PCHisLTx,andeligiblepa- bronchopulmonarydysplasia(BPD),congenitaldiaphragmatichernia
tients should be referred to a transplant centre for evaluation (CDH), and congenital pulmonary vascular
abnormalities.594–598
upon diagnosis.425,591 Pathological examination of the explanted Thesechildrenformaprominentanddistinctivegroupinpaediatric
lungswillconfirmthediagnosis.590 PH and are currently classified as PH group 3 associated with
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 65 ---
3682 ESC/ERSGuidelines
Infant Child AAdult
IPAH/HPAH
Complex CHD IPAH/HPAH Simple CHD PAH-CHD
1 PPHN PAH-CTD
PAH-CHD
PoPH
PAH-HIV
Congenital MS
2 Congenital PVS Left heart failure
Cardiomyopathy
PH classification
Developmental lung diseases
Trisomy 21 COPD
Bronchopulmonary dysplasia
3 chILD ILD
Congenital diaphragmatic hernia
Hypoventilation syndrome
Alveolar capillary dysplasia
4 Congenital PS Congenital PS CTEPH
Haematologic diseases
5 Metabolic disorders
Systemic diseases
Diabetes
Chromosomal abnormalities Hypertension
Comorbidities Congenital malformations
Syndromic features Heart failure
Renal failure
Risk factors Respiratory support Steroids ~
for outcome Suprasystemic PH ASD/VSD Risk assessment tool Risk assessment tool
Necrotizing enterocolitis
Echocardiography RHC+AVTa ~ RHC+AVTa
Diagnosis
RHC? Diagnostic algorithm Diagnostic algorithm
Optimize GORD treatment ~
Therapy respiratory support Inhaled NO, Treatment algorithm Treatment algorithm
Nutritional support PAH drugs
+/- +++
Evidence Extremely limited
Cohort studies RCTs
Figure10Neonatalandpaediatricvs.adultpulmonaryhypertension.ASD,atrialseptaldefect;AVT,acutevasoreactivitytesting;CHD,congenitalheart
disease;COPD,chronicobstructivepulmonarydisease;CTEPH,chronicthrombo-embolicpulmonaryhypertension;GORD,gastro-oesophagealreflux
disease;HPAH,heritablepulmonaryarterialhypertension;ILD,interstitiallungdisease;IPAH,idiopathicpulmonaryarterialhypertension;MS,mitralsten-
osis;NO,nitricoxide;PAH,pulmonaryarterialhypertension;PAH-CHD,PAHassociatedwithcongenitalheartdisease;PAH-CTD,PAHassociatedwith
connectivetissuedisease;PAH-HIV,PAHassociatedwithHIVinfection;PH,pulmonaryhypertension;PoPH,porto-pulmonaryhypertension;PPHN,
persistentpulmonaryhypertensionofthenewborn;PS,pulmonaryarterialstenosis;PVS,pulmonaryveinstenosis;RCT,randomizedcontrolledtrial;
RHC,rightheartcatheterization;VSD,ventricularseptaldefect.aInpatientswithidiopathic,heritableordrug-associatedPAH.Pulmonaryhypertension
inneonatesandinfantssignificantlydiffersinaetiology,pathophysiology,riskassessment,andtreatmentfromolderchildrenandadults,whilePHinolder
childrenhasmoresimilaritieswithPHinadults.
developmental lung disease (Table 6; Table S7). A significant and AnotherdistinctivefeatureofPHinchildrenisthehighburdenof
growingproportionofchildrenwithPHassociatedwithrespiratory geneticdisorders. Childhood PHisoften associated with chromo-
diseaseismadeupofpre-terminfantswithBPD.Also,newlyrecog- somal, genetic, and syndromic anomalies (11–52%). Like in adults,
nizedgeneticdevelopmentallungdisorders—includingalveolarcapil- genemutationsimplicatedinthepathogenesisofHPAHarefound
larydysplasia,TBX4-mutation-relatedlungdisorders,andsurfactant in20–30%ofsporadiccases,wherepaediatricHPAHseemstobe
abnormalities—arecurrentlyclassifiedinthiscategory(Figure10).599 characterized by an enrichment in TBX4 and ACVRL1
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 66 ---
ESC/ERSGuidelines 3683
variations.600,601Additionally,17%ofchildrenwithPAHhaveother inexperiencedpaediatricPHcentres.IndicationsforrepeatedRHCin
disordersknowntobeassociatedwithPAH,includingtrisomy21. childrenwithPHarecurrentlynotwelldefined.
Finally,23%ofchildrenwithPAHhavecopynumbervariationsnot TreatmentofchildrenwithPAHisbasedonriskstratification.599
previouslyassociatedwithPH.600,602,603 PredictorsofworseoutcomeinpaediatricPAHaresimilartothose
Giventhefrequentassociation ofpaediatricPAHwithchromo- inadults,andincludeclinicalevidenceofRVfailure,progressionof
somal,genetic,andsyndromicanomalies(forwhichthemechanistic symptoms, WHO-FC III–IV, certain echocardiographic parameters
basisforPAHisgenerallyuncertain),genetictestingmaybeconsid- (e.g.TAPSE),andelevatedserumNT-proBNP.A6MWD,350m
ered for defining aetiology and comorbidities, stratifying risk, and hasalsobeensuggestedasapredictorofworseoutcomeinpaediat-
identifying family members at risk; however, this should be after ricPH,butitsvalueinyoungchildrenislessestablished.Furtherprog-
appropriateexpertgeneticcounsellingforthechildandfamily(see nosticators identified in paediatric PAH are failure to thrive and
Section5.1.13). haemodynamic variables, such as RAP .10mmHg, the ratio of
TheclinicalPHclassification(Table6)isalsofollowedforpaediat- mean pulmonary-to-systemic blood pressure .0.75, and PVRI
ric PH. To improve applicability of this classification in infants and .20 WU·m2.602,606,607 Paediatric risk-assessment tools based on
childrenwithPH,ithasbeenadaptedtogiveroomtoPHassociated theseparametershavebeenretrospectivelyvalidatedinobservation-
with various congenital cardiovascular and pulmonary diseases or alpaediatricregistries.599,604a
specificpaediatricconditions(TablesS5–S8).599
7.8.3.Therapy
Theultimategoaloftreatmentshouldbetoimprovesurvivalandfa-
7.8.2.Diagnosisandriskassessment cilitatenormalchildhoodactivitieswithoutlimitations.Intheabsence
Historically, the definition of PH in children aged .3 months has ofRCTsinpaediatricPAH,recommendedtreatmentalgorithmsare
beenthesameasinadults.ThedefinitionforPHhasnowbeenre- extrapolatedfromthoseinadultsandenhancedwithdatafromob-
definedtomPAP.20mmHginadultsaswellasinchildren.Theim- servationalstudiesinchildrenwithPAH.599
pactofanmPAP21–24mmHgonoutcomesinchildrenisunknown. Observational cohort studies support treatment algorithms de-
However, in the interest of consistency and to facilitate transition signed for adults to be used for children (including the superiority
frompaediatrictoadultPHcare,itisrecommendedthattheupdated of combination therapy over monotherapy).608 Drugs investigated
definitionforPHalsobefollowedinchildren.Notreatmentrecom- in children, with or without formal approval by the European
mendations currently exist for this group of children (mPAP 21– MedicinesAgency(EMA)fortreatingchildrenwithPAH,areshown
24mmHg). inTable22.
RegardingthenewlyintroducedcriteriontoincludePVR.2WU Apaediatrictreatmentalgorithm,derivedfromthatforadults,is
to identify pre-capillary PH in adults, PVR had previously been in- basedonriskstratification,recommendinggeneralmeasures,high-
cludedinthedefinitionforPAHinchildren.Inchildren,bloodflows dose CCB therapy for responders to acute vasoreactivity testing
are traditionally indexed assuming that systemic and pulmonary (whereclosefollow-upismandatory,assomepatientsmayfaillong-
bloodflowschangeproportionallywithbodysize,whilethetranspul- termtherapy),oralorinhaledcombinationtherapyforchildrenat
monarypressuregradientdoesnot.Sincebloodflowisthedenom- lowrisk,andcombinationtherapywithi.v./s.c.prostacyclinanalogues
inatorintheequationforcalculatingPVR,theneedforindexingof forthoseathighrisk.599
PVRinchildrenisemphasized,andthecriterionofpulmonaryvascu- Inthecaseofinsufficientresponsetorecommendeddrugtherapy,
larresistanceindex(PVRI)≥3WU·m2inthedefinitionforPAHin orwhendrugsareunavailable,aPottsshunt(asurgicalorinterven-
childrenremainsunchanged.599 tional connection between the left PA and the descending aorta),
SincetheaetiologyofpaediatricPHisverydiverse,amethodical BAS, or LTx may be considered in children with severe PH (see
andcomprehensivediagnosticapproachiscrucialtoreachanaccur- Sections 6.3.6.1 and 6.3.8).599 Reported clinical experience with
atediagnosisandtreatmentplan.Asinadults,IPAHisadiagnosis‘per Pottsshuntsislimitedtojustover100patients,predominantlychil-
exclusion’.Adiagnosticwork-up,similartothatinadultsbutcusto- dren,withamortalityof12–25%andlong-termclinicalbenefitina
mizedforpaediatricPH,isrecommended.599Pre-terminfantswith subsetofchildrenwithlong-termfollow-up.456–459
BPDshouldbescreenedforPH,sincePHisprevalentinthispopu- Monitoring of treatment effect and disease course is pivotal in
lationandseriouslyaffectsoutcome.604 managingallpatientswithPAH(adultsandinchildren).Inchildren
Alsoinchildren,RHCisthegoldstandardfordefinitivelydiagnosing withPAH,clinicalriskscoresincludingWHO-FC,TAPSE,andserum
andestablishingthenatureofPH,andprovidesimportantdatafor NT-proBNP are potential treatment targets for goal-orientated
stratifyingrisk.604a,605To identify those suitable forhigh-doseCCB treatment.604a,609
treatment, acute vasoreactivity testing is recommended in children ContemporarytreatmentalgorithmsforinfantswithPPHNhave
withIPAH/HPAH.Thecriteriausedinadultsforapositiveacutere- beenproposedbutareoutsidethescopeoftheseguidelines.610
sponsehaveidentifiedchildrenwhowillshowsustainedbenefitfrom The recommendations discussed above apply to children with
CCBtherapy; however,these criteriado notdefine reversibility of PAH,whereasthespecificgroupofinfantswithneonatalPVD,most-
PAH or operability in children with CHD. Since RHC in children ly classified as PH associated with developmental lung disease and
with PH may be associated with major complications (in 1–3% of withheterogeneousaetiology,requireadistinctandcustomizedap-
cases,especiallyinyounginfantsandthoseinworseclinicalcondition), proach(Figure10).
risksandbenefitshavetobebalancedintheindividualchild.605Heart Inpre-terminfantswithBPDandPH,theunderlyinglungdisease
catheterizationinchildrenwithPAHshouldbeexclusivelyperformed shouldprimarilybetreated.Frequently,theseinfantsareadditionally
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 67 ---
3684 ESC/ERSGuidelines
Table22 Useofpulmonaryarterialhypertensiontherapiesinchildren
Drug Paediatricstudydata EuropeanMedicinesAgencyapproval Ref.
foruseinchildrenwithPAH
Phosphodiesterase5inhibitors(oral)
Sildenafil RCT,open-labelextension:tolerability,efficacy Yes,for≥1yearofage 613,614
Recommendeddosing:
,20kg:30mg/dayin3doses;≥20kg:60mg/
dayin3doses
Avoidhigherdosinginchildren(.3mg/kg/day)
Tadalafil RCT,open-label:safety,tolerability,pharmacokinetics No 615,616
Suggesteddosing:
0.5–1mg/kg/dayinonedose
Max:40mg/day
Evaluatedonlyin
childrenaged.3years
Endothelinreceptorantagonists(oral)
Bosentan Open-label,uncontrolled:safety,tolerability,pharmacokinetics, Yes,for≥1yearofage 617–620
efficacy Paediatricformulation
Recommendeddosing:
4mg/kg/dayin2doses
Max:250mg/day
Ambrisentan Open-label,uncontrolled:safety,tolerability,pharmacokinetics Yes,forchildrenaged.8years 621,622
Recommendeddosing:
2.5–10mg/dayinonedose
Macitentan Insufficientdatainchildren No
Open-label,ongoing:efficacy,safety,pharmacokineticsinchildren
aged2–18years
Prostacyclinanalogues(i.v./s.c.)
Epoprostenol Cohortstudies,retrospective No 623–626
i.v. Suggesteddosing:
Startingdose:1–2ng/kg/min
withoutaknownmaximum
Inchildren,astabledose
isusually40–80ng/kg/min
Doseincreasesmayberequired
Treprostinili.v./ Cohortstudies,retrospective:pharmacokinetics No 624,626,627
s.c. Suggesteddosing:
Startingdose:2ng/kg/min
withoutaknownmaximum
Inchildren,astabledose
isusually50–100ng/kg/min
Doseincreasesmayberequired
Other
Iloprost Insufficientdatainchildren No
(inhaled) Smallcaseseries,retrospective
Selexipag(oral) Insufficientdatainchildren No
Randomized,placebo-controlled,add-on,ongoing:safety,
tolerability,pharmacokineticsinchildrenaged2–18years
Riociguat(oral) Insufficientdatainchildren No
Open-label,ongoing:safety,tolerability,pharmacokineticsin
childrenaged6–18years
i.v.,intravenous;PAH,pulmonaryarterialhypertension;RCT,randomizedcontrolledtrial;s.c.,subcutaneous.
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 68 ---
ESC/ERSGuidelines 3685
treated with therapies for PAH, including sildenafil and bosentan; Inneonatesandinfants,adiagnosticand
however, these are not approved by the EMA for use in infants therapeuticapproachtoPHdistinctfromthatin
with group 3 PH and developmental lung diseases (BPD, CDH). olderchildrenandadultsshouldbeconsidered, IIa C
Theireffectsonoutcomesinthispopulationareunclear,anddata giventhefrequentassociationwithdevelopmental
enablingrobusttreatmentrecommendationsarelacking.Thesechil- vascularandparenchymallungdisease
drenshouldbetreatedbymultidisciplinaryteamsinvolvingcardiolo-
CCB,calciumchannelblocker;CO,cardiacoutput;HPAH,heritablepulmonaryarterial
gists, neonatologists, pulmonologists, and nutritionists. Pulmonary
hypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean
hypertension in these infants may disappear with lung healing, al- pulmonaryarterialpressure;PAH,pulmonaryarterialhypertension;PH,pulmonary
thoughlong-termcardiovascularsequelaehavebeenreported.611,612 hypertension;RHC,rightheartcatheterization.
aClassofrecommendation.
bLevelofevidence.
RecommendationTable21—Recommendationsfor
paediatricpulmonaryhypertension
8. Pulmonary hypertension
Recommendations Classa Levelb associated with left heart disease
Children (group 2)
Itisrecommendedtoperformthediagnostic
work-up,includingRHCandacutevasoreactivity 8.1. Definition, prognosis, and
I C
testing,andtreatchildrenwithPHatcentreswith pathophysiology
specificexpertiseinpaediatricPH
Among patients with LHD, PH and RV dysfunction are frequently
InchildrenwithPH,acomprehensivework-upfor presentandassociatedwithhighmortality.47Thisincludespatients
confirmingdiagnosisandspecificaetiologyis
withHFwithreduced,mildlyreduced,orpreservedejectionfraction
I C
recommended(similartothatinadults,but (HFrEF, HFmrEF, or HFpEF), left-sided valvular heart disease, and
adaptedforage) congenital/acquired cardiovascular conditions leading to post-
ForconfirmingPHdiagnosis,RHCisrecommended, capillaryPH.13,631–635Arguably,PH-LHDrepresentsthemostpreva-
I C
preferablybeforeinitiatinganyPAHtherapy lentformofPH,accountingfor65–80%ofcases.47
InchildrenwithIPAH/HPAH,acutevasoreactivity ConsistentwiththegeneraldefinitionsofPH,PH-LHD(group2
testingisrecommendedtodetectthosewhomay I C PH)isdefinedbyanmPAP.20mmHgandaPAWP.15mmHg.
benefitfromCCBtherapy Withinthishaemodynamicconditionofpost-capillaryPH,IpcPHis
Itisrecommendedtosimilarlydefineapositive defined by PVR ≤2 WU and CpcPH by PVR .2 WU (Table 5).
responsetoacutevasoreactivitytestinginchildren Thediastolicpressuregradient(DPG)(calculatedasthedifference
andadultsbyareductioninmPAP≥10mmHgto I C betweendPAPandPAWP)isnolongerusedtodistinguishbetween
reachanabsolutevalueofmPAP≤40mmHg, IpcPHandCpcPHbecauseofconflictingdataonprognosticationin
withanincreasedorunchangedCO
LHD.142
InchildrenwithPAH,atherapeuticstrategybased AcrossthespectrumofLHD,increasesinPAPandPVRareasso-
onriskstratificationandtreatmentresponseis ciated with an increased disease burden and a worse out-
recommended,extrapolatedfromthatinadults I C come.13,631,633,635 In a large patient cohort—predominantly with
butadaptedforage post-capillary PH—a PVR ≥2.2 WU was associated with adverse
outcomes and considered abnormal.13 However, even within this
Itisrecommendedtomonitorthetreatment
subgroupofpatientswithLHDandCpcPH,theriskofmortalityin-
responseinchildrenwithPAHbyseriallyassessing
apanelofdataderivedfromclinicalassessment, I C creaseswithprogressiveelevationinPVR.Inpatientswithadvanced
HFrEF and those with HFpEF or valvular heart disease, a PVR
echocardiographicevaluation,biochemical
.5WUcarriesadditionalprognosticinformationandisconsidered
markers,andexercisetolerancetests
Achievingandmaintainingalow-riskprofile clinically meaningful by physicians.142,450,631–639 Elevated PVR also
appearstobeassociatedwithdecreasedsurvivalinspecialsituations,
shouldbeconsideredasanadequatetreatment IIa C
suchasinpatientsundergoinginterventionsforcorrectingvalvular
responseforchildrenwithPAH
heart disease,634 heart transplantation,142,633 or LVAD implant-
Infants ation.142,637Basedonavailabledata,aPVR.5WUmayindicatea
Itisrecommendedtoscreeninfantswith I B severepre-capillarycomponent,thepresenceofwhichmayprompt
bronchopulmonarydysplasiaforPH628,629
physicianstoreferpatientstoPHcentresforspecializedcare.
Ininfantswith(oratriskof)bronchopulmonary TheprevalenceofPHinpatientswithLHDisdifficulttoassessand
dysplasiaandPH,treatinglungdisease—including
depends on the methodology of diagnostic testing (echocardiog-
hypoxia,aspiration,andstructuralairwaydisease I B raphy or invasive haemodynamics), cut-off values used to define
—andoptimizingrespiratorysupportis
PH,andpopulationsstudied.Observationalstudiessuggestanesti-
recommendedbeforeinitiatingPAHtherapy630 mated prevalence of PH of 40–72% in patients with HFrEF and
Continued
36–83%inthosewithHFpEF.48,639–643WhenPVRisusedtodefine
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 69 ---
3686 ESC/ERSGuidelines
Heart failure/cardiomyopathy Valvular heart disease
HFrEF HFmrEF HFpEF Aortic valve Mitral valve
EF ≤40% EF 41–49% EF ≥50% Stenosis/Regurgitation
Variable degree of pulmonary congestion, vasoconstriction, vascular remodelling
LA pressure Congestion Remodelling Right heart strain
LA pressure (mmHg)
20
15
10
5
20 40 60 80 100 120
LA volume (ml)
LA dysfunction Vasoconstriction Venous Arteriolar RV dysfunction
Pulmonary congestion
Controlled
RV–PA
LHD
uncoupling
Pulmonary vascular disease
No PH IpcPH CpcPHa
Left ventricular phenotype Right ventricular phenotype
Figure11Pathophysiologyofpulmonaryhypertensionassociatedwithleftheartdisease(group2).CpcPH,combinedpost-andpre-capillarypulmon-
aryhypertension;HFmrEF,heartfailurewithmildlyreducedejectionfraction;HFpEF,heartfailurewithpreservedejectionfraction;HFrEF,heartfailure
withreducedejectionfraction;IpcPH,isolatedpost-capillarypulmonaryhypertension;LA,leftatrial;LHD,leftheartdisease;RV,rightventricle/rightven-
tricular;PA,pulmonaryartery;PH,pulmonaryhypertension.aCpcPHisdefinedbypost-capillaryPHandPVR.2WU;aPVR.5WUmaybeconsidered
aseverepre-capillarycomponent.
apre-capillarycomponentinpatientswithHFandpost-capillaryPH, valvestenosisdevelopPH,652whichcanalsobefoundinmostpa-
(cid:4)20–30%ofpatients arecategorizedashavingCpcPH.47,644,645 In tientswithsignificantdegenerativeorfunctionalmitralregurgitation.
patientswithvalvularheartdisease,echocardiographicstudieshave The pathophysiology of PH-LHD combines several mechanisms
shownthatPHispresentinupto65%ofpatientswithsymptomatic (Figure11):(1)aninitialpassiveincreaseinLVfillingpressuresand
aortic
stenosis,646–651
while virtually all patients with severe mitral backward transmission into the pulmonary circulation; (2) PA
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 70 ---
ESC/ERSGuidelines 3687
endothelialdysfunction(includingvasoconstriction);(3)vascularre- PAH populations.142,450,661 In this context, validated scores for
modelling(whichmayoccurinbothvenulesand/orarterioles);(4) diagnosingHFpEF(HFA-PEFF,H2FPEF)16,662,663maybehelpfulfor
RV dilatation/dysfunction and functional
TR;653–656
and (5) altered detectingitasanunderlyingconditioninPH,andthepresenceorab-
RV–PA coupling.655–657 The haemodynamic profile of CpcPH vs. sence of risk factors for PAH or CTEPH should be determined.
IpcPHandelevatedPVRreflectspulmonaryvascularabnormalities, PatientswithsignsofpredominantRVstrainand/orPHshouldbe
whichcontributetoanincreasedRVafterload.Resultingdysfunction further evaluated. Patients shouldbe assessedorreassessed when
oftheRVisfrequentandassociatedwithaworseprognosisinpa- theyarefullyrecompensatedandinaclinicallystablecondition.
tients with PH-LHD. In HFpEF, where RV dysfunction may occur
viadistinctmechanisms(FigureS1),deteriorationofRV,butnotLV 8.2.2.Evaluationofpulmonaryhypertensionand
systolicfunction,hasbeenobservedovertime,andbothprevalent patientphenotyping
andincidentRVdysfunctionarepredictorsofmortality.658 PatientswithLHDandsuspectedPHshouldbeevaluatedfollowing
TheoccurrenceofPHinpatientswithLHDmayalsobedueto thediagnosticstrategyforPH(seeSection5).Thisrequiresidentify-
othercauses,includingundetectedCTEPHorPAH.Further,respira- ing clinical features and a multimodal approach using non-invasive
torycomorbiditiessuchasCOPDandsleepapnoeaarealsocom- diagnostic tests such as echocardiography, ECG, and BNP/
mon in patients with LHD and may contribute to PH and impact NT-proBNP levels. In the presence of mild PH and predominant
prognosis.PatientswithHFpEFandPHassociatedwithHFpEF75,76 LHD,nofurthertestingmaybenecessary.Otherwise,CTEPHand
mayalsopresentwithalowDLCO,whichisanindependentpredict- significantlungdiseaseshouldberuledoutbyV/QscanandPFTs,
orofoutcome.75 andadditionalcardiacimagingincludingcMRImaybeconsideredin
selected cases. For phenotyping, a combination of variables may
8.2. Diagnosis help to determinethe likelihood ofLHD, andHFpEF inparticular,
InpatientswithLHD,symptoms(e.g.exertionaldyspnoea)andphys- vs. other causes of PH (Table 23). Pulmonary hypertension asso-
ical signs of PH (e.g. peripheral oedema) frequently overlap with ciatedwithleftheartdiseaseislikelyinthepresenceofknowncar-
those of the underlying left heart condition and are mostly non- diacdisease,multiplecardiovascularcomorbidities/riskfactors,atrial
specific. However, while pulmonary congestion or pleural effusion fibrillationatdiagnosis,andspecificimagingfindings(LVhypertrophy,
indicateLHDastheunderlyingcauseofPH,otherfeaturesmaysug- increasedLAsize,andreducedLAstrain).Althoughexerciseecho-
gestthepresenceofrelevantPH(seeSection5.1.1). cardiographyhasbeenproposedtouncoverHFpEF,itisunableto
Routine diagnostic tests including BNP/NT-proBNP, ECG, and diagnoseorclassifyPHinthiscontext.Acombinationofclinicalfind-
echocardiographymayshowsignsofunderlyingLHD,butmayalso ingsandphenotypingisrequiredtodecideabouttheneedforfurther
indicatePH.WhileBNP/NT-proBNPcannotdiscriminatebetween invasiveassessment.
left-orright-sidedHF,ECGfindingssuchasrightaxisdeviationor
RV strain may suggest the presence of PH in patients with LHD. 8.2.3.Invasiveassessmentofhaemodynamics
Echocardiography can diagnose HFrEF and HFpEF; identify specific Thedecisiontoperformcardiaccatheterizationandtoinvasivelyas-
cardiac conditions, including those with restrictive filling pattern; sesscardiopulmonaryhaemodynamicsshoulddependonthepres-
anddiagnoseadditionalvalvularheartdisease;itmayalsodetectele- ence of an intermediate to high echocardiographic probability of
vatedsPAPandotherfeaturesofPH(RAarea,PAenlargement,RV/ PH,andshouldbedeterminedbytheneedtoobtainrelevantinfor-
LVratio,LVeccentricityindex,RVformingtheapex),leadingtoan mationforprognosticationormanagement.Inpatientswithahigh
echocardiographicprobabilityofPH(seeSection5.1.5).Astepwise, likelihood of LHD as the main cause of PH, or with established
compositeechocardiographicscoremaydiscriminatepre-vs.post- underlying LHD and mild PH (Table 23), invasive assessment for
capillary PH and predict PVD in patients with LHD.659,660 PH is usually not indicated. Indications for RHC in LHD include:
Additionalinformationmaybegatheredfromfurthertesting,includ- (1)suspectedPAHorCTEPH;(2)suspectedCpcPHwithasevere
ing biomarkers, imaging-derived markers of RV dysfunction, and pre-capillarycomponent,wherefurtherinformationwillaidpheno-
CPET-derivedvariables.142 typingandtreatmentdecisions(FigureS2);and(3)advancedHFand
Giventhecomplexityandvariabilityofcardiopulmonaryhaemo- evaluation for heart transplantation. While several haemodynamic
dynamics in patients with LHD, the distinction between post- and measures(mPAP,PVR,pulmonaryarterialcompliance[PAC],trans-
pre-capillary PH and the diagnosis of PH-LHD vs. other forms of pulmonary pressure gradient, and DPG) are associated with out-
PHcanbechallenging.Diagnosticcluesintheevaluationofsuspected comes in PH-LHD,142,632,635 the most robust and consistent data
PHinLHDinclude:(1)diagnosisandcontroloftheunderlyingLHD; areavailableforPVR.Invasiveassessmentshouldbeconductedinex-
(2) evaluation for PH and patient phenotyping; and (3) invasive perienced centres, when management of the underlying LHD has
haemodynamicevaluation,whenindicated. been optimized and patients are in a clinically stable condition.
With respect to respiratory variations of intrathoracic pressures,
8.2.1.Diagnosisandcontroloftheunderlyingleft allpressurereadingsshouldbetakenatend-expiration.
heartdisease AdditionaltestingduringRHCmaybeusefulfordistinguishingbe-
PatientswithsuspectedPH-LHDwillhaveanestablisheddiagnosisof
tweenPAHandHFpEF,18,23,664–669andtouncoverLHDinpatients
LHD,suchasHFrEF/HFmrEF,HFpEF,valvularheartdisease,and/or
withahighlikelihoodofPH-LHDandnormalrestingPAWP;670–673
CHD.ThedistinctionbetweenPHassociatedwithHFpEFandother bothexercisetestingandfluidchallengemaybeconsideredinspecial
formsofPH(e.g.PAH,CTEPH)maybechallenging,particularlygiven situations (seeSection5.1.12). Conditionsassociated withreduced
theincreasedburdenofcardiovascularcomorbiditiesinreal-world LVdiastoliccomplianceorvalvularheartdiseasemaybeassociated
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 71 ---
3688 ESC/ERSGuidelines
Table23 Patientphenotypingandlikelihoodforleftheartdiseaseascauseofpulmonaryhypertension
Feature PH-LHDunlikely Intermediate PH-LHDlikely
probability
Age ,60years 60–70years .70years
Obesity,hypertension,dyslipidaemia,glucoseintolerance/ Nofactors 1–2factors .2factors
diabetes
PresenceofknownLHD No Yes Yes
Previouscardiacintervention No No Yes
Atrialfibrillation No Paroxysmal Permanent/persistent
StructuralLHD No No Present
ECG NormalorsignsofRV MildLVH LBBBorLVH
strain
Echocardiography NoLAdilation NoLAdilation LAdilation(LAVI.34mL/
E/e′,13 Grade,2mitralflow m2)
LVH
Grade.2mitralflow
CPET HighVE/VCO slope ElevatedVE/VCO slope MildlyelevatedVE/VCO
2 2 2
NoEOV EOV slope
EOV
cMRI Noleftheartabnormalities LVH
LAdilation(strainorLA/RA
.1)
cMRI,cardiacmagneticresonanceimaging;CPET,cardiopulmonaryexercisetesting;E/e’,ratiobetweenearlymitralinflowvelocityandmitralannularearlydiastolicvelocity;ECG,
electrocardiogram;EOV,exerciseoscillatoryventilation;LA,leftatrial;LAVI,leftatrialvolumeindex;LBBB,leftbundlebranchblock;LHD,leftheartdisease;LVH,leftventricular
hypertrophy; PH, pulmonary hypertension; PH-LHD, left heart disease associated with pulmonary hypertension; RA, right atrium; RV, right ventricle; VE/VECO2, ventilatory
equivalentsforcarbondioxide.
AssigningthelikelihoodofLHDasacauseofPH.Thisassessmentmayhelptodecidewhichpatientsshouldundergoafullwork-up,includinginvasivehaemodynamicassessment(see
Figure11andFigureS2).
witharapidincreaseinPAWPwhenchallengedwithincreasedsys- mayhavevariableandpotentiallydetrimentaleffectsinsuchpatients
temic venous return.674 While the upper limit of normal remains andarethereforenotindicatedinPH-LHD.Managementstrategies
controversial,142,143,665,667 a PAWP cut-off of .18mmHg has forPHinvariousleftheartaetiologiesaredescribedbelow.
beensuggestedtoidentifyHFpEFastheunderlyingcauseofPH,des-
pitenormalPAWPatbaseline.143WhilethismayhelptoclassifyPH, 8.3.1.Pulmonaryhypertensionassociatedwith
therapeuticconsequencesofsuchtestingremaintobedetermined. left-sidedheartfailure
AsdifferentiatingbetweenseverePHassociatedwithHFpEFand 8.3.1.1.Heartfailurewithreducedejectionfraction
IPAHwithcardiaccomorbiditiesischallenging,patientswithanun- Patients with HFrEF or HFmrEF require guideline-directed treat-
clear diagnosis, particularly those with a predominant pre-capillary ment including established medical and interventional therapies.27
component(e.g.PVR.5WU),shouldbereferredtoaPHcentre In patients with advanced HFrEF, implanting an LVAD may signifi-
forindividualizedmanagement. cantly reduce or even normalize mPAP,675 although this is not
achievedinallpatients,676andanincreasedDPGemergedasanega-
8.3. Therapy tiveprognosticfactorafterLVADimplantation.677Withregardsto
TheprimarystrategyinmanagingPH-LHDisoptimizingtreatmentof PAHdrugs,bosentanwasassessedinanRCTofpatientswithPH
theunderlyingcardiacdisease.Nevertheless,apathophysiologicalse- associated with HFrEF,678 showing no efficacy but an increase in
quencerangingfromleft-sidedheartdiseaseviapulmonarycircula- adverse events compared with placebo, predominantly related to
tiontochronicrightheartstrain(atrestorexercise)ispresentin fluid retention. Small studies have suggested that sildenafil
manypatients.47SincedeteriorationofRVfunctionovertimeisas- may improve haemodynamics and exercise capacity in PH and
sociatedwithpooroutcomesinHFpEF,658preservingRVfunction HFrEF,679–681butRCTsarelacking.
shouldbeconsideredanimportanttreatmentgoal.Diureticsremain
thecornerstoneofmedicaltherapyinthepresenceoffluidretention 8.3.1.2.Heartfailurewithpreservedejectionfraction
duetoPH-LHD. InpatientswithHFpEF,bloodpressure,volumeload,andriskfactors
Thereislimitedandconflictingevidencefortheuseofdrugsap- shouldbecontrolled,whichmaylowerfillingpressuresandPAP.27
proved for PAH in patients with group 2 PH. Some medications Recently,theSGLT-2iempagliflozinimprovedoutcomesinpatients
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 72 ---
ESC/ERSGuidelines 3689
withanLVejectionfractionof40–60%.682Endothelinreceptoran- mitralregurgitationaccordingtotherecommendationsofthe2021
tagonistshavenotprovedsuccessfulinthispopulation,asbothbo- ESC/EACTS Guidelines for the management of valvular heart dis-
sentan683 and macitentan684 failed to show efficacy but rather led ease28 has a crucial role in improving haemodynamics in patients
to more adverse events (fluid retention) vs. placebo in patients with HFrEF, as this reduces mPAP and PAWP and improves the
with HFpEF-associated PH and HF with ejection fraction CI.699Nevertheless,registrydatahavedemonstratedthatevenmod-
.35%-associatedCpcPH,respectively.Phosphodiesterase5inhibi- eratelyelevatedsPAPnegativelyimpactspost-proceduraloutcomes
torswereassessedintwo smallRCTsinpatientswith HFpEFand aftercatheter-basedtherapy.700
PH with distinct haemodynamic characteristics. In patients with a
predominantlyIpcPHprofile,sildenafilhadnoeffectonmPAP(pri-
8.3.2.2.Aorticstenosis
mary endpoint) or other haemodynamic and clinical measures vs.
Inpatientswithaorticstenosisundergoingsurgicalorcatheter-based
placebo.685InpatientswithapredominantlyCpcPHprofile,sildenafil
aorticvalverepair,pre-interventionalPHisassociatedwithahigher
improvedhaemodynamics,RVfunction,andqualityoflifeat6and12
risk of in-hospital adverse events and adverse long-term out-
months vs. placebo.686 Furthermore, retrospective analyses and comes.646–651Althoughpost-proceduralimprovementinPHcorre-
registry data suggested improvements in exercise capacity with
lateswithsymptomreliefandfavourableoutcomes,persistenceof
PDE5itherapyinpatients withHFpEF-associatedCpcPHandwith
PHiscommon,andevenmoderatePHisassociatedwithahigher
aseverepre-capillarycomponent(PVRmostly.5WU).450,687
all-causemortality.646–651
Ofnote,medicaltherapyofPHpost-valvularrepairmaybeharm-
8.3.1.3.Interatrialshuntdevices
ful. A randomized study of 231 patients with surgically corrected
Recentdatasuggestthatspecificinterventionsmaybeconsideredinse-
valvularheartdiseaseandpersistentPHshowedthatsildenafilther-
lectedcasesofHFpEF,suchasinteratrialshuntdevicestounloadthe
apyvs.placebowasassociatedwithworseoutcomewhencompared
left heart. Whilethis wasassociated with short-termimprovements withplacebo;701however,thisstudydidnotdistinguishbetweendif-
inpulmonaryvascularfunction,688thelong-termeffectonthepulmon-
ferenttypesofPH(pre-capillary,IpcPH,andCpcPH).
arycirculationremainsunknown.TherecentREDUCELAP-HFIItrial
failed to show a reduction inHF events after placement ofanatrial
shuntdeviceinapopulationofHFpatientswithLVEF≥40%,689with 8.3.2.3.Tricuspidregurgitation
worseoutcomesinthepresenceofPVD.690Inaddition,asustainedin- SevereTRisassociatedwithvolumeoverload,increasedRVwork-
creaseinPAbloodflowmaybeamatterofconcern,asthismaytrigger load,andmaladaptiveremodelling,leadingtosymptomaticrightHF
andimpairedsurvival.702,703WhileprimaryTRisrelativelyrare,func-
vascularremodellinginpatientswithpre-existingPH.
tionalTRmayarisefromannulardilationinthepresenceofbothPH
andLHD. Transcatheter tricuspidvalveinterventionshaverecently
8.3.1.4.Remotepulmonaryarterialpressuremonitoringinheart
emerged,aimingatreducingTRandRVvolumeoverload.Ofnote,
failure
correcting TR in patients with PAH or PH in (non-valvular) LHD
TheimportanceofdecongestioninpatientswithHFisunderscored
withsignificantlyelevatedPVRand/orRVdysfunctionmustbeconsid-
by the use of implantable pressure sensors, remotely monitoring
PAPasasurrogateofleft-sidedfillingpressure.Pulmonaryarterial
eredwithgreatcaution,asthismaybehazardous.704Rightventricle–
PAcouplingisanindependentpredictorofall-causemortalityinsuch
pressure-basedadjustmentofHFtherapysubstantiallyreducedHF
patients.705 Patient selection appears crucial, and a comprehensive
hospitalizations and improved outcomes in both patients with
HFpEFandHFrEF,691–694withadjustmentofdiuretictherapybeing diagnostic approach integrating imaging modalities and invasive
haemodynamic assessment is necessary in the evaluation process the most prominent therapeutic consequence. Further strategies
priortotricuspidvalverepair,particularlysinceechocardiographyun-
tooptimizemanagementdependingonthehaemodynamicpheno-
derestimatessPAPinthepresenceofsevereTR.
typeinPH-LHDremaintobeestablished.InHFrEF,novelmedical
therapiessuchasARNIsandSGLT-2isreducedremotelymonitored
PAP and diuretic use,695–698 potentially providing opportunities to 8.3.3.Recommendationsontheuseofdrugs
furtheroptimizePAP-guidedHFtherapy. approvedforPAHinPH-LHD
TherecommendationsontheuseofdrugsapprovedforPAHinpa-
8.3.2.Pulmonaryhypertensionassociatedwith tients with PH-LHD have been established based on key narrative
valvularheartdisease question5(SupplementaryData,Section8.3).
Pulmonary hypertension frequently occurs as a consequence of The recommendations on the use of PDE5is in patients with
valvular heart disease. While surgical or interventional approaches CpcPH associated with HFpEF are based on PICO question II
forvalvularrepairimprovecardiopulmonaryhaemodynamicsbyre- (SupplementaryData, Section 8.4).TwoRCTsthatenrolled patients
ducingPAWPandPAPandimprovingforwardSV,699persistentPH withHFpEFandPHwereidentified,butnostudythatspecificallyen-
aftercorrectingvalvularheartdiseaseisfrequentandassociatedwith rolledpatientswithHFpEFandCpcPH.Harmfuleffectscannotbeex-
adverseoutcomes.634,700 cluded,eveniftheavailabledatafromclinicalstudies,caseseries,and
registriessuggestthatPDE5ismaybesafelyadministeredtopatients
8.3.2.1.Mitralvalvedisease withHFpEF-associatedCpcPH.Asaresult,ageneralrecommendation
Bothmitralstenosisandregurgitationregularlyleadtopost-capillary fororagainsttheuseofPDE5isinpatientswithHFpEFandCpcPHcan-
PH.Functional(secondary)mitralregurgitationoccursinbothHFrEF notbemade.However,itisclinicallyrelevanttomakearecommenda-
andHFpEF,andisanimportantcontributortoPHinLHD.Reducing tionagainsttheiruseforpatientswithHFpEFandIpcPH.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 73 ---
3690 ESC/ERSGuidelines
RecommendationTable22—Recommendationsforpulmonaryhypertensionassociatedwithleftheartdisease
RecommendationTable22A
Recommendations Classa Levelb
InpatientswithLHD,optimizingtreatmentoftheunderlyingconditionisrecommendedbeforeconsideringassessmentofsuspected
I A
PH27,28
RHCisrecommendedforsuspectedPHinpatientswithLHD,ifitaidsmanagementdecisions
I C
RHCisrecommendedinpatientswithseveretricuspidregurgitationwithorwithoutLHDpriortosurgicalorinterventionalvalverepair
I C
ForpatientswithLHDandsuspectedPHwithfeaturesofaseverepre-capillarycomponentand/ormarkersofRVdysfunction,referral
I C
toaPHcentreforacompletediagnosticwork-upisrecommended29,47,142
InpatientswithLHDandCpcPHwithaseverepre-capillarycomponent(e.g.PVR.5WU),anindividualizedapproachtotreatmentis
I C
recommended
WhenpatientswithPHandmultipleriskfactorsforLHD,whohaveanormalPAWPatrestbutanabnormalresponsetoexerciseor I C
fluidchallenge,aretreatedwithPAHdrugs,closemonitoringisrecommended
InpatientswithPHatRHC,aborderlinePAWP(13–15mmHg)andfeaturesofHFpEF,additionaltestingwithexerciseorfluidchallenge
IIb C
maybeconsideredtouncoverpost-capillaryPH133,143
DrugsapprovedforPAHarenotrecommendedinPH-LHDc631,678,683,684,701,706
III A
RecommendationTable22B
GRADE
Recommendations Qualityof Strengthof Classa Levelb
evidence recommendation
NorecommendationcanbegivenfororagainsttheuseofPDE5isinpatients Low None – –
withHFpEFandcombinedpost-andpre-capillaryPH
TheuseofPDE5isinpatientswithHFpEFandisolatedpost-capillaryPHisnot Low Conditional
III C
recommended
CpcPH,combinedpost-andpre-capillaryPH;ERA,endothelinreceptorantagonist;HF,heartfailure;HFpEF,heartfailurewithpreservedejectionfraction;HFrEF,heartfailurewith
reducedejectionfraction;LHD,leftheartdisease;PAH,pulmonaryarterialhypertension;PAWP,pulmonaryarterialwedgepressure;PDE5is,phosphodiesterase5inhibitors;PH,
pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right
ventricular;WU,Woodunits.
aClassofrecommendation.
bLevelofevidence.
cSafetyconcernshavebeenidentifiedwhenERAsareusedinpatientswithHF(HFpEFandHFrEF,withorwithoutPH)andwhensildenafilisusedinpatientswithpersistentPHafter
correctionofvalvularheartdisease.
9. Pulmonary hypertension usually mild in that setting: from six patients (5.7%) present-
ing with pre-capillary PH, none had mPAP .30mmHg and
associated with lung diseases and/
PH was associated with PFT alteration, suggesting that the
or hypoxia (group 3) rise in mPAP is associated with parenchymal involvement.711
Thus, PH in lymphangioleiomyomatosis is now classified in
Pulmonary hypertension is frequently observed in patients with group 3 PH.1
COPD and/or emphysema, ILD, combined pulmonary fibrosis and Inpatientswithlungdisease,PHiscategorizedasnon-severeor
emphysema (CPFE), and hypoventilation syndromes.52,165,707,708 severe, depending on haemodynamic findings (Figure 12). In the
Pulmonaryhypertensionisuncommoninobstructivesleepapnoea 2015 ESC/ERS Guidelines for the diagnosis and treatment of
unlessotherconditionscoexist,suchasCOPDordaytimehypoven- PH, severe PH was defined by mPAP .35mmHg or mPAP
tilation.709 At high altitude (.2500m) hypoxia-induced PH is ≥25mmHg with CI ,2.5L/min/m2.25,26 However, two recent
thought to affect .5% of the population, the development of PH studieshavedemonstratedthataPVR.5WUisabetterthresh-
beingrelatedtogeographyandgeneticfactors.710 oldforpredictingworseprognosisinpatientswithPHassociated
A PH screening study performed on a large cohort of .100 withbothCOPDandILD.712,713Basedonthesedata,thecurrent
patients with lymphangioleiomyomatosis confirmed that PH is guidelinesusedPVRtodistinguishbetweennon-severePH(PVR
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 74 ---
ESC/ERSGuidelines 3691
COPD CCCPPFFEE ILD
Remodelling of airways, lung parenchyma, and vessels
Emphysema Fibrosis Vascular pruning
RRemodelling of airways and parenchyma
Remodelling of pulmonary vessels
Severe PH
No PH Non-severe PH
(PVR >5WU)
Prevalence ~70% ~20% ~5–10%
Mostly ventilatory Mostly circulatory
exercise limitation exercise limitation
Hypoxaemia at rest and/or during exercise
Figure12Pathophysiologyofpulmonaryhypertensionassociatedwithlungdisease(group3).COPD,chronicobstructivepulmonarydisease;CPFE,
combinedpulmonaryfibrosisandemphysema;ILD, interstitiallungdisease;PH,pulmonaryhypertension;PVR,pulmonaryvascularresistance; WU,
Woodunits.Shownareunderlyinglungdiseases(upperpanel);contributingpathogenicpulmonaryalterationsofairways,parenchyma,andvessels
(middlepanel);andtherelationofairway/parenchymalremodellingandvascularremodellingtothedegreeofPHanditsconsequencesforexercise
limitation(ventilatoryvs.circulatory,lowerpanel).
≤5WU)andseverePH(PVR.5WU).Whereasnon-severePH Pulmonaryhypertensionpresentinginpatientswithlungdisease
iscommoninadvancedCOPDandILDdefinedbyspirometriccri- may bedue toa numberofcauses,includingundiagnosed CTEPH
teria, severe PH is uncommon, occurring in 1–5% of cases of orPAH.714,720 Cardiaccomorbidities arealsocommon inpatients
COPD and ,10% of patients with advanced ILD, with limited with lungdiseaseandmaycontributetoPH.A numberofdistinct
datainobesityhypoventilationsyndrome.714,715Evennon-severe phenotypesofPHinpatientswithlungdisease,includingapulmon-
PHinlungdiseasenegativelyimpactssymptomsandsurvival,and ary vascular phenotype, havebeen proposed.51,720 Thepulmonary
is associated with increased
hospitalization.715–717
Patients with vascularphenotypeischaracterizedbybetterpreservedspirometry,
lung disease and severe PH have a worse outcome than those low DLCO, hypoxaemia, a range of parenchymal involvement on
with non-severe PH, providing evidence that this distinction has lung imaging, and a circulatory limitation to
exercise.51,714,718–722
clinicalsignificance.51,712,713,718,719Itisnoteworthythatdevelop- Recent studies have shown that the clinical characteristics, disease
ingseverePHislargelyindependentofspirometrybutusuallyac- trajectory, response to treatment,451,718,719 and histological corre-
companiedbyhypoxaemia,lowPaCO ,andasignificantreduction lates723,724ofpatientswithseverePHandminorlungdiseasearedif-
2
inDLCO.51,714,718,719 ferenttothoseinpatientswithIPAH,includingapoorerprognosis.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 75 ---
3692 ESC/ERSGuidelines
9.1. Diagnosis 9.2.1.Pulmonaryhypertensionassociatedwith
Inpatientswithlungdisease,symptomsofPH,especiallyexertional chronicobstructivepulmonarydiseaseor
dyspnoea, overlap with those of the underlying condition. Physical emphysema
findingsmayalsobenon-specific,forexample:ankleswellingiscom- StudiesusingdrugsapprovedforPAHinpatientswithPHassociated
monduringepisodesofventilatoryfailureinCOPD,whereactiva-
withCOPDoremphysemahaveyieldedconflictingresultsandare
tion of the renin–angiotensin–aldosterone system may cause fluid mostlylimitedbysmallsamplesize,shortduration,andinsufficient
retention,usuallyinthesettingofpreservedRVfunction.
haemodynamiccharacterizationofPH.739,741,742Ina16weekRCT
Non-invasivetests—suchasECGshowingrightaxisdeviationor of28patientswithCOPDandseverePHconfirmedbyRHC,silde-
RVstrain,elevatedlevelsofBNP/NT-proBNP,CPET,orfeatureson
nafiltherapyresultedinstatisticallysignificantimprovementsinPVR
cross-sectionalimaging—maysuggestthediagnosisofPHinpatients andqualityoflife.743Registrydataidentifiedthat(cid:4)30%ofpatients
withlungdisease.725,726Echocardiographyremainsthemostwidely with COPD and severe PH, predominantly treated with PDE5is,
usednon-invasivediagnostictoolforassessingPH;however,theac- hadimprovedWHO-FC,6MWD,andPVRvs.baseline,andthose
curacy of echocardiography in patients with advanced respiratory with a treatment response had improved transplant-free sur-
diseases is low, with a TRV unmeasurable in .50% of patients in vival.51,718 However, inthe absence of large randomized trials, the
somestudies,andthereisatendencytooverestimatePAPandmis-
evidenceisinsufficienttosupportthegeneraluseofmedicationap-
classify patients with PH.86,87,727 More recent data suggest that a provedforPAHinpatientswithCOPDandPH.PatientswithCOPD
stepwise, composite, echocardiographic score can identify patients and suspected or confirmed severe PH should be referred to PH
withseverePH,withandwithoutanestimateofTRV,usingotherecho- centresforindividualdecision-making.
cardiographicfeaturesincludingRAarea,RV:LVratio,andLVeccentri-
city index.728 Where PH is suspected, combining echocardiography
9.2.2.Pulmonaryhypertensionassociatedwith
withacontrast-enhancedCTmayaiddiagnosticassessmentanddisease
classification.108,729–731 Pulmonary artery enlargement, RV outflow interstitiallungdisease
hypertrophy, and increased RV:LV ratio may suggest a diagnosis of Numerous phase 2 and phase 3 studies have investigated the use of
PH.108Ideally,assessmentsshouldbemadeorrepeatedwhenthepa- ERAs to treat ILD, all with negative results.740,744,745 In addition, the
tientisclinicallystable,asexacerbationscansignificantlyraisePAP. PDE5isildenafilhasbeeninvestigatedinphase3trialsofpatientswith
KeypartsofevaluatingsuspectedPHinlungdiseaseincludeintegrat-
ILD,alsowithnegativeresults.746,747FewdatafromRCTsareavailable
ing:(1)thepresenceorabsenceofriskfactorsforPAH,CTEPH,or forpatientswithPHassociatedwithILD,andmanyofthestudiesper-
LHD;(2)clinicalfeatures,includingdiseasetrajectory(e.g.rapidrecent
formedforthisindication748,749sufferedfromthesamelimitationsas
deteriorationvs.gradualchangeoveryears,andoxygenrequirements); theaforementionedstudiesinPHassociatedwithCOPD.Inaddition,
(3)PFTs,includingDLCOandbloodgasanalysis;(4)NT-proBNPmea- therewereseveraladversesafetysignals:ambrisentanwasassociated
surements,ECG,andechocardiography;and(5)cross-sectionalimaging withan increasedriskofclinical worseninginpatientswithILD with
withcontrast-enhancedCT,SPECT,orV/Qlungscanand,inselected
andwithoutPH,740,750whileriociguatwasassociatedwithanincreased
cases,cMRI732toassesstheneedforRHC.Cardiopulmonaryexercise riskofclinicalworseningevents,includingpotentialexcessmortality,in
testingmaybehelpfulinassessingventilatoryorcardiaclimitationinpa-
patientswithPHassociatedwithidiopathicinterstitialpneumonia.181
tients with lung disease,121,733 although data arelimited regarding its Incontrast,promisingresultshavebeenobtainedwiththeuseof
clinicaluseinidentifyingpatientswithPHinlungdisease. inhaledtreprostinil.Aphase3RCT(INCREASE)examinedinhaled
IndicationsforRHCinlungdiseaseincludeassessmentforsurgical treprostinilatatargetdoseof72µggivenfourtimesdailyin326pa-
treatments(selectedpatientsconsideredforLTxandlungvolumere-
tientswithPHassociatedwithILD.734,751ThePHdiagnosiswascon-
ductionsurgery),suspectedPAHorCTEPH,andwherefurtherinfor-
firmedbyRHCwithin1yearpriortoenrolment.Atweek16,the
mationwillaidphenotypingofdiseaseandconsiderationoftherapeutic placebo-corrected6MWDimprovedby31mwithinhaledtrepros-
interventions(FigureS3).712,718,734Suchtestingshouldideallybecon- tinil.TherewerealsoimprovementsinNT-proBNPandclinicalwor-
ductedinPHcentreswhenpatientsareclinicallystableandtreatment sening events, the latter driven by a lower proportion of patients
ofunderlyinglungdiseasehasbeenoptimized.Considerationshouldbe
whose6MWDdeclinedby.15%frombaseline.
giventohowpressuremeasurementsaremade,duetotheimpactof Given the significant impact of even non-severe PH in patients
changingintrathoracicpressuresonpulmonaryhaemodynamicsduring withlungdisease,eligiblepatientsshouldbereferredforLTxevalu-
therespiratorycycle(seeSection5.1.12).735 ation.InpatientswithILDandPH,inhaledtreprostinilmaybecon-
sidered based on the findings from the INCREASE study, but
furtherdataareneeded,especiallyonlong-termoutcomes.Therou-
9.2. Therapy tineuseofothermedicationapprovedforPAHisnotrecommended
The therapeutic approach togroup 3 PH starts with optimizing the inpatientswithILDandnon-severePH.ForpatientswithseverePH
treatmentoftheunderlyinglungdisease,includingsupplementaryoxy- and/orsevereRVdysfunction,orwherethereisuncertaintyregard-
genandnon-invasiveventilation,whereindicated,aswellasenrolment ingthetreatmentofPH,referraltoaPHcentreisrecommendedfor
intopulmonaryrehabilitationprogrammes.736Thereislimitedandcon- carefulevaluation, tofacilitate entryintoRCTs,andconsiderPAH
flictingevidencefortheuseofmedicationapprovedforPAHinpatients therapiesonanindividualbasis(FigureS3).Registrydatashowthat
withgroup3PH,andthesedrugsmayhavevariableandsometimes somepatientswithgroup3PHarebeingtreatedwithPAHmedica-
detrimentaleffectsonhaemodynamics,exercisecapacity,gasexchange, tion,predominantlyPDE5is,718,752,753butitisunclearifandtowhat
andoutcomesinthispatientpopulation.181,737–740 extentthesepatientsbenefitfromthistreatment.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 76 ---
ESC/ERSGuidelines 3693
9.2.3.Recommendationsontheuseofdrugs guidelines do not enable firm conclusions to be drawn. Given the
approvedforPAHinPHassociatedwithlungdisease lackofrobustevidence,theTaskForcemembersfeltunabletopro-
TherecommendationsontheuseofdrugsapprovedforPAHinpa- videarecommendationfororagainsttheuseofPDE5isinpatients
tientswithPHassociatedwithCOPDandILDhavebeenestablished withILDandseverePH,andrecommendthatthesepatientsarere-
based on key narrative questions 6 and 7 (Supplementary Data, ferredtoaPHcentreforindividualizeddecision-making.
Sections9.1and9.2,respectively).
TherecommendationsontheuseofPDE5isinpatientswithse- 10. Chronic thrombo-embolic
vere PH associated with ILD are based on PICO question III
pulmonary hypertension (group 4)
(Supplementary Data, Section 9.3). There are no direct data from
RCTs on the safety, tolerability, and efficacy of PDE5is in patients All patients whose symptoms can be attributed to
with PH associated with ILD. The indirect data included in the post-thrombo-embolic fibrotic obstructions within the PA are
RecommendationTable23—Recommendationsforpulmonaryhypertensionassociatedwithlungdiseaseand/or
hypoxia
RecommendationTable23A
Recommendations Classa Levelb
IfPHissuspectedinpatientswithlungdisease,itisrecommendedthatechocardiographycbeperformedandtheresultsinterpretedin
I C
conjunctionwithABG,PFTsincludingDLCO,andCTimaging
InpatientswithlungdiseaseandsuspectedPH,itisrecommendedtooptimizetreatmentoftheunderlyinglungdiseaseand,where
I C
indicated,hypoxaemia,sleep-disorderedbreathing,and/oralveolarhypoventilation
InpatientswithlungdiseaseandsuspectedseverePH,orwherethereisuncertaintyregardingthetreatmentofPH,referraltoaPH
I C
centreisrecommendedd
InpatientswithlungdiseaseandseverePH,anindividualizedapproachtotreatmentisrecommended
I C
ItisrecommendedtorefereligiblepatientswithlungdiseaseandPHforLTxevaluation
I C
InpatientswithlungdiseaseandsuspectedPH,RHCisrecommendediftheresultsareexpectedtoaidmanagementdecisions
I C
InhaledtreprostinilmaybeconsideredinpatientswithPHassociatedwithILD734
IIb B
TheuseofambrisentanisnotrecommendedinpatientswithPHassociatedwithIPF740
III B
TheuseofriociguatisnotrecommendedinpatientswithPHassociatedwithIIP181
III B
TheuseofPAHmedicationisnotrecommendedinpatientswithlungdiseaseandnon-severePHe
III C
RecommendationTable23B
GRADE
Recommendations Qualityof Strengthof Classa Levelb
evidence recommendation
PDE5ismaybeconsideredinpatientswithseverePHassociatedwithILD Verylow Conditional
IIb C
(individualdecision-makinginPHcentres)
TheuseofPDE5isinpatientswithILDandnon-severePHisnotrecommended Verylow Conditional
III C
ABG,arterialbloodgasanalysis;CT, computedtomography;DLCO, Lungdiffusioncapacityforcarbonmonoxide;IIP, idiopathicinterstitialpneumonia;IPF, idiopathicpulmonary
fibrosis;ILD, interstitiallungdisease;LTx, lungtransplantation;PAH, pulmonaryarterialhypertension;PDE5i, phosphodiesterase5inhibitor;PFT, pulmonaryfunctiontest;PH,
pulmonaryhypertension;RHC, rightheartcatheterization.
aClassofrecommendation.
bLevelofevidence.
cAssessmentsshouldideallybemadewhenthepatientisclinicallystable,asexacerbationscansignificantlyraisepulmonaryarterypressure.
dThisrecommendationdoesnotapplytopatientswithend-stagelungdiseasewhoarenotconsideredcandidatesforLTx.
eThisdoesnotincludeinhaledtreprostinil,whichmaybeconsideredinpatientswithPHassociatedwithILD,irrespectiveofPHseverity.
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 77 ---
3694 ESC/ERSGuidelines
CTEPH diagnostic algorithm fffor symptomaticpatients
CTEPH suspected from history
PH work-up
of PEa or risk factors fffor CTEPH
Perfusion imaging
(V/Q scan or new modalityb)
Any mismatched
perfusion defffects
AND
Echocardiography Abnormal exercise tests
Intermediate or N (CPETc,, stress echocardiography)
high probability of PH suggestive fffor CTEPD
Y
Refer to CTEPH/PH centre
Comprehensivework-upd
(TTTable 14,, ReCoTTTable 2)
CTPPPA + DSA
when CTPPPA is inconclusive AND RHC
Patients with confirmed CTEPH
TTTreatment assessment by MDT at CTEPH centre
(Class I)
Figure13Diagnosticstrategyinchronicthrombo-embolicpulmonaryhypertension.CPET,cardiopulmonaryexercisetest;CTEPD,chronicthrombo-
embolicpulmonarydisease;CTEPH,chronicthrombo-embolicpulmonaryhypertension;CTPA,computedtomographypulmonaryangiography;DECT,
dual-energycomputedtomography;DSA,digitalsubtractionangiography;MDT,multidisciplinaryteam;MRI,magneticresonanceimaging;N,no;PE,pul-
monaryembolism;P CO ,end-tidalpartialpressureofcarbondioxide;PH,pulmonaryhypertension;ReCo,recommendation;RHC,rightheartcath-
ET 2
eterization;sPAP,systolicpulmonaryarterialpressure;V/Q,ventilation/perfusion;VE/VCO ,ventilatoryequivalentsforcarbondioxide;VO /HR,oxygen
2 2
pulse;VO ,oxygenuptake;Y,yes.aCTEPHsuspectedfromhistoryofPE,includingelevatedsPAPonechocardiographyandsignssuggestingCTEPHon
2
CTPAperformedatthetimeoftheacutePE(Section5.1.7).bAlternativeperfusionimagingtechniques—suchasiodinesubtractionmapping,DECT,and
MRIperfusion—arecurrentlyunderevaluation.cTypicalpattern,includinglowP CO ,highVE/VCO ,lowVO /HR,andlowpeakVO (Section5.1.11). ET 2 2 2 2
dComprehensivework-upafter3monthsoftherapeuticanticoagulationorsoonerinunstableorrapidlydeterioratingpatients.Ideally,CTPA,DSA,and
RHCareperformedinCTEPHcentres,buttheyaresometimesperformedinPHcentres,dependingonthecountryandorganization.
consideredtohaveCTEPDwithorwithoutPH;CTEPHremainsthe definitioninSection3.1,Table5)and/orincreaseddeadspaceventila-
preferred term for patients with PH, as defined in Section 3.1 tion.54Excludingventilatorylimitation,deconditioningandpsychogenic
(Table 5).54 Chronic thrombo-embolic pulmonary disease describes hyperventilationsyndromebyCPETandLVmyocardialorvalvulardis-
symptomatic patients with mismatched perfusion defects on V/Q ease by echocardiography is of upmost importance when making
scanandwithsignsofchronic,organized,fibroticclotsonCTPAor therapeuticdecisionsinpatientswithCTEPDwithoutPH.
DSA,suchasring-likestenoses,webs/slits,andchronictotalocclusions
(pouchlesionsortaperedlesions),afteratleast3monthsoftherapeut- 10.1. Diagnosis
icanticoagulation.Pulmonaryhypertensioninthissettingisnotonlya Chronic thrombo-embolic pulmonary hypertension is a common
consequenceofPAobstructionbyorganizedfibroticclotsbutcanalso and important cause of PH, with a distinct management strategy.
berelatedtotheassociatedmicrovasculopathy.Inthosepatientswith- Thus,thepossibilityofCTEPHshouldbecarefullyconsideredinall
out PH at rest, breathlessness could be due to exercise PH (see patients with PH (Figure 13). In the context of acute PE, CTEPH
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 78 ---
ESC/ERSGuidelines 3695
should be considered: (1) if radiological signs (detailed in Section NOACs in CTEPH, but recurrent venous thrombo-embolism rates
5.1.7)suggestCTEPHontheCTPAperformedtodiagnosePE,112 werehigherinthosereceivingNOACs.762,763Inpatientswithantipho-
and/orifestimatedsPAPis.60mmHg112onechocardiogram;(2) spholipidsyndrome(10%oftheCTEPHpopulation),VKAsarerecom-
whendyspnoeaorfunctionallimitationspersistintheclinicalcourse mended.103,764,765Screeningforantiphospholipidsyndromeshouldbe
post-PE;754 and (3) in asymptomatic patients with risk factors for performedatCTEPHdiagnosis.Intheabsenceofanyevidenceinfavour
CTEPH or a high CTEPH prediction score.755 Clinical conditions oragainstprolongedanticoagulationinpatientswithCTEPDwithout
suchaspermanentintravasculardevices(pacemaker,long-termcen- PH, long-term anticoagulant therapy is based on individual decision-
trallines,ventriculoatrialshunts), inflammatorybowel diseases,es- making.ItisrecommendedwhentheriskofPErecurrenceisintermedi-
sential thrombocythaemia, polycythaemia vera, splenectomy, ateorhigh,therebyfollowingthe2019ESC/ERSGuidelinesforthediag-
antiphospholipid syndrome, high-dose thyroid hormone replace- nosisandmanagementofacutepulmonaryembolism(Table11).103
ment,andmalignancyareriskfactorsforCTEPH.54,103,756
AlternativecausesofPAobstructions(alsoincludedingroup4ofthe 10.2.1.Surgicaltreatment
PH classification)—including PA sarcomas, other malignant tumours SurgicalPEAisthetreatmentofchoiceforpatientswithaccessible
(e.g. renal carcinoma, uterine carcinoma, and germ-cell tumours of PAlesions.102Assurgerymaynormalizepulmonaryhaemodynamics
the testis), non-malignant tumours (e.g. uterine leiomyoma), arteriitis (65%decreaseinPVR)766andfunctionalcapacity,anexpertmultidis-
withoutCTD,congenitaloracquiredPAstenoses,parasites(hydatid ciplinary team including an experienced PEA surgeon (on-site or
cyst),andforeign-bodyembolism—havetobeconsideredinthediffer-
closelycollaborating)ismandatoryforevaluatingoperabilityandde-
entialdiagnosisofCTEPD.757Theycanbeexploredbyspecificaddition- cidingfinaltreatment.102
al imaging such as 18F-2-fluoro-2-deoxy-D-glucose-positron emission Operability is based on team experience, accessibility of PA le-
tomography (PET) scan, which can provide additional information sions,correlationbetweenseverityofPHanddegreeofPAobstruc-
whenPAsarcomaissuspected.758 tions, and comorbidities.767 The surgical technique is complex but
Ventilation/perfusion scintigraphy207 remains the most effective wellstandardizedwith.30yearsofexperience.Itconsistsofacom-
toolinexcludingCTEPD.Alternativeperfusionimagingtechniques plete bilateral endarterectomy of the PAs down to segmental and
—suchasiodinesubtractionmapping,DECT,andMRIperfusion—
subsegmentallevelsinphasesofdeephypothermiccirculatoryarrest
havenumeroustheoreticaladvantagesoverV/Qbutaremoretech- (Figure15).767,768InCTEPHcentres,surgicaloutcomesarefavour-
nically challenging and expensive, have limited availability, and cur- able, with peri-operative mortality rates ,2.5% due to improved
rentlylackmulticentrevalidation. management of cardiac and pulmonary complications and well-
Computedtomographypulmonaryangiographywithbi-planarre- established use of ECMO.768 Post-operative PH is frequently ob-
constructionisbroadlyusedfordiagnosingCTEPDandassessingop- served ((cid:4)25%),766 but long-term outcomes after PEA surgery are
erability,butanegativeCTPA,evenifhighquality,doesnotexclude excellent regarding survival (averaging 90% at 3 years) and quality
CTEPD,asdistaldiseasecanbemissed.Digitalsubtractionangiog- of life,769–771 even in patients with distal PA obstructions.772 On
raphyisstillusedtoassesstreatmentoptionswhenCTPAisincon- the other hand, patients with proximal operable disease declining
clusive. Selective segmental angiography, cone-beam CT, and area surgery have a poor long-term outcome, with a 5 year survival of
detectorCTallowformoreaccuratevisualizationofsubsegmental 53% compared with 83% in patients undergoing PEA.773
vasculatureandareusefulforproceduralguidanceforBPA.Theben- Therefore,PEAshouldbeofferedtoalloperablepatientswithafa-
efitsofthenewtechnologiesrequirevalidatinginprospectivetrials vourablerisk:benefitratio,ideallyduringapersonalconsultationbe-
before being recommended for routine clinical use; a large, tweenthepatientandthePEAsurgeon.102
European,multicentrestudyiscurrentlyongoing.759 Selected symptomatic patients with CTEPD without PH can be
successfully treated by PEA, with clinical and haemodynamic im-
10.2. Therapy provementsatrestandexercise.135,774Thosepatientswouldrequire
TheCTEPHtreatmentalgorithmincludesamultimodalapproachof
carefuldiscussiontobalanceriskandbenefit.
combinationsofpulmonaryendarterectomy(PEA),BPA,andmedic-
altherapiestotargetthemixedanatomicallesions:proximal,distal, 10.2.2.Medicaltherapy
andmicrovasculopathy,respectively(Figures14and15). To manage the microvascular component of CTEPH (Figure 15),
GeneralmeasuresrecommendedforPAHalsoapplytoCTEPH, medical therapies have been used off-label based on uncontrolled
includingsupervisedexercisetraining,whichiseffectiveandsafein studiesand/orregionalapprovals.Meanwhile,threeRCTshavesuc-
inoperableCTEPHpatients,760aswellasearlyafterPEA.761 cessfullybeenconducted.Thefirstphase3RCTinvestigatedtheef-
Lifelong therapeutic anticoagulation is recommended for patients ficacyofriociguatinpatientswithinoperableCTEPHorthosewith
withCTEPH,asrecurrentpulmonarythrombo-embolismaccompanied persistent/recurrent PH after PEA.775 Riociguat, after 16 weeks of
byinsufficientclotresolutionarekeypathophysiologicalfeaturesofthis therapy, improved 6MWD and reduced PVR by 31% compared
disease.TherearenoRCTsinCTEPHwithanyoftheapprovedanti- with placebo, and is approved for this indication. Treprostinil s.c.
coagulants; however, despite this lack of evidence, VKAs are recom- was investigated in a phase 3 RCT, which showed improved
mendedbyexperts,andaremostwidelyusedasbackgroundtherapy 6MWD at week 24 in patients with inoperable CTEPH or those
forpatientswithCTEPH.Morerecently,NOACshavemorefrequently withpersistent/recurrentPHafterPEAreceivingahighdosecom-
beenusedasalternativestoVKAs,again,lackingevidencefromRCTs.A paredwithalowdose;776s.c.treprostinilisapprovedforthisindica-
retrospectivecaseseriesfromtheUKandamulticentreprospective tion. In a phase 2 study including only patients with inoperable
registry (EXPERT) showed comparable bleeding rates for VKAs and CTEPH,macitentan10mgimproved PVR and6MWDvs. placebo
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 79 ---
3696 ESC/ERSGuidelines
Patients with confirmed CTEPHa
Lifffelong therapeutic anticoagulation
(Class I)
TTTreatment assessment by MDTb
(Class I)
Operable N
Y
PEA astreatment ofchoicec
(Class I)
Persistent/recurrent Medical therappy (ReCoTTTable 24)
Y
symptomatic PH (Class I)
N
BPPPAd
(Class I)
Long-termfffollow-up
at a CTEPH/PH centrec
(Class I)
Figure 14 Management strategy in chronic thrombo-embolic pulmonary hypertension. BPA, balloon pulmonary angioplasty; CTEPD, chronic
thrombo-embolicpulmonarydisease;CTEPH,chronicthrombo-embolicpulmonaryhypertension;MDT,multidisciplinaryteam;N,no;PAH,pulmonary
arterialhypertension;PEA,pulmonaryendarterectomy;PH,pulmonaryhypertension;PVR,pulmonaryvascularresistance;ReCo,recommendation;WU,
Wood units;Y, yes. aSelected symptomatic patients with CTEPD without PH can also be treated by PEA and BPA. bMDTmeeting can be virtual.
cTreatmentassessmentmaydiffer,dependingonthelevelofexpertiseinPEAandBPA.dForinoperablepatientswithPVR.4WU,medicaltherapy
shouldbeconsideredpriortoBPA;therearelimiteddataonBPAasfirst-linetherapy.
at 16 and 24 weeks, respectively.777 A phase 3RCT is ongoing to sessions needed and haemodynamic results are dependent on ex-
evaluate the safety and efficacy of macitentan 75mg in inoperable perience.781WhileBPAiseffective,itisassociatedwithseriouscom-
orpersistent/recurrentCTEPH(NCT04271475). plications, which may be fatal. Procedural and post-interventional
Other medical therapies—PDE5is (e.g. sildenafil) and ERAs (e.g. complications include vascular injury due to wire perforation, and
bosentan)—havebeenusedoff-label,astheirefficacyininoperable lung injury with haemoptysis and/or hypoxia.102,781,796,797 As with
CTEPH has not been proven by RCTs or registry data.769,778,779 all interventional procedures, a significant learning curve has been
However,oralcombinationtherapy,includingPDE5isandERAs,is shown, with reducing complication rates over time;781 therefore,
commonpracticeinpatientswithCTEPHwithseverehaemodynam- thisprocedureshouldbeperformedinhigh-volumeCTEPHcentres.
iccompromise.780 Astheratesofinterventionalcomplicationscanbereducedbymed-
icalpre-treatment,patientswithaPVR.4WUshouldbetreated
10.2.3.Interventionaltreatment beforeBPA(Figure15).798
Balloonpulmonaryangioplasty(Figure15)hasbecomeanestablished Selected symptomatic patients with CTEPD without PH and
treatmentforselectedpatientswithinoperableCTEPHorpersist- segmental/subsegmentallesionscansuccessfullybetreatedbyBPA,
ent/recurrent PH after PEA, improving haemodynamics (PVR de- with clinical and haemodynamic improvements at rest and
crease 49–66%), right heart function, and exercise capacity.781–794 exercise.799
Long-termoutcomesarepromising,butevidenceisstillscarce.795 PreliminarydataonPADNpointtowardsimprovedexercisecap-
A staged interventional procedure with a limited number of di- acityandpulmonaryhaemodynamicsinpatientswithpersistentPH
lated PA segments per session is preferred.102,788 The number of afterPEA;800furtherconfirmationisbeingawaited.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 80 ---
ESC/ERSGuidelines 3697
A B C D E
Proximal PA fibrotic Distal PA fibrotic
Microvasculopathy
obstructions obstructions
PEA Medical therapy
BPA
1 2 3
Multimodal CTEPH treatment
Figure15Overlapintreatments/multimodalityapproachesinchronicthrombo-embolicpulmonaryhypertension.BPA,balloonpulmonaryangio-
plasty;CTEPH,chronicthrombo-embolicpulmonaryhypertension;PA,pulmonaryartery;PEA,pulmonaryendarterectomy.Toppanels:(A)Proximal
PA fibrotic obstructions (vessel diameter 10–40mm). (B) Distal segmental and subsegmental PA fibrotic obstruction potentially suitable for both
PEAandBPAinterventions(vesseldiameter2–10mm).(C)DistalsubsegmentalPAfibroticobstructionsformaweb-lesioninasubsegmentalbranch
ofthePAsuitableforBPAinterventions(vesseldiameter0.5–5mm).(D)DistalsubsegmentalPAfibroticobstructionsformweb-likelesions,whichmight
beaccompaniedbymicrovasculopathy(vesseldiameter,0.5mm).(E)Microvasculopathy(vesseldiameter,0.05mm)treatedwithmedicaltherapy.
Bottompanels:(A)bottomleft:PEA;vesseldiameter(0.2–3cm).TherightPAisopenedandthesuctiondissectorisintroducedbetweentheartery
wallandfibrosis.Followingtheinsideofthearterydowntosegmentalandsubsegmentallevels,thefibroticmaterialissubsequentlyfreedfromthe
wallandremovedwithforceps.(A)bottomright:PEAspecimenwith‘tails’tosubsegmentalbranchesofthePA;cross-sectionofpartiallyorganized
andpermeabilizedthromboticlesionofthelargePAdissectedduringPEA.(B,C,D)Thewireisintroducedbetweenthefibroticmaterial(1),then
theballoonisinflated,leadingtoaruptureoftheweb(2).Fibroticmaterialisconnectedtothevesselwall(3).(E)SmallmuscularPAdisplayingeccentric
intimalfibrosisinvolvingintimalthickeningandproliferation—targetformedicaltherapies.
10.2.4.Multimodaltreatment Some patients with CTEPH may have mixed anatomical le-
Multimodaltherapyincludingsurgery,medication,andinterventionis sions,withsurgicallyaccessiblelesionsinonelungandinoperable
offeredtoselectedpatientswithCTEPH(Figure15).102 lesions in the other lung. Such patients might benefit from a
Usingmedicaltherapyinpatientswithhighpre-operativePVRto combined approach with BPA (prior to or at the same time as
improvepulmonaryhaemodynamicsbeforePEAiscommonpractice surgery) and PEA to decrease the surgical risk and improve
butstillcontroversial,asitisfelttodelaytimelysurgicalreferraland the final result.807
thereforedefinitivetreatment.801–803
The recommendations on BPA and medical therapy in patients
A significantproportion ofsymptomatic patients may have per- withinoperableCTEPHhavebeenestablishedbasedonkeynarra-
sistent or recurrent PH following PEA, which may also benefit tivequestion8(SupplementaryData,Section10.1).
frommedicaland/orinterventionaltherapies(Figure15).804–806An
Therecommendationontheuseofmedicaltherapybeforeinter-
mPAP ≥30mmHg has been associated with initiation of medical ventionaltherapyinpatientswithCTEPHwhoareconsideredinop-
therapies post-PEA, and an mPAP ≥38mmHg and PVR ≥5 WU erable but candidates for BPA is based on PICO question IV
withworselong-termsurvival.806 (SupplementaryData,Section10.2).Theincludedevidencesuggests
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 81 ---
3698 ESC/ERSGuidelines
thatpre-treatmentimprovespulmonaryhaemodynamicsandsafety normalizationofhaemodynamicsatrest,obtainedatRHC3–6months
oftheprocedure.ThisisconfirmedbytheclinicalexperienceofTask post-procedure(PEAorlastBPA),andimprovementinqualityoflife.
Forcemembers.However,duetothelowcertaintyoftheevidence,
therecommendationisconditional. 10.3. Chronic thrombo-embolic
pulmonary hypertension team and
10.2.5.Follow-up
Regardless of the result of PEA/BPA, patients should be regularly experience criteria
followed-up, including invasive assessment with RHC 3–6 months Tooptimizepatients’outcomes,CTEPHcentresshouldfulfilcriteria
after intervention, allowingfor consideration ofa multimodaltreat- foraPHcentre(Section12)andhaveaCTEPHmultidisciplinaryteam
mentapproach.Aftersuccessfultreatment,yearlynon-invasivefollow- consistingofaPEAsurgeon,BPAinterventionist,PHspecialist,and
up,includingechocardiographyandanevaluationofexercisecapacity, thoracicradiologist,trainedinhigh-volumePEAand/orBPAcentres.
isindicatedbecauserecurrentPHhasbeendescribed(Figure14).806 Theteamshouldmeetregularlytoreviewnewreferralsandpost-
Risk assessment with either the ESC/ERS or REVEAL risk score treatment follow-up cases. Ideally, CTEPH centres should have
developedforPAHhasbeenvalidatedinmedicallytreatedpatients PEA activities (.50/year)810 and BPAs (.30 patients/year or
withCTEPH,300,808,809butitisunknownifitsusehasanytherapeutic .100 procedures/year),781 as these figures have been associated
implicationoraffectsoutcome. withbetteroutcome.TheCTEPHcentresshouldalsomanagemed-
Therearenodataorconsensusonwhatisthetherapeutictargetafter icallytreatedpatients.Basedonregionalrequirements,thesenum-
PEA/BPAormedicaltherapyinCTEPH.Mostexpertsacceptachievinga bers may be adjusted for the country’s population, ideally
good functional class (WHO-FC I–II) and/or normalization or near concentratingcareandexpertiseinhigh-volumecentres.
RecommendationTable24—Recommendationsforchronicthrombo-embolicpulmonaryhypertensionandchronic
thrombo-embolicpulmonarydiseasewithoutpulmonaryhypertension
RecommendationTable24A
Recommendations Classa Levelb
CTEPH
Lifelong,therapeuticdosesofanticoagulationarerecommendedinallpatientswithCTEPH762
I C
AntiphospholipidsyndrometestingisrecommendedinpatientswithCTEPH
I C
InpatientswithCTEPHandantiphospholipidsyndrome,anticoagulationwithVKAsisrecommended103,764,765
I C
ItisrecommendedthatallpatientswithCTEPHarereviewedbyaCTEPHteamfortheassessmentofmultimodalitymanagement54
I C
PEAisrecommendedasthetreatmentofchoiceforpatientswithCTEPHandfibroticobstructionswithinpulmonaryarteriesaccessibleby
I B
surgery54,102
BPAisrecommendedinpatientswhoaretechnicallyinoperableorhaveresidualPHafterPEAanddistalobstructionsamenableto I B
BPA54,102,783,784,789,793,798,811
RiociguatisrecommendedforsymptomaticpatientswithinoperableCTEPHorpersistent/recurrentPHafterPEA775
I B
Long-termfollow-upisrecommendedafterPEAandBPA,aswellasforpatientswithCTEPHestablishedonmedicaltherapy782,805,806,812
I C
AmultimodalityapproachshouldbeconsideredforpatientswithpersistentPHafterPEAandforpatientswithinoperableCTEPH804,805,812
IIa C
Treprostinils.c.maybeconsideredinpatientsinWHO-FCIII–IVwhohaveinoperableCTEPHorpersistent/recurrentPHafterPEA776
IIb B
Off-labeluseofdrugsapprovedforPAHmaybeconsideredinsymptomaticpatientswhohaveinoperableCTEPH55,777–779,801
IIb B
InpatientswithinoperableCTEPH,acombinationofsGCstimulator/PDE5i,ERA,777orparenteralprostacyclinanalogues776maybeconsidered
IIb C
BPAmaybeconsideredfortechnicallyoperablepatientswithahighproportionofdistaldiseaseandanunfavourablerisk:benefitratioforPEA
IIb C
CTEPDwithoutPH
InpatientswithCTEPDwithoutPH,long-termanticoagulanttherapyshouldbeconsideredonanindividualbasisc
IIa C
PEAorBPAshouldbeconsideredinselectedsymptomaticpatientswithCTEPDwithoutPH
IIa C
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 82 ---
ESC/ERSGuidelines 3699
RecommendationTable24B
GRADE
Recommendations Qualityof Strengthof Classa Levelb
evidence recommendation
InpatientswithCTEPHwhoarecandidatesforBPA,medicaltherapyshouldbe Verylow Conditional
IIa B
consideredpriortotheintervention798
BPA, balloonpulmonaryangioplasty;CTEPD, chronicthrombo-embolicpulmonarydisease;CTEPH, chronicthrombo-embolicpulmonaryhypertension;ERA, endothelinreceptor
antagonist;PAH, pulmonaryarterialhypertension;PDE5i, phosphodiesterase5inhibitor;PEA, pulmonaryendarterectomy;PE, pulmonaryembolism;PH, pulmonaryhypertension;
s.c., subcutaneous;sGC, solubleguanylatecyclase;VKA, vitaminKantagonist;WHO-FC, WorldHealthOrganizationfunctionalclass.
aClassofrecommendation.
bLevelofevidence.
cLong-termanticoagulanttherapyisrecommendedwhentheriskofPErecurrenceisintermediateorhigh,103orwhenthereisnohistoryofvenousthrombo-embolism.
11. Pulmonary hypertension with involvement.Althoughgroup5PHrepresentsless-studiedforms
of PH, it constitutes a significant part of the worldwide burden
unclear and/or multifactorial
of PH.1 Group 5 PH includes: haematological disorders, such as
mechanisms (group 5) SCD and chronic myeloproliferative neoplasms; systemic disor-
ders,suchassarcoidosis;metabolicdiseases,suchasglycogenstor-
Pulmonaryhypertensionwithunclearand/ormultifactorialmechan- age disease; and others, such as chronic renal failure, pulmonary
isms(Table24)includesseveralconditionsthatmaybecomplicated tumour thrombotic microangiopathy, and fibrosing mediastinitis.
by complex and sometimes overlapping pulmonary vascular A common feature of these diseases is that the mechanisms of
PH are poorly understood and contributing factors may include,
aloneorincombination:hypoxicpulmonaryvasoconstriction,pul-
Table24 Pulmonaryhypertensionwithunclearand/ monaryvascularremodelling,thrombosis,fibroticdestructionand/
ormultifactorialmechanisms
or extrinsic compression of pulmonary vasculature, pulmonary
vasculitis, high-output cardiac failure, and left HF. These patients
Disordersassociatedwith
needcarefulassessmentandtreatmentshouldbedirectedtothe
pulmonaryhypertension
underlyingcondition.
1Haematologicaldisorders Inheritedandacquiredchronic
haemolyticanaemia
11.1. Haematological disorders
(cid:129) Sicklecelldisease
(cid:129) β-thalassaemia Inhaemoglobinopathiesandchronichaemolyticanaemias,including
(cid:129) Spherocytosis SCD,PHhasemergedasamajorcauseofmorbidityandmortality.
(cid:129) Stomatocytosis
TheprevalenceofPHconfirmedbyRHCwas6–10%instudiesof
(cid:129) Autoimmunedisorders
adultpatientswithstableSCD.93,94,813PatientswithSCDwithpre-
capillary PH are more commonly homozygous for haemoglobin S,
Chronicmyeloproliferative
while some have S-β0 thalassaemia (S-β0 thal) or haemoglobin
disorders
(cid:129) Chronicmyelogenous
SCD.814ThromboticlesionsareamajorcomponentofPHrelated
to SCD, more frequently in haemoglobin SCD.814 Patients with
leukaemia
(cid:129) Polycythaemiavera PHandSCD shouldbe followedby multidisciplinarySCD andPH
(cid:129) Idiopathicmyelofibrosis teams, since treatment of the anaemia is a key part of manage-
(cid:129) Essentialthrombocytopenia ment.814 There is a lack of data to support the use of PAH drugs
(cid:129) Others in patients with SCD-associated PH. In a study in patients with
SCD with TRV ≥2.7m/s and a 6MWD of 150–500m, sildenafil
2Systemicdisorders Sarcoidosis
showednotreatmenteffecton6MWD,TRV,orNT-proBNP,but
PulmonaryLangerhans’scell
appeared to increase hospitalization rates for pain.815 Preliminary
histiocytosis
evidence supports the short- and long-term benefits of chronic
Neurofibromatosistype1
blood-exchangetransfusionsinpatientswithpre-capillaryPHcom-
3Metabolicdisorders Glycogenstoragedisease
plicatingSCD.816Pre-capillaryPHcomplicatingSCDhasanimport-
Gaucherdisease
ant impact on survival, with an overall death rate of 2.0–5.3% in
4Chronicrenalfailurewith/
different populations with similar follow-up (26 months and 18
withouthaemodialysis months, respectively).94,817 In β-thalassaemia, invasive haemodyna-
5Pulmonarytumourthrombotic micevaluationconfirmedpre-capillaryPHin2.1%ofcases,whilea
microangiopathy post-capillaryprofilewasfoundin0.3%.818Potentialtreatmentstrat-
6Fibrosismediastinitis egies are awaiting an enhanced understanding of the
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 83 ---
3700 ESC/ERSGuidelines
pathophysiological mechanisms. In spherocytosis, splenectomy is a 11.3. Metabolic disorders
riskfactorforCTEPH.819
Glycogenstoragediseasesarecausedbygeneticalterationsofglyco-
MultiplecausesofPHhavebeendescribedinpatientswithchronic genmetabolism,andPHcasereportshavebeenrelatedtoglycogen
myeloproliferativedisorders.820Inchronicmyelogenousleukaemia, storagediseasetype1and2.829TheoccurrenceofPHhaspredom-
spleen enlargement and anaemia can give rise to hyperkinetic syn- inantlybeendescribedinglycogenstoragediseasetype1,whereit
drome.HepatosplenicenlargementcanalsocausePoPH.Casesof may partly be due to vasoconstrictive amines such as serotonin.
potentiallyreversibleDPAHhavebeendescribedwithdasatinib,bo- DrugsforPAHhavebeenusedinsomecases.830
sutinib,andponatinib.Inpolycythaemiaveraandessentialthrombo- UntreatedpatientswithGaucherdiseasemaydevelopPH,which
cythaemia, there is an increased risk of venous thrombo-embolic iscausedbyacombinationoffactors,includingasplenia,pluggingof
diseaseandCTEPH;moreover,abloodclotwithinthehepaticveins thevasculaturebyabnormalmacrophages,andpulmonaryvascular
can lead to Budd–Chiari syndrome and subsequent PoPH. remodelling.Treatmentwithenzyme-replacementtherapymayim-
Pulmonary extramedullary haematopoiesis complicating idiopathic provePH.
orsecondarymyelofibrosismayalsocontributetodyspnoeaandPH.
Group5PHmaybedescribedinotherhaematologicaldisorders, 11.4. Chronic kidney failure
such as common variable immunodeficiency; immunoglobulin G4
Althoughcommonlyrecognizedinchronicrenalfailure,thepatho-
(IgG4)-relateddisease;Castlemandisease;andpolyneuropathy,or-
genesisofPHremainspoorlyunderstoodandPHisobservedinpa-
ganomegaly, endocrinopathy, monoclonal immunoglobulin, skin
tientspriortoandwhilereceivingdifferentdialysismodalities.831A
changes(POEMS)syndrome.821–823
recent RHC study of 3504 patients with chronic kidney disease
found that CpcPH was the most common phenotype, and the
phenotype with the highest mortality.832 Post-capillary PH has
11.2. Systemic disorders
beendescribedin65%ofpatientsreceivinghaemodialysisand71%
The reported prevalence of PH in patients with sarcoidosis is 6–
ofpatientswithoutkidneyreplacement.833
20%.824Thecausesaremultifactorial,includingfibrosinglungdisease,
granulomatainthePAsand/orpulmonaryveins,fibrosingmediastini-
11.5. Pulmonary tumour thrombotic
tisand/orextrinsiccompressionbylymphnodes,pulmonaryvascu-
microangiopathy
litis, CTEPH, and PoPH.58,825 It is associated with significant
morbidityandincreasedmortalitycomparedwithsarcoidosiswith- Pulmonarytumourthromboticmicroangiopathydescribestumour-
outPH.58,825Inaregistry,factorsindependentlyassociatedwithout- cellmicroemboliwithocclusivefibrointimalremodellinginsmallPAs,
comesincludedphysiological(forcedexpiratoryvolumein1s/FVC pulmonaryveins,andlymphatics.ItisararecauseofPH,whicharises
ratioandDLCO)andfunctional(6MWD)parameters.58Inalarge duetomultiplemechanisms,butprobablyremainsunder-diagnosed,
study of severe, sarcoidosis-associated PH, PAH drugs improved
asevidencedbyautopsyfindings.834Thedisorderisassociatedwith
short-term pulmonary haemodynamics without improving carcinomas,notablygastriccarcinoma.Progressivevesselocclusion
6MWD.59SmallRCTshavesuggestedefficacyofPAHdrugsinthese ultimatelyresultsinPH,whichisoftensevere,ofsuddenonset,rap-
patients, which requires confirmation in larger studies.826 idlyprogressive,andaccompaniedbyprogressivehypoxaemia.Chest
Corticosteroids or immunosuppressive therapy may improve CTmayshowpatchyground-glassandseptalmarkings(masquerad-
haemodynamicsinselectedpatientswithactivegranulomatousdis- ingasPVOD).
ease.Ofnote,whenpulmonaryvascularcompressionissuspected
(fibrosing mediastinitis and/or extrinsic compression by lymph 11.6. Fibrosing mediastinitis
nodes),resultsfrompulmonaryangiographyandPETscansprovide Fibrosing mediastinitis is caused by fibrous tissue proliferating in the
additional information justifying endovascular and/or anti- mediastinum,encasingmediastinalvisceraandcompressingmediastinal
inflammatory approaches. Long-term survival remains poor in bronchovascularstructures.835Pre-orpost-capillaryPHcancomplicate
sarcoidosis-associated PH, which makes LTx a reasonable option thecourseoffibrosingmediastinitisduetoextrinsiccompressionofthe
forselectedseverecases. PAsand/orpulmonaryveins.Fibrosingmediastinitiscanbeidiopathicor
InpulmonaryLangerhans’scellhistiocytosis,diminishedexercise causedbyirradiation,infection(tuberculosis,histoplasmosis),andsys-
capacity does not appear to be due to ventilatory limitation but temicdiseases,suchassarcoidosisandIgG4-relateddisease,afibroin-
may be related to pulmonary vascular dysfunction. In 29 patients flammatorydiseasecharacterizedbyelevatedserumIgG4levelswith
with PH associated with pulmonary Langerhans’s cell histiocytosis, infiltration of IgG4+ plasma cells and severe fibrosis in affected tis-
PAH drugs improved haemodynamics without worsening oxygen sues.821 Treatment should be directed to the underlying condition.
levels.827 No clear clinical improvement has been described with PAH drugs.
Pulmonaryhypertensionassociatedwithneurofibromatosistype Surgical and endovascular procedures have been proposed to
1isararebutseverecomplicationcharacterizedbyfemalepredom- de-obstructorbypassthearterialand/orvenouscompressions.
inance (female/male ratio 3.9:1).828 Specific pulmonary vascular in- IntheabsenceofpositiveRCTsstudyingtheuseofPAHdrugsfor
volvement exists in these patients, and despite a potential treating group 5 PH, treating the underlying disorder remains the
short-term benefit of PAH drugs, prognosis remains poor, and standardofcare.836Importantly,someofthediseasesdescribedin
LTxshouldbeconsideredinselectedpatientswithseveredisease. Table 24 may have a pulmonary venous component that could be
In the presence of dyspnoea, screening for ILD by non-contrast madeworsewithPAHdrugs,implyingthatoff-labeluseofdrugsap-
CTandforPHbyechocardiographyisrequired.828 proved for PAH should be considered with great caution, if at all.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 84 ---
ESC/ERSGuidelines 3701
Placebo-controlled, randomized trials are currently recruiting in patient organizations and scientific societies. The purpose of a
well-phenotypedsubgroupsofPHwithunclearand/ormultifactorial PH centre is to: receive new referrals; assess and investigate the
mechanisms,suchassarcoidosis-associatedPH. cause of PH; carefully phenotype and routinely manage patients
withmedical,interventional,andsurgicalapproaches;workclosely
fi
12. De nition of a pulmonary withotherhealthcareproviderstoachievethebestoutcomesfor
hypertension centre patients;undertakeaudits(reportingpatientcasemixandquality
indicators); and be involved in clinical and translational research,
WhilePHisnotanuncommoncondition,severeformsofPH,es- and education. The requirements—comprising definition, multi-
peciallyPAHandCTEPH,requirehighlyspecializedmanagement.
disciplinarystructure,numberofcases,procedures,andstaffingle-
Sincemedicalcentreswithmultidisciplinaryteamsandahighvol- vels, as well as the skills and resources needed in a PH referral
umeofpatientsgenerallyofferbeststandardofcare,whichtrans- centre—aredescribedbelowandinFigure16.Criteriaforpaediatric
lates into better clinical outcomes, establishing PH centres is andCTEPHcentresaredescribedelsewhere(Sections7.8.3and10.3,
clinically and economically highly desirable and is supported by respectively).
Pulmonary hypertension centre
Co-ordinated by a core MDT member responsible for the multidisciplinary approach
Core MDT Extended MDT
Cardiologist/Pneumologist Cardiothoracic surgeon Adult CHD specialist Lung pathologist
At least 2 PH specialists treating At least 2 surgeons Cardiac radiologist Lung transplant
a sufficient number of patientsa (ECMO) physician/surgeonc
Cardiothoracic
Nurse specialist Interventional anaesthetist Paediatric cardiologist
radiologist/cardiologist
At least 2 PH nurses For diagnostic pulmonary Clinical geneticist/ Palliative care specialist
working (cid:2)50% on PH care angiography, embolization Genetic counsellorc
Physiotherapist
Social worker Study nurse Gynaecologist/
Obstetrician Psychologist
Case managerb Data manager
Responsible for the Responsible for data Hepatologist Rheumatologist
co-ordination of care collection, analysis, and
on patient level organization of audit meetings Intensive care specialist Thoracic radiologist
Processes
Patient care pathway and clinical management protocol
Steps from diagnosis to follow-up including advanced disease, palliative stage, and end of life
MDT meeting
Regular, to discuss multidisciplinary aspects of individual patient care
Patient empowerment and advocacy
Clear verbal, and written information for patients that describes diagnostic procedures and treatment options;
shared decision-making; collaboration with advocacy group
Interaction with external healthcare providers and other relevant stakeholders
GP, local specialist, social services,rehabilitation centres, national health services, labs,
insurers, school,work, sport club, psychologist, etc.
Quality control/Audits
Data collection/registration; monitoring of quality indicators;regular internal audits
Research, training, and education
Involvement in clinical and translational research: teaching courses on local, national, or international basis
Figure16Pulmonaryhypertensioncentreschematic.CHD,congenitalheartdisease;ECMO,extracorporealmembraneoxygenation;GP,general
practitioner;MDT,multidisciplinaryteam;PH,pulmonaryhypertension.aNumberadaptedaccordingtospecificcountrycharacteristics.bCasemanager
canbeanursespecialist,socialworker,physiotherapist,oradministrativeassistantinfunctionofthecentreorganization.cCanbelocatedinpartnercen-
tres.AdaptedfromBiganzolietal.846
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 85 ---
3702 ESC/ERSGuidelines
12.1. Facilities and skills required for a RecommendationTable25—Recommendationsfor
pulmonaryhypertensioncentres
pulmonary hypertension centre
Pulmonaryhypertensioncentrescareforasufficientnumberofpa-
Recommendations Classa Levelb
tientsonPHtherapy,aswellasnewreferrals,towarrantthisstatus.
According to the 2015 ESC/ERS Guidelines for the diagnosis and ItisrecommendedthatPHcentresprovidecare
treatmentofPHandtheEuropeanReferenceNetworkonrarere- byamultidisciplinaryteam(cardiologist,
spiratory diseases (ERN-LUNG) competency requirements, the pneumologist,rheumatologist,nursespecialist, I C
idealnumberofpatientsseenbyanadultcentreeachyearisnofew- radiologist,psychologicalandsocialworksupport,
erthan200,ofwhichatleasthalfhaveafinaldiagnosisofPAH;aPH andappropriateon-callexpertise)
centrefollowsatleast50patientswithPAHorCTEPHandreceives ItisrecommendedthatPHcentreshavedirect
at least two new referrals per month with documented PAH or linksandquickreferralpatternstootherservices I C
CTEPH.25,26,837–839 These numbers can be adapted according to (suchasgeneticcounselling,PEA/BPA,LTx,and
specificcountrycharacteristics(smallpopulation,largegeographical adultcongenitalheartdiseaseservice)
area) provided that strong working collaborations are established ItisrecommendedthatPHcentresmaintaina
I C
withhigh-volumecentres.Thisiscurrentlyfacilitatedbytheavailabil- patientregistry
ityofsecurevirtualplatforms(e.g.ERNclinicalpatientmanagement ItisrecommendedthatPHcentrescollaborate I C
system).840 withpatientassociations
Propertrainingofstaffmembersincludescorecompetencies,such AccreditationofthePHcentresshouldbe
asthoseoutlinedintheERSPulmonaryVascularDiseasesContinuing considered(e.g.https://ec.europa.eu/health/ern/ IIa C
Professional Development framework,841 and builds on entrustable assessment_en)
professionalactivities,describedintheESCCoreCurriculum.842 PHcentres’participationincollaborativeclinical
IIa C
Clinical, laboratory, and imaging facilities include: a ward where researchshouldbeconsidered
health care providers have expertise in PH; a specialist outpatient PHcentresshouldfollow-upasufficientnumber
service;anintermediate/ICU;24/7emergencycare;aninterventional
ofpatientstomaintainexpertise(atleast50
radiologyunit;diagnosticinvestigations,includingechocardiography,
patientswithPAHorCTEPHandatleasttwo
IIa C
CTscanning,nuclearmedicine,MRI,exercisetests,andPFTs;acar-
newreferralspermonthwithdocumentedPAH
diac catheterization laboratory; access to genetic counselling and
orCTEPH),andconsiderestablishing
testing;andfastandeasyaccesstocardiothoracicandvascularsur-
collaborationswithhigh-volumecentres
gery.Keydiagnosticproceduresareperformedinsufficientnumbers
to guarantee expertise (e.g. ERN-LUNG requirements).837 In ana- BPA, balloonpulmonaryangioplasty;CTEPH, chronicthrombo-embolicpulmonary
hypertension;LTx,lungtransplantation;PAH, pulmonaryarterialhypertension;PEA,
logywiththe‘advancedheartfailureunits’,843PHcentresofferthe
pulmonaryendarterectomy;PH, pulmonaryhypertension.
fullrangeofPAHtherapiesavailableintheircountry(includingi.v./ aClassofrecommendation.
s.c. prostacyclin derivatives) and have early referral protocols to
bLevelofevidence.
CTEPH,LTx, andrehabilitationcentres. Sinceevaluationandearly
availabilityofnewdrugsandtechniquesarecritical,PHcentrespar-
12.2. European Reference Network
ticipateincollaborativeclinicalresearch.
In 2017, the European Commission launched European Reference
Regularmultidisciplinaryteammeetings,includingcoremembers
Networks (ERNs) for rare diseases that included the ERN-LUNG
andon-demandinvitedmembers(extendedmultidisciplinaryteam)
withaPHcorenetwork.EuropeanReferenceNetworksarepatient-
asneeded(Figure16),arerequiredtoestablishandadaptindividual
centred networks of commissioned centres offering guidance and
patientcarepathways.Casemanagement(co-ordinationofindivid-
cross-border best standard of care in the European Union. The
ualpatientpathways)shouldincludeadministrative,social,andcare
PHnetworkincludesover20fullmembers,contributingeachyear
support. Remote accessibility of the PH centre by phone, mail, or
(cid:4)1500 new patients with PAH or CTEPH.844 It also includes UK
otherisavitalpartofthecare.Strategieshavetobeimplemented
supportingcentres,andaffiliatedpartners(whodonotnecessarily
in order to improve health literacy and shared decision-making,
havetofulfiltheminimumcompetencycriteriaoftheERN-LUNG
with the supportofdedicatedpatient decision tools.Transitioning
PH network). The ERN-LUNG requires and monitors standards
fromapaediatricPHcentretoanadultPHcentrerequiresadequate
forthesecentres.
planning to prevent gaps in care. Involving national and/or inter-
national patient associations helps to design patient-centric care
12.3. Patient associations and patient
andtospreadmedicalknowledgeamongpatientsandtheircarers.
Pulmonary hypertension centres should record patients’ data empowerment
using local, national, or international patient registries, and be able Pulmonary hypertension centres should inform patients about pa-
toreportprocessindicators(compliancewithdiagnosticandtreat- tientassociationsandencouragethemtojoinsuchgroups.Patient
ment guidelines, including LTx) and outcome indicators, such as associations are a valuable resource for managing patients, as they
WHO-FC,exercisecapacity,haemodynamics,qualityoflife,compli- provideeducationalandemotionalsupport,andcanhavepositiveef-
cations, and survival.They should undergoregularaudits to assess fectsoncoping,confidence,andoutlook.845Itisrecommendedthat
thequalityofdeliveredcare. PH centres collaborate with patient associations on initiatives to
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 86 ---
ESC/ERSGuidelines 3703
empowerpatientsandimprovethepatientexperience,addressing (13) ThetreatmentalgorithmforCTEPHhasbeenmodified,includ-
issues such as health literacy, digital skills, healthy lifestyles, mental ingmultimodaltherapywithsurgery,PHdrugs,andBPA.
health,andself-management.Healthcarecanbedeliveredmoreef-
fectivelyandefficientlyifpatientsarefullpartnersintheprocess.
14. Gaps in evidence
13. Key messages
14.1. Pulmonary arterial hypertension
(1) The haemodynamic definition of PH has been updated as (group 1)
mPAP.20mmHg.ThedefinitionofPAHalsoimpliesaPVR
(cid:129) TheefficacyandsafetyofPAHdrugsingroup1patientswithan
.2WUandPAWP≤15mmHg.Thesecut-offvaluesbetter
mPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be
reflect the limits of normal ranges, but do not yet translate
established.
into new therapeutic recommendations, since the efficacy of
(cid:129) The role of PAH drugs in different PAH subgroups, including PAH therapy in patients with PVD and an mPAP 21–
schistosomiasis-associatedPAH,needstobeexplored.
24mmHgand/orPVR2–3WUisstillunknown.
(cid:129) Risk-stratification assessment in PAH needs to be further pro-
(2) ThemaindiagnosticalgorithmforPHhasbeensimplifiedfol-
spectively validated through goal-orientated outcome studies,
lowingathree-stepapproach,fromsuspicionbyfirst-linephy-
andoptimizedforpatientswithPAHandcomorbidities.
sicians,detectionbyechocardiography,andconfirmationwith
(cid:129) NewPAHphenotypesobservedinpatientswithsignificantcardio-
RHCinPHcentres.Warningsignsassociatedwithworseout-
pulmonarycomorbiditiesarecommonandshouldbethefocusof
comes have been identified, which justify immediate referral
moreresearch.
andmanagementinPHcentres.
(cid:129) TheimportanceofPAHpatientphenotypesandtherelevanceof
(3) ScreeningstrategiesforPAHinpatientswithSScandinthoseat
comorbiditiesontreatmentgoalsandoutcomesmustbefurther
riskofHPAHareproposedbasedontheresultsofpublished
evaluated.
cohort studies. Their implementation may shorten the time
(cid:129) TheimpactofPAHtherapiesandtreatmentstrategiesonsurvival
fromsymptomonsettodiagnosisofPAH.
needstobefurtherassessed.
(4) AnimprovedrecognitionofCTandechocardiographicsignsof
(cid:129) Pulmonary arterial hypertension drugs targeting novel pathways
CTEPHatthetimeofanacutePEevent,togetherwithasys-
are emerging and the impact of add-on use of this medication
tematic follow-up of patients with acute PE, as indicated in
onoutcomeshastobeevaluatedinRCTs.
the 2019 ESC/ERS Guidelines for the diagnosis and manage-
(cid:129) The role of RV imaging techniques (echocardiography, cMRI) in
mentofacutepulmonaryembolism,shouldhelptoremediate
diagnosingandstratifyingriskinPAHneedstobefurtherstudied.
theunderdiagnosisofCTEPH.
Theproposedcut-offvaluesforriskstratificationneedtobeprop-
(5) Thethree-stratarisk-stratificationassessmentinPAHhasbeen
erlyvalidatedinmulticentrestudies.
refinedafterbeingvalidatedinmultipleregistries.TheMRIand
(cid:129) TheroleofCPETintheearlydiagnosisofPAHinpopulationsat
echocardiographiccriteriahavebeenaddedtotheESC/ERSta-
risk of developing PAH, and in assessing prognosis in PAH on
ble,refiningnon-invasiveevaluationatdiagnosis.
topofclinicalandhaemodynamicdata,needsfurtherinvestigation.
(6) Afour-stratariskstratification,dividingthelarge,intermediate-risk
(cid:129) TheroleofexerciseechocardiographyandexerciseRHCinpa-
groupintointermediate–lowandintermediate–highrisk,ispro-
tientsatriskofdevelopingPAH,withabnormalCPETbutnormal
posedatfollow-up.
restechocardiogram,alsoneedsfurtherevaluation.
(7) The treatment algorithm for PAH has been simplified, with a
(cid:129) Theuseofmechanicalcirculatorysupport,particularlyinrevers-
clearfocusonriskassessment,cardiopulmonarycomorbidities,
iblePHorinpatientswithadvancedrightHFwithanexitstrategy
andtreatmentgoals.Initialcombinationtherapyandtreatment
(suchasLTx),hastobefurtherstudied.
escalationatfollow-upwhenappropriatearecurrentstandards.
(cid:129) Differences in natural history and treatment response between
(8) TheTaskForcehasattemptedtoclosethegapbetweenpaedi-
adultsandchildrenshouldbefurtherinvestigated.
atricandadultPAHcare,withtherapeuticandfollow-upstrat-
(cid:129) FurtherstudiesareneededontheeffectsofPADNinPAHandin
egies based on risk stratification and treatment response,
otherPHgroups.
extrapolatedfromthatinadultsbutadaptedforage.
(cid:129) Theimpactofcentrevolume,organization,andexpertiseontreat-
(9) The recommendations on sex-related issues in patients with
mentoutcomeneedsfurtherinvestigation.
PAH,includingpregnancy,havebeenupdated,withinformation
andshareddecision-makingaskeypoints.
(10) The recommendations for rehabilitation and exercise pro- 14.2.Pulmonaryhypertensionassociated
grammesinPHhavebeenupdatedfollowingthereleaseofadd-
with left heart disease (group 2)
itionalsupportiveevidence.
(11) Forthefirsttime,thereisarecommendationforPHmedical (cid:129) Themanagementofpatientswithgroup2PHneedsfurtherstudy
therapyingroup3PH,basedonasinglepositiveRCTinpa- withRCTs.
tientswithILD. (cid:129) Additionalresearchisneededtofacilitatenon-invasivediagnosisof
(12) The concept of CTEPD with or without PH has been intro- HFpEF-associatedPHanddistinguishingitfromPAH.
duced, enabling further research on the natural history and (cid:129) Theroleof fluidchallenge and exercisetesting to reveal left HF
managementintheabsenceofPH. needsfurthervalidation.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 87 ---
3704 ESC/ERSGuidelines
(cid:129) FurtherstudiesfocusingonPDE5isinpatientswithHFpEFanda (cid:129) InpatientswithsuspectedCTEPH,thediagnosticroleofDECTor
CpcPHphenotypeareneededandcurrentlyunderway. iodine subtraction mapping vs. V/Q lung scintigraphy has to be
(cid:129) TheeffectsthatnewHFmedication(ARNIs,SGLT-2is)hasonPH, validated.
throughreverseremodellingoftheLV,needfurtherinvestigation. (cid:129) The effect of drug therapy on the outcome of patients with
CTEPHneedstobeestablished.
(cid:129) ThetreatmentgoalsinpatientswithCTEPHhavetobeclarified,as
14.3.Pulmonaryhypertensionassociated
itisstillunclearifnormalizingmPAPandPVRtranslatesintoim-
with lung diseases and/or hypoxia
provedoutcomes.
(group 3) (cid:129) TheroleofBPAvs.PEAshouldbefurtherclarified:whichtreat-
(cid:129) Themanagementofpatientswithgroup3PHhastobefurther mentinwhichpatient?Aretheyequivalentforthetreatmentof
segmental/subsegmentaldisease?
studiedinRCTs.
(cid:129) Refiningphenotypeswillbecrucial,asthiswillinformdevelopment (cid:129) In inoperable CTEPH or persistent/recurrent PH after PEA, the
potential role of combination therapy of PH drugs must be
oftrials.
(cid:129) ClinicalrelevanceandtherapeuticimplicationsofseverePHinlung assessed.
(cid:129) Theroleofmedicaltreatmentsasbridgestointerventionalandop-
diseaseneedtobeinvestigated.
(cid:129) Long-term data on the effects of inhaled treprostinil (and other erativetreatmentsneedstobeformallytested.
(cid:129) Randomized controlled trials are needed to discriminate the ef-
PAHdrugs)inpatientswithPHassociatedwithlungdiseaseare
fectsofPEAandearlyfollow-uprehabilitation.
needed.
(cid:129) Theimpactofthehypobaricandhypoxicenvironmentofthe.150 (cid:129) The effect of PEA, BPA, and medical therapy on patients with
millionpeoplelivingat.2500maltitudehastobeclarified,andstudies CTEPDwithoutPHisnotestablished.
needtobeperformedtoassesspotentialtreatmentstrategiesforPH.
14.5. Pulmonary hypertension with
14.4. Chronic thrombo-embolic unclear and/or multifactorial
pulmonary hypertension (group 4) mechanisms (group 5)
(cid:129) The differentiation between acute and chronic PE in imaging (cid:129) Further research needs to inform management of group 5 PH,
(CTPA)hastobeimproved. suchasSCD-associatedPHandsarcoidosis-associatedPH.
‘ ’ ‘ ’
15. What to do and What not to do messages from the Guidelines
Recommendations Classa Levelb
Recommendationsforrightheartcatheterizationandvasoreactivitytesting
Rightheartcatheterization
ItisrecommendedthatRHCisperformedtoconfirmthediagnosisofPH(especiallyPAHorCTEPH)andtosupporttreatment
I B
decisions
InpatientswithsuspectedorknownPH,itisrecommendedthatRHCisperformedinexperiencedcentres
I C
ItisrecommendedthatRHCcomprisesacompletesetofhaemodynamicsandisperformedfollowingstandardizedprotocols
I C
Vasoreactivitytesting
VasoreactivitytestingisrecommendedinpatientswithI/H/DPAHtodetectthosewhocanbetreatedwithhighdosesofaCCB
I B
ItisrecommendedthatvasoreactivitytestingisperformedatPHcentres
I C
ItisrecommendedtoconsiderapositiveresponsetovasoreactivitytestingbyareductioninmPAP≥10mmHgtoreachanabsolute
I C
valueofmPAP≤40mmHgwithanincreasedorunchangedCOc
Inhalednitricoxide,inhalediloprost,ori.v.epoprostenolarerecommendedforperformingvasoreactivitytesting
I C
Vasoreactivitytesting,foridentifyingcandidatesforCCBtherapy,isnotrecommendedinpatientswithPAHotherthanI/H/DPAHand
III C
inPHgroups2,3,4,and5
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 88 ---
ESC/ERSGuidelines 3705
Recommendationsfordiagnosticstrategy
Echocardiography
Echocardiographyisrecommendedasthefirst-line,non-invasive,diagnosticinvestigationinsuspectedPH
I B
ItisrecommendedtoassignanechocardiographicprobabilityofPH,basedonanabnormalTRVandthepresenceofother
I B
echocardiographicsignssuggestiveofPH(seeTable10)
ItisrecommendedtomaintainthecurrentthresholdforTRV(.2.8m/s)forechocardiographicprobabilityofPHaccordingtothe
I C
updatedhaemodynamicdefinition
Imaging
Ventilation/perfusionorperfusionlungscanisrecommendedinpatientswithunexplainedPHtoassessforCTEPH
I C
CTpulmonaryangiographyisrecommendedinthework-upofpatientswithsuspectedCTEPH
I C
Routinebiochemistry,haematology,immunology,HIVtesting,andthyroidfunctiontestsarerecommendedinallpatientswithPAH,to
I C
identifyassociatedconditions
Abdominalultrasoundisrecommendedforthescreeningofportalhypertension
I C
Otherdiagnostictests
PulmonaryfunctiontestswithDLCOarerecommendedintheinitialevaluationofpatientswithPH
I C
OpenorthoracoscopiclungbiopsyisnotrecommendedinpatientswithPAH
III C
Recommendationsforscreeningandimproveddetectionofpulmonaryarterialhypertensionandchronicthrombo-embolic
pulmonaryhypertension
Systemicsclerosis
InpatientswithSSc,anannualevaluationoftheriskofhavingPAHisrecommended
I B
InadultpatientswithSScwith.3years’diseaseduration,anFVC≥40%,andaDLCO,60%,theDETECTalgorithmisrecommended
I B
toidentifyasymptomaticpatientswithPAH
InpatientswithSSc,wherebreathlessnessremainsunexplainedfollowingnon-invasiveassessment,RHCisrecommendedtoexclude
I C
PAH
CTEPH/CTEPD
Inpatientswithpersistentornew-onsetdyspnoeaorexerciselimitationfollowingPE,furtherdiagnosticevaluationtoassessfor
I C
CTEPH/CTEPDisrecommended
Forsymptomaticpatientswithmismatchedperfusionlungdefectsbeyond3monthsofanticoagulationforacutePE,referraltoaPH/
I C
CTEPHcentreisrecommendedafterconsideringtheresultsofechocardiography,BNP/NT-proBNP,and/orCPET
Other
CounsellingregardingtheriskofPAHandannualscreeningarerecommendedinindividualswhotestpositiveforPAH-causing
I B
mutationsandinfirst-degreerelativesofpatientswithHPAH
Inpatientsreferredforlivertransplantation,echocardiographyisrecommendedasascreeningtestforPH
I C
Recommendationsforevaluatingthediseaseseverityandriskofdeathinpatientswithpulmonaryarterialhypertension
ItisrecommendedtoevaluatediseaseseverityinpatientswithPAHwithapanelofdataderivedfromclinicalassessment,exercisetests,
I B
biochemicalmarkers,echocardiography,andhaemodynamicevaluations
Achievingandmaintainingalow-riskprofileonoptimizedmedicaltherapyisrecommendedasatreatmentgoalinpatientswithPAH
I B
Forriskstratificationatthetimeofdiagnosis,theuseofathree-stratamodel(low,intermediate,andhighrisk)isrecommended,taking
I B
intoaccountallavailabledataincludinghaemodynamics
Forriskstratificationduringfollow-up,theuseofafour-stratamodel(low,intermediate–low,intermediate–high,andhighrisk)basedon
I B
WHO-FC,6MWD,andBNP/NT-proBNPisrecommended,withadditionalvariablestakenintoaccountasnecessary
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 89 ---
3706 ESC/ERSGuidelines
Recommendationsforgeneralmeasuresandspecialcircumstances
Generalmeasures
SupervisedexercisetrainingisrecommendedinpatientswithPAHundermedicaltherapy
I A
PsychosocialsupportisrecommendedinpatientswithPAH
I C
ImmunizationofpatientswithPAHagainstSARS-CoV-2,influenza,andStreptococcuspneumoniaeisrecommended
I C
DiuretictreatmentisrecommendedinpatientswithPAHwithsignsofRVfailureandfluidretention
I C
Long-termoxygentherapyisrecommendedinpatientswithPAHwhosearterialbloodoxygenpressureis,8kPa(60mmHg)d
I C
Inthepresenceofiron-deficiencyanaemia,correctionofironstatusisrecommendedinpatientswithPAH
I C
TheuseofACEis,ARBs,ARNIs,SGLT-2is,beta-blockers,orivabradineisnotrecommendedinpatientswithPAHunlessrequiredby III C
comorbidities(i.e.highbloodpressure,coronaryarterydisease,leftHF,orarrhythmias)
Specialcircumstances
In-flightoxygenadministrationisrecommendedforpatientsusingoxygenorwhosearterialbloodoxygenpressureis,8kPa
I C
(60mmHg)atsealevel
Recommendationsforwomenofchildbearingpotential
ItisrecommendedthatwomenofchildbearingpotentialwithPAHarecounselledatthetimeofdiagnosisabouttherisksand
uncertaintiesassociatedwithbecomingpregnant;thisshouldincludeadviceagainstbecomingpregnant,andreferralforpsychological I C
supportwhereneeded
ItisrecommendedtoprovidewomenofchildbearingpotentialwithPAHwithclearcontraceptiveadvice,consideringtheindividual
I C
needsofthewomanbutrecognizingthattheimplicationsofcontraceptivefailurearesignificantinPAH
ItisrecommendedthatwomenwithPAHwhoconsiderpregnancyorwhobecomepregnantreceivepromptcounsellinginan
experiencedPHcentre,tofacilitategeneticcounsellingandshareddecision-making,andtoprovidepsychologicalsupporttothepatients I C
andtheirfamilieswhereneeded
ForwomenwithPAHhavingterminationofpregnancy,itisrecommendedthatthisbeperformedinPHcentres,withpsychological
I C
supportprovidedtothepatientsandtheirfamilies
Asteratogenicpotentialhasbeenreportedinpre-clinicalmodelsforendothelinreceptorantagonistsandriociguat,thesedrugsarenot
III B
recommendedduringpregnancy
Recommendationsforthetreatmentofvasoreactivepatientswithidiopathic,heritable,ordrug-associatedpulmonaryarterial
hypertension
HighdosesofCCBsarerecommendedinpatientswithIPAH,HPAH,orDPAHwhoareresponderstoacutevasoreactivitytesting
I C
Closefollow-upwithcompletereassessmentafter3–4monthsoftherapy(includingRHC)isrecommendedinpatientswithIPAH,
I C
HPAH,orDPAHtreatedwithhighdosesofCCBs
ContinuinghighdosesofCCBsisrecommendedinpatientswithIPAH,HPAH,orDPAHinWHO-FCIorIIwithmarked
I C
haemodynamicimprovement(mPAP,30mmHgandPVR,4WU)
InitiatingPAHtherapyisrecommendedinpatientswhoremaininWHO-FCIIIorIVorthosewithoutmarkedhaemodynamic
I C
improvementafterhighdosesofCCBs
CCBsarenotrecommendedinpatientswithoutavasoreactivitystudyornon-responders,unlessprescribedforotherindications(e.g.
III C
Raynaud’sphenomenon)
Recommendationsforinitialoraldrugcombinationtherapyforpatientswithidiopathic,heritable,ordrug-associatedpulmonary
arterialhypertensionwithoutcardiopulmonarycomorbiditiese
Initialcombinationtherapywithambrisentanandtadalafilisrecommended
I B
Initialcombinationtherapywithmacitentanandtadalafilisrecommended
I B
Initialcombinationtherapywithmacitentan,tadalafil,andselexipagisnotrecommended
III B
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 90 ---
ESC/ERSGuidelines 3707
Recommendationsforsequentialdrugcombinationtherapyforpatientswithidiopathic,heritable,ordrug-associatedpulmonary
arterialhypertension
Generalrecommendationforsequentialcombinationtherapy
Itisrecommendedtobasetreatmentescalationsonriskassessmentandgeneraltreatmentstrategies(seetreatmentalgorithm)
I C
Evidencefromstudieswithacompositemorbidity/mortalityendpointastheprimaryoutcomemeasure
TheadditionofmacitentantoPDE5isororal/inhaledprostacyclinanaloguesisrecommendedtoreducetheriskofmorbidity/mortality
I B
events
TheadditionofselexipagtoERAsfand/orPDE5isisrecommendedtoreducetheriskofmorbidity/mortalityevents
I B
TheadditionoforaltreprostiniltoERAorPDE5i/riociguatmonotherapyisrecommendedtoreducetheriskofmorbidity/mortality I B
events
Theadditionofbosentantosildenafilisnotrecommendedtoreducetheriskofmorbidity/mortalityevents
III B
Evidencefromstudieswithchangein6MWDastheprimaryoutcomemeasure
Theadditionofsildenafiltoepoprostenolisrecommendedtoimproveexercisecapacity
I B
Evidencefromstudieswithsafetyofcombinationtherapyasprimaryoutcomemeasure
CombiningriociguatandPDE5isisnotrecommendedg
III B
Recommendationsforintensivecaremanagementforpulmonaryarterialhypertension
WhenmanagingpatientswithrightHFintheICU,itisrecommendedtoinvolvephysicianswithexpertise,treatcausativefactors,and
I C
usesupportivemeasures,includinginotropesandvasopressors,fluidmanagement,andPAHdrugs,asappropriate
Recommendationsforlungtransplantation
ItisrecommendedthatpotentiallyeligiblecandidatesarereferredforLTxevaluationwhentheyhaveaninadequateresponsetooral
I C
combinationtherapy,indicatedbyanintermediate–highorhighriskorbyaREVEALriskscore.7
ItisrecommendedtolistpatientsforLTxwhopresentwithahighriskofdeathorwithaREVEALriskscore≥10despitereceiving
I C
optimizedmedicaltherapyincludings.c.ori.v.prostacyclinanalogues
Recommendationsforpulmonaryarterialhypertensionassociatedwithdrugsortoxins
Itisrecommendedtomakeadiagnosisofdrug-ortoxin-associatedPAHinpatientswhohadrelevantexposureandinwhomother
I C
causesofPHhavebeenexcluded
Inpatientswithsuspecteddrug-ortoxin-associatedPAH,itisrecommendedtoimmediatelydiscontinuethecausativeagentwhenever
I C
possible
Recommendationsforpulmonaryarterialhypertensionassociatedwithconnectivetissuedisease
InpatientswithPAHassociatedwithCTD,treatmentoftheunderlyingconditionaccordingtocurrentguidelinesisrecommended
I A
InpatientswithPAHassociatedwithCTD,thesametreatmentalgorithmasforpatientswithIPAHisrecommended I C
Recommendationsforpulmonaryarterialhypertensionassociatedwithhumanimmunodeficiencyvirusinfection
InpatientswithPAHassociatedwithHIVinfection,antiretroviraltreatmentaccordingtocurrentguidelinesisrecommended
I A
Recommendationsforpulmonaryarterialhypertensionassociatedwithportalhypertension
EchocardiographyisrecommendedinpatientswithliverdiseaseorportalhypertensionwithsignsorsymptomssuggestiveofPH,andas
I C
ascreeningtoolinpatientsevaluatedforlivertransplantationortransjugularportosystemicshunt
ItisrecommendedthatpatientswithPAHassociatedwithportalhypertensionarereferredtocentreswithexpertiseinmanagingboth
I C
conditions
DrugsapprovedforPAHarenotrecommendedforpatientswithportalhypertensionandunclassifiedPH(i.e.elevatedmPAP,highCO,
III C
andanormalPVR)
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 91 ---
3708 ESC/ERSGuidelines
Recommendationsforshuntclosureinpatientswithpulmonary-systemicflowratio.1.5:1basedoncalculatedpulmonaryvascular
resistance
InpatientswithanASD,VSD,orPDAandaPVR,3WU,shuntclosureisrecommended
I C
InpatientswithanASDandaPVR.5WUdespitePAHtreatment,shuntclosureisnotrecommended
III C
Recommendationsforpulmonaryarterialhypertensionassociatedwithadultcongenitalheartdisease
Riskassessment
RiskassessmentisrecommendedforpatientswithpersistentPAHafterdefectclosure
I C
Treatment
BosentanisrecommendedinsymptomaticpatientswithEisenmengersyndrometoimproveexercisecapacity
I B
InwomenwithEisenmengersyndrome,pregnancyisnotrecommended
III C
InpatientswithEisenmengersyndrome,routinephlebotomytolowerelevatedhaematocritisnotrecommended
III C
Recommendationsforpulmonaryarterialhypertensionwithsignsofvenous/capillaryinvolvement
Acombinationofclinicalandradiologicalfindings,ABG,PFTs,andgenetictestingisrecommendedtodiagnosePAHwithsignsofvenous
I A
and/orcapillaryinvolvement(PVOD/PCH)
IdentificationofbiallelicEIF2AK4mutationsisrecommendedtoconfirmadiagnosisofheritablePVOD/PCH
I A
ReferralofeligiblepatientswithPVOD/PCHtoatransplantcentreforevaluationisrecommendedassoonasthediagnosisisestablished
I C
LungbiopsyisnotrecommendedtoconfirmadiagnosisofPVOD/PCH
III C
Recommendationsforpaediatricpulmonaryhypertension
Children
Itisrecommendedtoperformthediagnosticwork-up,includingRHCandacutevasoreactivitytesting,andtreatchildrenwithPHat
I C
centreswithspecificexpertiseinpaediatricPH
InchildrenwithPH,acomprehensivework-upforconfirmingdiagnosisandspecificaetiologyisrecommended(similartothatinadults,
I C
butadaptedforage)
ForconfirmingPHdiagnosis,RHCisrecommended,preferablybeforeinitiatinganyPAHtherapy I C
InchildrenwithIPAH/HPAH,acutevasoreactivitytestingisrecommendedtodetectthosewhomaybenefitfromCCBtherapy I C
ItisrecommendedtosimilarlydefineapositiveresponsetoacutevasoreactivitytestinginchildrenandadultsbyareductioninmPAP
I C
≥10mmHgtoreachanabsolutevalueofmPAP≤40mmHg,withanincreasedorunchangedCO
InchildrenwithPAH,atherapeuticstrategybasedonriskstratificationandtreatmentresponseisrecommended,extrapolatedfrom
I C
thatinadults,butadaptedforage
ItisrecommendedtomonitorthetreatmentresponseinchildrenwithPAHbyseriallyassessingapanelofdataderivedfromclinical
I C
assessment,echocardiographicevaluation,biochemicalmarkers,andexercisetolerancetests
Infants
ItisrecommendedtoscreeninfantswithbronchopulmonarydysplasiaforPH I B
Ininfantswith(oratriskof)bronchopulmonarydysplasiaandPH,treatinglungdisease—includinghypoxia,aspiration,andstructural
I B
airwaydisease—andoptimizingrespiratorysupportisrecommendedbeforeinitiatingPAHtherapy
Recommendationsforpulmonaryhypertensionassociatedwithleftheartdisease
InpatientswithLHD,optimizingtreatmentoftheunderlyingconditionisrecommendedbeforeconsideringassessmentof
I A
suspectedPH
RHCisrecommendedforsuspectedPHinpatientswithLHD,ifitaidsmanagementdecisions
I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 92 ---
ESC/ERSGuidelines 3709
RHCisrecommendedinpatientswithseveretricuspidregurgitationwithorwithoutLHDpriortosurgicalorinterventionalvalverepair
I C
ForpatientswithLHDandsuspectedPHwithfeaturesofaseverepre-capillarycomponentand/ormarkersofRVdysfunction,referral
I C
toaPHcentreforacompletediagnosticwork-upisrecommended
InpatientswithLHDandCpcPHwithaseverepre-capillarycomponent(e.g.PVR.5WU),anindividualizedapproachtotreatmentis
I C
recommended
WhenpatientswithPHandmultipleriskfactorsforLHD,whohaveanormalPAWPatrestbutanabnormalresponsetoexerciseor
I C
fluidchallenge,aretreatedwithPAHdrugs,closemonitoringisrecommended
DrugsapprovedforPAHarenotrecommendedinPH-LHDh
III A
Recommendationsforpulmonaryhypertensionassociatedwithlungdiseaseand/orhypoxia
IfPHissuspectedinpatientswithlungdisease,itisrecommendedthatechocardiographyibeperformedandresultsinterpretedin
I C
conjunctionwithABG,PFTsincludingDLCO,andCTimaging
InpatientswithlungdiseaseandsuspectedPH,itisrecommendedtooptimizetreatmentoftheunderlyinglungdiseaseand,where
I C
indicated,hypoxaemia,sleep-disorderedbreathing,and/oralveolarhypoventilation
InpatientswithlungdiseaseandsuspectedseverePH,orwherethereisuncertaintyregardingthetreatmentofPH,referraltoaPH
I C
centreisrecommendedj
InpatientswithlungdiseaseandseverePH,anindividualizedapproachtotreatmentisrecommended
I C
ItisrecommendedtorefereligiblepatientswithlungdiseaseandPHforLTxevaluation
I C
InpatientswithlungdiseaseandsuspectedPH,RHCisrecommendediftheresultsareexpectedtoaidmanagementdecisions
I C
TheuseofambrisentanisnotrecommendedinpatientswithPHassociatedwithIPF
III B
TheuseofriociguatisnotrecommendedinpatientswithPHassociatedwithIIP
III B
TheuseofPAHmedicationisnotrecommendedinpatientswithlungdiseaseandnon-severePHk
III C
Recommendationsforchronicthrombo-embolicpulmonaryhypertensionandchronicthrombo-embolicpulmonarydiseasewithout
pulmonaryhypertension
CTEPH
Lifelong,therapeuticdosesofanticoagulationarerecommendedinallpatientswithCTEPH
I C
AntiphospholipidsyndrometestingisrecommendedinpatientswithCTEPH
I C
InpatientswithCTEPHandantiphospholipidsyndrome,anticoagulationwithVKAsisrecommended
I C
ItisrecommendedthatallpatientswithCTEPHarereviewedbyaCTEPHteamfortheassessmentofmultimodalitymanagement
I C
PEAisrecommendedasthetreatmentofchoiceforpatientswithCTEPHandfibroticobstructionswithinpulmonaryarteriesaccessible
I B
bysurgery
BPAisrecommendedinpatientswhoaretechnicallyinoperableorhaveresidualPHafterPEAanddistalobstructionsamenabletoBPA
I B
RiociguatisrecommendedforsymptomaticpatientswithinoperableCTEPHorpersistent/recurrentPHafterPEA
I B
Long-termfollow-upisrecommendedafterPEAandBPA,aswellasforpatientswithCTEPHestablishedonmedicaltherapy
I C
Recommendationsforpulmonaryhypertensioncentres
ItisrecommendedthatPHcentresprovidecarebyamultidisciplinaryteam(cardiologist,pneumologist,rheumatologist,nursespecialist,
I C
radiologist,psychologicalandsocialworksupport,appropriateon-callexpertise)
ItisrecommendedthatPHcentreshavedirectlinksandquickreferralpatternstootherservices(suchasgeneticcounselling,PEA/BPA,
I C
LTx,adultcongenitalheartdiseaseservice)
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 93 ---
3710 ESC/ERSGuidelines
ItisrecommendedthatPHcentresmaintainapatientregistry
I C
ItisrecommendedthatPHcentrescollaboratewithpatientassociations
I C
6MWD,6-minutewalkingdistance;ABG,arterialbloodgasanalysis;ACEi,angiotensin-convertingenzymeinhibitor;ARB,angiotensinreceptorblocker;ARNI,angiotensinreceptor–
neprilysin inhibitor; ASD, atrial septal defect; BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB,
calciumchannelblocker;CpcPH,combinedpost-andpre-capillarypulmonaryhypertension;CPET,cardiopulmonaryexercisetesting;CT,computedtomography;CTD,connective
tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon
monoxide;DPAH,drug-associatedpulmonaryarterialhypertension;ERA,endothelinreceptorantagonist;FVC,forcedvitalcapacity;HF,heartfailure;HFpEF,heartfailurewith
preserved ejection fraction; HIV, human immunodeficiency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; I/H/DPAH, idiopathic, heritable,
drug-associatedpulmonaryarterialhypertension;IIP,idiopathicinterstitialpneumonia;ILD,interstitiallungdisease;IPAH,idiopathicpulmonaryarterialhypertension;IPF,idiopathic
pulmonaryfibrosis;i.v.,intravenous;LHD,leftheartdisease;LTx,lungtransplantation;mPAP,meanpulmonaryarterialpressure;PAH,pulmonaryarterialhypertension;PAWP,
pulmonaryarterialwedgepressure;PCH,pulmonarycapillaryhaemangiomatosis;PDA,patentductusarteriosus;PDE5i,phosphodiesterase5inhibitor;PE,pulmonaryembolism;
PEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD,
pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; s.c., subcutaneous; SGLT-2i, sodium–glucose
cotransporter-2 inhibitor; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD, ventricular septal defect; WHO-FC, World Health
Organizationfunctionalclass;WU,Woodunits.
aClassofrecommendation.
bLevelofevidence.
cTestingshouldalsobeperformedinpatientswithabaselinemPAP≤40mmHg,inwhomthesamerespondercriteriaapply.
dMeasuredonatleasttwooccasions.
eCardiopulmonarycomorbiditiesarepredominantlyencounteredinelderlypatientsandincluderiskfactorsforHFpEFsuchasobesity,diabetes,coronaryheartdisease,ahistoryof
hypertension,and/oralowDLCO.
fERAusedintheGRIPHONstudywerebosentanandambrisentan.
gThePATENTplusstudyinvestigatedthecombinationofsildenafilandriociguat;however,combiningriociguatwithanyPDE5iiscontraindicated.
hSafetyconcernshavebeenidentifiedwhenERAsareusedinpatientswithHF(HFpEFandHFrEF,withorwithoutPH)andwhensildenafilisusedinpatientswithpersistentPHafter
correctionofvalvularheartdisease.
iAssessmentsshouldideallybemadewhenthepatientisclinicallystable,asexacerbationscansignificantlyraisepulmonaryarterypressure.
jThisrecommendationdoesnotapplytopatientswithend-stagelungdiseasewhoarenotconsideredcandidatesforLTx.
kThisdoesnotincludeinhaledtreprostinil,whichmaybeconsideredinpatientswithPHassociatedwithILDirrespectiveofPHseverity.
‘Whattodo’and‘Whatnottodo’messagesdevelopedwithGRADEEvidencetoDecisionframework
GRADE
Recommendations Qualityof Strengthof Classa Levelb
evidence recommendation
InpatientswithIPAH/HPAH/DPAHwhopresentatloworintermediateriskof Low Conditional
I B
death,initialcombinationtherapywithaPDE5iandanERAisrecommended
TheuseofPDE5iinpatientswithHFpEFandisolatedpost-capillaryPHisnot Low Conditional
III C
recommended
TheuseofPDE5iinpatientswithILDandnon-severePHisnotrecommended Verylow Conditional
III C
DPAH,drug-associatedpulmonaryarterialhypertension;ERA,endothelinreceptorantagonist;HPAH,heritablepulmonaryarterialhypertension;HFpEF,heartfailurewithpreserved
ejectionfraction;ILD,interstitiallungdisease;PDE5i,phosphodiesterase5inhibitor;PH,pulmonaryhypertension.
aClassofrecommendation.
bLevelofevidence.
16. Quality indicators methodsfordevelopingtheESCQIsforthequantificationofcare
andoutcomesforcardiovasculardiseases.847Todate,theESChas
Qualityindicators(QIs)aretoolsthatmaybeusedtoevaluatecare
developedQIsuitesforanumberofcardiovasculardiseases850–852
quality,includingstructural,process,andoutcomesofcare.847They and embedded these in respective ESC Clinical Practice guide-
mayalsoserveasamechanismforenhancingadherencetoguideline lines.27,477,853,854 Furthermore, the ESC aims to integrate its QIs
recommendations through associated quality-improvement initia- with clinical registries such as the EurObservational Research
tives and benchmarking of care providers.848,849 As such, the role Programme and the European Unified Registries On Heart Care
of QIs in improving care and outcomes for cardiovascular disease EvaluationandRandomizedTrials(EuroHeart)project855toprovide
is increasingly being recognized by health care authorities, profes- real-worlddataaboutthepatternsandoutcomesofcareforcardio-
sionalorganizations,payers,andthepublic.847 vasculardiseaseacrossEurope.
TheESCunderstandstheneedformeasuringandreportingqual- InparallelwiththewritingofthisClinicalPracticeGuideline,apro-
ity and outcomes of cardiovascular care, and has established cesshasbeeninitiatedtodevelopQIsforpatientswithPHusingthe
2202SRE/CSE©
2202SRE/CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 94 ---
ESC/ERSGuidelines 3711
ESC methodology and throughcollaboration with domain experts France,AIPI,AssociazioneItalianaIpertensionePolmonare,Bologna,
and the Heart Failure Association of the ESC. Such QIs may be Italy; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de
usedforevaluatingthequalityofcareforpatientswithPH,anden- Clinicas,UniversidadeFederal doParana,Curitiba,Brazil; Hossein
ableimportantaspectsofcaredeliverytobecaptured.TheseQIs, Ardeschir Ghofrani, Department of Internal Medicine,
alongsidetheirspecificationsanddevelopmentprocess,willbepub- University Hospital Giessen, Justus-Liebig University, Giessen,
lishedseparately. Germany, Department of Pneumology, Kerckhoff Klinik, Bad
Nauheim, Germany, Department of Medicine, Imperial College
London, London, United Kingdom; George Giannakoulas,
17. Supplementary data
Cardiology Department, Aristotle University of Thessaloniki,
AHEPAUniversityHospital,Thessaloniki,Greece;DavidG.Kiely,
SupplementarydataisavailableatEuropeanHeartJournalonlinein-
Department of Infection, Immunity and Cardiovascular Disease,
cludingkeynarrativequestion(1-8)andPICOquestions(I-IV).
University of Sheffield, Sheffield, United Kingdom, Sheffield
PulmonaryVascularDiseaseUnit,SheffieldTeachingHospitalsNHS
18. Data availability statement Foundation Trust, Sheffield, United Kingdom, Insigneo Institute,
University of Sheffield, Sheffield, United Kingdom; Eckhard
Nonewdataweregeneratedoranalysedinsupportofthisresearch.
Mayer, Thoracic Surgery, Kerckhoff Clinic, Bad Nauheim,
Germany; Gergely Meszaros (Hungary), ESC Patient Forum,
19. Author information Sophia Antipolis, France, European Lung Foundation (ELF),
Sheffield,UnitedKingdom;Blin Nagavci,InstituteforEvidencein
Author/TaskForceMemberAffiliations:MarcHumbert*, Medicine, Faculty of Medicine and Medical Center, University of
Faculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, Freiburg, Freiburg, Germany; Karen M. Olsson, Clinic of
France, Service de Pneumologie et Soins Intensifs Respiratoires, Respiratory Medicine, Hannover Medical School, member of the
Centre de Référence de l’Hypertension Pulmonaire, Hôpital German Center of Lung Research (DZL), Hannover, Germany;
Bicêtre,AssistancePubliqueHôpitauxdeParis,LeKremlin-Bicêtre, Joanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal
France, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le Papworth Hospital, Cambridge, United Kingdom; Jennifer
Plessis-Robinson, France; Gabor Kovacs, University Clinic of K. Quint, NHLI, Imperial College London, London, United
Internal Medicine, Division of Pulmonology, Medical University of Kingdom; Göran Rådegran, Department of Cardiology, Clinical
Graz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular Sciences Lund, Faculty of Medicine, Lund, Sweden, The
Research, Graz, Austria; Marius M. Hoeper, Respiratory Haemodynamic Lab, The Section for Heart Failure and Valvular
Medicine, Hannover Medical School, Hanover, Germany, Disease, VO. Heart and Lung Medicine, Skåne University Hospital,
Biomedical Research in End-stage and Obstructive Lung Disease Lund,Sweden; GeraldSimonneau, FacultéMédecine,Université
(BREATH), member of the German Centre of Lung Research Paris Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de
(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento l’Hypertension Pulmonaire, Hopital Marie-Lannelongue, Le
diScienzeClinicheInternistiche,AnestesiologicheeCardiovascolari, Plessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,
Sapienza Università di Roma, Roma, Italy, Dipartimento Université Paris-Saclay, Le Kremlin-Bicêtre, France, Service de
Cardio-Toraco-Vascolare e Chirurgia dei Trapianti d’Organo, Pneumologie et Soins Intensifs Respiratoires, Centre de Référence
Policlinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for de l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique
Congenital Heart Diseases, Beatrix Children’s Hospital, Dept of Hôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S
Paediatric Cardiology, University Medical Center Groningen, 999, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France;
University of Groningen, Groningen, Netherlands; Margarita Thomy Tonia, Institute of Social and Preventive Medicine,
Brida, Department of Sports andRehabilitationMedicine,Medical UniversityofBern,Bern,Switzerland;MarkToshner,HeartLung
FacultyUniversityofRijeka,Rijeka,Croatia,AdultCongenitalHeart Research Institute, Dept of Medicine, University of Cambridge,
Centre and National Centre for Pulmonary Hypertension, Royal Cambridge, United Kingdom, Royal Papworth NHS Trust;
Brompton & Harefield Hospitals, Guys & St Thomas’s NHS Trust, Jean-Luc Vachiery, Department of Cardiology, Pulmonary
London, United Kingdom; Jørn Carlsen, Department of Vascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,
Cardiology, Copenhagen University Hospital, Rigshospitalet, Brussels,Belgium;andAntonVonkNoordegraaf,Pulmonology,
Copenhagen,Denmark,DepartmentofClinicalMedicine;Facultyof AmsterdamUMC,Amsterdam,Netherlands.
Health and Medical Sciences, University of Copenhagen, *MarcHumbertissupportedbytheInvestissementd’Avenirpro-
Copenhagen, Denmark;AndrewJ.S. Coats, FacultyofMedicine, gramme managed by the French National Research Agency under
University of Warwick, Coventry, United Kingdom, Faculty of thegrantcontractANR-18-RHUS-0006(DESTINATION2024).
Medicine, Monash University Melbourne, Australia; Pilar
Escribano-Subias, Pulmonary Hypertension Unit, Cardiology
Department, Hospital Universitario 12 de Octubre, Madrid, Spain,
20. Appendix
CIBER-CV(CentrodeInvestigacionesBiomédicasEnReddeenfer-
medades CardioVasculares), Instituto de Salud Carlos III, Madrid,
Spain, Facultad de Medicina, Universidad Complutense, Madrid, ESC/ERS Scientific Document Group
Spain;PisanaFerrari(Italy),ESCPatientForum,SophiaAntipolis, IncludesDocumentReviewersandESCNationalCardiacSocieties.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 95 ---
3712 ESC/ERSGuidelines
Document Reviewers: Markus Schwerzmann (ESC Review Cardiology,AndreiCodreanu;Malta:MalteseCardiacSociety,Josef
Coordinator) (Switzerland), Anh-Tuan Dinh-Xuan (ERS Review Micallef;Moldova(Republicof):MoldavianSocietyofCardiology,
Coordinator) (France), Andy Bush (United Kingdom), Magdy Eleonora Vataman; Montenegro: Montenegro Society of
Abdelhamid(Egypt),VictorAboyans(France),EloisaArbustini(Italy), Cardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of
Riccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice Cardiology, Said Chraibi; Netherlands: Netherlands Society of
Beghetti (Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes Cardiology,MarcoC.Post;NorthMacedonia:NorthMacedonian
(Croatia), Robin Condliffe (United Kingdom), Frances de Man Society of Cardiology, Elizabeta Srbinovska Kostovska; Norway:
(Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France), Norwegian Society of Cardiology, Arne Kristian Andreassen;
Sean Gaine (Ireland), Nazzareno Galié (Italy), Wendy Gin-Sing Poland: Polish Cardiac Society, Marcin Kurzyna; Portugal:
(United Kingdom), John Granton (Canada), Ekkehard Grünig PortugueseSocietyofCardiology,RuiPlácido;Romania:Romanian
(Germany), Paul M. Hassoun (United States of America), Merel Society of Cardiology, Ioan Mircea Coman; Russian Federation:
Hellemons(Netherlands), Tiny Jaarsma (Sweden), BarbroKjellström RussianSociety of Cardiology, Oksana Vasiltseva; San Marino: San
(Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology
(Russian Federation), Konstantinos C. Koskinas (Switzerland), Dipak Society of Serbia, Arsen D. Ristić; Slovakia: Slovak Society of
Kotecha (United Kingdom), Irene Lang (Austria), Basil S. Lewis Cardiology, Iveta Šimkova; Slovenia: Slovenian Society of
(Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United Cardiology, Gregor Poglajen; Spain: Spanish Society of Cardiology,
Kingdom), Maja-Lisa Løchen (Norway), Alexander G. Mathioudakis María Lázaro Salvador; Sweden: Swedish Society of Cardiology,
(United Kingdom), Richard Mindham (United Kingdom), Shahin Stefan Söderberg; Switzerland: Swiss Society of Cardiology, Silvia
Moledina (United Kingdom), Robert Naeije (Belgium), Jens Cosedis Ulrich; Syrian Arab Republic: Syrian Cardiovascular Association,
Nielsen (Denmark), Horst Olschewski (Austria), Isabelle Opitz Mhd Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology
(Switzerland), Steffen E. Petersen (United Kingdom), Eva Prescott and Cardio-Vascular Surgery, Fatma Ouarda; Turkey: Turkish
(Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal), SocietyofCardiology,BulentMutlu;Ukraine:UkrainianAssociation
Arsen D. Ristić (Serbia), Nicolas Roche (France), Rita Rodrigues ofCardiology,YuriySirenko;UnitedKingdomofGreatBritain
(Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil), and Northern Ireland: British Cardiovascular Society, J. Gerry
Andrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United Coghlan; and Uzbekistan: Association of Cardiologists of
Kingdom), Silvia Ulrich (Switzerland), Martin R. Wilkins (United Uzbekistan,TimurAbdullaev.
Kingdom),andStephenJohnWort(UnitedKingdom).
ESC Clinical Practice Guidelines (CPG) Committee: Colin
ESCNationalCardiacSocietiesactivelyinvolvedinthereview Baigent(Chairperson)(UnitedKingdom),MagdyAbdelhamid(Egypt),
processofthe2022ESC/ERSGuidelinesforthediagnosisandtreat- Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena
ment of pulmonary hypertension: Algeria: Algerian Society of Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach
Cardiology, Messaad Krim; Armenia: Armenian Cardiologists (United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė
Association, Hamlet Hayrapetyan; Austria: Austrian Society of (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),
Cardiology, Irene Lang; Azerbaijan: Azerbaijan Society of Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale
Cardiology, Oktay Musayev; Belarus: Belorussian Scientific Society (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung
of Cardiologists, Irina Lazareva; Bosnia and Herzegovina: (France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian
Association of Cardiologists of Bosnia and Herzegovina, Šekib Federation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Vasil Velchev; (UnitedKingdom),UlfLandmesser(Germany),BasilS.Lewis(Israel),
Croatia: Croatian Cardiac Society, Maja Cikes; Cyprus: Cyprus Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard
SocietyofCardiology,IoannisMichaloliakos;Czechia:CzechSociety Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),
ofCardiology,PavelJansa;Denmark:DanishSocietyofCardiology, Steffen E. Petersen (United Kingdom), Eva Prescott (Denmark),
Søren Mellemkjær; Egypt: Egyptian Society of Cardiology, Ahmed Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian
Hassan; Estonia: Estonian Society of Cardiology, Ly Anton; M.Touyz(Canada/UnitedKingdom).
Finland: Finnish Cardiac Society, Markku Pentikäinen; France:
FrenchSocietyofCardiology,NicolasMeneveau;Georgia:Georgian Independent Research Methodologists: Rebecca L. Morgan
SocietyofCardiology,MikheilTsverava;Germany:GermanCardiac (UnitedStatesofAmerica)andKapeenaSivakumaran(Canada).
Society, Mareike Lankeit; Greece: Hellenic Society of Cardiology,
Athanasios Manginas; Hungary: Hungarian Society of Cardiology,
21. References
Istvan Hizoh; Ireland: Irish Cardiac Society, Vincent Maher; Israel:
Israel Heart Society, Rafael Hirsch; Italy: Italian Federation of
1.SimonneauG,MontaniD,CelermajerDS,DentonCP,GatzoulisMA,KrowkaM,
Cardiology, Nazzareno Galié; Kazakhstan: Association of etal.Haemodynamicdefinitionsandupdatedclinicalclassificationofpulmonary
CardiologistsofKazakhstan,MuratA.Mukarov;Kosovo(Republic hypertension.EurRespirJ2019;53:1801913.
2.GuyattG,OxmanAD,AklEA,KunzR,VistG,BrozekJ,etal.GRADEguidelines:
of): KosovoSocietyofCardiology, PranveraIbrahimi; Kyrgyzstan: 1.Introduction-GRADEevidenceprofilesandsummaryoffindingstables.JClin
Kyrgyz Society of Cardiology, Sooronbaev Talant, Latvia: Latvian Epidemiol2011;64:383–394.
Society of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society 3.Alonso-CoelloP,OxmanAD,MobergJ,Brignardello-PetersenR,AklEA,DavoliM,
etal.GRADEEvidencetoDecision(EtD)frameworks:asystematicandtranspar-
of Cardiology, Ghassan Kiwan; Lithuania: Lithuanian Society of
entapproachtomakingwellinformedhealthcarechoices.2:Clinicalpracticeguide-
Cardiology, Lina Gumbienė; Luxembourg: LuxembourgSocietyof lines.BMJ2016;353:i2089.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 96 ---
ESC/ERSGuidelines 3713
4.NagavciB,ToniaT,RocheN,GentonC,VaccaroV,HumbertM,etal.European 26.GalièN,HumbertM,VachieryJL,GibbsS,LangI,TorbickiA,etal.2015ESC/ERS
RespiratorySocietyclinicalpracticeguidelines:methodologicalguidance.ERJOpen Guidelinesforthediagnosisandtreatmentofpulmonaryhypertension:TheJoint
Res2022;8:0655–2021. TaskForcefortheDiagnosisandTreatmentofPulmonaryHypertensionofthe
5.SchünemannHB,GuyattG,OxmanA.GRADEhandbookforgradingqualityofevi- European Society of Cardiology (ESC) and the European Respiratory Society
denceandstrengthofrecommendations.TheGRADEWorkingGroup;2013. (ERS): Endorsed by: Association for European Paediatric and Congenital
6.MiravitllesM,ToniaT,RigauD,RocheN,GentonC,VaccaroV,etal.Newerafor Cardiology (AEPC), International Society for Heart and Lung Transplantation
EuropeanRespiratorySocietyclinicalpracticeguidelines:joiningefficiencyandhigh (ISHLT).EurHeartJ2016;37:67–119.
methodologicalstandards.EurRespirJ2018;51:1800221. 27.McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,BohmM,etal.2021
7.KovacsG,BergholdA,ScheidlS,OlschewskiH.Pulmonaryarterialpressureduring ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure.
restandexerciseinhealthysubjects:asystematicreview.EurRespirJ2009;34: EurHeartJ2021;42:3599–3726.
888–894. 28.VahanianA,BeyersdorfF,PrazF,MilojevicM,BaldusS,BauersachsJ,etal.2021
8.KovacsG,OlschewskiA,BergholdA,OlschewskiH.Pulmonaryvascularresis- ESC/EACTSGuidelinesforthemanagementofvalvularheartdisease.EurHeartJ
tancesduringexerciseinnormalsubjects:asystematicreview.EurRespirJ2012; 2022;43:561–632.
39:319–328. 29.HoeperMM,HumbertM,SouzaR,IdreesM,KawutSM,Sliwa-HahnleK,etal.A
9.WolskE,BakkestromR,ThomsenJH,BallingL,AndersenMJ,DahlJS,etal.Thein- globalviewofpulmonaryhypertension.LancetRespirMed2016;4:306–322.
fluenceofageonhemodynamicparametersduringrestandexerciseinhealthyin- 30.NHS Digital. National Audit of Pulmonary Hypertension 10th Annual Report,
dividuals.JACCHeartFail2017;5:337–346. Great Britain, 2018-19. https://digital.nhs.uk/data-and-information/publications/
10.Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. statistical/national-pulmonary-hypertension-audit/2019# (24 March 2022, date
Associationofborderlinepulmonaryhypertensionwithmortalityandhospitaliza- lastaccessed22July2022).
tion in a large patient cohort: insights from the Veterans Affairs Clinical 31.LeberL,BeaudetA,MullerA.Epidemiologyofpulmonaryarterialhypertensionand
Assessment,Reporting,andTrackingprogram.Circulation2016;133:1240–1248. chronicthromboembolicpulmonaryhypertension:identificationofthemostac-
11.DouschanP,KovacsG,AvianA,ForisV,GruberF,OlschewskiA,etal.Mildeleva- curate estimates from a systematic literature review. Pulm Circ 2021;11:
tionofpulmonaryarterialpressureasapredictorofmortality.AmJRespirCritCare 2045894020977300.
Med2018;197:509–516. 32.LauEMT,GiannoulatouE,CelermajerDS,HumbertM.Epidemiologyandtreat-
12.KolteD,LakshmananS,JankowichMD,BrittainEL,MaronBA,ChoudharyG.Mild
mentofpulmonaryarterialhypertension.NatRevCardiol2017;14:603–614.
pulmonaryhypertensionisassociatedwithincreasedmortality:asystematicreview 33.MontaniD,GirerdB,JaisX,LavenezianaP,LauEMT,BouchachiA,etal.Screening
andmeta-analysis.JAmHeartAssoc2018;7:e009729. forpulmonaryarterialhypertensioninadultscarryingaBMPR2mutation.TheEur
13.MaronBA,BrittainEL,HessE,WaldoSW,BaronAE,HuangS,etal.Pulmonary RespirJ2020;58:2004229.
34.Certain MC, Chaumais MC, Jais X, Savale L, Seferian A, Parent F, et al.
vascularresistanceandclinicaloutcomesinpatientswithpulmonaryhypertension:
aretrospectivecohortstudy.LancetRespirMed2020;8:873–884. Characteristicsandlong-termoutcomesofpulmonaryvenoocclusivediseasein-
ducedbymitomycinC.Chest2021;159:1197–1207.
14.XanthouliP,JordanS,MildeN,MarraA,BlankN,EgenlaufB,etal.Haemodynamic
35.CornetL,KhouriC,RoustitM,GuignabertC,ChaumaisMC,HumbertM,etal.
phenotypesandsurvivalinpatientswithsystemicsclerosis:theimpactofthenew
definitionofpulmonaryarterialhypertension.AnnRheumDis2020;79:370–378. Pulmonary arterial hypertension associated with protein kinase inhibitors: a
pharmacovigilance-pharmacodynamicstudy.EurRespirJ2019;53:1802472.
15.PaulusWJ,TschopeC,SandersonJE,RusconiC,FlachskampfFA,RademakersFE,
36.McGeeM,WhiteheadN,MartinJ,CollinsN.Drug-associatedpulmonaryarterial
etal.Howtodiagnosediastolicheartfailure:aconsensusstatementonthediagno-
hypertension.ClinToxicol2018;56:801–809.
sisofheartfailurewithnormalleftventricularejectionfractionbytheHeartFailure
37.McGregorPC,BoosalisV,AragamJ.Carfilzomib-inducedpulmonaryhypertension
andEchocardiographyAssociationsoftheEuropeanSocietyofCardiology.Eur
HeartJ2007;28:2539–2550. withassociatedrightventriculardysfunction:Acasereport.SAGEOpenMedCase
Rep2021;9:2050313X21994031.
16.PieskeB,TschopeC,deBoerRA,FraserAG,AnkerSD,DonalE,etal.Howto
38.MontaniD,LauEM,DescathaA,JaisX,SavaleL,AndujarP,etal.Occupationalex-
diagnoseheartfailurewithpreservedejectionfraction:theHFA-PEFFdiagnostical-
posuretoorganicsolvents:ariskfactorforpulmonaryveno-occlusivedisease.Eur
gorithm:aconsensusrecommendationfromtheHeartFailureAssociation(HFA) RespirJ2015;46:1721–1731.
oftheEuropeanSocietyofCardiology(ESC).EurHeartJ2019;40:3297–3317.
39.SavaleL,ChaumaisMC,CottinV,BergotE,FrachonI,PrevotG,etal.Pulmonary
17.ZederK,BanfiC,Steinrisser-AllexG,MaronBA,HumbertM,LewisGD,etal.
hypertension associated with benfluorex exposure. Eur Respir J 2012;40:
Diagnostic,prognosticanddifferential-diagnosticrelevanceofpulmonaryhemo- 1164–1172.
dynamicsduringexercise-asystematicreview.EurRespirJ2022;2:103181.
40.WeatheraldJ,BondeelleL,ChaumaisMC,GuignabertC,SavaleL,JaisX,etal.
18.HoJE,ZernEK,LauES,WoosterL,BaileyCS,CunninghamT,etal.Exercisepul-
PulmonarycomplicationsofBcr-Abltyrosinekinaseinhibitors.EurRespirJ2020;
monaryhypertensionpredictsclinicaloutcomesinpatientswithdyspneaoneffort.
56:2000279.
JAmCollCardiol2020;75:17–26.
41.PhilenRM,PosadaM.Toxicoilsyndromeandeosinophilia-myalgiasyndrome:May
19.StammA,SaxerS,LichtblauM,HaslerED,JordanS,HuberLC,etal.Exercisepul- 8–10,1991,WorldHealthOrganizationmeetingreport.SeminArthritisRheum
monaryhaemodynamicspredictoutcomeinpatientswithsystemicsclerosis.Eur 1993;23:104–124.
RespirJ2016;48:1658–1667.
42.HertzmanPA,ClauwDJ,KaufmanLD,VargaJ,SilverRM,ThackerHL,etal.The
20.HaslerED,Muller-MottetS,FurianM,SaxerS,HuberLC,MaggioriniM,etal.
eosinophilia-myalgiasyndrome:statusof205patientsandresultsoftreatment2
Pressure-flowduringexercisecatheterizationpredictssurvivalinpulmonaryhyper-
yearsafteronset.AnnInternMed1995;122:851–855.
tension.Chest2016;150:57–67.
43.WalkerAM,LanglebenD,KorelitzJJ,RichS,RubinLJ,StromBL,etal.Temporal
21.LewisGD,MurphyRM,ShahRV,PappagianopoulosPP,MalhotraR,BlochKD,etal. trendsanddrugexposuresinpulmonaryhypertension:anAmericanexperience.
Pulmonaryvascularresponsepatternsduringexerciseinleftventricularsystolic AmHeartJ2006;152:521–526.
dysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011;4: 44.ChenSC,DastamaniA,PintusD,YauD,AftabS,BathL,etal.Diazoxide-induced
276–285.
pulmonaryhypertensioninhyperinsulinaemichypoglycaemia:Recommendations
22.ZederK,AvianA,BachmaierG,DouschanP,ForisV,SassmannT,etal.Exercise fromamulticentrestudyintheUK.ClinEndocrinol(Oxf)2019;91:770–775.
pulmonary resistances predict long-term survival in systemic sclerosis. Chest 45.TimlinMR,BlackAB,DelaneyHM,MatosRI,PercivalCS.Developmentofpulmon-
2021;159:781–790.
aryhypertensionduringtreatmentwithdiazoxide:acaseseriesandliteraturere-
23.EismanAS,ShahRV,DhakalBP,PappagianopoulosPP,WoosterL,BaileyC,etal. view.PediatrCardiol2017;38:1247–1250.
Pulmonarycapillarywedgepressurepatternsduringexercisepredictexercisecap- 46.GlobalBurdenofDiseaseStudyCollaborators.Global,regional,andnationalinci-
acityandincidentheartfailure.CircHeartFail2018;11:e004750. dence,prevalence,andyearslivedwithdisabilityfor301acuteandchronicdiseases
24.BentleyRF,BarkerM,EsfandiariS,WrightSP,ValleFH,GrantonJT,etal.Normal and injuries in 188 countries, 1990-2013: a systematic analysis for the Global
andabnormalrelationshipsofpulmonaryarterytowedgepressureduringexercise. BurdenofDiseaseStudy2013.Lancet2015;386:743–800.
JAmHeartAssoc2020;9:e016339. 47.RosenkranzS,GibbsJS,WachterR,DeMarcoT,Vonk-NoordegraafA,VachieryJL.
25.GalièN,HumbertM,VachieryJL,GibbsS,LangI,TorbickiA,etal.2015ESC/ERS Leftventricularheartfailureandpulmonaryhypertension.EurHeartJ2016;37:
Guidelinesforthediagnosisandtreatmentofpulmonaryhypertension:TheJoint 942–954.
TaskForcefortheDiagnosisandTreatmentofPulmonaryHypertensionofthe 48.LamCS,RogerVL,RodehefferRJ,BorlaugBA,EndersFT,RedfieldMM.Pulmonary
European Society of Cardiology (ESC) and the European Respiratory Society hypertensioninheartfailurewithpreservedejectionfraction:acommunity-based
(ERS): Endorsed by: Association for European Paediatric and Congenital study.JAmCollCardiol2009;53:1119–1126.
Cardiology (AEPC), International Society for Heart and Lung Transplantation 49.TichelbackerT,DumitrescuD,GerhardtF,SternD,WissmullerM,AdamM,etal.
(ISHLT).EurRespirJ2015;46:903–975. Pulmonaryhypertensionandvalvularheartdisease.Herz2019;44:491–501.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 97 ---
3714 ESC/ERSGuidelines
50. Weber L, Rickli H, Haager PK, Joerg L, Weilenmann D, Brenner R, et al. 75.HoeperMM,MeyerK,RademacherJ,FugeJ,WelteT,OlssonKM.Diffusioncap-
Haemodynamic mechanisms and long-term prognostic impact of pulmonary acityandmortalityinpatientswithpulmonaryhypertensionduetoheartfailure
hypertensioninpatientswithsevereaorticstenosisundergoingvalvereplacement. withpreservedejectionfraction.JACCHeartFail2016;4:441–449.
EurJHeartFail2019;21:172–181. 76.OlsonTP,JohnsonBD,BorlaugBA.Impairedpulmonarydiffusioninheartfailure
51. HurdmanJ,CondliffeR,ElliotCA,SwiftA,RajaramS,DaviesC,etal.Pulmonary withpreservedejectionfraction.JACCHeartFail2016;4:490–498.
hypertensioninCOPD:resultsfromtheASPIREregistry.EurRespirJ2013;41: 77.OlssonKM,FugeJ,MeyerK,WelteT,HoeperMM.Moreonidiopathicpulmonary
1292–1301. arterialhypertensionwithalowdiffusingcapacity.EurRespirJ2017;50:1700354.
52. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. 78.TripP,NossentEJ,deManFS,vandenBerkIA,BoonstraA,GroepenhoffH,etal.
Pulmonaryhypertensioninchroniclungdiseaseandhypoxia.EurRespirJ2019; Severelyreduceddiffusioncapacityinidiopathicpulmonaryarterialhypertension:
53:1801914. patientcharacteristicsandtreatmentresponses.EurRespirJ2013;42:1575–1585.
53. NaeijeR.Pulmonaryhypertensionathighaltitude.EurRespirJ2019;53:1900985. 79.MelotC,NaeijeR.Pulmonaryvasculardiseases.ComprPhysiol2011;1:593–619.
54. DelcroixM,TorbickiA,GopalanD,SitbonO,KlokFA,LangI,etal.ERSstatement 80.HarbaumL,FugeJ,KampJC,HennigsJK,SimonM,SinningC,etal.Bloodcarbon
on chronic thromboembolic pulmonary hypertension. Eur Respir J 2020;57: dioxidetensionandriskinpulmonaryarterialhypertension.IntJCardiol2020;318:
2002828. 131–137.
55. KrammT,WilkensH,FugeJ,SchäfersH-J,GuthS,WiedenrothCB,etal.Incidence 81.JilwanFN,EscourrouP,GarciaG,JaisX,HumbertM,RoismanG.Highoccurrence
and characteristics of chronic thromboembolic pulmonary hypertension in ofhypoxemicsleeprespiratorydisordersinprecapillarypulmonaryhypertension
Germany. Clinical research in cardiology: official journal of the German Cardiac andmechanisms.Chest2013;143:47–55.
Society1–6(2018)doi:10.1007/s00392-018-1215-5. 82.RudskiLG,LaiWW,AfilaloJ,HuaL,HandschumacherMD,ChandrasekaranK,
56. SwietlikEM,RuggieroA,FletcherAJ,TaboadaD,KnightbridgeE,HarlowL,etal. etal.Guidelinesfortheechocardiographicassessmentoftherightheartinadults:
Limitationsofrestinghaemodynamicsinchronicthromboembolicdiseasewithout a report from the American Society of Echocardiography endorsed by the
pulmonaryhypertension.EurRespirJ2019;53:1801787. EuropeanAssociationofEchocardiography,aregisteredbranchoftheEuropean 57. KalantariS,Gomberg-MaitlandM.Group5pulmonaryhypertension:theorphan’s SocietyofCardiology,andtheCanadianSocietyofEchocardiography.JAmSoc
orphandisease.CardiolClin2016;34:443–449. Echocardiogr2010;23:685–713.
58. ShlobinOA,KouranosV,BarnettSD,AlhamadEH,CulverDA,BarneyJ,etal. 83.Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al.
Physiologicalpredictorsofsurvivalinpatientswithsarcoidosis-associatedpulmon- Recommendationsforcardiacchamberquantificationbyechocardiographyinadults:
ary hypertension: results from an international registry. Eur Respir J 2020;55:
an update from the American Society of Echocardiography and the European
1901747. AssociationofCardiovascularImaging.EurHeartJCardiovascImaging2015;16:233–270.
59. BouclyA,CottinV,NunesH,JaisX,TaziA,PrevotG,etal.Managementandlong-
84.GalderisiM,CosynsB,EdvardsenT,CardimN,DelgadoV,DiSalvoG,etal.
term outcomesof sarcoidosis-associated pulmonary hypertension. EurRespir J
Standardizationofadulttransthoracicechocardiographyreportinginagreement
2017;50:1700465. withrecentchamberquantification,diastolicfunction,andheartvalvediseasere-
60. RichS,DantzkerDR,AyresSM,BergofskyEH,BrundageBH,DetreKM,etal.
commendations:anexpertconsensusdocumentoftheEuropeanAssociationof
Primarypulmonaryhypertension.Anationalprospectivestudy.AnnInternMed CardiovascularImaging.EurHeartJCardiovascImaging2017;18:1301–1310.
1987;107:216–223.
85.FarberHW,ForemanAJ,MillerDP,McGoonMD.REVEALRegistry:correlationof
61. JingZC,XuXQ,HanZY,WuY,DengKW,WangH,etal.Registryandsurvival
rightheartcatheterizationandechocardiographyinpatientswithpulmonaryarter-
studyinChinesepatientswithidiopathicandfamilialpulmonaryarterialhyperten- ialhypertension.CongestHeartFail2011;17:56–64.
sion.Chest2007;132:373–379.
86.ArcasoySM,ChristieJD,FerrariVA,SuttonMS,ZismanDA,BlumenthalNP,etal.
62. GalièN,SaiaF,PalazziniM,ManesA,RussoV,BacchiReggianiML,etal.Leftmain
Echocardiographic assessment of pulmonary hypertension in patients with ad-
coronaryarterycompressioninpatientswithpulmonaryarterialhypertensionand
angina.JAmCollCardiol2017;69:2808–2817.
vancedlungdisease.AmJRespirCritCareMed2003;167:735–740.
87.FisherMR,ForfiaPR,ChameraE,Housten-HarrisT,ChampionHC,GirgisRE,etal.
63. KovacsG,AvianA,ForisV,TschernerM,KqikuX,DouschanP,etal.UseofECG
AccuracyofDopplerechocardiographyinthehemodynamicassessmentofpul-
andothersimplenon-invasivetoolstoassesspulmonaryhypertension.PLoSOne
monaryhypertension.AmJRespirCritCareMed2009;179:615–621
2016;11:e0168706.
88.D’Alto M, Di Maio M, Romeo E, Argiento P, Blasi E, Di Vilio A, et al.
64. BondermanD,WexbergP,MartischnigAM,HeinzlH,LangMB,SadushiR,etal.A
Echocardiographic probability of pulmonary hypertension: a validation study.
noninvasivealgorithmtoexcludepre-capillarypulmonaryhypertension.EurRespirJ
2011;37:1096–1103. Eur Respir J. 2022;2102548. doi:10.1183/13993003.02548-2021. Epub ahead of
print.
65. KlokFA,SurieS,KempfT,EikenboomJ,vanStraalenJP,vanKralingenKW,etal.A
89.JankowichM,MaronBA,ChoudharyG.Mildlyelevatedpulmonaryarterysystolic
simplenon-invasivediagnosticalgorithmforrulingoutchronicthromboembolic
pressure on echocardiography: bridging the gap in current guidelines. Lancet
pulmonary hypertension in patients after acute pulmonary embolism. Thromb
Res2011;128:21–26.
RespirMed2021;9:1185–1191.
90.Huston JH, Maron BA, French J, Huang S, Thayer T, Farber-Eger EH, et al.
66. HenkensIR,MouchaersKT,Vonk-NoordegraafA,BoonstraA,SwenneCA,Maan
AC,etal.ImprovedECGdetectionofpresenceandseverityofrightventricular Association of mild echocardiographic pulmonary hypertension with mortality
pressure load validated with cardiac magnetic resonance imaging. Am J Physiol
andrightventricularfunction.JAMACardiol2019;4:1112–1121.
HeartCircPhysiol2008;294:H2150–H2157. 91.GallH,YogeswaranA,FugeJ,SommerN,GrimmingerF,SeegerW,etal.Validityof
67. RichJD,ThenappanT,FreedB,PatelAR,ThistedRA,ChildersR,etal.QTcpro-
echocardiographictricuspidregurgitationgradienttoscreenfornewdefinitionof
longationisassociatedwithimpairedrightventricularfunctionandpredictsmortal- pulmonaryhypertension.EClinMed2021;34:100822.
ityinpulmonaryhypertension.IntJCardiol2013;167:669–676. 92.D’AltoM,RomeoE,ArgientoP,D’AndreaA,VanderpoolR,CorreraA,etal.
68. Remy-JardinM,RyersonCJ,SchieblerML,LeungANC,WildJM,HoeperMM,etal. Accuracyandprecisionof echocardiographyversusright heartcatheterization
Imagingofpulmonaryhypertensioninadults:apositionpaperfromtheFleischner fortheassessmentofpulmonaryhypertension.IntJCardiol2013;168:4058–4062.
Society.EurRespirJ2021;57:2004455. 93.FonsecaGH,SouzaR,SalemiVM,JardimCV,GualandroSF.Pulmonaryhyperten-
69. AschaM,RenapurkarRD,TonelliAR.Areviewofimagingmodalitiesinpulmonary siondiagnosedbyrightheartcatheterisationinsicklecelldisease.EurRespirJ2012;
hypertension.AnnThoracMed2017;12:61–73. 39:112–118.
70. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. 94.ParentF,BachirD,InamoJ,LionnetF,DrissF,LokoG,etal.Ahemodynamicstudy
Definitionsanddiagnosisofpulmonaryhypertension.JAmCollCardiol2013;62: ofpulmonaryhypertensioninsicklecelldisease.NEnglJMed2011;365:44–53.
D42–D50. 95.GrunigE,HennP,D’AndreaA,ClaussenM,EhlkenN,MaierF,etal.Referenceva-
71. SunXG,HansenJE,OudizRJ,WassermanK.Pulmonaryfunctioninprimarypul- luesforanddeterminantsofrightatrialareainhealthyadultsby2-dimensional
monaryhypertension.JAmCollCardiol2003;41:1028–1035. echocardiography.CircCardiovascImaging2013;6:117–124.
72. MeyerFJ,EwertR,HoeperMM,OlschewskiH,BehrJ,WinklerJ,etal.Peripheral 96.TelloK,WanJ,DalmerA,VanderpoolR,GhofraniHA,NaeijeR,etal.Validationof
airwayobstructioninprimarypulmonaryhypertension.Thorax2002;57:473–476. thetricuspidannularplanesystolicexcursion/systolicpulmonaryarterypressure
73. Alonso-GonzalezR,BorgiaF,DillerGP,InuzukaR,KempnyA,Martinez-NaharroA, ratiofortheassessmentofrightventricular-arterialcouplinginseverepulmonary
etal.Abnormallungfunctioninadultswithcongenitalheartdisease:prevalence,rela- hypertension.CircCardiovascImaging2019;12:e009047.
tiontocardiacanatomy,andassociationwithsurvival.Circulation2013;127:882–890. 97.TelloK,AxmannJ,GhofraniHA,NaeijeR,NarcinN,RiethA,etal.Relevanceofthe
74. Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, et al. TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 2018;266:
Phenotypingofidiopathicpulmonaryarterialhypertension:aregistryanalysis.Lancet 229–235.
Respir Med 2022. Jun 28:S2213-2600(22)00097-2. doi: 10.1016/S2213-2600(22) 98.GuazziM,DixonD,LabateV,Beussink-NelsonL,BanderaF,CutticaMJ,etal.RV
00097-2.Epubaheadofprint.PMID:35777416 contractilefunctionanditscouplingtopulmonarycirculationinheartfailurewith
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 98 ---
ESC/ERSGuidelines 3715
preservedejection fraction: stratification of clinicalphenotypes andoutcomes. 120. SunXG,HansenJE,OudizRJ,WassermanK.Exercisepathophysiologyinpatients
JACCCardiovascImaging2017;10:1211–1221. withprimarypulmonaryhypertension.Circulation2001;104:429–435.
99.ArklesJS,OpotowskyAR,OjedaJ,RogersF,LiuT,PrassanaV,etal.Shapeofthe 121. BoerrigterBG,BogaardHJ,TripP,GroepenhoffH,RietemaH,HolverdaS,etal.
rightventricularDopplerenvelopepredictshemodynamicsandrightheartfunction VentilatoryandcardiocirculatoryexerciseprofilesinCOPD:theroleofpulmonary
inpulmonaryhypertension.AmJRespirCritCareMed2011;183:268–276. hypertension.Chest2012;142:1166–1174.
100.TakahamaH,McCullyRB,FrantzRP,KaneGC.UnravelingtheRVejectionDoppler 122. CaravitaS,FainiA,DeboeckG,BondueA,NaeijeR,ParatiG,etal.Pulmonary
envelope:insightintopulmonaryarteryhemodynamicsanddiseaseseverity.JACC hypertensionandventilationduringexercise:roleofthepre-capillarycomponent.
CardiovascImaging2017;10:1268–1277. JHeartLungTransplant2017;36:754–762.
101.BaumgartnerH,DeBackerJ,Babu-NarayanSV,BudtsW,ChessaM,DillerGP,etal. 123. Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, et al.
2020ESCGuidelinesforthemanagementofadultcongenitalheartdisease.Eur Cardiopulmonaryexercisetestingfordetectingpulmonaryarterialhypertension
HeartJ2021;42:563–645. insystemicsclerosis.Heart2017;103:774–782.
102.KimNH,DelcroixM,JaisX,MadaniMM,MatsubaraH,MayerE,etal.Chronic 124. MehraMR,CanterCE,HannanMM,SemigranMJ,UberPA,BaranDA,etal.The
thromboembolicpulmonaryhypertension.EurRespirJ2019;53:1801915. 2016InternationalSocietyforHeartLungTransplantationlistingcriteriaforheart
103.KonstantinidesSV,MeyerG,BecattiniC,FauuenoH,BuenoH,GeersingGJ,etal. transplantation:a10-yearupdate.JHeartLungTransplant2016;35:1–23.
2019ESCGuidelinesforthediagnosisandmanagementofacutepulmonaryem- 125. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al.
bolismdevelopedincollaborationwiththeEuropeanRespiratorySociety(ERS). Complicationsofrightheartcatheterizationproceduresinpatientswithpulmon-
EurHeartJ2020;41:543–603. aryhypertensioninexperiencedcenters.JAmCollCardiol2006;48:2546–2552.
104.HeJ,FangW,LvB,HeJG,XiongCM,LiuZH,etal.Diagnosisofchronicthrombo- 126. KovacsG,AvianA,OlschewskiA,OlschewskiH.Zeroreferencelevelforright
embolic pulmonary hypertension: comparison of ventilation/perfusion scanning heartcatheterisation.EurRespirJ2013;42:1586–1594.
andmultidetectorcomputedtomographypulmonaryangiographywithpulmonary 127. OpotowskyAR,HessE,MaronBA,BrittainEL,BaronAE,MaddoxTM,etal.
angiography.NuclMedCommun2012;33:459–463. ThermodilutionvsestimatedFickcardiacoutputmeasurementinclinicalpractice:
105.Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. ananalysisofmortalityfromtheVeteransAffairsClinicalAssessment,Reporting,
Ventilation-perfusionscintigraphyismoresensitivethanmultidetectorCTPAin andTracking(VACART)ProgramandVanderbiltUniversity.JAMACardiol2017;
detectingchronicthromboembolicpulmonarydiseaseasatreatablecauseofpul- 2:1090–1099.
monaryhypertension.JNuclMed2007;48:680–684. 128. VirayMC,BonnoEL,GabrielleND,MaronBA,AtkinsJ,AmorosoNS,etal.Roleof
106.GiordanoJ,KhungS,DuhamelA,Hossein-FoucherC,BellevreD,LamblinN,etal. pulmonaryarterywedgepressuresaturationduringrightheartcatheterization:a
Lungperfusioncharacteristicsinpulmonaryarterialhypertension(PAH)andper- prospectivestudy.CircHeartFail2020;13:e007981.
ipheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH): 129. SitbonO,HumbertM,JaisX,IoosV,HamidAM,ProvencherS,etal.Long-term
dual-energyCTexperiencein31patients.EurRadiol2017;27:1631–1639. responsetocalciumchannelblockersinidiopathicpulmonaryarterialhyperten-
107.SeferianA,HelalB,JaisX,GirerdB,PriceLC,GuntherS,etal.Ventilation/perfusion sion.Circulation2005;111:3105–3111.
lungscaninpulmonaryveno-occlusivedisease.EurRespirJ2012;40:75–83. 130. HoeperMM,OlschewskiH,GhofraniHA,WilkensH,WinklerJ,BorstMM,etal.A
108.SwiftAJ,DwivediK,JohnsC,GargP,ChinM,CurrieBJ,etal.Diagnosticaccuracyof comparisonoftheacutehemodynamiceffectsofinhalednitricoxideandaerosol-
CTpulmonaryangiographyinsuspectedpulmonaryhypertension.EurRadiol2020; izediloprostinprimarypulmonaryhypertension.GermanPPHstudygroup.JAm
30:4918–4929. CollCardiol2000;35:176–182.
109.DongC,ZhouM,LiuD,LongX,GuoT,KongX.Diagnosticaccuracyofcomputed 131. OpitzCF,WenselR,BettmannM,SchaffarczykR,LinscheidM,HetzerR,etal.
tomographyforchronicthromboembolicpulmonaryhypertension:asystematic Assessment of the vasodilator response in primary pulmonary hypertension.
reviewandmeta-analysis.PLoSOne2015;10:e0126985. Comparingprostacyclinandiloprostadministeredbyeitherinfusionorinhalation.
110.RajaramS,SwiftAJ,CapenerD,TelferA,DaviesC,HillC,etal.Diagnosticaccuracy EurHeartJ2003;24:356–365.
ofcontrast-enhancedMRangiographyandunenhancedprotonMRimagingcom- 132. JingZC,JiangX,HanZY,XuXQ,WangY,WuY,etal.Iloprostforpulmonaryvaso-
paredwithCTpulmonary angiographyinchronicthromboembolicpulmonary dilatortestinginidiopathicpulmonaryarterialhypertension.EurRespirJ2009;33:
hypertension.EurRadiol2012;22:310–317. 1354–1360.
111.Ende-VerhaarYM,MeijboomLJ,KroftLJM,BeenenLFM,BoonGJAM,Middeldorp 133. KovacsG,HerveP,BarberaJA,ChaouatA,ChemlaD,CondliffeR,etal.Anofficial
S,etal.Usefulnessofstandardcomputedtomographypulmonaryangiographyper- EuropeanRespiratorySocietystatement:pulmonaryhaemodynamicsduringexer-
formed for acute pulmonary embolism for identification of chronic thrombo- cise.EurRespirJ2017;50:1700578.
embolicpulmonaryhypertension:resultsoftheInShapeIIIstudy.JHeartLung 134. ClaeysM,ClaessenG,LaGercheA,PetitT,BelgeC,MeynsB,etal.Impairedcar-
Transplant2019;38:731–738. diacreserveandabnormalvascularloadlimitexercisecapacityinchronicthrombo-
112.Guerin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, et al. embolicdisease.JACCCardiovascImaging2019;12:1444–1456.
Prevalenceofchronicthromboembolicpulmonaryhypertensionafteracutepul- 135. Guth S, Wiedenroth CB, Rieth A, Richter MJ, Gruenig E, Ghofrani HA, et al.
monary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Exerciserightheartcatheterizationbeforeandafterpulmonaryendarterectomy
Haemost2014;112:598–605. inpatientswithchronicthromboembolicdisease.EurRespirJ2018;52:1800458.
113.Tamura M, Yamada Y, Kawakami T, Kataoka M, Iwabuchi Y, Sugiura H, et al. 136. GodinasL,LauEM,ChemlaD,LadorF,SavaleL,MontaniD,etal.Diagnosticcon-
DiagnosticaccuracyoflungsubtractioniodinemappingCTfortheevaluationof cordanceofdifferentcriteriaforexercisepulmonaryhypertensioninsubjectswith
pulmonaryperfusioninpatientswithchronicthromboembolicpulmonaryhyper- normalrestingpulmonaryarterypressure.EurRespirJ2016;48:254–257.
tension:correlationwithperfusionSPECT/CT.IntJCardiol2017;243:538–543. 137. Naeije R, Vanderpool R, Dhakal BP, Saggar R, Saggar R, Vachiery JL, et al.
114.MasyM,GiordanoJ,PetytG,Hossein-FoucherC,DuhamelA,KyhengM,etal. Exercise-inducedpulmonaryhypertension:physiologicalbasisandmethodological
Dual-energyCT(DECT)lungperfusioninpulmonaryhypertension:concordance concerns.AmJRespirCritCareMed2013;187:576–583.
rate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary 138. NishimuraRA,OttoCM,BonowRO,CarabelloBA,ErwinJPIII,GuytonRA,etal.
hypertension(CTEPH).EurRadiol2018;28:5100–5110. 2014AHA/ACCguidelineforthemanagementofpatientswithvalvularheartdis-
115.HinrichsJB,MarquardtS,vonFalckC,HoeperMM,OlssonKM,WackerFK,etal. ease:areportoftheAmericanCollegeofCardiology/AmericanHeartAssociation
ComparisonofC-armcomputedtomographyanddigitalsubtractionangiography TaskForceonPracticeGuidelines.JThoracCardiovascSurg2014;148:e1–e132.
in patients with chronic thromboembolic pulmonary hypertension. Cardiovasc 139. EsfandiariS,WrightSP,GoodmanJM,SassonZ,MakS.Pulmonaryarterywedge
InterventRadiol2016;39:53–63. pressurerelativetoexerciseworkrateinoldermenandwomen.MedSciSports
116.HinrichsJB,RenneJ,HoeperMM,OlssonKM,WackerFK,MeyerBC.Balloonpul- Exerc2017;49:1297–1304.
monaryangioplasty:applicabilityofC-ArmCTforprocedureguidance.EurRadiol 140. BoerrigterBG,WaxmanAB,WesterhofN,Vonk-NoordegraafA,SystromDM.
2016;26:4064–4071. MeasuringcentralpulmonarypressuresduringexerciseinCOPD:howtocope
117.SwiftAJ,LuH,UthoffJ,GargP,CoglianoM,TaylorJ,etal.Amachinelearningcar- withrespiratoryeffects.EurRespirJ2014;43:1316–1325.
diacmagneticresonanceapproachtoextractdiseasefeaturesandautomatepul- 141. Andersen MJ, Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Dahl JS, et al.
monaryarterialhypertensiondiagnosis.EurHeartJCardiovascImaging2021;22: Hemodynamicresponsetorapidsalineinfusioncomparedwithexerciseinhealthy
236–245. participantsaged20–80years.JCardiacFailure2019;25:902–910.
118.ConnorsJM.Thrombophiliatestingandvenousthrombosis.NEnglJMed2017; 142. Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al.
377:2298. Pulmonaryhypertensionduetoleftheartdisease.EurRespirJ2019;53:1801897.
119.RosenkranzS,HowardLS,Gomberg-MaitlandM,HoeperMM.Systemicconse- 143. D’AltoM,RomeoE,ArgientoP,MotojiY,CorreraA,DiMarcoGM,etal.Clinical
quences of pulmonary hypertension and right-sided heart failure. Circulation relevanceoffluidchallengeinpatientsevaluatedforpulmonaryhypertension.Chest
2020;141:678–693. 2017;151:119–126.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 99 ---
3716 ESC/ERSGuidelines
144. van de Bovenkamp AA, Wijkstra N, Oosterveer FPT, Vonk Noordegraaf A, 168. Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al.
BogaardHJ,vanRossumAC,etal.Thevalueofpassivelegraiseduringrightheart Macitentanforthe treatmentofportopulmonary hypertension(PORTICO):a
catheterizationindiagnosingheartfailurewithpreservedejectionfraction.Circ multicentre,randomised,double-blind,placebo-controlled,phase4trial.Lancet
HeartFail2022;15:e008935. RespirMed2019;7:594–604.
145. D’AltoM,DimopoulosK,CoghlanJG,KovacsG,RosenkranzS,NaeijeR.Right 169. ArmstrongI,BillingsC,KielyDG,YorkeJ,HarriesC,ClaytonS,etal.Thepatient
heartcatheterizationforthediagnosisofpulmonaryhypertension:controversies experienceofpulmonaryhypertension:alargecross-sectionalstudyofUKpa-
andpracticalissues.HeartFailClin2018;14:467–477. tients.BMCPulmMed2019;19:67.
146. RichS,KaufmannE,LevyPS.Theeffectofhighdosesofcalcium-channelblockers 170. StrangeG,GabbayE,KermeenF,WilliamsT,CarringtonM,StewartS,etal.Time
onsurvivalinprimarypulmonaryhypertension.NEnglJMed1992;327:76–81. fromsymptomstodefinitivediagnosisofidiopathicpulmonaryarterialhyperten-
147. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. sion:thedelaystudy.PulmCirc2013;3:89–94.
Diagnosisanddifferentialassessmentofpulmonaryarterialhypertension.JAm 171. IvarssonB,JohanssonA,KjellstromB.Theodysseyfromsymptomtodiagnosisof
CollCardiol2004;43:40S–47S. pulmonaryhypertensionfromthepatientsandspousesperspective.JPrimCare
148. MorrellNW,AldredMA,ChungWK,ElliottCG,NicholsWC,SoubrierF,etal. Community Health 2021;12:21501327211029241. doi: 10.1177/
Geneticsandgenomicsofpulmonaryarterialhypertension.EurRespirJ2019;53: 21501327211029241
1801899. 172. KielyDG,LawrieA,HumbertM.Screeningstrategiesforpulmonaryarterialhyper-
149. GrafS,HaimelM,BledaM,HadinnapolaC,SouthgateL,LiW,etal.Identificationof tension.EurHeartJSuppl2019;21:K9–K20.
raresequencevariationunderlyingheritablepulmonaryarterialhypertension.Nat 173. CoghlanJG,DentonCP,GrunigE,BondermanD,DistlerO,KhannaD,etal.
Commun2018;9:1416. Evidence-baseddetectionofpulmonaryarterialhypertensioninsystemicsclerosis:
150. ZhuN,SwietlikEM,WelchCL,PauciuloMW,HagenJJ,ZhouX,etal.Rarevariant theDETECTstudy.AnnRheumDis2014;73:1340–1349.
analysisof4241pulmonaryarterialhypertensioncasesfromaninternationalcon- 174. WeatheraldJ,MontaniD,JevnikarM,JaisX,SavaleL,HumbertM.Screeningfor
sortiumimplicatesFBLN2,PDGFD,andraredenovovariantsinPAH.GenomeMed pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019;28:
2021;13:80. 190023.
151. SongJ,EichstaedtCA,VialesRR,BenjaminN,HarutyunovaS,FischerC,etal. 175. KrowkaMJ,FallonMB,KawutSM,FuhrmannV,HeimbachJK,RamsayMA,etal.
Identification of genetic defects in pulmonary arterial hypertension by a new InternationalLiverTransplantSocietyPracticeGuidelines:diagnosisandmanage-
genepaneldiagnostictool.ClinSci(Lond)2016;130:2043–2052. ment of hepatopulmonary syndrome and portopulmonary hypertension.
152. InternationalPPHC,LaneKB,MachadoRD,PauciuloMW,ThomsonJR,PhillipsJA Transplantation2016;100:1440–1452.
III,etal.HeterozygousgermlinemutationsinBMPR2,encodingaTGF-betarecep- 176. MancusoL,ScordatoF,PieriM,ValerioE,MancusoA.Managementofportopul-
tor,causefamilialprimarypulmonaryhypertension.NatGenet2000;26:81–84. monary hypertension: new perspectives. World J Gastroenterol 2013;19:
153. Bohnen MS, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, et al. 8252–8257.
Loss-of-function ABCC8 mutations in pulmonary arterial hypertension. Circ 177. SitbonO,Lascoux-CombeC,DelfraissyJF,YeniPG,RaffiF,DeZuttereD,etal.
GenomPrecisMed2018;11:e002087. PrevalenceofHIV-relatedpulmonaryarterialhypertensioninthecurrentanti-
154. MaL,Roman-CamposD,AustinED,EyriesM,SampsonKS,SoubrierF,etal.Ano- retroviraltherapyera.AmJRespirCritCareMed2008;177:108–113.
velchannelopathyinpulmonaryarterialhypertension.NEnglJMed2013;369: 178. Ende-VerhaarYM,CannegieterSC,VonkNoordegraafA,DelcroixM,PruszczykP,
351–361. MairuhuAT,etal.Incidenceofchronicthromboembolicpulmonaryhypertension
155. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, et al. afteracutepulmonaryembolism:acontemporaryviewofthepublishedliterature.
MoleculargeneticcharacterizationofSMADsignalingmoleculesinpulmonaryar- EurRespirJ2017;49:1601792.
terialhypertension.HumMutat2011;32:1385–1389. 179. Ende-VerhaarYM,HuismanMV,KlokFA.Toscreenornottoscreenforchronic
156. Garg A, Kircher M, Del Campo M, Amato RS, Agarwal AK, University of thromboembolic pulmonary hypertension after acute pulmonary embolism.
WashingtonCenterforMendelianGenomics.Wholeexomesequencingidentifies ThrombRes2017;151:1–7.
denovoheterozygousCAV1mutationsassociatedwithanovelneonatalonsetli- 180. KielyDG,DoyleO,DrageE,JennerH,SalvatelliV,DanielsFA,etal.Utilisingarti-
podystrophysyndrome.AmJMedGenetA2015;167A:1796–1806. ficialintelligencetodeterminepatientsatriskofararedisease:idiopathicpulmon-
157. Kerstjens-FrederikseWS,BongersEM,RoofthooftMT,LeterEM,DouwesJM,Van aryarterialhypertension.PulmCirc2019;9:2045894019890549.
Dijk A, et al. TBX4 mutations (small patella syndrome) are associated with 181. NathanSD,BehrJ,CollardHR,CottinV,HoeperMM,MartinezFJ,etal.Riociguat
childhood-onsetpulmonaryarterialhypertension.JMedGenet2013;50:500–506. foridiopathicinterstitialpneumonia-associatedpulmonaryhypertension(RISE-IIP):
158. EyriesM,MontaniD,GirerdB,PerretC,LeroyA,LonjouC,etal.EIF2AK4muta- a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019;7:
tions cause pulmonary veno-occlusive disease, a recessive form of pulmonary 780–790.
hypertension.NatGenet2014;46:65–69. 182. NagelC,HennP,EhlkenN,D’AndreaA,BlankN,BossoneE,etal.StressDoppler
159. SwietlikEM,GreeneD,ZhuN,MegyK,CoglianoM,RajaramS,etal.Bayesianin- echocardiographyforearlydetectionofsystemicsclerosis-associatedpulmonary
ferenceassociatesrareKDRvariantswithspecificphenotypesinpulmonaryarterial arterialhypertension.ArthritisResTher2015;17:165.
hypertension.CircGenomPrecisMed2020;14:e003155. 183. SemaluluT,RudskiL,HuynhT,LanglebenD,WangM,CanadianScleroderma
160. ChidaA,ShintaniM,YagiH,FujiwaraM,KojimaY,SatoH,etal.Outcomesofchild- ResearchGroup,etal.Anevidence-basedstrategytoscreenforpulmonaryarterial
hoodpulmonaryarterialhypertensioninBMPR2andALK1mutationcarriers.AmJ hypertensioninsystemicsclerosis.SeminArthritisRheum2020;50:1421–1427.
Cardiol2012;110:586–593. 184. VandecasteeleE,DriegheB,MelsensK,ThevissenK,DePauwM,DeschepperE,
161. HoeperMM,PauschC,GrünigE,KloseH,StaehlerG,HuscherD,etal.Idiopathic etal.Screeningforpulmonaryarterialhypertensioninanunselectedprospective
pulmonaryarterialhypertensionphenotypesdeterminedbyclusteranalysisfrom systemicsclerosiscohort.EurRespirJ2017;49:1602275.
theCOMPERAregistry.JHeartLungTranspl2020;39:1435–1444. 185. CoghlanJG,WolfM,DistlerO,DentonCP,DoelbergM,HarutyunovaS,etal.
162. BadagliaccaR,PosciaR,PezzutoB,PapaS,NonaA,ManconeM,etal.Pulmonary Incidenceofpulmonaryhypertensionanddeterminingfactorsinpatientswithsys-
arterialdilatationinpulmonaryhypertension:prevalenceandprognosticrelevance. temicsclerosis.EurRespirJ2018;51:1701197.
Cardiology2012;121:76–82. 186. HachullaE,GressinV,GuillevinL,CarpentierP,DiotE,SibiliaJ,etal.Earlydetection
163. Santaniello A, Casella R, Vicenzi M, Rota I, Montanelli G, De Santis M, et al. ofpulmonaryarterialhypertensioninsystemicsclerosis:aFrenchnationwidepro-
Cardiopulmonaryexercisetestinginacombinedscreeningapproachtoindividuate spectivemulticenterstudy.ArthritisRheum2005;52:3792–3800.
pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2020;59: 187. HumbertM,YaiciA,deGrooteP,MontaniD,SitbonO,LaunayD,etal.Screening
1581–1586. forpulmonaryarterialhypertensioninpatientswithsystemicsclerosis:clinicalchar-
164. AlbrechtT,BlomleyMJ,CosgroveDO,Taylor-RobinsonSD,JayaramV,Eckersley acteristicsatdiagnosisandlong-termsurvival.ArthritisRheum2011;63:3522–3530.
R,etal.Non-invasivediagnosisofhepaticcirrhosisbytransit-timeanalysisofan 188. ThakkarV,StevensW,PriorD,YoussefP,LiewD,GabbayE,etal.Theinclusionof
ultrasoundcontrastagent.Lancet1999;353:1579–1583. N-terminalpro-brainnatriureticpeptideinasensitivescreeningstrategyforsys-
165. CottinV,LePavecJ,PrevotG,MalH,HumbertM,SimonneauG,etal.Pulmonary temicsclerosis-relatedpulmonaryarterialhypertension:acohortstudy.Arthritis
hypertensioninpatientswithcombinedpulmonaryfibrosisandemphysemasyn- ResTher2013;15:R193.
drome.EurRespirJ2010;35:105–111. 189. HaoY,ThakkarV,StevensW,MorrisroeK,PriorD,RabusaC,etal.Acomparison
166. GalièN,BarberaJA,FrostAE,GhofraniHA,HoeperMM,McLaughlinVV,etal. ofthepredictiveaccuracyofthreescreeningmodelsforpulmonaryarterialhyper-
Initialuseofambrisentanplustadalafilinpulmonaryarterialhypertension.NEngl tensioninsystemicsclerosis.ArthritisResTher2015;17:7.
JMed2015;373:834–844. 190. Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S, et al.
167. PulidoT,AdzerikhoI,ChannickRN,DelcroixM,GalièN,GhofraniHA,etal. Epidemiologyanddiseasecharacteristicsofsystemicsclerosis-relatedpulmonary
Macitentanandmorbidityandmortalityinpulmonaryarterialhypertension.N arterialhypertension:resultsfromareal-lifescreeningprogramme.ArthritisRes
EnglJMed2013;369:809–818. Ther2017;19:42.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 100 ---
ESC/ERSGuidelines 3717
191.MorrisroeK,HuqM,StevensW,RabusaC,ProudmanSM,NikpourM,etal.Risk 214. HumbertM,SitbonO,YaiciA,MontaniD,O’CallaghanDS,JaisX,etal.Survivalin
factorsfordevelopmentofpulmonaryarterialhypertensioninAustraliansystemic incidentandprevalentcohortsofpatientswithpulmonaryarterialhypertension.
sclerosispatients:resultsfromalargemulticentercohortstudy.BMCPulmMed EurRespirJ2010;36:549–555.
2016;16:134. 215. McLaughlinVV,SitbonO,BadeschDB,BarstRJ,BlackC,GalièN,etal.Survivalwith
192.SmithV,VanhaeckeA,VandecasteeleE,GuerraM,PaolinoS,MelsensK,etal. first-linebosentaninpatientswithprimarypulmonaryhypertension.EurRespirJ
Nailfoldvideocapillaroscopyinsystemicsclerosis-relatedpulmonaryarterialhyper- 2005;25:244–249.
tension:asystematicliteraturereview.JRheumatol2020;47:888–895. 216. NickelN,GolponH,GreerM,KnudsenL,OlssonK,WesterkampV,etal.The
193.LarkinEK,NewmanJH,AustinED,HemnesAR,WheelerL,RobbinsIM,etal. prognosticimpactoffollow-upassessmentsinpatientswithidiopathicpulmonary
Longitudinalanalysiscastsdoubtonthepresenceofgeneticanticipationinheritable arterialhypertension.EurRespirJ2012;39:589–596.
pulmonaryarterialhypertension.AmJRespirCritCareMed2012;186:892–896. 217. AmsallemM,SweattAJ,AymamiMC,KuznetsovaT,SelejM,LuH,etal.Rightheart
194.ColleIO,MoreauR,GodinhoE,BelghitiJ,EttoriF,Cohen-SolalA,etal.Diagnosisof end-systolicremodelingindexstronglypredictsoutcomesinpulmonaryarterial
portopulmonaryhypertensionincandidatesforlivertransplantation:aprospective hypertension:comparison withvalidatedmodels.CircCardiovasc Imaging 2017;
study.Hepatology2003;37:401–409.
10:e005771.
195.KimWR,KrowkaMJ,PlevakDJ,LeeJ,RettkeSR,FrantzRP,etal.Accuracyof 218. RaymondRJ,HinderliterAL,WillisPW,RalphD,CaldwellEJ,WilliamsW,etal.
Dopplerechocardiographyintheassessmentofpulmonaryhypertensioninliver Echocardiographicpredictorsofadverseoutcomesinprimarypulmonaryhyper-
transplantcandidates.LiverTranspl2000;6:453–458. tension.JAmCollCardiol2002;39:1214–1219.
196.Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, et al. 219. BadagliaccaR,PapaS,ValliG,PezzutoB,PosciaR,ManziG,etal.Echocardiography
Echocardiographyforthedetectionofportopulmonaryhypertensioninlivertrans- combinedwithcardiopulmonaryexercisetestingforthepredictionofoutcomein
plantcandidates:ananalysisofcutoffvalues.LiverTranspl2013;19:602–610. idiopathicpulmonaryarterialhypertension.Chest2016;150:1313–1322.
197.Golpe R, Perez-de-Llano LA, Castro-Anon O, Vazquez-Caruncho M, 220. BadagliaccaR,PapaS,ManziG,MiottiC,LuongoF,SciomerS,etal.Usefulnessof
Gonzalez-JuanateyC,Veres-RacamondeA,etal.Rightventricledysfunctionand adding echocardiography of the right heart to risk-assessment scores in
pulmonaryhypertensioninhemodynamicallystablepulmonaryembolism.Respir prostanoid-treated pulmonary arterial hypertension. JACC Cardiovasc Imaging
Med2010;104:1370–1376.
2020;13:2054–2056.
198.Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. 221. ErnandeL,CottinV,LerouxPY,GirerdN,HuezS,MulliezA,etal.Rightisovolumic
Incidenceofchronicthromboembolicpulmonaryhypertensionafterpulmonary
contraction velocity predicts survival in pulmonary hypertension. J Am Soc
embolism.NEnglJMed2004;350:2257–2264.
Echocardiogr2013;26:297–306.
199.SimonneauG,HoeperMM.Evaluationoftheincidenceofrarediseases:difficulties
222. ForfiaPR,FisherMR,MathaiSC,Housten-HarrisT,HemnesAR,BorlaugBA,etal.
anduncertainties,theexampleofchronicthromboembolicpulmonaryhyperten-
Tricuspidannulardisplacementpredictssurvivalinpulmonaryhypertension.AmJ
sion.EurRespirJ2017;49:1602522. RespirCritCareMed2006;174:1034–1041.
200.Coquoz N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellrath JM, et al. 223. GhioS,MercurioV,FortuniF,ForfiaPR,GallH,GhofraniA,etal.Acomprehensive
MulticentreobservationalscreeningsurveyforthedetectionofCTEPHfollowing echocardiographicmethodforriskstratificationinpulmonaryarterialhyperten-
pulmonaryembolism.EurRespirJ2018;51:1702505.
sion.EurRespirJ2020;56:2000513.
201.Valerio LM, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L, et al.
224. SachdevA,VillarragaHR,FrantzRP,McGoonMD,HsiaoJF,MaaloufJF,etal.Right
FOCUS Investigators. Chronic thromboembolic pulmonary hypertension and
ventricular strainfor prediction of survival in patients with pulmonary arterial
impairmentafterpulmonaryembolism:theFOCUSstudy.EurHeartJ2022;43: hypertension.Chest2011;139:1299–1309.
3387–3398.
225. VonkNoordegraafA,ChinKM,HaddadF,HassounPM,HemnesAR,HopkinsSR,
202.NijkeuterM,HovensMM,DavidsonBL,HuismanMV.Resolutionofthromboem-
etal.Pathophysiologyoftherightventricleandofthepulmonarycirculationinpul-
boliinpatientswithacutepulmonaryembolism:asystematicreview.Chest2006;
129:192–197. monaryhypertension:anupdate.EurRespirJ2019;53:1801900.
226. BatalO,DardariZ,CostabileC,GorcsanJ,ArenaVC,MathierMA.Prognosticva-
203.SanchezO,HelleyD,CouchonS,RouxA,DelavalA,TrinquartL,etal.Perfusion
defectsafterpulmonaryembolism:riskfactorsandclinicalsignificance.JThromb lueofpericardialeffusiononserialechocardiogramsinpulmonaryarterialhyper-
Haemost2010;8:1248–1255.
tension.Echocardiography2015;32:1471–1476.
227. ChenL,LarsenCM,LeRJ,ConnollyHM,PislaruSV,MurphyJG,etal.Theprognos-
204.WartskiM,CollignonMA.Incompleterecoveryoflungperfusionafter3monthsin
ticsignificanceoftricuspidvalveregurgitationinpulmonaryarterialhypertension.
patients with acute pulmonary embolism treated with antithrombotic agents.
THESEEStudyGroup.Tinzaparinouheparinstandard:evaluationdansl’Embolie
ClinRespirJ2018;12:1572–1580.
Pulmonairestudy.JNuclMed2000;41:1043–1048. 228. FenstadER,LeRJ,SinakLJ,Maradit-KremersH,AmmashNM,AyalewAM,etal.
Pericardialeffusionsinpulmonaryarterialhypertension:characteristics,prognosis,
205.NilssonLT,AnderssonT,LarsenF,LangIM,LivP,SoderbergS.Dyspneaafterpul-
androleofdrainage.Chest2013;144:1530–1538.
monaryembolism:anation-widepopulation-basedcase-controlstudy.PulmCirc
229. BadagliaccaR,PosciaR,PezzutoB,PapaS,RealiM,PesceF,etal.Prognosticrele-
2021;11:20458940211046831.
vanceofrightheartreverseremodelinginidiopathicpulmonaryarterialhyperten-
206.Boon G, Ende-Verhaar YM, Bavalia R, El Bouazzaoui LH, Delcroix M,
Dzikowska-Diduch O,etal.Non-invasiveearlyexclusionofchronicthrombo-
sion.JHeartLungTranspl2018;37:195–205.
embolicpulmonaryhypertensionafteracutepulmonaryembolism:theInShapeII 230. BadanoLP,AddetiaK,PontoneG,TorlascoC,LangRM,ParatiG,etal.Advanced
study.Thorax2021;76:1002–1009. imagingofrightventricularanatomyandfunction.Heart2020;106:1469–1476.
207.HelmersenD,ProvencherS,HirschAM,VanDamA,DennieC,dePerrotM,etal. 231. Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, et al.
Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian
Identificationofcardiacmagneticresonanceimagingthresholdsforriskstratifica-
Thoracic Society clinical practice guideline update. Can J Respir Crit Care Sleep tion in pulmonary arterial hypertension. Am J Respir Crit Care Med 2020;201:
Med2019;3:177–198. 458–466.
208.DelcroixM,KerrK,FedulloP.Chronicthromboembolicpulmonaryhypertension. 232. SwiftAJ,CapenerD,JohnsC,HamiltonN,RothmanA,ElliotC,etal.Magneticres-
Epidemiologyandriskfactors.AnnAmThoracSoc2016;13:S201–S206. onanceimagingintheprognosticevaluationofpatientswithpulmonaryarterial
209.KlokFA,TescheC,RappoldL,DellasC,HasenfussG,HuismanMV,etal.Externalval-
hypertension.AmJRespirCritCareMed2017;196:228–239.
idationofasimplenon-invasivealgorithmtoruleoutchronicthromboembolicpulmon- 233. vandeVeerdonkMC,KindT,MarcusJT,MauritzGJ,HeymansMW,BogaardHJ,
aryhypertensionafteracutepulmonaryembolism.ThrombRes2015;135:796–801. etal.Progressiverightventriculardysfunctioninpatientswithpulmonaryarterial
210.BarstRJ,ChungL,ZamanianRT,TurnerM,McGoonMD.Functionalclassimprove- hypertensionrespondingtotherapy.JAmCollCardiol2011;58:2511–2519.
mentand3-yearsurvivaloutcomesinpatientswithpulmonaryarterialhyperten- 234. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG,
sionintheREVEALRegistry.Chest2013;144:160–168. Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume,
211.NickelN,GolponH,GreerM,KnudsenL,OlssonK,WesterkampV,etal.The andfunctioninidiopathicpulmonaryarterialhypertension.EurHeartJ2007;28:
prognosticimpactoffollow-upassessmentsinpatientswithidiopathicpulmonary 1250–1257.
arterialhypertension.EurRespirJ2012;39:589–596. 235. AlabedS,ShahinY,GargP,AlandejaniF,JohnsCS,LewisRA,etal.Cardiac-MRI
212.SitbonO,HumbertM,NunesH,ParentF,GarciaG,HerveP,etal.Long-termintra- predictsclinicalworseningandmortalityinpulmonaryarterialhypertension:asys-
venousepoprostenolinfusioninprimarypulmonaryhypertension:prognosticfac- tematicreviewandmeta-analysis.JACCCardiovascImaging2021;14:931–942.
torsandsurvival.JAmCollCardiol2002;40:780–788. 236. SwiftAJ,WilsonF,CoglianoM,KendallL,AlandejaniF,AlabedS,etal.Repeatability
213.BenzaRL,MillerDP,Gomberg-MaitlandM,FrantzRP,ForemanAJ,CoffeyCS,etal. andsensitivitytochangeofnon-invasiveendpointsinPAH:theRESPIREstudy.
Predictingsurvivalinpulmonaryarterialhypertension:insightsfromtheRegistryto Thorax2021;76:1032–1035.
Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease 237. van der Bruggen CE, Handoko ML, Bogaard HJ, Marcus JT, Oosterveer FPT,
Management(REVEAL).Circulation2010;122:164–172. MeijboomLJ,etal.ThevalueofhemodynamicmeasurementsorcardiacMRIin
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 101 ---
3718 ESC/ERSGuidelines
thefollow-upofpatientswithidiopathicpulmonaryarterialhypertension.Chest 261. BadagliaccaR,PapaS,PosciaR,ValliG,PezzutoB,ManziG,etal.Theaddedvalueof
2021;159:1575–1585. cardiopulmonaryexercisetestinginthefollow-upofpulmonaryarterialhyperten-
238. WeatheraldJ,BouclyA,ChemlaD,SavaleL,PengM,JevnikarM,etal.Prognostic sion.JHeartLungTranspl2019;38:306–314.
valueoffollow-uphemodynamicvariablesafterinitialmanagementinpulmonary 262. DeboeckG,ScodittiC,HuezS,VachieryJL,LamotteM,SharplesL,etal.Exercise
arterialhypertension.Circulation2018;137:693–704. testing to predict outcome in idiopathic versus associated pulmonary arterial
239. vanWolferenSA,vandeVeerdonkMC,MauritzGJ,JacobsW,MarcusJT,Marques hypertension.EurRespirJ2012;40:1410–1419.
KMJ,etal.Clinicallysignificantchangeinstrokevolumeinpulmonaryhypertension. 263. WenselR,FrancisDP,MeyerFJ,OpitzCF,BruchL,HalankM,etal.Incremental
Chest2011;139:1003–1009. prognosticvalueofcardiopulmonaryexercisetestingandrestinghaemodynamics
240. HuisIn‘tVeldAE,VandeVeerdonkMC,SpruijtO,GroeneveldtJA,MarcusJT, inpulmonaryarterialhypertension.IntJCardiol2013;167:1193–1198.
WesterhofN,etal.EXPRESS:preserving rightventricularfunctioninpatients 264. BadagliaccaR,RischardF,GiudiceFL,HowardL,PapaS,ValliG,etal.Incremental
withpulmonaryarterialhypertension:singlecentreexperiencewithacardiacmag- valueofcardiopulmonaryexercisetestinginintermediate-riskpulmonaryarterial
netic resonance imaging-guided treatment strategy. Pulm Circ 2019.
hypertension.JHeartLungTransplant2022;41:780–790.
doi:10.1177/2045894018824553.Epubaheadofprint. 265. BouzinaH,RådegranG.Lowplasmastemcellfactorcombinedwithhightrans-
241. vandeVeerdonkMC,HuisInTVeldAE,MarcusJT,WesterhofN,HeymansMW,
forminggrowthfactor-αidentifieshigh-riskpatientsinpulmonaryarterialhyper-
BogaardHJ,etal.Upfrontcombinationtherapyreducesrightventricularvolumesin tension.ERJOpenRes2018;4:00035-02018.
pulmonaryarterialhypertension.EurRespirJ2017;49:1700007. 266. ChinKM,RubinLJ,ChannickR,DiScalaL,GaineS,GalièN,etal.Associationof
242. vandeVeerdonkMC,MarcusJT,WesterhofN,deManFS,BoonstraA,Heymans N-terminalprobrainnatriureticpeptideandlong-termoutcomeinpatientswith
MW,etal.Signsofrightventriculardeteriorationinclinicallystablepatientswith pulmonary arterial hypertension: insights from the phase III GRIPHON study.
pulmonaryarterialhypertension.Chest2015;147:1063–1071. Circulation2019;139:2440–2450.
243. D’AlonzoGE,BarstRJ,AyresSM,BergofskyEH,BrundageBH,DetreKM,etal. 267. FrantzRP,FarberHW,BadeschDB,ElliottCG,FrostAE,McGoonMD,etal.
Survivalinpatientswithprimarypulmonaryhypertension.Resultsfromanational Baselineandserialbrainnatriureticpeptidelevelpredicts5-yearoverallsurvival
prospectiveregistry.AnnInternMed1991;115:343–349. inpatientswithpulmonaryarterialhypertension:datafromtheREVEALregistry.
244. HumbertM,SitbonO,ChaouatA,BertocchiM,HabibG,GressinV,etal.Survivalin
Chest2018;154:126–135.
268. HarbaumL,GhataorheP,WhartonJ,JimenezB,HowardLSG,GibbsJSR,etal.
patients with idiopathic, familial, and anorexigen-associated pulmonary arterial
hypertensioninthemodernmanagementera.Circulation2010;122:156–163.
ReducedplasmalevelsofsmallHDLparticlestransportingfibrinolyticproteinsin
245. McLaughlinVV,ShillingtonA,RichS.Survivalinprimarypulmonaryhypertension:
pulmonaryarterialhypertension.Thorax2019;74:380–389.
theimpactofepoprostenoltherapy.Circulation2002;106:1477–1482. 269. NaalT,AbuhalimehB,KhirfanG,DweikRA,TangWHW,TonelliAR.Serumchlor-
idelevelstrackwithsurvivalinpatientswithpulmonaryarterialhypertension.Chest
246. ProvencherS,ChemlaD,HerveP,SitbonO,HumbertM,SimonneauG.Heartrate
2018;154:541–549.
responsesduringthe6-minutewalktestinpulmonaryarterialhypertension.Eur
RespirJ2006;27:114–120. 270. NikolicI,YungLM,YangP,MalhotraR,Paskin-FlerlageS,DinterT,etal.Bonemor-
phogeneticprotein9isamechanisticbiomarkerofportopulmonaryhypertension.
247. SitbonO,BenzaRL,BadeschDB,BarstRJ,ElliottCG,GressinV,etal.Validationof
AmJRespirCritCareMed2019;199:891–902.
twopredictivemodelsforsurvivalinpulmonaryarterialhypertension.EurRespirJ
2015;46:152–164. 271. RhodesCJ,WhartonJ,GhataorheP,WatsonG,GirerdB,HowardLS,etal.Plasma
proteomeanalysisinpatientswithpulmonaryarterialhypertension:anobserva-
248. ThenappanT,ShahSJ,RichS,TianL,ArcherSL,Gomberg-MaitlandM.Survivalin
pulmonaryarterialhypertension:areappraisaloftheNIHriskstratificationequa-
tionalcohortstudy.LancetRespirMed2017;5:717–726.
tion.EurRespirJ2010;35:1079–1087. 272. WetzlV,TiedeSL,FaerberL,WeissmannN,SchermulyRT,GhofraniHA,etal.
PlasmaMMP2/TIMP4ratioatfollow-upassessmentpredictsdiseaseprogression
249. BenzaRL,Gomberg-MaitlandM,ElliottCG,FarberHW,ForemanAJ,FrostAE,
ofidiopathicpulmonaryarterialhypertension.Lung2017;195:489–496.
et al. Predicting survival in patients with pulmonary arterial hypertension: the
273. ArvidssonM,AhmedA,BouzinaH,RådegranG.Matrixmetalloproteinase7indiag-
REVEALriskscorecalculator2.0andcomparisonwithESC/ERS-basedriskassess-
nosisanddifferentiationof pulmonary arterialhypertension. PulmCirc2019;9:
mentstrategies.Chest2019;156:323–337.
2045894019895414.
250. BenzaRL,Gomberg-MaitlandM,MillerDP,FrostA,FrantzRP,ForemanAJ,etal.
274. KylhammarD,HesselstrandR,NielsenS,ScheeleC,RadegranG.Angiogenicand
TheREVEALregistryriskscorecalculatorinpatientsnewlydiagnosedwithpul- inflammatorybiomarkersforscreeningandfollow-upinpatientswithpulmonary
monaryarterialhypertension.Chest2012;141:354–362.
arterialhypertension.ScandJRheumatol2018;47:319–324.
251. SavareseG,PaolilloS,CostanzoP,D’AmoreC,CecereM,LoscoT,etal.Do
275. SalebyJ,BouzinaH,AhmedS,LundgrenJ,RadegranG.Plasmareceptortyrosine
changesof6-minutewalkdistancepredictclinicaleventsinpatientswithpulmonary
kinaseRETinpulmonaryarterialhypertensiondiagnosisanddifferentiation.ERJ
arterialhypertension?Ameta-analysisof22randomizedtrials.JAmCollCardiol OpenRes2019;5:00037–02019.
2012;60:1192–1201. 276. vanBonL,AffandiAJ,BroenJ,ChristmannRB,MarijnissenRJ,StawskiL,etal.
252. ZelnikerTA,HuscherD,Vonk-NoordegraafA,EwertR,LangeTJ,KloseH,etal. Proteome-wideanalysisandCXCL4asabiomarkerinsystemicsclerosis.NEngl
The6MWTasaprognostictoolinpulmonaryarterialhypertension:resultsfrom JMed2014;370:433–443.
theCOMPERAregistry.ClinResCardiol2018;107:460–470.
277. FerrerE,DunmoreBJ,HassanD,OrmistonML,MooreS,DeightonJ,etal.Apo-
253. FarberHW,MillerDP,McGoonMD,FrostAE,BentonWW,BenzaRL.Predicting tentialroleforexosomaltranslationallycontrolledtumorproteinexportinvascu-
outcomesinpulmonaryarterialhypertensionbasedonthe6-minutewalkdistance. larremodelinginpulmonaryarterialhypertension.AmJRespirCellMolBiol2018;59:
JHeartLungTranspl2015;34:362–368. 467–478.
254. HeresiGA,RaoY.Follow-upfunctionalclassand6-minutewalkdistanceidentify 278. LavoieJR,OrmistonML,Perez-IratxetaC,CourtmanDW,JiangB,FerrerE,etal.
long-termsurvivalinpulmonaryarterialhypertension.Lung2020;198:933–938.
Proteomicanalysisimplicatestranslationallycontrolledtumorproteinasanovel
255. SouzaR,ChannickRN,DelcroixM,GalièN,GhofraniHA,JansaP,etal.Association mediator of occlusive vascular remodeling in pulmonary arterial hypertension.
betweensix-minutewalkdistanceandlong-termoutcomesinpatientswithpul- Circulation2014;129:2125–2135.
monaryarterialhypertension:datafromtherandomizedSERAPHINtrial.PLoS 279. WarwickG,ThomasPS,YatesDH.Biomarkersinpulmonaryhypertension.Eur
One2018;13:e0193226. RespirJ2008;32:503–512.
256. HallidaySJ,WangL,YuC,VickersBP,NewmanJH,FremontRD,etal.Six-minute 280. HoeperM,PauschC,OlssonK,HuscherD,PittrowD,GrünigE,etal.COMPERA
walkdistanceinhealthyyoungadults.RespirMed2020;165:105933. 2.0:arefined4-stratariskassessmentmodelforpulmonaryarterialhypertension.
257. Khirfan G, Naal T, Abuhalimeh B, Newman J, Heresi GA, Dweik RA, et al. EurRespirJ2022;60:2102311.
Hypoxemiainpatientswithidiopathicorheritablepulmonaryarterialhyperten- 281. DelcroixM,HowardL.Pulmonaryarterialhypertension:theburdenofdiseaseand
sion.PLoSOne2018;13:e0191869. impactonqualityoflife.EurRespirRev2015;24:621–629.
258. LewisRA,BillingsCG,HurdmanJA,SmithIA,AustinM,ArmstrongIJ,etal.Maximal 282. YorkeJ,CorrisP,GaineS,GibbsJS,KielyDG,HarriesC,etal.emPHasis-10:devel-
exercisetestingusingtheincrementalshuttlewalkingtestcanbeusedtorisk- opmentofahealth-relatedqualityoflifemeasureinpulmonaryhypertension.Eur
stratifypatientswithpulmonaryarterialhypertension.AnnAmThoracSoc2021; RespirJ2014;43:1106–1113.
18:34–43. 283. McGoonMD,FerrariP,ArmstrongI,DenisM,HowardLS,LoweG,etal.Theim-
259. LavenezianaP,DiPaoloM,PalangeP.Theclinicalvalueofcardiopulmonaryexer- portanceofpatientperspectivesinpulmonaryhypertension.EurRespirJ2019;53:
cisetestinginthemodernera.EurRespirRev2021;30:200187. 1801919.
260. WenselR,OpitzCF,AnkerSD,WinklerJ,HoffkenG,KleberFX,etal.Assessment 284. Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L’amri M, Gain K, et al.
ofsurvivalinpatientswithprimarypulmonaryhypertension:importanceofcardio- PsychometricperformanceoftheCAMPHORandSF-36inpulmonaryhyperten-
pulmonaryexercisetesting.Circulation2002;106:319–324. sion.BMCPulmMed2013;13:45.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 102 ---
ESC/ERSGuidelines 3719
285.Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD. 306. YogeswaranA,RichterMJ,SommerN,GhofraniHA,SeegerW,TelloK,etal.
Comparisonofcardiacandpulmonary-specificquality-of-lifemeasuresinpulmon- Advancedriskstratificationofintermediateriskgroupinpulmonaryarterialhyper-
aryarterialhypertension.EurRespirJ2011;38:608–616. tension.PulmCirc2020;10:2045894020961739.
286.McKennaSP,DoughtyN,MeadsDM,DowardLC,Pepke-ZabaJ.TheCambridge 307. ZeltJGE,HossainA,SunLY,MehtaS,ChandyG,DaviesRA,etal.Incorporationof
Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of renalfunctioninmortalityriskassessmentforpulmonaryarterialhypertension.J
health-relatedqualityoflifeandqualityoflifeforpatientswithpulmonaryhyper-
HeartLungTransplant2020;39:675–685.
tension.QualLifeRes2006;15:103–115. 308. BouclyA,WeatheraldJ,SavaleL,deGrooteP,CottinV,PrévotG,etal.External
287.LewisRA,ArmstrongI,BergbaumC,BrewisMJ,CannonJ,CharalampopoulosA,
validationofarefined4-stratariskassessmentscorefromtheFrenchpulmonary
etal.EmPHasis-10health-relatedqualityoflifescorepredictsoutcomesinpatients hypertensionregistry.EurRespirJ2022;59:2102419.
withidiopathicandconnectivetissuedisease-associatedpulmonaryarterialhyper- 309. OlssonKM,RichterMJ,KampJC,GallH,HeineA,GhofraniHA,etal.Intravenous
tension:resultsfromaUKmulticentrestudy.EurRespirJ2021;57:2000124. treprostinilasanadd-ontherapyinpatientswithpulmonaryarterialhypertension.J
288.BonnerN,AbetzL,MeunierJ,SikiricaM,MathaiSC.Developmentandvalidationof
HeartLungTransplant2019;38:748–756.
310. TonelliAR,SahayS,GordonKW,EdwardsLD,AllmonAG,BroderickM,etal.
thelivingwithpulmonaryhypertensionquestionnaireinpulmonaryarterialhyper-
Impactofinhaledtreprostinilonriskstratificationwithnoninvasiveparameters:a
tensionpatients.HealthQualLifeOutcomes2013;11:161.
post hoc analysis of the TRIUMPH and BEAT studies. Pulm Circ 2020;10:
289.McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schuler R, et al.
2045894020977025.
Development of the Pulmonary Arterial Hypertension-Symptoms and Impact
311. Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, et al.
(PAH-SYMPACT®)questionnaire:anewpatient-reportedoutcomeinstrument
Haemodynamicsandserialriskassessmentinsystemicsclerosisassociatedpulmon-
forPAH.RespirRes2016;17:72.
aryarterialhypertension.EurRespirJ2018;52:1800678.
290.McCabeC,BennettM,DoughtyN,MacKenzieRossR,SharplesL,Pepke-ZabaJ.
312. ChanL,ChinLMK,KennedyM,WoolstenhulmeJG,NathanSD,WeinsteinAA,
Patient-reportedoutcomesassessedbytheCAMPHORquestionnairepredictclin- etal.Benefitsofintensivetreadmillexercisetrainingoncardiorespiratoryfunction
ical deterioration in idiopathic pulmonary arterial hypertension and chronic
and quality of life in patients with pulmonary hypertension. Chest 2013;143:
thromboembolicpulmonaryhypertension.Chest2013;144:522–530.
333–343.
291.MinJ,BadeschD,ChakinalaM,ElwingJ,FrantzR,HornE,etal.Predictionof 313. deManFS,HandokoML,GroepenhoffH,van‘tHulAJ,AbbinkJ,KoppersRJ,etal.
health-relatedqualityoflifeandhospitalizationinpulmonaryarterialhypertension:
Effectsofexercisetraininginpatientswithidiopathicpulmonaryarterialhyperten-
thePulmonaryHypertensionAssociationRegistry.AmJRespirCritCareMed2021; sion.EurRespirJ2009;34:669–675.
203:761–764.
314. EhlkenN,LichtblauM,KloseH,WeidenhammerJ,FischerC,NechwatalR,etal.
292.KylhammarD,KjellstromB,HjalmarssonC,JanssonK,NisellM,SoderbergS,etal. Exercisetrainingimprovespeakoxygenconsumptionandhaemodynamicsinpa-
Acomprehensiveriskstratificationatearlyfollow-updeterminesprognosisinpul-
tients with severe pulmonary arterial hypertension and inoperable chronic
monaryarterialhypertension.EurHeartJ2018;39:4175–4181.
thrombo-embolicpulmonaryhypertension:aprospective,randomized,controlled
293.HoeperMM,KramerT,PanZ,EichstaedtCA,SpiesshoeferJ,BenjaminN,etal. trial.EurHeartJ2016;37:35–44.
Mortalityinpulmonaryarterialhypertension:predictionbythe2015Europeanpul- 315. GrunigE,MacKenzieA,PeacockAJ,EichstaedtCA,BenjaminN,NechwatalR,etal.
monary hypertension guidelines risk stratification model. EurRespir J 2017;50: Standardizedexercisetrainingisfeasible,safe,andeffectiveinpulmonaryarterial
1700740. and chronic thromboembolic pulmonary hypertension: results from a large
294.HjalmarssonC,KjellströmB,JanssonK,NisellM,KylhammarD,KavianipourM, Europeanmulticentrerandomizedcontrolledtrial.EurHeartJ2021;42:2284–2295.
et al. Early risk prediction in patients with idiopathic versus connective tissue 316. MerelesD, Ehlken N, Kreuscher S,Ghofrani S, Hoeper MM,Halank M, et al.
disease-associatedpulmonaryarterialhypertension:callforarefinedassessment. Exerciseandrespiratorytrainingimproveexercisecapacityandqualityoflifeinpa-
ERJOpenRes2021;7:00854-02020. tients with severe chronic pulmonary hypertension. Circulation 2006;114:
295.BouclyA,WeatheraldJ,SavaleL,JaisX,CottinV,PrevotG,etal.Riskassessment, 1482–1489.
prognosisandguidelineimplementationinpulmonaryarterialhypertension.Eur 317. GrunigE,EichstaedtC,BarberaJA,BenjaminN,BlancoI,BossoneE,etal.ERS
RespirJ2017;50:1700889. statementonexercisetrainingandrehabilitationinpatientswithseverechronic
296.BenzaRL,KanwarMK,RainaA,ScottJV,ZhaoCL,SelejM,etal.Developmentand pulmonaryhypertension.EurRespirJ2019;53:1800332.
validationofanabridgedversionoftheREVEAL2.0riskscorecalculator,REVEAL 318. JohnsonSR,GrantonJT,MehtaS.Thromboticarteriopathyandanticoagulationin
Lite2,foruseinpatientswithpulmonaryarterialhypertension.Chest2021;159:
pulmonaryhypertension.Chest2006;130:545–552.
337–346. 319. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al.
297.BouzinaH,RådegranG,ButlerO,HesselstrandR,HjalmarssonC,HollK,etal. Anticoagulationandsurvivalinpulmonaryarterialhypertension:resultsfromthe
Longitudinalchangesinriskstatusinpulmonaryarterialhypertension.ESCHeart Comparative,ProspectiveRegistryofNewlyInitiatedTherapiesforPulmonary
Fail2021;8:680–690. Hypertension(COMPERA).Circulation2014;129:57–65.
298.D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, et al. 320. PrestonIR,RobertsKE,MillerDP,SenGP,SelejM,BentonWW,etal.Effectof
warfarintreatmentonsurvivalofpatientswithpulmonaryarterialhypertension
Hemodynamics and risk assessment 2 years after the initiation of upfront
ambrisentan–tadalafil in pulmonary arterial hypertension. J Heart Lung (PAH) in the Registry to Evaluate Early and Long-term PAH Disease
Transpl2020;39:1389–1397. Management(REVEAL).Circulation2015;132:2403–2411.
321. KhanMS,UsmanMS,SiddiqiTJ,KhanSU,MuradMH,MookadamF,etal.Isantic- 299.HjalmarssonC,RådegranG,KylhammarD,RundqvistB,MultingJ,NisellMD,etal.
Impactofageandcomorbidityonriskstratificationinidiopathicpulmonaryarterial oagulation beneficial in pulmonary arterial hypertension? Circ Cardiovasc Qual
Outcomes2018;11:e004757.
hypertension.EurRespirJ2018;51:1702310.
322. WangP,HuL,YinY,YanD,ZhengH,ZhangJ,etal.Cananticoagulantsimprovethe
300.HumbertM,FarberHW,GhofraniHA,BenzaRL,BusseD,MeierC,etal.Riskas-
survivalrateforpatientswithidiopathicpulmonaryarterialhypertension?Asys-
sessmentinpulmonaryarterialhypertensionandchronicthromboembolicpul- tematicreviewandmeta-analysis.ThrombRes2020;196:251–256.
monaryhypertension.EurRespirJ2019;53:1802004. 323. StickelS,Gin-SingW,WagenaarM,GibbsJSR.Thepracticalmanagementoffluid
301.KuwanaM,BlairC,TakahashiT,LangleyJ,CoghlanJG.Initialcombinationtherapy
retentioninadultswithrightheartfailureduetopulmonaryarterialhypertension.
ofambrisentanandtadalafilinconnectivetissuedisease-associatedpulmonaryar-
EurHeartJSuppl2019;21:K46–K53.
terialhypertension(CTD-PAH)inthemodifiedintention-to-treatpopulationof
324. SandovalJ,AguirreJS,PulidoT,Martinez-GuerraML,SantosE,AlvaradoP,etal.
theAMBITIONstudy:posthocanalysis.AnnRheumDis2020;79:626–634.
Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J
302.Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M, RespirCritCareMed2001;164:1682–1687.
KjellstromB,etal.Predictingmortalityduringlong-termfollow-upinpulmonary 325. WeitzenblumE,SautegeauA,EhrhartM,MammosserM,PelletierA.Long-term
arterialhypertension.ERJOpenRes2021;7:00837-02020. oxygentherapycanreversetheprogressionofpulmonaryhypertensioninpatients
303.SitbonO,ChinKM,ChannickRN,BenzaRL,DiScalaL,GaineS,etal.Riskassess- withchronicobstructivepulmonarydisease.AmRevRespirDis1985;131:493–498.
mentinpulmonaryarterialhypertension:insightsfromtheGRIPHONstudy.J 326. UlrichS,SaxerS,HaslerED,SchwarzEI,SchneiderSR,FurianM,etal.Effectof
HeartLungTranspl2020;39:300–309. domiciliary oxygen therapy on exercise capacity and quality of life in patients
304.RhodesCJ,WhartonJ,SwietlikEM,HarbaumL,GirerdB,CoghlanJG,etal.Using withpulmonaryarterialorchronicthromboembolicpulmonaryhypertension:a
theplasmaproteomeforriskstratifyingpatientswithpulmonaryarterialhyperten- randomised,placebo-controlledtrial.EurRespirJ2019;54:1900276.
sion.AmJRespirCritCareMed2022;205:1102–1111. 327. UlrichS,HaslerED,SaxerS,FurianM,Muller-MottetS,KeuschS,etal.Effectof
305.BenzaRL,LohmuellerLC,KraisangkaJ,KanwarM.Riskassessmentinpulmonary breathingoxygen-enrichedaironexerciseperformanceinpatientswithprecapil-
arterialhypertensionpatients:thelongandshortofit.AdvPulmHypertens2018; larypulmonaryhypertension:randomized,sham-controlledcross-overtrial.Eur
16:125–135. HeartJ2017;38:1159–1168.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 103 ---
3720 ESC/ERSGuidelines
328. AdirY,HumbertM,ChaouatA.Sleep-relatedbreathingdisordersandpulmonary 352. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J, et al.
hypertension.EurRespirJ2021;57:2002258. Managementofpulmonaryarterialhypertensionduringpregnancy:aretrospective,
329. McDonaghT,DamyT,DoehnerW,LamCSP,SindoneA,vanderMeerP,etal. multicenterexperience.Chest2013;143:1330–1336.
Screening,diagnosisandtreatmentofirondeficiencyinchronicheartfailure:put- 353. JaisX,OlssonKM,BarberaJA,BlancoI,TorbickiA,PeacockA,etal.Pregnancyout-
tingthe2016EuropeanSocietyofCardiologyheartfailureguidelinesintoclinical comesinpulmonaryarterialhypertensioninthemodernmanagementera.Eur
practice.EurJHeartFail2018;20:1664–1672. RespirJ2012;40:881–885.
330. RhodesCJ,HowardLS,BusbridgeM,AshbyD,KondiliE,GibbsJS,etal.Irondefi- 354. KielyDG,CondliffeR,WebsterV,MillsGH,WrenchI,GandhiSV,etal.Improved
ciencyandraisedhepcidininidiopathicpulmonaryarterialhypertension:clinical survivalinpregnancyandpulmonaryhypertensionusingamultiprofessionalap-
prevalence,outcomes,andmechanisticinsights.JAmCollCardiol2011;58:300–309. proach.BJOG2010;117:565–574.
331. RuiterG,LankhorstS,BoonstraA,PostmusPE,ZweegmanS,WesterhofN,etal. 355. LuoJ,ShiH,XuL,SuW,LiJ.Pregnancyoutcomesinpatientswithpulmonaryar-
Irondeficiencyiscommoninidiopathicpulmonaryarterialhypertension.EurRespir
terialhypertension:aretrospectivestudy.Medicine2020;99:e20285.
J2011;37:1386–1391.
356. KampJC,vonKaisenbergC,GreveS,WinterL,ParkDH,FugeJ,etal.Pregnancyin
332. RuiterG,LanserIJ,deManFS,vanderLaarseWJ,WhartonJ,WilkinsMR,etal.Iron
pulmonaryarterialhypertension:midtermoutcomesofmothersandoffspring.J
deficiencyinsystemicsclerosispatientswithandwithoutpulmonaryhypertension.
HeartLungTransplant2021;40:229–233.
Rheumatology2014;53:285–292.
357. CorbachN,BerlierC,LichtblauM,SchwarzEI,GautschiF,GrothA,etal.Favorable
333. VanDeBruaeneA,DelcroixM,PasquetA,DeBackerJ,DePauwM,NaeijeR,etal.
pregnancyoutcomesinwomenwithwell-controlledpulmonaryarterialhyperten-
IrondeficiencyisassociatedwithadverseoutcomeinEisenmengerpatients.Eur
sion.FrontMed(Lausanne)2021;8:689764.
HeartJ2011;32:2790–2799.
358. BostockS,ShearesK,CannonJ,TaboadaD,Pepke-ZabaJ,ToshnerM.Thepoten-
334. SonnweberT,NairzM,TheurlI,PetzerV,TymoszukP,HaschkaD,etal.Thecru-
tialeffectsofpregnancyinapatientwithidiopathicpulmonaryarterialhypertension
cialimpactofirondeficiencydefinitionforthecourseofprecapillarypulmonary
respondingtocalciumchannelblockade.EurRespirJ2017;50:1701141.
hypertension.PLoSOne2018;13:e0203396.
359. deRaafMA,BeekhuijzenM,GuignabertC,VonkNoordegraafA,BogaardHJ.
335. Ruiter G, MandersE, HappeCM,Schalij I,Groepenhoff H,HowardLS,et al.
Endothelin-1receptorantagonistsinfetaldevelopmentandpulmonaryarterial
Intravenousirontherapyinpatientswithidiopathicpulmonaryarterialhyperten-
sionandirondeficiency.PulmCirc2015;5:466–472. hypertension.ReprodToxicol2015;56:45–51.
360. DunnL,GreerR,FlenadyV,KumarS.Sildenafilinpregnancy:asystematicreviewof
336. ViethenT,GerhardtF,DumitrescuD,Knoop-BuschS,TenFreyhausH,Rudolph
maternaltoleranceandobstetricandperinataloutcomes.FetalDiagnTher2017;41:
TK,etal.Ferriccarboxymaltoseimprovesexercisecapacityandqualityoflifeinpa-
tientswithpulmonaryarterialhypertensionandirondeficiency:apilotstudy.IntJ 81–88.
Cardiol2014;175:233–239. 361. vanGiersbergenPL,HalabiA,DingemanseJ.Pharmacokineticinteractionbetween
337. KramerT,WissmullerM,NatsinaK,GerhardtF,TenFreyhausH,DumitrescuD, bosentanandtheoralcontraceptivesnorethisteroneandethinylestradiol.IntJClin
etal.Ferriccarboxymaltoseinpatientswithpulmonaryarterialhypertensionand
PharmacolTher2006;44:113–118.
iron deficiency: a long-term study. J Cachexia Sarcopenia Muscle 2021;12: 362. MeyerS,McLaughlinVV,SeyfarthHJ,BullTM,VizzaCD,Gomberg-MaitlandM,
1501–1512. etal.Outcomesofnoncardiac,nonobstetricsurgeryinpatientswithPAH:aninter-
338. OlssonKM,FugeJ,BrodT,KampJC,SchmittoJ,KempfT,etal.Oralironsupple- nationalprospectivesurvey.EurRespirJ2013;41:1302–1307.
mentationwithferricmaltolinpatientswithpulmonaryhypertension.EurRespirJ 363. HassanHJ,HoustenT,BalasubramanianA,SimpsonCE,DamicoRL,MathaiSC,
2020;56:2000616. etal.Anovelapproachtoperioperativeriskassessmentforpatientswithpulmon-
339. Howard LSGE, He J, Watson GMJ, Huang L, Wharton J, Luo Q, et al. aryhypertension.ERJOpenRes2021;7:00257-02021.
Supplementationwithironinpulmonaryarterialhypertension.Tworandomized 364. Non-cardiacsurgery:HalvorsenS,MehilliJ,CasseseS,HallTS,AbdelhamidM,
crossovertrials.AnnAmThoracSoc2021;18:981–988. BarbatoE,etal.2022ESCGuidelinesoncardiovascularassessmentandmanage-
340. LarischA,NeebC,deZwaanM,PabstC,TiedeH,GhofraniA,etal.Mentaldistress mentofpatientsundergoingnon-cardiacsurgery.EurHeartJ2022.https://doi.
andwishforpsychosomatictreatmentofpatientswithpulmonaryhypertension. org/10.1093/eurheartj/ehac270.
PsychotherPsychosomMedPsychol2014;64:384–389. 365. BurnsRM,PeacockAJ,JohnsonMK,ChurchAC.Hypoxaemiainpatientswithpul-
341. OlssonKM,MeltendorfT,FugeJ,KampJC,ParkDH,RichterMJ,etal.Prevalenceof monaryarterialhypertensionduringsimulatedairtravel.RespirMed2013;107:
mentaldisordersandimpactonqualityoflifeinpatientswithpulmonaryarterial 298–304.
hypertension.FrontPsychiatry2021;31:667602. 366. KylhammarD,RådegranG.Theprincipalpathwaysinvolvedintheinvivomodula-
342. PfeufferE,KrannichH,HalankM,WilkensH,KolbP,JanyB,etal.Anxiety,depres- tionofhypoxicpulmonaryvasoconstriction,pulmonaryarterialremodellingand
sion,andhealth-relatedQOLinpatientsdiagnosedwithPAHorCTEPH.Lung pulmonaryhypertension.ActaPhysiol2017;219:728–756.
2017;195:759–768.
367. CodeofFederalRegulations.ChapterI,SubchapterC,Part25,SubpartD,Subjgrp-
343. ZhouX,ShiH,YangY,ZhangZ,ZhaiZ,WangC.Anxietyanddepressioninpa- Pressurization. Section 25.841 - Pressurized cabins. Washington, DC: US
tientswithpulmonaryarterialhypertensionandchronicthromboembolicpulmon- GovernmentPrintingOffice;2012.
ary hypertension: results from a Chinese survey. Exp Ther Med 2020;19: 368. GrothA,SaxerS,BaderPR,LichtblauM,FurianM,SchneiderSR,etal.Acutehemo-
3124–3132.
dynamicchangesbybreathinghypoxicandhyperoxicgasmixturesinpulmonary
344. KingmanM,HinzmannB,SweetO,VachieryJL.Livingwithpulmonaryhyperten-
arterialandchronicthromboembolicpulmonaryhypertension.IntJCardiol2018;
sion:uniqueinsightsfromaninternationalethnographicstudy.BMJOpen2014;4: 270:262–267.
e004735.
369. RoubinianN,ElliottCG,BarnettCF,BlancPD,ChenJ,DeMarcoT,etal.Effectsof
345. HarzheimD,KloseH,PinadoFP,EhlkenN,NagelC,FischerC,etal.Anxietyand
commercialairtravelonpatientswithpulmonaryhypertensionairtravelandpul-
depressiondisordersinpatientswithpulmonaryarterialhypertensionandchronic
monaryhypertension.Chest2012;142:885–892.
thromboembolicpulmonaryhypertension.RespirRes2013;14:104.
370. SchneiderSR,MayerLC,LichtblauM,BerlierC,SchwarzEI,SaxerS,etal.Effectof 346. AnandV,VallabhajosyulaS,CheungpasitpornW,FrantzRP,CajigasHR,StrandJJ,
normobarichypoxiaonexerciseperformanceinpulmonaryhypertension:rando-
etal.Inpatientpalliativecareuseinpatientswithpulmonaryarterialhypertension:
temporaltrends,predictors,andoutcomes.Chest2020;158:2568–2578.
mizedtrial.Chest2021;159:757–771.
371. SeccombeLM,ChowV,ZhaoW,LauEMT,RogersPG,NgACC,etal.Rightheart
347. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:
487–497. functionduringsimulatedaltitudeinpatientswithpulmonaryarterialhypertension.
348. Kjellstrom B, Sandqvist A, Hjalmarsson C, Nisell M, Nasman P, Ivarsson B. OpenHeart2017;4:e000532.
Adherencetodisease-specificdrugtreatmentamongpatientswithpulmonaryar- 372. ThammM,VoswinckelR,TiedeH,LendeckelF,GrimmingerF,SeegerW,etal.Air
terialhypertensionorchronicthromboembolicpulmonaryhypertension.ERJOpen travelcanbesafeandwelltoleratedinpatientswithclinicallystablepulmonary
Res2020;6:00299-02020.
hypertension.PulmCirc2011;1:239–243.
349. ShahNB,MitchellRE,ProctorST,ChoiL,DeClercqJ,JollyJA,etal.Highratesof 373. CramerD,WardS,GeddesD.Assessmentofoxygensupplementationduringair
medicationadherenceinpatientswithpulmonaryarterialhypertension:aninte-
travel.Thorax1996;51:202–203.
gratedspecialtypharmacyapproach.PLoSOne2019;14:e0217798. 374. DubroffJ,MelendresL,LinY,BeeneDR,KetaiL.Highgeographicprevalenceof
350. WeissBM,ZempL,SeifertB,HessOM.Outcomeofpulmonaryvasculardiseasein pulmonaryarteryhypertension:associationswithethnicity,druguse,andaltitude.
pregnancy:asystematicoverviewfrom1978through1996.JAmCollCardiol1998; PulmCirc2020;10:2045894019894534.
31:1650–1657. 375. FakhriS,HannonK,MouldenK,PetersonR,HountrasP,BullT,etal.Residenceat
351. BedardE,DimopoulosK,GatzoulisMA.Hastherebeenanyprogressmadeon moderatelyhighaltitudeanditsrelationshipwithWHOGroup1pulmonaryarter-
pregnancyoutcomesamongwomenwithpulmonaryarterialhypertension?Eur ial hypertension symptom severity and clinical characteristics: the Pulmonary
HeartJ2009;30:256–265. HypertensionAssociationRegistry.PulmCirc2020;10:2045894020964342.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 104 ---
ESC/ERSGuidelines 3721
376.SchneiderSR,MayerLC,LichtblauM,BerlierC,SchwarzEI,SaxerS,etal.Effectofa 400. RubinLJ,MendozaJ,HoodM,McGoonM,BarstR,WilliamsWB,etal.Treatment
day-triptoaltitude(2500m)onexerciseperformanceinpulmonaryhypertension: of primary pulmonary hypertension with continuous intravenous prostacyclin
randomisedcrossovertrial.ERJOpenRes2021;7:00314-02021. (epoprostenol).Resultsofarandomizedtrial.AnnInternMed1990;112:485–491.
377.MakowskiCT,RissmillerRW,BullingtonWM.Riociguat:anovelnewdrugfor 401. BadeschDB,TapsonVF,McGoonMD,BrundageBH,RubinLJ,WigleyFM,etal.
treatmentofpulmonaryhypertension.Pharmacotherapy2015;35:502–519. Continuousintravenousepoprostenolforpulmonaryhypertensionduetothe
378.MontaniD,SavaleL,NataliD,JaisX,HerveP,GarciaG,etal.Long-termresponse sclerodermaspectrumofdisease.Arandomized,controlledtrial.AnnInternMed
tocalcium-channelblockersinnon-idiopathicpulmonaryarterialhypertension.Eur 2000;132:425–434.
HeartJ2010;31:1898–1907. 402. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH.
379.GalièN,UssiaG,PassarelliP,ParlangeliR,BranziA,MagnaniB.Roleofpharmaco- Improvement in pulmonary hemodynamics during intravenous epoprostenol
logictestsinthetreatmentofprimarypulmonaryhypertension.AmJCardiol1995; (prostacyclin):astudyof15patientswithmoderatetosevereportopulmonary
75:55A–62A. hypertension.Hepatology1999;30:641–648.
380.ClozelM,MarestaA,HumbertM.Endothelinreceptorantagonists.HandbExp 403. NunesH,HumbertM,SitbonO,MorseJH,DengZ,KnowlesJA,etal.Prognostic
Pharmacol2013;218:199–227. factorsforsurvivalinhumanimmunodeficiencyvirus-associatedpulmonaryarterial
381.XingJ,CaoY,YuY,LiH,SongZ,YuH.Invitromicropatternedhumanpluripotent
hypertension.AmJRespirCritCareMed2003;167:1433–1439.
404. RosenzweigEB,KersteinD,BarstRJ.Long-termprostacyclinforpulmonaryhyper-
stemcelltest(microP-hPST)formorphometric-basedteratogenscreening.SciRep
tensionwithassociatedcongenitalheartdefects.Circulation1999;99:1858–1865.
2017;7:8491.
405. BouclyA,O’ConnellC,SavaleL,O’CallaghanDS,JaisX,MontaniD,etal.Tunnelled
382.Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al.
centralvenousline-associatedinfectionsinpatientswithpulmonaryarterialhyper-
Ambrisentanforthetreatmentofpulmonaryarterialhypertension:resultsofthe
tensiontreatedwithintravenousprostacyclin.PresseMed2016;45:20–28.
ambrisentan in pulmonary arterial hypertension, randomized, double-blind,
406. DoranAK,IvyDD,BarstRJ,HillN,MuraliS,BenzaRL,etal.Guidelinesforthepre-
placebo-controlled,multicenter,efficacy(ARIES)study1and2.Circulation2008;
ventionofcentralvenouscatheter-relatedbloodstreaminfectionswithprostanoid
117:3010–3019. therapyforpulmonaryarterialhypertension.IntJClinPractSuppl2008;(160):5–9.
383.RubinLJ,BadeschDB,BarstRJ,GalièN,BlackCM,KeoghA,etal.Bosentantherapy
407. OlschewskiH,SimonneauG,GalièN,HigenbottamT,NaeijeR,RubinLJ,etal.Inhaled
forpulmonaryarterialhypertension.NEnglJMed2002;346:896–903. iloprostforseverepulmonaryhypertension.NEnglJMed2002;347:322–329.
384.HumbertM,SegalES,KielyDG,CarlsenJ,SchwierinB,HoeperMM.Resultsof
408. SimonneauG,BarstRJ,GalièN,NaeijeR,RichS,BourgeRC,etal.Continuoussub-
European post-marketing surveillance of bosentan in pulmonary hypertension.
cutaneousinfusionoftreprostinil,aprostacyclinanalogue,inpatientswithpulmon-
EurRespirJ2007;30:338–344.
aryarterialhypertension:adouble-blind,randomized,placebo-controlledtrial.AmJ
385.PaulGA,GibbsJS,BoobisAR,AbbasA,WilkinsMR.Bosentandecreasestheplasma RespirCritCareMed2002;165:800–804.
concentrationofsildenafilwhencoprescribedinpulmonaryhypertension.BrJClin
409. BourgeRC,WaxmanAB,Gomberg-MaitlandM,ShapiroSM,TarverJHIII,Zwicke
Pharmacol2005;60:107–112.
DL,etal.Treprostiniladministeredtotreatpulmonaryarterialhypertensionusinga
386.WeberC,BankenL,BirnboeckH,SchulzR.Effectoftheendothelin-receptoran- fully implantable programmable intravascular delivery system: results of the
tagonistbosentanonthepharmacokineticsandpharmacodynamicsofwarfarin.J DelIVeryforPAHtrial.Chest2016;150:27–34.
ClinPharmacol1999;39:847–854. 410. RichterMJ,HarutyunovaS,BollmannT,ClassenS,GallH,GerhardtMdF,etal.
387.Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Long-term safety and outcome of intravenous treprostinil via an implanted
Pharmacokineticinteractionbetweentadalafilandbosentaninhealthymalesub- pumpinpulmonaryhypertension.JHeartLungTransplant2018;37:1235–1244.
jects.JClinPharmacol2008;48:610–618. 411. McLaughlinVV,BenzaRL,RubinLJ,ChannickRN,VoswinckelR,TapsonVF,etal.
388.GhofraniHA,OsterlohIH,GrimmingerF.Sildenafil:fromanginatoerectiledys- Additionofinhaledtreprostiniltooraltherapyforpulmonaryarterialhypertension:
functiontopulmonaryhypertensionandbeyond.NatRevDrugDiscov2006;5: arandomizedcontrolledclinicaltrial.JAmCollCardiol2010;55:1915–1922.
689–702. 412. TapsonVF,JingZC,XuKF,PanL,FeldmanJ,KielyDG,etal.Oraltreprostinilforthe
389.GalièN,MullerK,ScaliseAV,GrunigE.PATENTPLUS:ablinded,randomisedand treatmentofpulmonaryarterialhypertensioninpatientsreceivingbackgrounden-
extensionstudyofriociguatplussildenafilinpulmonaryarterialhypertension.Eur dothelinreceptorantagonistandphosphodiesterasetype5inhibitortherapy(the
RespirJ2015;45:1314–1322. FREEDOM-C2study):arandomizedcontrolledtrial.Chest2013;144:952–958.
390.GalièN,GhofraniHA,TorbickiA,BarstRJ,RubinLJ,BadeschD,etal.Sildenafilcit- 413. TapsonVF,TorresF,KermeenF,KeoghAM,AllenRP,FrantzRP,etal.Oraltre-
rate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353: prostinilforthetreatmentofpulmonaryarterialhypertensioninpatientsonback-
2148–2157. groundendothelinreceptorantagonistand/orphosphodiesterasetype5inhibitor
391.SastryBK,NarasimhanC,ReddyNK,RajuBS.Clinicalefficacyofsildenafilinpri- therapy(theFREEDOM-Cstudy):arandomizedcontrolledtrial.Chest2012;142:
marypulmonaryhypertension:arandomized,placebo-controlled,double-blind,
1383–1390.
crossoverstudy.JAmCollCardiol2004;43:1149–1153. 414. JingZC,ParikhK,PulidoT,Jerjes-SanchezC,WhiteRJ,AllenR,etal.Efficacyand
392.SimonneauG,RubinLJ,GalièN,BarstRJ,FlemingTR,FrostAE,etal.Additionof safetyoforaltreprostinilmonotherapyforthetreatmentofpulmonaryarterial sildenafiltolong-termintravenousepoprostenoltherapyinpatientswithpulmon- hypertension:arandomized,controlledtrial.Circulation2013;127:624–633.
aryarterialhypertension:arandomizedtrial.AnnInternMed2008;149:521–530. 415. WhiteRJ,Jerjes-SanchezC,BohnsMeyerGM,PulidoT,SepulvedaP,WangKY,
393.GalièN,BrundageBH,GhofraniHA,OudizRJ,SimonneauG,SafdarZ,etal. etal.Combinationtherapywithoraltreprostinilforpulmonaryarterialhyperten-
Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119: sion.Adouble-blindplacebo-controlledclinicaltrial.AmJRespirCritCareMed2020;
2894–2903.
201:707–717.
416. BarstRJ,McGoonM,McLaughlinV,TapsonV,RichS,RubinL,etal.Beraprostther-
394.SchermulyRT,JanssenW,WeissmannN,StaschJP,GrimmingerF,GhofraniHA.
apyforpulmonaryarterialhypertension.JAmCollCardiol2003;41:2119–2125.
Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig
417. GalièN,HumbertM,VachieryJL,VizzaCD,KneusslM,ManesA,etal.Effectsof
Drugs2011;20:567–576.
beraprostsodium,anoralprostacyclinanalogue,inpatientswithpulmonaryarterial
395.GhofraniHA,GalièN,GrimmingerF,GrunigE,HumbertM,JingZC,etal.Riociguat
hypertension:arandomized,double-blind,placebo-controlledtrial.JAmCollCardiol
forthetreatmentofpulmonaryarterialhypertension.NEnglJMed2013;369: 2002;39:1496–1502.
330–340.
418. SimonneauG,TorbickiA,HoeperMM,DelcroixM,KarlocaiK,GalièN,etal.
396.GalièN,ManesA,BranziA.Prostanoidsforpulmonaryarterialhypertension.AmJ
Selexipag:anoral,selectiveprostacyclinreceptoragonistforthetreatmentofpul-
RespirMed2003;2:123–137.
monaryarterialhypertension.EurRespirJ2012;40:874–880.
397.JonesDA,BenjaminCW,LinsemanDA.Activationofthromboxaneandprostacyc-
419. SitbonO,ChannickR,ChinKM,FreyA,GaineS,GalièN,etal.Selexipagforthe
linreceptorselicitsopposingeffectsonvascularsmoothmusclecellgrowthand treatmentofpulmonaryarterialhypertension.NEnglJMed2015;373:2522–2533.
mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48: 419a. McLaughlinV,ChannickRN,GhofraniH-A,LemariéJ-C,NaeijeR,PackerM,etal.
890–896. Bosentanaddedtosildenafiltherapyinpatientswithpulmonaryarterialhyperten-
398.Sitbon O, DelcroixM, Bergot E, Boonstra AB, Granton J, Langleben D, et al. sion.EurRespirJ2015;46:405–413.
EPITOME-2:Anopen-labelstudyassessingthetransitiontoanewformulation 420. HoeperMM,McLaughlinVV,BarberaJA,FrostAE,GhofraniHA,PeacockAJ,etal.
of intravenous epoprostenol in patients with pulmonary arterial hypertension. Initialcombinationtherapywithambrisentanandtadalafilandmortalityinpatients
AmHeartJ2014;167:210–217. withpulmonaryarterialhypertension:asecondaryanalysisoftheresultsfromthe
399.BarstRJ,RubinLJ,LongWA,McGoonMD,RichS,BadeschDB,etal.Acomparison randomised,controlledAMBITIONstudy.LancetRespirMed2016;4:894–901.
ofcontinuousintravenousepoprostenol(prostacyclin)withconventionaltherapy 421. ChinKM,SitbonO,DoelbergM,FeldmanJ,GibbsJSR,GrunigE,etal.Three-versus
forprimarypulmonaryhypertension.ThePrimaryPulmonaryHypertensionStudy two-drugtherapyforpatientswithnewlydiagnosedpulmonaryarterialhyperten-
Group.NEnglJMed1996;334:296–302. sion.JAmCollCardiol2021;78:1393–1403.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 105 ---
3722 ESC/ERSGuidelines
422. BadagliaccaR,D’AltoM,GhioS,ArgientoP,BellomoV,BrunettiND,etal.Risk 444. DardiF,ManesA,PalazziniM,BachettiC,MazzantiG,RinaldiA,etal.Combining
reductionandhemodynamicswithinitialcombinationtherapyinpulmonaryarter- bosentanandsildenafilinpulmonaryarterialhypertensionpatientsfailingmono-
ialhypertension.AmJRespirCritCareMed2021;203:484–492. therapy:real-worldinsights.EurRespirJ2015;46:414–421.
423. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al. 445. IversenK,JensenAS,JensenTV,VejlstrupNG,SondergaardL.Combinationther-
Ambrisentanandtadalafilup-frontcombinationtherapyinscleroderma-associated apywithbosentanandsildenafilinEisenmengersyndrome:arandomized,placebo-
pulmonaryarterialhypertension.AmJRespirCritCareMed2015;192:1102–1110. controlled,double-blindedtrial.EurHeartJ2010;31:1124–1131.
424. KirtaniaL,MaitiR,SrinivasanA,MishraA.Effectofcombinationtherapyofen- 446. VizzaCD,JansaP,TealS,DombiT,ZhouD.Sildenafildosedconcomitantlywith
dothelinreceptorantagonistandphosphodiesterase-5inhibitoronclinicalout- bosentanforadultpulmonaryarterialhypertensioninarandomizedcontrolled
come and pulmonary haemodynamics in patients with pulmonary arterial trial.BMCCardiovascDisord2017;17:239.
hypertension:ameta-analysis.ClinDrugInvestig2019;39:1031–1044. 447. HoeperMM,HuscherD,GhofraniHA,DelcroixM,DistlerO,SchweigerC,etal.
425. MontaniD,LauEM,DorfmullerP,GirerdB,JaisX,SavaleL,etal.Pulmonary Elderlypatientsdiagnosedwithidiopathicpulmonaryarterialhypertension:results
veno-occlusivedisease.EurRespirJ2016;47:1518–1534. fromtheCOMPERAregistry.IntJCardiol2013;168:871–880.
426. SitbonO,JaisX,SavaleL,CottinV,BergotE,MacariEA,etal.Upfronttriplecom- 448. KhouV,AndersonJJ,StrangeG,CorriganC,CollinsN,CelermajerDS,etal.
binationtherapyinpulmonaryarterialhypertension:apilotstudy.EurRespirJ2014; Diagnosticdelayinpulmonaryarterialhypertension:insightsfromtheAustralian
43:1691–1697. andNewZealandpulmonaryhypertensionregistry.Respirology2020;25:863–871.
427. D’AltoM,BadagliaccaR,ArgientoP,RomeoE,FarroA,PapaS,etal.Riskreduction 449. McLaughlinVV,VachieryJL,OudizRJ,RosenkranzS,GalièN,BarberaJA,etal.
andrightheartreverseremodelingbyupfronttriplecombinationtherapyinpul- Patientswithpulmonaryarterialhypertensionwithandwithoutcardiovascular
monaryarterialhypertension.Chest2020;157:376–383. riskfactors:resultsfromtheAMBITIONtrial.JHeartLungTransplant2019;38:
428. BouclyA,SavaleL,JaisX,BauerF,BergotE,BertolettiL,etal.Associationbetween 1286–1295.
initialtreatmentstrategyandlong-termsurvivalinpulmonaryarterialhypertension. 450. OpitzCF,HoeperMM,GibbsJS,KaemmererH,Pepke-ZabaJ,CoghlanJG,etal.
AmJRespirCritCareMed2021;204:842–854. Pre-capillary, combined, and post-capillary pulmonary hypertension: a patho-
429. HoeperMM,Al-HitiH,BenzaRL,ChangSA,CorrisPA,GibbsJSR,etal.Switching physiologicalcontinuum.JAmCollCardiol2016;68:368–378.
toriociguatversusmaintenancetherapywithphosphodiesterase-5inhibitorsinpa- 451. LewisRA,ThompsonAAR,BillingsCG,CharalampopoulosA,ElliotCA,Hamilton
tientswithpulmonaryarterialhypertension(REPLACE):amulticentre,open-label, N,etal.Mildparenchymallungdiseaseand/orlowdiffusioncapacityimpactssur-
randomisedcontrolledtrial.LancetRespirMed2021;9:573–584. vivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryar-
430. SitbonO,CottinV,CanuetM,ClersonP,GressinV,PerchenetL,etal.Initialcom- terialhypertension.EurRespirJ2020;55:2000041.
binationtherapyofmacitentanandtadalafilinpulmonaryarterialhypertension.Eur 452. Valentin S, Maurac A, Sitbon O, Beurnier A, Gomez E, Guillaumot A, et al.
RespirJ2020;56:2000673.doi:10.1183/13993003.00673-2020. Outcomesofpatientswithdecreasedarterialoxyhaemoglobinsaturationonpul-
431. CoghlanJG,ChannickR,ChinK,DiScalaL,GalièN,GhofraniHA,etal.Targeting monaryarterialhypertensiondrugs.EurRespirJ2021;58:2004066.
theprostacyclinpathwaywithselexipaginpatientswithpulmonaryarterialhyper- 453. RosenkranzS,ChannickR,ChinKM,JennerB,GaineS,GalièN,etal.Theimpactof
tensionreceivingdoublecombinationtherapy:insightsfromtherandomizedcon- comorbiditiesonselexipagtreatmenteffectinpatientswithpulmonaryarterial
trolledGRIPHONstudy.AmJCardiovascDrugs2018;18:37–47. hypertension:insightsfromtheGRIPHONstudy.EurJHeartFail2022;24:205–214.
432. LajoieAC,LauziereG,LegaJC,LacasseY,MartinS,SimardS,etal.Combination 454. KhanMS,MemonMM,AminE,YamaniN,KhanSU,FigueredoVM,etal.Useof
therapyversusmonotherapyforpulmonaryarterialhypertension:ameta-analysis. balloonatrialseptostomyinpatientswithadvancedpulmonaryarterialhyperten-
LancetRespirMed2016;4:291–305. sion:asystematicreviewandmeta-analysis.Chest2019;156:53–63.
433. HoeperMM,PauschC,GrunigE,StaehlerG,HuscherD,PittrowD,etal.Temporal 455. SandovalJ,GasparJ,PulidoT,BautistaE,Martinez-GuerraML,ZeballosM,etal.
trendsinpulmonaryarterialhypertension:resultsfromtheCOMPERAregistry. Gradedballoondilationatrialseptostomyinsevereprimarypulmonaryhyperten-
EurRespirJ2022;59:2102024.doi:10.1183/13993003.02024-2021. sion.Atherapeuticalternativeforpatientsnonresponsivetovasodilatortreatment.
434. ZeltJGE, SugarmanJ, WeatheraldJ, PartridgeACR,LiangJC,SwistonJ, etal. JAmCollCardiol1998;32:297–304.
MortalitytrendsinpulmonaryarterialhypertensioninCanada:atemporalanalysis 456. AggarwalM,GradyRM,ChoudhryS,AnwarS,EghtesadyP,SinghGK.Pottsshunt
of survival per ESC/ERS Guideline Era. Eur Respir J 2022;59:2101552. doi: improvesrightventricularfunctionandcouplingwithpulmonarycirculationinchil-
10.1183/13993003.01552-2021. drenwithsuprasystemicpulmonaryarterialhypertension.CircCardiovascImaging
435. HoeperMM,SimonneauG,CorrisPA,GhofraniHA,KlingerJR,LanglebenD,etal. 2018;11:e007964.
RESPITE:switchingtoriociguatinpulmonaryarterialhypertensionpatientswith 457. BaruteauAE,BelliE,BoudjemlineY,LauxD,LevyM,SimonneauG,etal.Palliative
inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017;50: Pottsshuntforthetreatmentofchildrenwithdrug-refractorypulmonaryarterial
1602425. hypertension:updateddatafromthefirst24patients.EurJCardiothoracSurg2015;
436. BartolomeSD,SoodN,ShahTG,StyrvokyK,TorresF,ChinKM.Mortalityinpa- 47:e105–e110.
tientswithpulmonaryarterialhypertensiontreatedwithcontinuousprostanoids. 458. Grady RM, Canter M, Shmalts A, Coleman R, Beghetti M, Berger RM, et al.
Chest2018;154:532–540. Pulmonary-to-systemicarterialshuntinchildrenwithseverepulmonaryhyperten-
437. GalièN,JansaP,PulidoT,ChannickRN,DelcroixM,GhofraniHA,etal.SERAPHIN sion.JAmCollCardiol2021;78:468–477.
haemodynamicsubstudy:theeffectofthedualendothelinreceptorantagonistma- 459. RosenzweigEB,AnkolaA,KrishnanU,MiddlesworthW,BachaE,BacchettaM.A
citentanonhaemodynamicparametersandNT-proBNPlevelsandtheirassoci- novelunidirectional-valvedshuntapproachforend-stagepulmonaryarterialhyper-
ationwithdiseaseprogressioninpatientswithpulmonaryarterialhypertension. tension:earlyexperienceinadolescentsandadults.JThoracCardiovascSurg2021;
EurHeartJ2017;38:1147–1155. 161:1438–1446.e1432.
438. SimonneauG,RubinLJ,GalièN,BarstRJ,FlemingTR,FrostA,etal.Long-termsil- 460. CiarkaA,DoanV,Velez-RoaS,NaeijeR,vandeBorneP.Prognosticsignificanceof
denafiladdedtointravenousepoprostenol inpatientswithpulmonaryarterial sympatheticnervoussystemactivationinpulmonaryarterialhypertension.AmJ
hypertension.JHeartLungTransplant2014;33:689–697. RespirCritCareMed2010;181:1269–1275.
439. BenzaRL,SeegerW,McLaughlinVV,ChannickRN,VoswinckelR,TapsonVF,etal. 461. Velez-RoaS,CiarkaA,NajemB,VachieryJL,NaeijeR,vandeBorneP.Increased
Long-termeffectsofinhaledtreprostinilinpatientswithpulmonaryarterialhyper- sympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;
tension:theTreprostinilSodiumInhalationUsedintheManagementofPulmonary 110:1308–1312.
Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung 462. JuratschCE,JengoJA,CastagnaJ,LaksMM.Experimentalpulmonaryhypertension
Transplant2011;30:1327–1333. producedbysurgicalandchemicaldenervationofthepulmonaryvasculature.Chest
440. RubinLJ,GalièN,GrimmingerF,GrunigE,HumbertM,JingZC,etal.Riociguatfor 1980;77:525–530.
thetreatmentofpulmonaryarterialhypertension:along-termextensionstudy 463. RothmanA,JonasM,CastelD,TzafririAR,TraxlerH,ShavD,etal.Pulmonaryar-
(PATENT-2).EurRespirJ2015;45:1303–1313. terydenervationusingcatheter-basedultrasonicenergy.EuroIntervention2019;15:
441. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al. 722–730.
Combininginhalediloprostwithbosentaninpatientswithidiopathicpulmonaryar- 464. ChenSL,ZhangFF,XuJ,XieDJ,ZhouL,NguyenT,etal.Pulmonaryarterydenerv-
terialhypertension.EurRespirJ2006;28:691–694. ation to treat pulmonary arterial hypertension: the single-center, prospective,
442. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. first-in-manPADN-1study(first-in-manpulmonaryarterydenervationfortreat-
Randomizedstudyofaddinginhalediloprosttoexistingbosentaninpulmonaryar- mentofpulmonaryarteryhypertension).JAmCollCardiol2013;62:1092–1100.
terialhypertension.AmJRespirCritCareMed2006;174:1257–1263. 465. RothmanAMK,VachieryJL,HowardLS,MikhailGW,LangIM,JonasM,etal.
443. BadeschDB,FeldmanJ,KeoghA,MathierMA,OudizRJ,ShapiroS,etal.ARIES-3: Intravascularultrasoundpulmonaryarterydenervationtotreatpulmonaryarterial
ambrisentantherapyinadiversepopulationofpatientswithpulmonaryhyperten- hypertension(TROPHY1):multicenter,earlyfeasibilitystudy.JACCCardiovascInterv
sion.CardiovascTher2012;30:93–99. 2020;13:989–999.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 106 ---
ESC/ERSGuidelines 3723
466.SztrymfB,SouzaR,BertolettiL,JaisX,SitbonO,PriceLC,etal.Prognosticfactors 489. MakSM,StricklandN,GopalanD.Complicationsofpulmonaryhypertension:apic-
ofacuteheartfailureinpatientswithpulmonaryarterialhypertension.EurRespirJ torialreview.BrJRadiol2017;90:20160745.
2010;35:1286–1293. 490. Nuche J, Montero Cabezas JM, Alonso Charterina S, Escribano Subias P.
467.Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al. Management of incidentally diagnosed pulmonary artery dissection in patients
Outcomesofhospitalisationforrightheartfailureinpulmonaryarterialhyperten- withpulmonaryarterialhypertension.EurJCardiothoracSurg2019;56:210–212.
sion.EurRespirJ2011;38:359–367. 491. RussoV,ZompatoriM,GalièN.Extensiverightpulmonaryarterydissectionina
468.HoeperMM,BenzaRL,CorrisP,dePerrotM,FadelE,KeoghAM,etal.Intensive youngpatientwithchronicpulmonaryhypertension.Heart2012;98:265–266.
care,rightventricularsupportandlungtransplantationinpatientswithpulmonary 492. ZylkowskaJ,KurzynaM,FlorczykM,BurakowskaB,GrzegorczykF,BurakowskiJ,
hypertension.EurRespirJ2019;53:1801906. etal.Pulmonaryarterydilatationcorrelateswiththeriskofunexpecteddeathin
469.Kapur NK, Esposito ML, Bader Y, Morine KJ, Kiernan MS, Pham DT, et al. chronic arterial or thromboembolic pulmonary hypertension. Chest 2012;142:
Mechanical circulatory support devices for acute right ventricular failure. 1406–1416.
Circulation2017;136:314–326. 493. FlorczykM,WieteskaM,KurzynaM,GosciniakP,Pepke-ZabaJ,BiedermanA,etal.
470.KonstamMA,KiernanMS,BernsteinD,BozkurtB,JacobM,KapurNK,etal. Acuteandchronicdissectionofpulmonaryartery:newchallengesinpulmonaryar-
Evaluation and management of right-sided heart failure: a scientific statement terialhypertension?PulmCirc2018;8:2045893217749114.
fromtheAmericanHeartAssociation.Circulation2018;137:e578–e622. 494. VelazquezMartinM,MonteroCabezasJM,HuertasS,NucheJ,AlbarranA,Delgado
471.OlssonKM,RichterMJ,KampJC,GallH,GhofraniHA,FugeJ,etal.Refinedrisk JF,etal.Clinicalrelevanceofaddingintravascularultrasoundtocoronaryangiog-
stratificationinpulmonaryarterialhypertensionandtimingoflungtransplantation. raphyforthediagnosisofextrinsicleftmaincoronaryarterycompressionbyapul-
EurRespirJ2022.doi:10.1183/13993003.03087-2021.Epubaheadofprint. monaryarteryaneurysminpulmonaryhypertension.CatheterCardiovascInterv
472.MoserB,JakschP,TaghaviS,MurakozyG,LangG,HagerH,etal.Lungtransplant- 2021;98:691–700.
ationforidiopathicpulmonaryarterialhypertensiononintraoperativeandpost- 495. TorresF,FarberH,RisticA,McLaughlinV,AdamsJ,ZhangJ,etal.Efficacyandsafety
operativelyprolongedextracorporealmembraneoxygenationprovidesoptimally ofralinepag,anoveloralIPagonist,inPAHpatientsonmonoordualbackground
controlledreperfusionandexcellentoutcome.EurJCardiothoracSurg2018;53: therapy:resultsfromaphase2randomised,parallelgroup,placebo-controlledtrial.
178–185. EurRespirJ2019;54:1901030.
473.ChristieJD,EdwardsLB,KucheryavayaAY,BendenC,DipchandAI,DobbelsF, 496. HumbertM,McLaughlinV,GibbsJSR,Gomberg-MaitlandM,HoeperMM,Preston
et al. The Registry of the International Society for Heart and Lung IR,etal.Sotaterceptforthetreatmentofpulmonaryarterialhypertension.NEnglJ
Transplantation:29thadultlungandheart-lungtransplantreport-2012.JHeart Med2021;384:1204–1215.
LungTransplant2012;31:1073–1086. 497. ChinKM,ChannickRN,RubinLJ.Ismethamphetamineuseassociatedwithidio-
474.EganTM,EdwardsLB.Effectofthelungallocationscoreonlungtransplantationin pathicpulmonaryarterialhypertension?Chest2006;130:1657–1663.
theUnitedStates.JHeartLungTransplant2016;35:433–439. 498. ZamanianRT, HedlinH,Greuenwald P,Wilson DM,SegalJI,JordenM,et al.
475.SavaleL,LePavecJ,MercierO,MussotS,JaisX,FabreD,etal.Impactofhigh- Features and outcomes of methamphetamine-associated pulmonary arterial
priorityallocationonlungandheart-lungtransplantationforpulmonaryhyperten- hypertension.AmJRespirCritCareMed2018;197:788–800.
sion.AnnThoracSurg2017;104:404–411. 499. SavaleL,SattlerC,GuntherS,MontaniD,ChaumaisMC,PerrinS,etal.Pulmonary
476.YusenRD,EdwardsLB,KucheryavayaAY,BendenC,DipchandAI,GoldfarbSB, arterialhypertension in patientstreated withinterferon. EurRespir J 2014;44:
et al. The Registry of the International Society for Heart and Lung 1627–1634.
Transplantation: Thirty-second Official Adult Lung and Heart-Lung 500. WeatheraldJ,ChaumaisMC,SavaleL,JaisX,SeferianA,CanuetM,etal.Long-term
Transplantation Report–2015; Focus Theme: Early Graft Failure. J Heart Lung outcomes of dasatinib-induced pulmonary arterial hypertension: a population-
Transplant2015;34:1264–1277. basedstudy.EurRespirJ2017;50:1700217.
477.HindricksG,PotparaT,DagresN,ArbeloE,BaxJJ,Blomstrom-LundqvistC,etal. 501. Cardio-Oncology:LyonAR,López-FernándezT,CouchLS,AsteggianoR,Aznar
2020ESCGuidelinesforthediagnosisandmanagementofatrialfibrillationdevel- MC, Bergler-Klein J, et al. Guidelines on cardio-oncology. Eur Heart J 2022.
opedincollaborationwiththeEuropeanAssociationforCardio-ThoracicSurgery https://doi.org/10.1093/eurheartj/ehac244.
(EACTS):theTaskForceforthediagnosisandmanagementofatrialfibrillationof 502. AvouacJ,AiroP,MeuneC,BerettaL,DieudeP,CaramaschiP,etal.Prevalenceof
theEuropeanSocietyofCardiology(ESC)developedwiththespecialcontribution pulmonaryhypertensioninsystemicsclerosisinEuropeanCaucasiansandmetaa-
oftheEuropeanHeartRhythmAssociation(EHRA)oftheESC.EurHeartJ2021; nalysisof5studies.JRheumatol2010;37:2290–2298.
42:373–498. 503. LaunayD,MontaniD,HassounPM,CottinV,LePavecJ,ClersonP,etal.Clinical
478.WanamakerB,CascinoT,McLaughlinV,OralH,LatchamsettyR,SiontisKC.Atrial phenotypesandsurvivalofpre-capillarypulmonaryhypertensioninsystemicscler-
arrhythmiasinpulmonaryhypertension:pathogenesis,prognosisandmanagement. osis.PLoSOne2018;13:e0197112.
ArrhythmElectrophysiolRev2018;7:43–48. 504. LaunayD,SobanskiV,HachullaE,HumbertM.Pulmonaryhypertensioninsystemic
479.AndersenMO,DiederichsenSZ,SvendsenJH,CarlsenJ.Assessmentofcardiacar- sclerosis:differentphenotypes.EurRespirRev2017;26:170056.
rhythmias using long-term continuous monitoring in patients with pulmonary 505. HachullaE,JaisX,CinquettiG,ClersonP,RottatL,LaunayD,etal.Pulmonaryar-
hypertension.IntJCardiol2021;334:110–115. terialhypertensionassociatedwithsystemiclupuserythematosus:resultsfromthe
480.OlssonKM,NickelNP,TongersJ,HoeperMM.Atrialflutterandfibrillationinpa- FrenchPulmonaryHypertensionRegistry.Chest2018;153:143–151.
tientswithpulmonaryhypertension.IntJCardiol2013;167:2300–2305. 506. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al.
481.WenL,SunML,AnP,JiangX,SunK,ZhengL,etal.Frequencyofsupraventricular Immunosuppressive therapy in lupus- and mixed connective tissue
arrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J disease-associated pulmonary arterial hypertension: a retrospective analysis of
Cardiol2014;114:1420–1425. twenty-threecases.ArthritisRheum2008;58:521–531.
482.LuesebrinkU,FischerD,GezginF,DunckerD,KoenigT,OswaldH,etal.Ablation 507. QianJ,LiM,ZhangX,WangQ,ZhaoJ,TianZ,etal.Long-termprognosisofpa-
oftypicalrightatrialflutterinpatientswithpulmonaryhypertension.HeartLung tientswithsystemiclupuserythematosus-associatedpulmonaryarterialhyperten-
Circ2012;21:695–699. sion:CSTAR-PAHcohortstudy.EurRespirJ2019;53:1800081.
483.Santangeli P, Zado ES, Hutchinson MD, Riley MP, Lin D, Frankel DS, et al. 508. SangesS,YelnikCM,SitbonO,BenvenisteO,MariampillaiK,Phillips-HoulbracqM,
Prevalenceanddistributionoffocaltriggersinpersistentandlong-standingpersist- etal.Pulmonaryarterialhypertensioninidiopathicinflammatorymyopathies:data
entatrialfibrillation.HeartRhythm2016;13:374–382. fromtheFrenchpulmonaryhypertensionregistryandreviewoftheliterature.
484.GhignaMR,GuignabertC,MontaniD,GirerdB,JaisX,SavaleL,etal.BMPR2mu- Medicine(Baltimore)2016;95:e4911.
tationstatusinfluencesbronchialvascularchangesinpulmonaryarterialhyperten- 509. WangJ,LiM,WangQ,ZhangX,QianJ,ZhaoJ,etal.Pulmonaryarterialhyperten-
sion.EurRespirJ2016;48:1668–1681. sionassociatedwithprimarySjogren’ssyndrome:amulticentrecohortstudyfrom
485.RascitiE,SverzellatiN,SilvaM,CasadeiA,AttinaD,PalazziniM,etal.Bronchialar- China.EurRespirJ2020;56:1902157.
teryembolizationforthetreatmentofhaemoptysisinpulmonaryhypertension. 510. MontaniD,HenryJ,O’ConnellC,JaisX,CottinV,LaunayD,etal.Associationbe-
RadiolMed2017;122:257–264. tweenrheumatoidarthritisandpulmonaryhypertension:datafromtheFrench
486.YangS,WangJ,KuangT,GongJ,MaZ,ShenYH,etal.Efficacyandsafetyofbron- PulmonaryHypertensionRegistry.Respiration2018;95:244–250.
chialarteryembolizationonhemoptysisinchronicthromboembolicpulmonary 511. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al.
hypertension:apilotprospectivecohortstudy.CritCareMed2019;47:e182–e189. PulmonaryarterialhypertensioninFrance:resultsfromanationalregistry.AmJ
487.Demerouti EA, Manginas AN, Athanassopoulos GD, Karatasakis GT. RespirCritCareMed2006;173:1023–1030.
Complicationsleadingtosuddencardiacdeathinpulmonaryarterialhypertension. 512. HumbertM,KhaltaevN,BousquetJ,SouzaR.Pulmonaryhypertension:froman
RespirCare2013;58:1246–1254. orphandiseasetoapublichealthproblem.Chest2007;132:365–367.
488.KreibichM,SiepeM,KrollJ,HohnR,GrohmannJ,BeyersdorfF.Aneurysmsofthe 513. GuntherS,JaisX,MaitreS,BerezneA,DorfmullerP,SeferianA,etal.Computed
pulmonaryartery.Circulation2015;131:310–316. tomographyfindingsofpulmonaryvenoocclusivediseaseinsclerodermapatients
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 107 ---
3724 ESC/ERSGuidelines
presenting with precapillary pulmonary hypertension. Arthritis Rheum 2012;64: 536. MuirheadGJ,WulffMB,FieldingA,KleinermansD,BussN.Pharmacokineticinter-
2995–3005. actionsbetweensildenafilandsaquinavir/ritonavir.BrJClinPharmacol2000;50:
514. HsuS,Kokkonen-SimonKM,KirkJA,KolbTM,DamicoRL,MathaiSC,etal.Right 99–107.
ventricular myofilament functional differences in humans with systemic 537. GarraffoR,LavrutT,FerrandoS,DurantJ,RouyrreN,MacGregorTR,etal.Effect
sclerosis-associatedversusidiopathicpulmonaryarterialhypertension.Circulation oftipranavir/ritonavircombinationonthepharmacokineticsoftadalafilinhealthy
2018;137:2360–2370. volunteers.JClinPharmacol2011;51:1071–1078.
515. ChauvelotL,GamondesD,BerthillerJ,NievesA,RenardS,Catella-ChatronJ,etal. 538. AguilarRV,FarberHW.Epoprostenol(prostacyclin)therapyinHIV-associatedpul-
Hemodynamicresponsetotreatmentandoutcomesinpulmonaryhypertension
monaryhypertension.AmJRespirCritCareMed2000;162:1846–1850.
associatedwithinterstitiallungdiseaseversuspulmonaryarterialhypertensionin 539. Cea-CalvoL,EscribanoSubiasP,TellodeMenessesR,LazaroSalvadorM,Gomez
systemicsclerosis:datafromastudyidentifyingprognosticfactorsinpulmonary SanchezMA,DelgadoJimenezJF,etal.TreatmentofHIV-associatedpulmonary
hypertensionwithtreprostinil.RevEspCardiol2003;56:421–425.
hypertension associated with interstitial lung disease. Arthritis Rheum 2021;73:
295–304. 540. GhofraniHA,FrieseG,DischerT,OlschewskiH,SchermulyRT,WeissmannN,
etal.InhalediloprostisapotentacutepulmonaryvasodilatorinHIV-relatedsevere
516. LaunayD,SitbonO,HachullaE,MouthonL,GressinV,RottatL,etal.Survivalin
pulmonaryhypertension.EurRespirJ2004;23:321–326.
systemicsclerosis-associatedpulmonaryarterialhypertensioninthemodernman-
agementera.AnnRheumDis2013;72:1940–1946. 541. BignaJJ,SimePS,Koulla-ShiroS.HIVrelatedpulmonaryarterialhypertension:epi-
demiologyinAfrica,physiopathology,androleofantiretroviraltreatment.AIDSRes
517. RamjugS,HussainN,HurdmanJ,BillingsC,CharalampopoulosA,ElliotCA,etal.
Ther2015;12:36.
Idiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a
542. RyomL,CotterA,DeMiguelR,BeguelinC,PodlekarevaD,ArribasJR,etal.2019
comparisonofdemographic,hemodynamic,andMRIcharacteristicsandoutcomes.
updateoftheEuropeanAIDSClinicalSocietyGuidelinesfortreatmentofpeople
Chest2017;152:92–102.
livingwithHIVversion10.0.HIVMed2020;21:617–624.
518. PanJ,LeiL,ZhaoC.Comparisonbetweentheefficacyofcombinationtherapyand
543. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, et al.
monotherapyinconnectivetissuediseaseassociatedpulmonaryarterialhyperten-
Portopulmonary hypertension: a report from the US-based REVEAL Registry.
sion: a systematic review and meta-analysis. Clin Exp Rheumatol 2018;36: Chest2012;141:906–915.
1095–1102.
544. Lazaro Salvador M, Quezada Loaiza CA, Rodriguez Padial L, Barbera JA,
519. SanchezO,SitbonO,JaisX,SimonneauG,HumbertM.Immunosuppressivether- Lopez-MeseguerM,Lopez-ReyesR,etal.Portopulmonaryhypertension:prognosis
apyinconnectivetissuediseases-associatedpulmonaryarterialhypertension.Chest andmanagementinthecurrenttreatmentera-resultsfromtheREHAPregistry.
2006;130:182–189. InternMedJ2021;51:355–365.
520. HumbertM,CoghlanJG,GhofraniHA,GrimmingerF,HeJG,RiemekastenG,etal. 545. Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al.
Riociguatforthetreatmentofpulmonaryarterialhypertensionassociatedwith Portopulmonaryhypertensioninthecurrenteraofpulmonaryhypertensionman-
connectivetissuedisease:resultsfromPATENT-1andPATENT-2.AnnRheum agement.JHepatol2020;73:130–139.
Dis2017;76:422–426. 546. BaigesA,TuronF,Simon-TaleroM,TasaycoS,BuenoJ,ZekriniK,etal.Congenital
521. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. extrahepaticportosystemicshunts(Abernethymalformation):aninternationalob-
Hemodynamicsandsurvivalinpatientswithpulmonaryarterialhypertensionre- servationalstudy.Hepatology2020;71:658–669.
latedtosystemicsclerosis.Chest2003;123:344–350. 547. FussnerLA,IyerVN,Cartin-CebaR,LinG,WattKD,KrowkaMJ.Intrapulmonary
522. TrombettaAC,PizzorniC,RuaroB,PaolinoS,SulliA,SmithV,etal.Effectsoflong- vasculardilatationsarecommoninportopulmonaryhypertensionandmaybeas-
termtreatmentwithbosentanandiloprostonnailfoldabsolutecapillarynumber, sociatedwithdecreasedsurvival.LiverTranspl2015;21:1355–1364.
fingertipbloodperfusion,andclinicalstatusinsystemicsclerosis.JRheumatol2016; 548. HoeperMM,HalankM,MarxC,HoeffkenG,SeyfarthHJ,SchauerJ,etal.Bosentan
43:2033–2041. therapyforportopulmonaryhypertension.EurRespirJ2005;25:502–508.
523. PradereP,TudoracheI,MagnussonJ,SavaleL,BrugiereO,DouvryB,etal.Lung 549. OlssonKM,MeyerK,BerlinerD,HoeperMM.Developmentofhepatopulmonary
transplantationforsclerodermalungdisease:Aninternational,multicenter,obser- syndrome during combination therapy for portopulmonary hypertension. Eur
vationalcohortstudy.JHeartLungTransplant2018;37:903–911. RespirJ2019;53:1801880.
524. GaineS,ChinK,CoghlanG,ChannickR,DiScalaL,GalièN,etal.Selexipagforthe 550. KrowkaMJ,PlevakDJ,FindlayJY,RosenCB,WiesnerRH,KromRA.Pulmonary
treatmentofconnectivetissuedisease-associatedpulmonaryarterialhypertension. hemodynamicsandperioperativecardiopulmonary-relatedmortalityinpatients
EurRespirJ2017;50:1602493. withportopulmonaryhypertensionundergoinglivertransplantation.LiverTranspl
525. BarbaroG,LucchiniA,PellicelliAM,GrisorioB,GiancasproG,FauarbariniG,etal.
2000;6:443–450.
HighlyactiveantiretroviraltherapycomparedwithHAARTandbosentanincom- 551. Cartin-CebaR,BurgerC,SwansonK,VargasH,AqelB,KeavenyAP,etal.Clinical
outcomesafterlivertransplantationinpatientswithportopulmonaryhyperten-
binationinpatientswithHIV-associatedpulmonaryhypertension.Heart2006;92:
1164–1166.
sion.Transplantation2021;105:2283–2290.
552. Deroo R, Trepo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, et al.
526. DeganoB,GuillaumeM,SavaleL,MontaniD,JaisX,YaiciA,etal.HIV-associated
Vasomodulatorsandlivertransplantationforportopulmonaryhypertension:evi-
pulmonaryarterialhypertension:survivalandprognosticfactorsinthemodern
therapeuticera.AIDS2010;24:67–75. dence from a systematic review and meta-analysis. Hepatology 2020;72:
1701–1716.
527. SitbonO.HIV-relatedpulmonaryarterialhypertension:clinicalpresentationand
553. SaddCJ,OsmanF,LiZ,ChybowskiA,DeckerC,HendersonB,etal.Long-term management.AIDS2008;22:S55–S62.
outcomesandsurvivalinmoderate-severeportopulmonaryhypertensionafterli-
528. OpravilM,SereniD.NaturalhistoryofHIV-associatedpulmonaryarterialhyper- vertransplant.Transplantation2021;105:346–353.
tension:trendsintheHAARTera.AIDS(London,England)2008;22:S35–S40.
554. SavaleL,SattlerC,CoillyA,ContiF,RenardS,FrancozC,etal.Long-termoutcome
529. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al.
inlivertransplantationcandidateswithportopulmonaryhypertension.Hepatology
Platelet-derived growth factor expression in primary pulmonary hypertension: 2017;65:1683–1692.
comparisonofHIVseropositiveandHIVseronegativepatients.EurRespirJ1998;
555. DillerGP,KempnyA,Alonso-GonzalezR,SwanL,UebingA,LiW,etal.Survival
11:554–559.
prospectsandcircumstancesofdeathincontemporaryadultcongenitalheartdis-
530. MehtaNJ,KhanIA,MehtaRN,SepkowitzDA.HIV-relatedpulmonaryhyperten-
ease patients under follow-up at a large tertiary centre. Circulation 2015;132:
sion:analyticreviewof131cases.Chest2000;118:1133–1141. 2118–2125.
531. ZuberJP,CalmyA,EvisonJM,HasseB,SchifferV,WagelsT,etal.Pulmonaryar- 556. vanRielAC,SchuuringMJ,vanHessenID,ZwindermanAH,CozijnsenL,Reichert
terialhypertensionrelatedtoHIVinfection:improvedhemodynamicsandsurvival CL,etal.Contemporaryprevalenceofpulmonaryarterialhypertensioninadult
associatedwithantiretroviraltherapy.ClinInfectDis2004;38:1178–1185. congenitalheartdiseasefollowingtheupdatedclinicalclassification.IntJCardiol
532. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al. 2014;174:299–305.
Bosentanforthetreatmentofhumanimmunodeficiencyvirus-associatedpulmon-
557. LammersAE,BauerLJ,DillerGP,HelmPC,Abdul-KhaliqH,BauerUMM,etal.
aryarterialhypertension.AmJRespirCritCareMed2004;170:1212–1217. Pulmonaryhypertensionaftershunt closureinpatientswithsimplecongenital
533. DeganoB,YaiciA,LePavecJ,SavaleL,JaisX,CamaraB,etal.Long-termeffectsof heartdefects.IntJCardiol2020;308:28–32.
bosentan in patientswith HIV-associated pulmonary arterialhypertension. Eur 558. NtiloudiD,ZanosS,GatzoulisMA,KarvounisH,GiannakoulasG.Howtoevaluate
RespirJ2009;33:92–98. patientswithcongenital heart disease-relatedpulmonary arterialhypertension.
534. CarlsenJ,KjeldsenK,GerstoftJ.Sildenafilasasuccessfultreatmentofotherwise ExpertRevCardiovascTher2019;17:11–18.
fatalHIV-relatedpulmonaryhypertension.AIDS2002;16:1568–1569. 559. DimopoulosK,CondliffeR,TullohRMR,CliftP,Alonso-GonzalezR,BedairR,etal.
535. SchumacherYO,ZdebikA,HuonkerM,KreiselW.SildenafilinHIV-relatedpul- Echocardiographicscreeningforpulmonaryhypertensionincongenitalheartdis-
monaryhypertension.AIDS2001;15:1747–1748. ease:JACCreviewtopicoftheweek.JAmCollCardiol2018;72:2778–2788.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 108 ---
ESC/ERSGuidelines 3725
560.KempnyA,DimopoulosK,FraisseA,DillerGP,PriceLC,RafiqI,etal.Bloodvis- 585. DimopoulosK,MuthiahK,Alonso-GonzalezR,BannerNR,WortSJ,SwanL,etal.
cosityanditsrelevancetothediagnosisandmanagementofpulmonaryhyperten- Heartorheart-lungtransplantationforpatientswithcongenitalheartdiseasein
sion.JAmCollCardiol2019;73:2640–2642. England.Heart2019;105:596–602.
561.ArvanitakiA,GiannakoulasG,BaumgartnerH,LammersAE.Eisenmengersyn- 586. Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, et al.
drome:diagnosis,prognosisandclinicalmanagement.Heart2020;106:1638–1645. Cardiopulmonarymanifestationsofhepatosplenicschistosomiasis.Circulation
562.DillerGP,KortenMA,BauerUM,MieraO,TutarelO,KaemmererH,etal.Current 2009;119:1518–1523.
therapyandoutcomeofEisenmengersyndrome:dataoftheGermanNational 587. KnaflD,GergesC,KingCH,HumbertM,BustinduyAL.Schistosomiasis-associated
Registerforcongenitalheartdefects.EurHeartJ2016;37:1449–1455. pulmonaryarterialhypertension:asystematicreview.EurRespirRev2020;29:190089.
563.Kempny A, Hjortshoj CS, Gu H, Li W, Opotowsky AR, Landzberg MJ, et al. 588. FernandesCJC,PilotoB,CastroM,GavilanesOleasF,AlvesJLJr,LopesPradaLF,
PredictorsofdeathincontemporaryadultpatientswithEisenmengersyndrome: etal.Survivalofpatientswithschistosomiasis-associatedpulmonaryarterialhyper-
amulticenterstudy.Circulation2017;135:1432–1440. tensioninthemodernmanagementera.EurRespirJ2018;51:1800307.
564.ArvindB,RelanJ,KothariSS.“Treatandrepair”strategyforshuntlesions:acritical 589. Weatherald J, Dorfmuller P, Perros F, Ghigna MR, Girerd B, Humbert M, et al.
review.PulmCirc2020;10:2045894020917885. Pulmonarycapillaryhaemangiomatosis:adistinctentity?EurRespirRev2020;29:190168.
565.BridaM,NashatH,GatzoulisMA.Pulmonaryarterialhypertension:closingthegap 590. HumbertM,GuignabertC,BonnetS,DorfmullerP,KlingerJR,NicollsMR,etal.
incongenitalheartdisease.CurrOpinPulmMed2020;26:422–428. Pathologyandpathobiologyofpulmonaryhypertension:stateoftheartandre-
566.vanderFeenDE,BarteldsB,deBoerRA,BergerRMF.Assessmentofreversibilityin searchperspectives.EurRespirJ2019;53:1801887.
pulmonaryarterialhypertensionandcongenitalheartdisease.Heart2019;105: 591. MontaniD,GirerdB,JaisX,LevyM,AmarD,SavaleL,etal.Clinicalphenotypesand
276–282. outcomes of heritable and sporadic pulmonary veno-occlusive disease: a
567.Becker-GrunigT,KloseH,EhlkenN,LichtblauM,NagelC,FischerC,etal.Efficacy population-basedstudy.LancetRespirMed2017;5:125–134.
ofexercisetraininginpulmonaryarterialhypertensionassociatedwithcongenital 592. Perez-OlivaresC,SeguradelaCalT,Flox-CamachoA,NucheJ,TenorioJ,Martinez
heartdisease.IntJCardiol2013;168:375–381. MenacaA,etal.Theroleofcardiopulmonaryexercisetestinidentifyingpulmonary
568.HartopoAB,AnggrahiniDW,NurdiatiDS,EmotoN,DinartiLK.Severepulmon- veno-occlusivedisease.EurRespirJ2021;57:2100115.
aryhypertensionandreducedrightventriclesystolicfunctionassociatedwithma- 593. BergbaumC,SamaranayakeCB,PitcherA,WeingartE,SempleT,KokosiM,etal.A
ternalmortalityinpregnantuncorrectedcongenitalheartdiseases.PulmCirc2019; caseseriesontheuseofsteroidsandmycophenolatemofetilinidiopathicandher-
itablepulmonaryveno-occlusivedisease:istherearoleforimmunosuppression?
9:2045894019884516.
569.LiQ,DimopoulosK,LiuT,XuZ,LiuQ,LiY,etal.Peripartumoutcomesinalarge EurRespirJ2021;57:2004354.
594. vanLoonRL,RoofthooftMT,HillegeHL,tenHarkelAD,vanOsch-GeversM,Delhaas
populationofwomenwithpulmonaryarterialhypertensionassociatedwithcon-
genitalheartdisease.EurJPrevCardiol2019;26:1067–1076. T,etal.PediatricpulmonaryhypertensionintheNetherlands:epidemiologyandchar-
acterizationduringtheperiod1991to2005.Circulation2011;124:1755–1764.
570.Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,
595. delCerroMarinMJ,SabateRotesA,RodriguezOgandoA,MendozaSotoA,
CifkovaR,DeBonisM,etal.2018ESCGuidelinesforthemanagementofcardio-
vasculardiseasesduringpregnancy.EurHeartJ2018;39:3165–3241. QueroJimenezM,GavilanCamachoJL,etal.Assessingpulmonaryhypertensive
vasculardiseasein childhood. Datafromthe Spanish registry.Am JRespir Crit
571.BlancheC,Alonso-GonzalezR,UribarriA,KempnyA,SwanL,PriceL,etal.Useof
CareMed2014;190:1421–1429.
intravenousironincyanoticpatientswithcongenitalheartdiseaseand/orpulmon-
aryhypertension.IntJCardiol2018;267:79–83. 596. LiL,JickS,BreitensteinS,HernandezG,MichelA,VizcayaD.Pulmonaryarterial
hypertensionintheUSA:anepidemiologicalstudyinalargeinsuredpediatricpopu-
572.BertolettiL,MismettiV,GiannakoulasG.Useofanticoagulantsinpatientswithpul-
monaryhypertension.Hamostaseologie2020;40:348–355.
lation.PulmCirc2017;7:126–136.
597. BergerRM,BeghettiM,HumplT,RaskobGE,IvyDD,JingZC,etal.Clinicalfeatures
573.FreisingerE,GerssJ,MakowskiL,MarschallU,ReineckeH,BaumgartnerH,etal.
ofpaediatricpulmonaryhypertension:aregistrystudy.Lancet2012;379:537–546.
Currentuseandsafetyofnoveloralanticoagulantsinadultswithcongenitalheart
598. AbmanSH,MullenMP,SleeperLA,AustinED,RosenzweigEB,KinsellaJP,etal.
disease:resultsofanationwideanalysisincludingmorethan44000patients.Eur
Characterisationofpaediatricpulmonaryhypertensivevasculardiseasefromthe
HeartJ2020;41:4168–4177.
PPHNetRegistry.EurRespirJ2021;59:2003337.
574.GalièN,BeghettiM,GatzoulisMA,GrantonJ,BergerRM,LauerA,etal.Bosentan
599. RosenzweigEB,AbmanSH,AdatiaI,BeghettiM,BonnetD,HaworthS,etal.
therapyinpatientswithEisenmengersyndrome:amulticenter,double-blind,ran- Paediatricpulmonaryarterialhypertension:updatesondefinition,classification,
domized,placebo-controlledstudy.Circulation2006;114:48–54.
diagnosticsandmanagement.EurRespirJ2019;53:1801916.
575.GatzoulisMA,LandzbergM,BeghettiM,BergerRM,EfficaceM,GesangS,etal.
600. Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR, Breeman KTN,
Evaluation of Macitentan in patients with Eisenmenger syndrome. Circulation
TimensW,VosYJ,etal.Thegeneticepidemiologyofpediatricpulmonaryarterial
2019;139:51–63.
hypertension.JPediatr2020;225:65–73.e65.
576.Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB.
601. LevyM,EyriesM,SzezepanskiI,LadouceurM,NadaudS,BonnetD,etal.Genetic
Ambrisentanforpulmonaryarterialhypertensionduetocongenitalheartdisease.
analysesinacohortofchildrenwithpulmonaryhypertension.EurRespirJ2016;48:
AmJCardiol2011;107:1381–1385. 1118–1126.
577.NashatH,KempnyA,HarriesC,DormandN,Alonso-GonzalezR,PriceLC,etal.A
602. MouraniPM,AbmanSH.Pulmonaryhypertensionandvascularabnormalitiesin
single-centre, placebo-controlled, double-blind randomised cross-over study of bronchopulmonarydysplasia.ClinPerinatol2015;42:839–855.
nebulised iloprost in patients with Eisenmengersyndrome: A pilot study.Int J 603. vanLoonRL,RoofthooftMT,vanOsch-GeversM,DelhaasT,StrengersJL,Blom
Cardiol2020;299:131–135.
NA,etal.Clinicalcharacterizationofpediatricpulmonaryhypertension:complex
578.D’AltoM,ConstantineA,BalintOH,RomeoE,ArgientoP,AblonczyL,etal.The presentationanddiagnosis.JPediatr2009;155:176–182.e171.
effectsofparenteralprostacyclintherapyasadd-ontreatmenttooralcompounds 604. Arjaans S, Zwart EAH, Ploegstra MJ, Bos AF, Kooi EMW, Hillege HL, et al.
inEisenmengersyndrome.EurRespirJ2019;54:1901401. Identificationofgapsinthecurrentknowledgeonpulmonaryhypertensioninex-
579.ManesA,PalazziniM,LeciE,BacchiReggianiML,BranziA,GalièN.Currentera tremelypreterminfants:asystematicreviewandmeta-analysis.PaediatrPerinatal
survivalofpatientswithpulmonaryarterialhypertensionassociatedwithcongenital Epidemiol2018;32:258–267.
heart disease: a comparison between clinical subgroups. Eur Heart J 2014;35: 604a. HaarmanMG,DoJM,PloegstraMJ,RoofthooftMTR,Vissia-KazemierTR,Hillege
716–724. HL,etal.Theclinicalvalueofproposedriskstratificationtoolsinpediatricpul-
580.SavaleL,ManesA.Pulmonaryarterialhypertensionpopulationsofspecialinterest: monaryarterialhypertension.AmJRespirCritCareMed2019;200:1312–1315.
portopulmonary hypertension and pulmonary arterial hypertension associated 605. BeghettiM,Schulze-NeickI,BergerRM,IvyDD,BonnetD,WeintraubRG,etal.
withcongenitalheartdisease.EurHeartJSuppl2019;21:K37–K45. Haemodynamiccharacterisationandheartcatheterisationcomplicationsinchildren
581.DimopoulosK,DillerGP,OpotowskyAR,D’AltoM,GuH,GiannakoulasG,etal. withpulmonaryhypertension:insightsfromtheGlobalTOPPRegistry(trackingout-
Definitionandmanagementofsegmentalpulmonaryhypertension.JAmHeart comesandpracticeinpaediatricpulmonaryhypertension).IntJCardiol2016;203:
Assoc2018;7:e008587. 325–330.
582.AmedroP,GavottoA,AbassiH,PicotMC,MateckiS,Malekzadeh-MilaniS,etal. 606. PloegstraMJ,ZijlstraWMH,DouwesJM,HillegeHL,BergerRMF.Prognosticfac-
Efficacyofphosphodiesterasetype5inhibitorsinuniventricularcongenitalheart tors in pediatric pulmonary arterial hypertension: a systematic review and
disease:theSV-INHIBITIONstudydesign.ESCHeartFail2020;7:747–756. meta-analysis.IntJCardiol2015;184:198–207.
583.GoldbergDJ,ZakV,GoldsteinBH,SchumacherKR,RhodesJ,PennyDJ,etal. 607. IvyDD,RosenzweigEB,LemarieJC,BrandM,RosenbergD,BarstRJ.Long-term
ResultsoftheFUELTrial.Circulation2020;141:641–651. outcomesinchildrenwithpulmonaryarterialhypertensiontreatedwithbosentan
584.RidderbosFS,HagdornQAJ,BergerRMF.Pulmonaryvasodilatortherapyastreat- inreal-worldclinicalsettings.AmJCardiol2010;106:1332–1338.
mentforpatientswithaFontancirculation:theEmperor’snewclothes?PulmCirc 608. ZijlstraWMH,DouwesJM,RosenzweigEB,SchokkerS,KrishnanU,Roofthooft
2018;8:2045894018811148. MTR,etal.Survivaldifferencesinpediatricpulmonaryarterialhypertension:clues
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 109 ---
3726 ESC/ERSGuidelines
toabetterunderstandingofoutcomeandoptimaltreatmentstrategies.JAmColl 632. CaravitaS,DewachterC,SorannaD,D’AraujoSC,KhaldiA,ZambonA,etal.
Cardiol2014;63:2159–2169. Haemodynamicstopredictoutcomeinpulmonaryhypertensionduetoleftheart
609. PloegstraMJ,DouwesJM,RoofthooftMT,ZijlstraWM,HillegeHL,BergerRM. disease:ameta-analysis.EurRespirJ2018;51:1702427.
Identificationof treatmentgoalsin paediatricpulmonary arterialhypertension. 633. CrawfordTC,LearyPJ,FraserCDIII,Suarez-PierreA,MagruderJT,Baumgartner
EurRespirJ2014;44:1616–1626. WA,etal.Impactofthenewpulmonaryhypertensiondefinitiononhearttrans-
610. SinghY,LakshminrusimhaS.Pathophysiologyandmanagementofpersistentpul- plant outcomes: expanding the hemodynamic risk profile. Chest 2020;157:
monaryhypertensionofthenewborn.ClinPerinatol2021;48:595–618. 151–161.
611. ArjaansS,HaarmanMG,RoofthooftMTR,FriesMWF,KooiEMW,BosAF,etal. 634. O’SullivanCJ,WenaweserP,CeylanO,Rat-WirtzlerJ,StorteckyS,HegD,etal.
Fateofpulmonaryhypertensionassociatedwithbronchopulmonarydysplasiabe- Effectofpulmonaryhypertensionhemodynamicpresentationonclinicaloutcomes
yond36weekspostmenstrualage.ArchDisChildFetalNeonatalEd2021;106: inpatientswithseveresymptomaticaorticvalvestenosisundergoingtranscatheter
45–50.
aorticvalveimplantation:insightsfromthenewproposedpulmonaryhypertension
612. GossKN,BeshishAG,BartonGP,HaraldsdottirK,LevinTS,TetriLH,etal.Early classification.CircCardiovascInterv2015;8:e002358.
pulmonaryvasculardiseaseinyoungadultsbornpreterm.AmJRespirCritCareMed 635. VanderpoolRR,SaulM,NouraieM,GladwinMT,SimonMA.Associationbetween
2018;198:1549–1558.
hemodynamicmarkersofpulmonaryhypertensionandoutcomesinheartfailure
613. BarstRJ,BeghettiM,PulidoT,LaytonG,KonourinaI,ZhangM,etal.STARTS-2: withpreservedejectionfraction.JAMACardiol2018;3:298–306.
long-termsurvivalwithoralsildenafilmonotherapyintreatment-naivepediatric
636. Murali S, Kormos RL, Uretsky BF, Schechter D, Reddy PS, Denys BG, et al.
pulmonaryarterialhypertension.Circulation2014;129:1914–1923.
Preoperativepulmonaryhemodynamicsandearlymortalityafterorthotopiccar-
614. BarstRJ,IvyDD,GaitanG,SzatmariA,RudzinskiA,GarciaAE,etal.Arandomized, diactransplantation:thePittsburghexperience.AmHeartJ1993;126:896–904.
double-blind,placebo-controlled,dose-rangingstudyoforalsildenafilcitratein
637. ZimpferD,ZrunekP,RoethyW,CzernyM,SchimaH,HuberL,etal.Leftventricu-
treatment-naivechildrenwithpulmonaryarterialhypertension.Circulation2012; larassistdevicesdecreasefixedpulmonaryhypertensionincardiactransplantcan-
125:324–334. didates.JThoracCardiovascSurg2007;133:689–695.
615. IvyD,BonnetD,BergerR,MeyerG,BayganiS,LiB.Efficacyandsafetyoftadalafilin 638. Al-NaamaniN,PrestonIR,PaulusJK,HillNS,RobertsKE.Pulmonaryarterialcap-
apediatricpopulationwithpulmonaryarterialhypertension:phase3randomized, acitanceisanimportantpredictorofmortalityinheartfailurewithapreserved
double-blindplacebo-controlledstudy.PulmCirc2021;11:20458940211024955. ejectionfraction.JACCHeartFail2015;3:467–474.
616. SmallD,Ferguson-SellsL,DahdahN,BonnetD,LandryJ,LiB.Pharmacokinetics
639. MillerWL,GrillDE,BorlaugBA.Clinicalfeatures,hemodynamics,andoutcomesof
andsafetyoftadalafilinapaediatricpopulationwithpulmonaryarterialhyperten-
pulmonaryhypertensionduetochronicheartfailurewithreducedejectionfrac-
sion:amultipleascending-dosestudy.BrJClinPharmacol2019;85:2302–2309.
tion:pulmonaryhypertensionandheartfailure.JACCHeartFail2013;1:290–299.
617. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al.
640. LeungCC,MoondraV,CatherwoodE,AndrusBW.Prevalenceandriskfactorsof
Pharmacokinetics,safety,andefficacyofbosentaninpediatricpatientswithpul-
pulmonaryhypertensioninpatientswithelevatedpulmonaryvenouspressureand
monaryarterialhypertension.ClinPharmacolTher2003;73:372–382.
preservedejectionfraction.AmJCardiol2010;106:284–286.
618. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, et al. 641. ShahAM,ShahSJ,AnandIS,SweitzerNK,O’MearaE,HeitnerJF,etal.Cardiac
Pharmacokineticandclinicalprofileofanovelformulationofbosentaninchildren
structureandfunctioninheartfailurewithpreservedejectionfraction:baseline
withpulmonaryarterialhypertension:theFUTURE-1study.BrJClinPharmacol findings from the echocardiographic study of the Treatment of Preserved
2009;68:948–955.
CardiacFunctionHeartFailurewithanAldosteroneAntagonisttrial.CircHeart
619. BergerRM,HaworthSG,BonnetD,DulacY,FraisseA,GalièN,etal.FUTURE-2: Fail2014;7:104–115.
resultsfromanopen-label,long-termsafetyandtolerabilityextensionstudyusing
642. GhioS,GavazziA,CampanaC,InserraC,KlersyC,SebastianiR,etal.Independent
thepediatricFormUlationofbosenTaninpUlmonaryarterialhypeRtEnsion.IntJ
Cardiol2016;202:52–58. andadditiveprognosticvalueofrightventricularsystolicfunctionandpulmonary
arterypressureinpatientswithchronicheartfailure.JAmCollCardiol2001;37:
620. BergerRMF,GehinM,BeghettiM,IvyD,Kusic-PajicA,CornelisseP,etal.Abosen-
183–188.
tanpharmacokineticstudytoinvestigatedosingregimensinpaediatricpatientswith
643. TampakakisE,LearyPJ,SelbyVN,DeMarcoT,CappolaTP,FelkerGM,etal.The
pulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017;83:
1734–1744. diastolicpulmonarygradientdoesnotpredictsurvivalinpatientswithpulmonary
hypertensionduetoleftheartdisease.JACCHeartFail2015;3:9–16.
621. IvyD,BeghettiM,Juaneda-SimianE,MillerD,LukasM,IoannouC,etal.Arando-
mizedstudyofsafetyandefficacyoftwodosesofambrisentantotreatpulmonary 644. NaeijeR,GergesM,VachieryJL,CaravitaS,GergesC,LangIM.Hemodynamicphe-
notypingofpulmonaryhypertensioninleftheartfailure.CircHeartFail2017;10:
arterialhypertensioninpediatricpatientsaged8yearsupto18years.JPediatr
e004082.
2020;5:100055.
645. GuazziM,NaeijeR. Pulmonaryhypertension inheartfailure:pathophysiology,
622. Takatsuki S,RosenzweigEB,ZuckermanW, BradyD,Calderbank M,Ivy DD.
Clinicalsafety,pharmacokinetics,andefficacyofambrisentantherapyinchildren pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 2017;69:
withpulmonaryarterialhypertension.PediatrPulmonol2013;48:27–34.
1718–1734.
646. ZlotnickDM,OuelletteML,MalenkaDJ,DeSimoneJP,LeavittBJ,HelmRE,etal.
623. BarstRJ,MaislinG,FishmanAP.Vasodilatortherapyforprimarypulmonaryhyper-
tensioninchildren.Circulation1999;99:1197–1208. Effectofpreoperativepulmonaryhypertensiononoutcomesinpatientswithse-
624. HopperRK,WangY,DeMatteoV,SantoA,KawutSM,ElciOU,etal.Rightven- vere aortic stenosis following surgical aortic valve replacement. Am J Cardiol
tricularfunctionmirrorsclinicalimprovementwithuseofprostacyclinanalogues
2013;112:1635–1640.
inpediatricpulmonaryhypertension.PulmCirc2018;8:2045894018759247. 647. MelbySJ,MoonMR,LindmanBR,BaileyMS,HillLL,DamianoRJJr.Impactofpul-
625. LammersAE,HislopAA,FlynnY,HaworthSG.Epoprostenoltreatmentinchildren monaryhypertensiononoutcomesafteraorticvalvereplacementforaorticvalve
withseverepulmonaryhypertension.Heart2007;93:739–743. stenosis.JThoracCardiovascSurg2011;141:1424–1430.
626. DouwesJM,ZijlstraWM,RosenzweigEB,PloegstraMJ,KrishnanUS,HaarmanMG, 648. Lucon A, Oger E, Bedossa M, Boulmier D, Verhoye JP, Eltchaninoff H, et al.
etal.Parenteralprostanoidsinpediatricpulmonaryarterialhypertension:start Prognosticimplicationsofpulmonaryhypertensioninpatientswithsevereaortic
early,dosehigh,combine.AnnAmThoracSoc2022;19:227–237. stenosis undergoing transcatheter aortic valve implantation: study from the
627. TellaJB,KulikTJ,McSweeneyJE,SleeperLA,LuM,MullenMP.Prostanoidsinpedi-
FRANCE2Registry.CircCardiovascInterv2014;7:240–247.
atricpulmonaryhypertension:clinicalresponse,time-to-effect,anddose-response. 649. FaggianoP,Antonini-CanterinF,RibichiniF,D’AloiaA,FerreroV,CervesatoE,
PulmCirc2020;10:2045894020944858. etal.Pulmonaryarteryhypertensioninadultpatientswithsymptomaticvalvular
628. Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, et al. aorticstenosis.AmJCardiol2000;85:204–208.
Evaluationandmanagementofpulmonaryhypertensioninchildrenwithbroncho- 650. ZuernCS,EickC,RizasK,StoleriuC,WoernleB,WildhirtS,etal.Prognosticvalue
pulmonarydysplasia.JPediatr2017;188:24–34.e21. ofmild-to-moderatepulmonaryhypertensioninpatientswithsevereaorticvalve
629. VayalthrikkovilS,VorhiesE,StritzkeA,BashirRA,MohammadK,KamaluddeenM, stenosisundergoingaorticvalvereplacement.ClinResCardiol2012;101:81–88.
etal.Prospectivestudyofpulmonaryhypertensioninpreterminfantswithbronch- 651. RoquesF,NashefSA,MichelP,GauducheauE,deVincentiisC,BaudetE,etal.Risk
opulmonarydysplasia.PediatrPulmonol2019;54:171–178. factorsandoutcomeinEuropeancardiacsurgery:analysisoftheEuroSCORE
630. AbmanSH,CollacoJM,ShepherdEG,KeszlerM,Cuevas-GuamanM,WeltySE, multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:
etal.Interdisciplinarycareofchildrenwithseverebronchopulmonarydysplasia.J 816–822;discussion822–813.
Pediatr2017;181:12–28.e11. 652. Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet 2009;374:
631. BermejoJ,Gonzalez-MansillaA,MombielaT,FernandezAI,Martinez-LegazpiP, 1271–1283.
YottiR,etal.Persistentpulmonaryhypertensionincorrectedvalvularheartdis- 653. DreyfusGD,MartinRP,ChanKM,DulguerovF,AlexandrescuC.Functionaltricus-
ease:hemodynamicinsightsandlong-termsurvival.JAmHeartAssoc2021;10: pidregurgitation:aneedtoreviseourunderstanding.JAmCollCardiol2015;65:
e019949. 2331–2336.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 110 ---
ESC/ERSGuidelines 3727
654.MuraruD,ParatiG,BadanoL.Theimportanceandthechallengesofpredictingthe 678. KaluskiE,CotterG,LeitmanM,Milo-CotterO,KrakoverR,KobrinI,etal.Clinical
progressionoffunctionaltricuspidregurgitation.JACCCardiovascImaging2020;13: andhemodynamiceffectsofbosentandoseoptimizationinsymptomaticheartfail-
1652–1654. urepatientswithseveresystolicdysfunction,associatedwithsecondarypulmonary
655.AndersenMJ,HwangSJ,KaneGC,MelenovskyV,OlsonTP,FetterlyK,etal. hypertension–amulti-centerrandomizedstudy.Cardiology2008;109:273–280.
Enhancedpulmonaryvasodilatorreserveandabnormalrightventricular:pulmon- 679. LewisGD,ShahR,ShahzadK,CamusoJM,PappagianopoulosPP,HungJ,etal.
aryarterycouplinginheartfailurewithpreservedejectionfraction.CircHeartFail Sildenafilimprovesexercisecapacityandqualityoflifeinpatientswithsystolicheart
2015;8:542–550. failureandsecondarypulmonaryhypertension.Circulation2007;116:1555–1562.
656.TedfordRJ,HassounPM,MathaiSC,GirgisRE,RussellSD,ThiemannDR,etal. 680. DumitrescuD,SeckC,MohleL,ErdmannE,RosenkranzS.Therapeuticpotentialof
Pulmonarycapillarywedgepressureaugmentsrightventricularpulsatileloading. sildenafilinpatientswithheartfailureandreactivepulmonaryhypertension.IntJ
Circulation2012;125:289–297. Cardiol2012;154:205–206.
657.BoschL,LamCSP,GongL,ChanSP,SimD,YeoD,etal.Rightventriculardysfunc- 681. WuX,YangT,ZhouQ,LiS,HuangL.Additionaluseofaphosphodiesterase5in-
tioninleft-sidedheartfailurewithpreservedversusreducedejectionfraction.EurJ hibitorinpatientswithpulmonaryhypertensionsecondarytochronicsystolicheart
HeartFail2017;19:1664–1671. failure:ameta-analysis.EurJHeartFail2014;16:444–453.
658.ObokataM,ReddyYNV,MelenovskyV,PislaruS,BorlaugBA.Deteriorationin 682. AnkerSD,ButlerJ,FilippatosG,FerreiraJP,BocchiE,BohmM,etal.Empagliflozinin
rightventricularstructureandfunctionovertimeinpatientswithheartfailure
heartfailurewithapreservedejectionfraction.NEnglJMed2021;385:1451–1461.
andpreservedejectionfraction.EurHeartJ2019;40:689–697. 683. KollerB,Steringer-MascherbauerR,EbnerCH,WeberT,AmmerM,EichingerJ,
659.D’Alto M, Romeo E, Argiento P, Pavelescu A, Melot C, D’Andrea A, et al. etal.Pilotstudyofendothelinreceptorblockadeinheartfailurewithdiastolicdys-
Echocardiographicpredictionofpre-versuspostcapillarypulmonaryhypertension. functionandpulmonaryhypertension(BADDHY-trial).HeartLungCirc2017;26:
JAmSocEchocardiogr2015;28:108–115. 433–441.
660.D’AltoM,RomeoE,ArgientoP,PavelescuA,D’AndreaA,DiMarcoGM,etal.A 684. VachieryJL,DelcroixM,Al-HitiH,EfficaceM,HutyraM,LackG,etal.Macitentanin
simpleechocardiographicscoreforthediagnosisofpulmonaryvasculardiseasein pulmonaryhypertensionduetoleftventriculardysfunction.EurRespirJ2018;51:
heartfailure.JCardiovascMed2017;18:237–243. 1701886.
661.Hoeper MM, Lam CSP, Vachiery JL, Bauersachs J, Gerges C, Lang IM, et al. 685. HoendermisES,LiuLC,HummelYM,vanderMeerP,deBoerRA,BergerRM,etal.
Pulmonaryhypertensioninheartfailurewithpreservedejectionfraction:aplea
Effectsofsildenafiloninvasivehaemodynamicsandexercisecapacityinheartfailure
forproperphenotypingandfurtherresearch.EurHeartJ2017;38:2869–2873. patientswithpreservedejectionfractionandpulmonaryhypertension:arando-
662.ChurchillTW,LiSX,CurreriL,ZernEK,LauES,LiuEE,etal.Evaluationof2ex-
mizedcontrolledtrial.EurHeartJ2015;36:2565–2573.
686. GuazziM,VicenziM,ArenaR,GuazziMD.Pulmonaryhypertensioninheartfailure
istingdiagnosticscoresforheartfailurewithpreservedejectionfractionagainsta
comprehensivelyphenotypedcohort.Circulation2021;143:289–291. withpreservedejectionfraction:atargetofphosphodiesterase-5inhibitionina
663.ReddyYNV,CarterRE,ObokataM,RedfieldMM,BorlaugBA.Asimple,evidence-
1-yearstudy.Circulation2011;124:164–174.
687. KramerT,DumitrescuD,GerhardtF,OrlovaK,TenFreyhausH,HellmichM,etal.
basedapproachtohelpguidediagnosisofheartfailurewithpreservedejection
fraction.Circulation2018;138:861–870. Therapeuticpotentialofphosphodiesterasetype5inhibitorsinheartfailurewith
preserved ejection fraction and combined post- and pre-capillary pulmonary
664.AndersenMJ,ErsbollM,Bro-JeppesenJ,GustafssonF,HassagerC,KoberL,etal.
hypertension.IntJCardiol2019;283:152–158.
Exercisehemodynamicsinpatientswithandwithoutdiastolicdysfunctionandpre-
servedejectionfractionaftermyocardialinfarction.CircHeartFail2012;5:444–451. 688. ObokataM,ReddyYNV,ShahSJ,KayeDM,GustafssonF,HasenfubetaG,etal.
Effectsofinteratrialshuntonpulmonaryvascularfunctioninheartfailurewithpre-
665.AndersenMJ,OlsonTP,MelenovskyV,KaneGC,BorlaugBA.Differentialhemo-
servedejectionfraction.JAmCollCardiol2019;74:2539–2550.
dynamiceffectsofexerciseandvolumeexpansioninpeoplewithandwithoutheart
689. ShahSJ,BorlaugBA,ChungES,CutlipDE,DebonnaireP,FailPS,etal.Atrialshunt
failure.CircHeartFail2015;8:41–48.
666.BorlaugBA,NishimuraRA,SorajjaP,LamCS,RedfieldMM.Exercisehemodynam- device for heart failure with preserved and mildly reduced ejection fraction
(REDUCELAP-HFII):arandomised,multicentre,blinded,sham-controlledtrial.
icsenhancediagnosisofearlyheartfailurewithpreservedejectionfraction.Circ Lancet2022;399:1130–1140.
HeartFail2010;3:588–595.
690. BorlaugBA,BlairJ,BergmannMW,BuggerH,BurkhoffD,BruchL,etal.Latentpul-
667.Fujimoto N, Borlaug BA, Lewis GD, Hastings JL, Shafer KM, Bhella PS, et al.
monaryvasculardiseasemayaltertheresponsetotherapeuticatrialshuntdevicein
Hemodynamicresponsestorapidsalineloading:theimpactofage,sex,andheart heartfailure.Circulation2022;145:1592–1604.
failure.Circulation2013;127:55–62.
691. AbrahamWT,StevensonLW,BourgeRC,LindenfeldJA,BaumanJG,AdamsonPB,
668.HoJE,ZernEK,WoosterL,BaileyCS,CunninghamT,EismanAS,etal.Differential etal.Sustainedefficacyofpulmonaryarterypressuretoguideadjustmentofchron-
clinicalprofiles,exerciseresponses,andoutcomesassociatedwithexistingHFpEF
icheartfailuretherapy:completefollow-upresultsfromtheCHAMPIONrando-
definitions.Circulation2019;140:353–365.
misedtrial.Lancet2016;387:453–461.
669.BarattoC,CaravitaS,SorannaD,FainiA,DewachterC,ZambonA,etal.Current
692. AngermannCE,AssmusB,AnkerSD,AsselbergsFW,BrachmannJ,BrettME,etal.
limitationsofinvasiveexercisehemodynamicsforthediagnosisofheartfailurewith
Pulmonaryarterypressure-guidedtherapyinambulatorypatientswithsymptom-
preservedejectionfraction.CircHeartFail2021;14:e007555.
aticheartfailure:theCardioMEMSEuropeanMonitoringStudyforHeartFailure
670.FoxBD,ShimonyA,LanglebenD,HirschA,RudskiL,SchlesingerR,etal.High (MEMS-HF).EurJHeartFail2020;22:1891–1901.
prevalenceofoccultleftheartdiseaseinscleroderma-pulmonaryhypertension. 693. ShavelleDM,DesaiAS,AbrahamWT,BourgeRC,RavalN,RathmanLD,etal.
EurRespirJ2013;42:1083–1091.
Lowerratesofheartfailureandall-causehospitalizationsduringpulmonaryartery
671.LewisGD,BossoneE,NaeijeR,GrunigE,SaggarR,LancellottiP,etal.Pulmonary pressure-guidedtherapyforambulatoryheartfailure:one-yearoutcomesfromthe
vascular hemodynamic response to exercise in cardiopulmonary diseases. CardioMEMSPost-ApprovalStudy.CircHeartFail2020;13:e006863.
Circulation2013;128:1470–1479.
694. LindenfeldJ,ZileMR,DesaiAS,BhattK,DucharmeA,HorstmanshofD,etal.
672.MaorE,GrossmanY,BalmorRG,SegelM,FeferP,Ben-ZekryS,etal.Exercise Haemodynamic-guidedmanagementofheartfailure(GUIDE-HF):arandomised
haemodynamicsmayunmaskthediagnosisofdiastolicdysfunctionamongpatients controlledtrial.Lancet2021;398:991–1001.
withpulmonaryhypertension.EurJHeartFail2015;17:151–158.
695. Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al.
673.RobbinsIM,HemnesAR,PughME,BrittainEL,ZhaoDX,PianaRN,etal.High Empagliflozineffectsonpulmonaryarterypressureinpatientswithheartfailure:
prevalenceofoccultpulmonaryvenoushypertensionrevealedbyfluidchallenge resultsfromtheEMBRACE-HFtrial.Circulation2021;143:1673–1686.
inpulmonaryhypertension.CircHeartFail2014;7:116–122.
696. TranJS,HavakukO,McLeodJM,HwangJ,KwongHY,ShavelleD,etal.Acutepul-
674.BorlaugBA.Invasiveassessmentofpulmonaryhypertension:timeforamorefluid
monarypressurechangeaftertransitiontosacubitril/valsartaninpatientswith
approach?CircHeartFail2014;7:2–4. heartfailurereducedejectionfraction.ESCHeartFail2021;8:1706–1710.
675.SelimAM,WadhwaniL,BurdorfA,RaichlinE,LowesB,ZoltyR.Leftventricular 697. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, et al.
assistdevicesinpulmonaryhypertensiongroup2withsignificantlyelevatedpul-
Reducedloopdiureticuseinpatientstakingsacubitril/valsartancomparedwithen-
monaryvascularresistance:abridgetocure.HeartLungCirc2019;28:946–952. alapril:thePARADIGM-HFtrial.EurJHeartFail2019;21:337–341.
676.Al-KindiSG,FarhoudM,ZachariasM,GinwallaMB,ElAmmCA,BenattiRD,etal. 698. WachterR,FonsecaAF,BalasB,KapE,EngelhardJ,SchliengerR,etal.Real-world
Leftventricularassistdevicesorinotropesfordecreasingpulmonaryvascularre- treatmentpatternsofsacubitril/valsartan:alongitudinalcohortstudyinGermany.
sistanceinpatientswithpulmonaryhypertensionlistedforhearttransplantation. EurJHeartFail2019;21:588–597.
JCardFail2017;23:209–215. 699. GaemperliO,MoccettiM,SurderD,BiaggiP,HurlimannD,KretschmarO,etal.
677.ImamuraT,ChungB,NguyenA,RodgersD,SayerG,AdatyaS,etal.Decoupling Acutehaemodynamicchangesafterpercutaneousmitralvalverepair:relationto
betweendiastolicpulmonaryarterypressureandpulmonarycapillarywedgepres- mid-termoutcomes.Heart2012;98:126–132.
sureasaprognosticfactoraftercontinuousflowventricularassistdeviceimplant- 700. TiggesE,BlankenbergS,vonBardelebenRS,ZurnC,BekeredjianR,OuarrakT,
ation.CircHeartFail2017;10:e003882. et al. Implication of pulmonary hypertension in patients undergoing MitraClip
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 111 ---
3728 ESC/ERSGuidelines
therapy:resultsfromtheGermantranscathetermitralvalveinterventions(TRAMI) 723. CarlsenJ,HasseriisAndersenK,BoesgaardS,IversenM,SteinbruchelD,Bogelund
registry.EurJHeartFail2018;20:585–594. AndersenC.Pulmonaryarteriallesionsinexplantedlungsaftertransplantationcor-
701. Bermejo J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, Castano M, relatewithseverityofpulmonaryhypertensioninchronicobstructivepulmonary
Segovia-CuberoJ,etal.Sildenafilforimprovingoutcomesinpatientswithcor- disease.JHeartLungTransplant2013;32:347–354.
rectedvalvularheartdiseaseandpersistentpulmonaryhypertension:amulticenter, 724. BunelV,GuyardA,DauriatG,DanelC,MontaniD,GauvainC,etal.Pulmonary
double-blind,randomizedclinicaltrial.EurHeartJ2018;39:1255–1264.
arterialhistologiclesionsinpatientswithCOPDwithseverepulmonaryhyperten-
702. ChorinE,RozenbaumZ,TopilskyY,KonigsteinM,Ziv-BaranT,RichertE,etal. sion.Chest2019;156:33–44.
Tricuspidregurgitationandlong-termclinicaloutcomes.EurHeartJCardiovasc 725. KovacsG,AvianA,DouschanP,ForisV,OlschewskiA,OlschewskiH.Patientswith
Imaging2020;21:157–165.
pulmonaryarterialhypertensionlessrepresentedinclinicaltrials-whoarethey
703. TopilskyY,NkomoVT,VaturyO,MichelenaHI,LetourneauT,SuriRM,etal. andhowarethey?AmJRespirCritCareMed2016;193:A3979.
Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 726. Torres-Castro R, Gimeno-Santos E, Vilaro J, Roque-Figuls M, Moises J,
2014;7:1185–1194.
Vasconcello-CastilloL,etal.Effectofpulmonaryhypertensiononexercisetoler-
704. LurzP,OrbanM,BeslerC,BraunD,SchlotterF,NoackT,etal.Clinicalcharacter-
anceinpatientswithCOPD:aprognosticsystematicreviewandmeta-analysis.
istics,diagnosis,andriskstratificationofpulmonaryhypertensioninseveretricuspid
EurRespirRev2021;30:200321.
regurgitationandimplicationsfortranscathetertricuspidvalverepair.EurHeartJ
727. NathanSD,ShlobinOA,BarnettSD,SaggarR,BelperioJA,RossDJ,etal.Rightven-
2020;41:2785–2795.
tricularsystolicpressurebyechocardiographyasapredictorofpulmonaryhyper-
705. BrenerMI,LurzP,HausleiterJ,Rodes-CabauJ,FamN,KodaliSK,etal.Right
tensioninidiopathicpulmonaryfibrosis.RespirMed2008;102:1305–1310.
ventricular-pulmonaryarterialcouplingandafterloadreserveinpatientsundergo-
728. BaxS,BredyC,KempnyA,DimopoulosK,DevarajA,WalshS,etal.Astepwise
ingtranscathetertricuspidvalverepair.JAmCollCardiol2022;79:448–461.
compositeechocardiographicscorepredictsseverepulmonaryhypertensioninpa-
706. CaoJY,WalesKM,CordinaR,LauEMT,CelermajerDS.Pulmonaryvasodilator
therapiesareofnobenefitinpulmonaryhypertensionduetoleftheartdisease: tientswithinterstitiallungdisease.ERJOpenRes2018;4:00124-2017.
Ameta-analysis.IntJCardiol2018;273:213–220. 729. BaxS,JacobJ,AhmedR,BredyC,DimopoulosK,KempnyA,etal.Rightventricular
toleftventricularratioatCTpulmonaryangiogrampredictsmortalityininterstitial
707. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, et al.
“Naturalhistory”ofpulmonaryhypertensioninaseriesof131patientswithchron- lungdisease.Chest2020;157:89–98.
icobstructivelungdisease.AmJRespirCritCareMed2001;164:219–224. 730. ChinM,JohnsC,CurrieBJ,WeatherleyN,HillC,ElliotC,etal.Pulmonaryartery
708. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, sizeininterstitiallungdiseaseandpulmonaryhypertension:associationwithinter-
CharpentierC,etal.PrognosticfactorsinCOPDpatientsreceivinglong-termoxy- stitiallungdiseaseseverityanddiagnosticutility.FrontCardiovascMed2018;5:53.
gen therapy. Importance of pulmonary artery pressure. Chest 1995;107: 731. KielyDG,LevinD,HassounP,IvyDD,JonePN,BwikaJ,etal.Statementonimaging
1193–1198. and pulmonary hypertension from the Pulmonary Vascular Research Institute
709. ThurnheerR,UlrichS,BlochKE.Precapillarypulmonaryhypertensionandsleep- (PVRI).PulmCirc2019;9:2045894019841990.
disorderedbreathing:istherealink?Respiration2017;93:65–77. 732. JohnsCS,RajaramS,CapenerDA,OramC,ElliotC,CondliffeR,etal.Non-invasive
710. Leon-VelardeF,MaggioriniM,ReevesJT,AldashevA,AsmusI,BernardiL,etal. methodsforestimatingmPAPinCOPDusingcardiovascularmagneticresonance
Consensus statement on chronicand subacute high altitude diseases. High Alt imaging.EurRadiol2018;28:1438–1448.
MedBiol2005;6:147–157. 733. PynnaertC,LamotteM,NaeijeR.AerobicexercisecapacityinCOPDpatientswith
711. FreitasCSG,BaldiBG,JardimC,AraujoMS,SobralJB,HeidenGI,etal.Pulmonary andwithoutpulmonaryhypertension.RespirMed2010;104:121–126.
hypertensioninlymphangioleiomyomatosis:prevalence,severityandtheroleof 734. WaxmanA,Restrepo-JaramilloR,ThenappanT,RavichandranA,EngelP,BajwaA,
carbonmonoxidediffusioncapacityasascreeningmethod.OrphanetJRareDis etal.Inhaledtreprostinilinpulmonaryhypertensionduetointerstitiallungdisease.
2017;12:74. NEnglJMed2021;384:325–334.
712. ZederK,AvianA,BachmaierG,DouschanP,ForisV,SassmannT,etal.Elevated 735. KovacsG,AvianA,PiennM,NaeijeR,OlschewskiH.Readingpulmonaryvascular
pulmonaryvascularresistancepredictsmortalityinCOPDpatients.EurRespirJ pressuretracings.Howtohandletheproblemsofzerolevelingandrespiratory
2021;58:2100944. swings.AmJRespirCritCareMed2014;190:252–257.
713. Olsson KM, Hoeper MM, Pausch C, Grunig E, Huscher D, Pittrow D, et al. 736. BlancoI,SantosS,GeaJ,GuellR,TorresF,Gimeno-SantosE,etal.Sildenafiltoim-
Pulmonaryvascularresistancepredictsmortalityinpatientswithpulmonaryhyper- proverespiratoryrehabilitationoutcomesinCOPD:acontrolledtrial.EurRespirJ
tensionassociatedwithinterstitiallungdisease:resultsfromtheCOMPERAregis- 2013;42:982–992.
try.EurRespirJ2021;58:2101483. 737. GhofraniHA,WiedemannR,RoseF,SchermulyRT,OlschewskiH,WeissmannN,
714. ChaouatA,BugnetAS,KadaouiN,SchottR,EnacheI,DucoloneA,etal.Severe etal.Sildenafilfortreatmentoflungfibrosisandpulmonaryhypertension:arando-
pulmonaryhypertensionandchronicobstructivepulmonarydisease.AmJRespir misedcontrolledtrial.Lancet2002;360:895–900.
CritCareMed2005;172:189–194.
738. OlschewskiH,GhofraniHA,WalmrathD,SchermulyR,Temmesfeld-WollbruckB,
715. LettieriCJ,NathanSD,BarnettSD,AhmadS,ShorrAF.Prevalenceandoutcomes GrimmingerF,etal.Inhaledprostacyclinandiloprostinseverepulmonaryhyper- ofpulmonaryarterialhypertensioninadvancedidiopathicpulmonaryfibrosis.Chest
tensionsecondarytolungfibrosis.AmJRespirCritCareMed1999;160:600–607.
2006;129:746–752.
739. StolzD,RaschH,LinkaA,DiValentinoM,MeyerA,BrutscheM,etal.Arando-
716. MedrekSK,SharafkhanehA,SpiegelmanAM,KakA,PanditLM.Admissionfor mised,controlledtrialofbosentaninsevereCOPD.EurRespirJ2008;32:619–628.
COPDexacerbationisassociatedwiththeclinicaldiagnosisofpulmonaryhyper- 740. RaghuG,BehrJ,BrownKK,EganJJ,KawutSM,FlahertyKR,etal.Treatmentofidio-
tension:resultsfromaRetrospectiveLongitudinalStudyofaVeteranPopulation. pathicpulmonaryfibrosiswithambrisentan:aparallel,randomizedtrial.AnnIntern
COPD2017;14:484–489.
Med2013;158:641–649.
717. KesslerR,FallerM,FourgautG,MennecierB,WeitzenblumE.Predictivefactorsof 741. GoudieAR,LipworthBJ,HopkinsonPJ,WeiL,StruthersAD.Tadalafilinpatients
hospitalizationforacuteexacerbationinaseriesof64patientswithchronicob-
structivepulmonarydisease.AmJRespirCritCareMed1999;159:158–164. with chronic obstructive pulmonary disease: a randomised, double-blind,
parallel-group,placebo-controlledtrial.LancetRespirMed2014;2:293–300.
718. VizzaCD,HoeperMM,HuscherD,PittrowD,BenjaminN,OlssonKM,etal.
742. LedererDJ,BartelsMN,SchlugerNW,BroganF,JellenP,ThomashowBM,etal.
PulmonaryhypertensioninpatientswithCOPD:resultsfromCOMPERA.Chest
2021;160:678–689.
Sildenafilforchronicobstructivepulmonarydisease:arandomizedcrossovertrial.
COPD2012;9:268–275.
719. DauriatG,Reynaud-GaubertM,CottinV,LamiaB,MontaniD,CanuetM,etal.
743. VituloP,StanziolaA,ConfalonieriM,LibertucciD,OggionniT,RottoliP,etal.
Severepulmonaryhypertensionassociatedwithchronicobstructivepulmonary
Sildenafilinseverepulmonaryhypertensionassociatedwithchronicobstructive
disease:aprospectiveFrenchmulticentercohort.JHeartLungTransplant2021;
40:1009–1018. pulmonary disease: A randomized controlled multicenter clinical trial. J Heart
720. KovacsG,AgustiA,BarberaJA,CelliB,CrinerG,HumbertM,etal.Pulmonaryvas-
LungTransplant2017;36:166–174.
cularinvolvementinCOPD-isthereapulmonaryvascularphenotype?AmJRespir 744. KingTEJr,BehrJ,BrownKK,duBoisRM,LancasterL,deAndradeJA,etal.
CritCareMed2018;198:1000–1011. BUILD-1:arandomizedplacebo-controlledtrialofbosentaninidiopathicpulmon-
721. AndersenKH,IversenM,KjaergaardJ,MortensenJ,Nielsen-KudskJE,BendstrupE, aryfibrosis.AmJRespirCritCareMed2008;177:75–81.
etal.Prevalence,predictors,andsurvivalinpulmonaryhypertensionrelatedtoend- 745. KingTEJr,BrownKK,RaghuG,duBoisRM,LynchDA,MartinezF,etal.BUILD-3:a
stage chronicobstructive pulmonary disease.J Heart Lung Transplant2012;31: randomized,controlledtrialofbosentaninidiopathicpulmonaryfibrosis.AmJ
373–380. RespirCritCareMed2011;184:92–99.
722. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, et al. 746. IdiopathicPulmonaryFibrosisClinicalResearchNetwork,ZismanDA,SchwarzM,
PulmonaryhemodynamicsinadvancedCOPDcandidatesforlungvolumereduc- AnstromKJ,CollardHR,FlahertyKR,etal.Acontrolledtrialofsildenafilinad-
tionsurgeryorlungtransplantation.Chest2005;127:1531–1536. vancedidiopathicpulmonaryfibrosis.NEnglJMed2010;363:620–628.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 112 ---
ESC/ERSGuidelines 3729
747.KolbM,RaghuG,WellsAU,BehrJ,RicheldiL,SchinzelB,etal.Nintedanibplussil- 770. NewnhamM,BunclarkK,AbrahamN,AliS,Amaral-AlmeidaL,CannonJE,etal.
denafil inpatients withidiopathic pulmonary fibrosis.N EnglJ Med 2018;379: CAMPHORscore:patient-reportedoutcomesareimprovedbypulmonaryend-
1722–1731. arterectomy in chronic thromboembolic pulmonary hypertension. Eur Respir J
748.CorteTJ,KeirGJ,DimopoulosK,HowardL,CorrisPA,ParfittL,etal.Bosentanin 2020;56:1902096.
pulmonaryhypertensionassociatedwithfibroticidiopathicinterstitialpneumonia. 771. Vuylsteke A, Sharples L, Charman G, Kneeshaw J, Tsui S, Dunning J, et al.
AmJRespirCritCareMed2014;190:208–217. Circulatoryarrestversuscerebralperfusionduringpulmonaryendarterectomy
749.HanMK,BachDS,HaganPG,YowE,FlahertyKR,ToewsGB,etal.Sildenafilpre- surgery(PEACOG):arandomisedcontrolledtrial.Lancet2011;378:1379–1387.
servesexercisecapacityinpatientswithidiopathicpulmonaryfibrosisandright- 772. D’Armini AM, Morsolini M, Mattiucci G, Grazioli V, Pin M, Valentini A, et al.
sidedventriculardysfunction.Chest2013;143:1699–1708. Pulmonaryendarterectomyfordistalchronicthromboembolicpulmonaryhyper-
750.RaghuG,NathanSD,BehrJ,BrownKK,EganJJ,KawutSM,etal.Pulmonaryhyper- tension.JThoracCardiovascSurg2014;148:1005–1011.
tensioninidiopathicpulmonaryfibrosiswithmild-to-moderaterestriction.Eur 773. QuaderySR,SwiftAJ,BillingsCG,ThompsonAAR,ElliotCA,HurdmanJ,etal.The
RespirJ2015;46:1370–1377. impactofpatientchoiceonsurvivalinchronicthromboembolicpulmonaryhyper-
751.NathanSD,TapsonVF,ElwingJ,RischardF,MehtaJ,ShapiroS,etal.Efficacyofin- tension.EurRespirJ2018;52:1800589.
haledtreprostinilonmultiplediseaseprogressioneventsinpatientswithpulmon- 774. TaboadaD,Pepke-ZabaJ,JenkinsDP,BermanM,TreacyCM,CannonJE,etal.
aryhypertensionduetoparenchymallungdiseaseintheINCREASEtrial.AmJ Outcomeofpulmonaryendarterectomyinsymptomaticchronicthromboembolic
RespirCritCareMed2022;205:198–207. disease.EurRespirJ2014;44:1635–1645.
752.GallH,FelixJF,SchneckFK,MilgerK,SommerN,VoswinckelR,etal.TheGiessen 775. GhofraniHA,D’ArminiAM,GrimmingerF,HoeperMM,JansaP,KimNH,etal.
pulmonaryhypertensionregistry:survivalinpulmonaryhypertensionsubgroups.J Riociguatforthetreatmentofchronicthromboembolicpulmonaryhypertension.
HeartLungTransplant2017;36:957–967. NEnglJMed2013;369:319–329.
753.HoeperMM,BehrJ,HeldM,GrunigE,VizzaCD,Vonk-NoordegraafA,etal. 776. Sadushi-KoliciR,JansaP,KopecG,TorbickiA,Skoro-SajerN,CampeanIA,etal.
Pulmonaryhypertensioninpatientswithchronicfibrosingidiopathicinterstitial Subcutaneous treprostinil for the treatment of severe non-operable chronic
pneumonias.PLoSOne2015;10:e0141911. thromboembolicpulmonaryhypertension(CTREPH):adouble-blind,phase3,ran-
754.KlokFA,DelcroixM,BogaardHJ.Chronicthromboembolicpulmonaryhyperten- domisedcontrolledtrial.LancetRespirMed2019;7:239–248.
sionfromtheperspectiveofpatientswithpulmonaryembolism.JThrombHaemost 777. GhofraniHA,SimonneauG,D’ArminiAM,FedulloP,HowardLS,JaisX,etal.
2018;16:1040–1051. Macitentanforthetreatmentofinoperablechronicthromboembolicpulmonary
755.KlokFA,Dzikowska-DiduchO,KostrubiecM,VliegenHW,PruszczykP,Hasenfuss hypertension (MERIT-1): results from the multicentre, phase 2, randomised,
G,etal.Derivationofaclinicalpredictionscoreforchronicthromboembolicpul- double-blind,placebo-controlledstudy.LancetRespirMed2017;5:785–794.
monaryhypertensionafteracutepulmonaryembolism.JThrombHaemost2016;14: 778. JaisX,D’ArminiAM,JansaP,TorbickiA,DelcroixM,GhofraniHA,etal.Bosentan
121–128. fortreatmentofinoperablechronicthromboembolicpulmonaryhypertension:
756.BondermanD,WilkensH,WakounigS,SchafersHJ,JansaP,LindnerJ,etal.Risk BENEFiT(BosentanEffectsiniNopErableFormsofchronIcThromboembolicpul-
factorsforchronicthromboembolicpulmonaryhypertension.EurRespirJ2009; monaryhypertension),arandomized,placebo-controlledtrial.JAmCollCardiol
33:325–331. 2008;52:2127–2134.
757.NarechaniaS,RenapurkarR,HeresiGA.Mimickersofchronicthromboembolic 779. ReichenbergerF,VoswinckelR,EnkeB,RutschM,ElFechtaliE,SchmehlT,etal.
pulmonary hypertension on imaging tests: a review. Pulm Circ 2020;10: Long-termtreatmentwithsildenafilinchronicthromboembolicpulmonaryhyper-
2045894019882620. tension.EurRespirJ2007;30:922–927.
758.XiXY,GaoW,GongJN,GuoXJ,WuJY,YangYH,etal.Valueof(18)F-FDGPET/ 780. GuthS,D’ArminiAM,DelcroixM,NakayamaK,FadelE,HooleSP,etal.Current
CTindifferentiatingmalignancyofpulmonaryarteryfrompulmonarythrombo- strategiesformanagingchronicthromboembolicpulmonaryhypertension:results
embolism:acohortstudyandliteraturereview.IntJCardiovascImaging2019;35: oftheworldwideprospectiveCTEPHRegistry.ERJOpenRes2021;7:00850–02020.
1395–1403. 781. BrenotP,JaisX,TaniguchiY,GarciaAlonsoC,GerardinB,MussotS,etal.French
759.LaschF,KarchA,KochA,DerlinT,VoskrebenzevA,AlsadyTM,etal.Comparison experienceofballoonpulmonaryangioplastyforchronicthromboembolicpul-
ofMRIandVQ-SPECTasascreeningtestforpatientswithsuspectedCTEPH: monaryhypertension.EurRespirJ2019;53:1802095.
CHANGE-MRIstudydesignandrationale.FrontCardiovascMed2020;7:51. 782. Darocha S, Pietura R, Pietrasik A, Norwa J, Dobosiewicz A, Pilka M, et al.
760.NagelC,PrangeF,GuthS,HerbJ,EhlkenN,FischerC,etal.Exercisetrainingim- Improvementinqualityoflifeandhemodynamicsinchronicthromboembolicpul-
provesexercisecapacityandqualityoflifeinpatientswithinoperableorresidual monaryhypertensiontreatedwithballoonpulmonaryangioplasty.CircJ2017;81:
chronicthromboembolicpulmonaryhypertension.PLoSOne2012;7:e41603. 552–557.
761.NagelC,NasereddinM,BenjaminN,EgenlaufB,HarutyunovaS,EichstaedtCA, 783. FukuiS,OgoT,MoritaY,TsujiA,TateishiE,OzakiK,etal.Rightventricularreverse
etal.Supervisedexercisetraininginpatientswithchronicthromboembolicpul- remodellingafterballoonpulmonaryangioplasty.EurRespirJ2014;43:1394–1402.
monaryhypertensionasearlyfollow-uptreatmentafterpulmonaryendarterec- 784. KataokaM,InamiT,HayashidaK,ShimuraN,IshiguroH,AbeT,etal.Percutaneous
tomy:aprospectivecohortstudy.Respiration2020;99:577–588. transluminalpulmonaryangioplastyforthetreatmentofchronicthromboembolic
762.BunclarkK,NewnhamM,ChiuYD,RuggieroA,VillarSS,CannonJE,etal.Amulti- pulmonaryhypertension.CircCardiovascInterv2012;5:756–762.
centerstudyofanticoagulationinoperablechronicthromboembolicpulmonary 785. KriechbaumSD,WiedenrothCB,PetersK,BardeMA,AjnwojnerR,WolterJS,
hypertension.JThrombHaemost2020;18:114–122. etal.Galectin-3,GDF-15,andsST2fortheassessmentofdiseaseseverityandther-
763.HumbertMS,SimonneauG,PittrowD,DelcroixM,Pepke-ZabaJ,LanglebenD, apyresponseinpatientssufferingfrominoperablechronicthromboembolicpul-
etal.Oralanticoagulants(NOACandVKA)inchronicthromboembolicpulmonary monaryhypertension.Biomarkers2020;25:578–586.
hypertension.JHeartLungTransplant2022;41:716–721. 786. KriechbaumSD,ScherwitzL,WiedenrothCB,RudolphF,WolterJS,HaasM,etal.
764.Ordi-Ros J, Saez-Comet L, Perez-Conesa M, Vidal X, Riera-Mestre A, Mid-regionalpro-atrialnatriureticpeptideandcopeptinasindicatorsofdiseasese-
Castro-SalomoA,etal.RivaroxabanversusvitaminKantagonistinantiphospholi- verityandtherapyresponseinCTEPH.ERJOpenRes2020;6:00356-02020.
pid syndrome: a randomized noninferiority trial. Ann Intern Med 2019;171: 787. LangI,MeyerBC,OgoT,MatsubaraH,KurzynaM,GhofraniHA,etal.Balloonpul-
685–694. monary angioplasty in chronic thromboembolic pulmonary hypertension. Eur
765.PengoV,DenasG,ZoppellaroG,JoseSP,HoxhaA,RuffattiA,etal.Rivaroxabanvs RespirRev2017;26:160119.
warfarininhigh-riskpatientswithantiphospholipidsyndrome.Blood2018;132: 788. MahmudE,BehnamfarO,AngL,PatelMP,PochD,KimNH.Balloonpulmonary
1365–1371. angioplastyforchronicthromboembolicpulmonaryhypertension.IntervCardiol
766.HsiehWC,JansaP,HuangWC,NiznanskyM,OmaraM,LindnerJ.Residualpul- Clin2018;7:103–117.
monaryhypertensionafterpulmonaryendarterectomy:ameta-analysis.JThorac 789. MizoguchiH,OgawaA,MunemasaM,MikouchiH,ItoH,MatsubaraH.Refinedbal-
CardiovascSurg2018;156:1275–1287. loonpulmonaryangioplastyforinoperablepatientswithchronicthromboembolic
767.Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, KimNH, et al. pulmonaryhypertension.CircCardiovascInterv2012;5:748–755.
Pulmonaryendarterectomy:recentchangesinasingleinstitution’sexperienceof 790. OgawaA,MatsubaraH.Afterthedawn-balloonpulmonaryangioplastyforpatients
morethan2,700patients.AnnThoracSurg2012;94:97–103;discussion103. withchronicthromboembolicpulmonaryhypertension.CircJ2018;82:1222–1230.
768.LankeitM,KriegV,HobohmL,KolmelS,LiebetrauC,KonstantinidesS,etal. 791. OlssonKM,WiedenrothCB,KampJC,BreitheckerA,FugeJ,KrombachGA,etal.
Pulmonaryendarterectomyinchronicthromboembolicpulmonaryhypertension. Balloon pulmonary angioplasty for inoperable patients with chronic thrombo-
JHeartLungTransplant2018;37:250–258. embolic pulmonary hypertension: the initial German experience. Eur Respir J
769.DelcroixM,LangI,Pepke-ZabaJ,JansaP,D’ArminiAM,SnijderR,etal.Long-term 2017;49:1602409.
outcomeofpatientswithchronicthromboembolicpulmonaryhypertension:re- 792. RollerFC,KriechbaumS,BreitheckerA,LiebetrauC,HaasM,SchneiderC,etal.
sultsfromaninternationalprospectiveregistry.Circulation2016;133:859–871. CorrelationofnativeT1mappingwithrightventricularfunctionandpulmonary
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 113 ---
3730 ESC/ERSGuidelines
haemodynamicsinpatientswithchronicthromboembolicpulmonaryhypertension 814. SavaleL,HabibiA,LionnetF,MaitreB,CottinV,JaisX,etal.Clinicalphenotypes
beforeandafterballoonpulmonaryangioplasty.EurRadiol2019;29:1565–1573. andoutcomesofprecapillarypulmonaryhypertensionofsicklecelldisease.Eur
793. SugimuraK,FukumotoY,SatohK,NochiokaK,MiuraY,AokiT,etal.Percutaneous RespirJ2019;54:1900585.
transluminalpulmonaryangioplastymarkedlyimprovespulmonaryhemodynamics 815. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, et al.
and long-term prognosis in patients with chronic thromboembolic pulmonary Hospitalizationforpaininpatientswithsicklecelldiseasetreatedwithsildenafil
hypertension.CircJ2012;76:485–488. forelevatedTRVandlowexercisecapacity.Blood2011;118:855–864.
794. OgawaA,SatohT,FukudaT,SugimuraK,FukumotoY,EmotoN,etal.Balloonpul- 816. TurpinM,Chantalat-AugerC,ParentF,DrissF,LionnetF,HabibiA,etal.Chronic
monaryangioplastyforchronicthromboembolicpulmonaryhypertension:results bloodexchangetransfusionsinthemanagementofpre-capillarypulmonaryhyper-
ofamulticenterregistry.CircCardiovascQualOutcomes2017;10:e004029. tensioncomplicatingsicklecelldisease.EurRespirJ2018;52:1800272.
795. Inami T, Kataoka M, Yanagisawa R, Ishiguro H, Shimura N, Fukuda K, et al. 817. GladwinMT,SachdevV,JisonML,ShizukudaY,PlehnJF,MinterK,etal.Pulmonary
Long-termoutcomesafterpercutaneoustransluminalpulmonaryangioplastyfor hypertensionasariskfactorfordeathinpatientswithsicklecelldisease.NEnglJ
chronic thromboembolic pulmonary hypertension. Circulation 2016;134: Med2004;350:886–895.
2030–2032. 818. DerchiG,GalanelloR,BinaP,CappelliniMD,PigaA,LaiME,etal.Prevalenceand
796. EjiriK,OgawaA,FujiiS,ItoH,MatsubaraH.Vascularinjuryisamajorcauseoflung riskfactorsforpulmonaryarterialhypertensioninalargegroupofbeta-thalassemia
injuryafterballoonpulmonaryangioplastyinpatientswithchronicthromboembol- patientsusingrightheartcatheterization:aWebthalstudy.Circulation2014;129:
icpulmonaryhypertension.CircCardiovascInterv2018;11:e005884.
338–345.
797. ShimokawaharaH,OgawaA,MizoguchiH,YagiH,IkemiyagiH,MatsubaraH. 819. JaisX,IoosV,JardimC,SitbonO,ParentF,HamidA,etal.Splenectomyandchronic
Vesselstretchingisacauseoflumenenlargementimmediatelyafterballoonpul-
thromboembolicpulmonaryhypertension.Thorax2005;60:1031–1034.
monary angioplasty: intravascular ultrasound analysis in patients with chronic 820. AdirY,HumbertM.Pulmonaryhypertensioninpatientswithchronicmyeloproli-
thromboembolicpulmonaryhypertension.CircCardiovascInterv2018;11:e006010.
ferativedisorders.EurRespirJ2010;35:1396–1406.
798. JaïsX,BrenotP,BouvaistH,JevnikarM,CanuetM,ChabanneC,etal.Balloonpul- 821. TakanashiS,AkiyamaM,SuzukiK,OtomoK,TakeuchiT.IgG4-relatedfibrosing
monary angioplasty versus riociguat for the treatment of inoperable chronic mediastinitisdiagnosedwithcomputedtomography-guidedpercutaneousneedle
thromboembolicpulmonaryhypertension(RACE):amulticentre,phase3,open-la- biopsy:twocasereportsandareviewoftheliterature.Medicine2018;97:e10935.
822. Montani D, Achouh L, Marcelin AG, Viard JP, Hermine O, Canioni D, et al.
bel,randomisedcontrolledtrialandancillaryfollow-upstudy.LancetRespirMed
Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated
2022.doi:10.1016/S2213-2600(22)00214-4.
799. WiedenrothCB,OlssonKM,GuthS,BreitheckerA,HaasM,KampJC,etal.Balloon
Castleman’sdisease.EurRespirJ2005;26:969–972.
823. JouveP,HumbertM,ChauveheidMP,JaisX,PapoT.POEMSsyndrome-related
pulmonaryangioplastyforinoperablepatientswithchronicthromboembolicdis-
pulmonaryhypertensionissteroid-responsive.RespirMed2007;101:353–355.
ease.PulmCirc2018;8:2045893217753122.
824. SavaleL,HuitemaM,ShlobinO,KouranosV,NathanSD,NunesH,etal.WASOG
800. RomanovA,CherniavskiyA,NovikovaN,EdemskiyA,PonomarevD,ShabanovV,
statementonthediagnosisandmanagementofsarcoidosis-associatedpulmonary
etal.Pulmonaryarterydenervationforpatientswithresidualpulmonaryhyperten-
sionafterpulmonaryendarterectomy.JAmCollCardiol2020;76:916–926. hypertension.EurRespirRev2022;31:210165.
825. BandyopadhyayD,HumbertM.Anupdateonsarcoidosis-associatedpulmonary
801. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, et al.
hypertension.CurrOpinPulmMed2020;26:582–590.
Continuousintravenousepoprostenolfor chronicthromboembolicpulmonary
hypertension.EurRespirJ2004;23:595–600. 826. BaughmanRP,ShlobinOA,GuptaR,EngelPJ,StewartJI,LowerEE,etal.Riociguat
forsarcoidosis-associatedpulmonaryhypertension:resultsofa1-yeardouble-
802. NagayaN,SasakiN,AndoM,OginoH,SakamakiF,KyotaniS,etal.Prostacyclin
blind,placebo-controlledtrial.Chest2022;161:448–457.
therapy before pulmonary thromboendarterectomy in patients with chronic
827. LePavecJ,LorillonG,JaisX,TcherakianC,FeuilletS,DorfmullerP,etal.Pulmonary
thromboembolicpulmonaryhypertension.Chest2003;123:338–343.
Langerhanscellhistiocytosis-associatedpulmonaryhypertension:clinicalcharacter-
803. ReesinkHJ,SurieS,KloekJJ,TanHL,TepaskeR,FedulloPF,etal.Bosentanasa
isticsandimpactofpulmonaryarterialhypertensiontherapies.Chest2012;142:
bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary 1150–1157.
hypertension.JThoracCardiovascSurg2010;139:85–91.
828. JutantEM,JaisX,GirerdB,SavaleL,GhignaMR,PerrosF,etal.Phenotypeandout-
804. AraszkiewiczA,DarochaS,PietrasikA,PieturaR,JankiewiczS,BanaszkiewiczM, comesofpulmonaryhypertensionassociatedwithneurofibromatosistype1.AmJ
etal.Balloonpulmonaryangioplastyforthetreatmentofresidualorrecurrentpul- RespirCritCareMed2020;202:843–852.
monaryhypertension afterpulmonary endarterectomy.Int JCardiol2019;278:
829. Oliveros,E,Vaidya,A.Metabolicdisordersofpulmonaryhypertension.AdvPulm
232–237.
Hypertens2021;20:35–39.
805. ShimuraN,KataokaM,InamiT,YanagisawaR,IshiguroH,KawakamiT,etal.
830. HumbertM,LabruneP,SimonneauG.Severepulmonaryarterialhypertensionin
Additionalpercutaneoustransluminalpulmonaryangioplastyforresidualorrecur- type1glycogenstoragedisease.EurJPediatr2002;161:S93–S96.
rentpulmonaryhypertensionafterpulmonaryendarterectomy.IntJCardiol2015;
831. KawarB,EllamT,JacksonC,KielyDG.Pulmonaryhypertensioninrenaldisease:
183:138–142.
epidemiology, potential mechanisms and implications. Am J Nephrol 2013;37:
806. CannonJE,SuL,KielyDG,PageK,ToshnerM,SwietlikE,etal.Dynamicriskstrati- 281–290.
ficationofpatientlong-termoutcomeafterpulmonaryendarterectomy:results
832. EdmonstonDL,ParikhKS,RajagopalS,ShawLK,AbrahamD,GrabnerA,etal.
FromtheUKNationalCohort.Circulation2016;133:1761–1771.
PulmonaryhypertensionsubtypesandmortalityinCKD.AmJKidneyDis2020;
807. WiedenrothCB,LiebetrauC,BreitheckerA,GuthS,LautzeHJ,OrtmannE,etal. 75:713–724.
Combinedpulmonaryendarterectomyandballoonpulmonaryangioplastyinpa- 833. Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G, et al.
tients with chronic thromboembolic pulmonary hypertension. J Heart Lung Pulmonaryhypertensioninpatientswithchronickidneydiseaseondialysisand
Transplant2016;35:591–596.
withoutdialysis:resultsofthePEPPER-study.PLoSOne2012;7:e35310.
808. DelcroixM,StaehlerG,GallH,GrunigE,HeldM,HalankM,etal.Riskassessmentin 834. PriceLC,SecklMJ,DorfmullerP,WortSJ.Tumoralpulmonaryhypertension.Eur
medicallytreatedchronicthromboembolicpulmonaryhypertensionpatients.Eur RespirRev2019;28:180065.
RespirJ2018;52:1800248. 835. SeferianA,SteriadeA,JaisX,PlancheO,SavaleL,ParentF,etal.Pulmonaryhyper-
809. BenzaRL,FarberHW,FrostA,GrunigE,HoeperMM,BusseD,etal.REVEALrisk tensioncomplicatingfibrosingmediastinitis.Medicine2015;94:e1800.
scoreinpatientswithchronicthromboembolicpulmonaryhypertensionreceiving 836. BaughmanRP,CulverDA,CordovaFC,PadillaM,GibsonKF,LowerEE,etal.
riociguat.JHeartLungTransplant2018;37:836–843.
Bosentanforsarcoidosis-associatedpulmonaryhypertension:adouble-blindpla-
810. MayerE,JenkinsD,LindnerJ,D’ArminiA,KloekJ,MeynsB,etal.Surgicalmanage- cebocontrolledrandomizedtrial.Chest2014;145:810–817.
mentandoutcomeofpatientswithchronicthromboembolicpulmonaryhyperten- 837. HumbertMG,GaliéN,Meszaros G.Competencyrequirementsfor ERN-lung
sion:resultsfromaninternationalprospectiveregistry.JThoracCardiovascSurg PH centres. https://ern-lung.eu/inhalt/wp-content/uploads/2020/10/PH-MCC.pdf.
2011;141:702–710. (24June2022,datelastaccessed22July2022).
811. AndreassenAK,RagnarssonA,GudeE,GeiranO,AndersenR.Balloonpulmonary 838. Doyle-CoxC,NicholsonG,StewartT,Gin-SingW.Currentorganizationofspe-
angioplastyinpatientswithinoperablechronicthromboembolicpulmonaryhyper- cialistpulmonaryhypertensionclinics:resultsofaninternationalsurvey.PulmCirc
tension.Heart2013;99:1415–1420. 2019;9:2045894019855611.
812. WiedenrothCB,GhofraniHA,AdameitMSD,BreitheckerA,HaasM,Kriechbaum 839. SaundersH,HelgesonSA,AbdelrahimA,Rottman-PietrzakK,ReamsV,ZeigerTK,
S,etal.Sequentialtreatmentwithriociguatandballoonpulmonaryangioplastyfor etal.Comparingdiagnosisandtreatmentofpulmonaryhypertensionpatientsata
patientswithinoperablechronicthromboembolicpulmonaryhypertension.Pulm pulmonaryhypertensioncenterversuscommunitycenters.Diseases2022;10:5.
Circ2018;8:2045894018783996. 840. European Reference Network. Clinical Patient Management System (CPMS).
813. MehariA,GladwinMT,TianX,MachadoRF,KatoGJ.Mortalityinadultswithsickle https://ern-euro-nmd.eu/clinical-patient-management-system/ (24 March 2022,
celldiseaseandpulmonaryhypertension.JAMA2012;307:1254–1256. datelastaccessed22July2022).
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
--- Страница 114 ---
ESC/ERSGuidelines 3731
841.ERS.ContinuingProfessionalDevelopment-PulmonaryVascularDiseases.https:// 850. ArbeloE,AktaaS,BollmannA,D’AvilaA,DrossartI,DwightJ,etal.Qualityindi-
www.ersnet.org/wp-content/uploads/2021/02/Continuing-professional-development- catorsforthecareandoutcomesofadultswithatrialfibrillation.Europace2021;23:
Pulmonary-Vascular-Diseases.pdf(24March2022,datelastaccessed22July2022). 494–495.
842.TannerFC,BrooksN,FoxKF,GoncalvesL,KearneyP,MichalisL,etal.ESCcore 851. SchieleF,AktaaS,RosselloX,AhrensI,ClaeysMJ,ColletJP,etal.2020Updateof
curriculumforthecardiologist.EurHeartJ2020;41:3605–3692. the quality indicators for acute myocardial infarction: a position paper of the
843.Crespo-LeiroMG,MetraM,LundLH,MilicicD,CostanzoMR,FilippatosG,etal. AssociationforAcuteCardiovascularCare:thestudygroupforqualityindicators
Advancedheartfailure:apositionstatementoftheHeartFailureAssociationofthe fromtheACVCandtheNSTE-ACSguidelinegroup.EurHeartJAcuteCardiovasc
EuropeanSocietyofCardiology.EurJHeartFail2018;20:1505–1535. Care2021;10:224–233.
844.Google Maps. ERN-LUNG reference centres. https://www.google.com/maps/d/ 852. AktaaS,AbdinA,ArbeloE,BurriH,VernooyK,Blomstrom-LundqvistC,etal.
viewer?mid=1VVJW2YWYN1q6NYMWPdk78nltgTOptt4C&ll=50. EuropeanSocietyofCardiologyqualityindicatorsforthecareandoutcomesof
878853000000014%2C4.6743529999999955&z=8 (24 March 2022, date last cardiac pacing: developed by the Working Group for Cardiac Pacing Quality
accessed22July2022). IndicatorsincollaborationwiththeEuropeanHeartRhythmAssociationofthe
845.GiriPC,StevensGJ,Merrill-HenryJ,OyoyoU,BalasubramanianVP.Participationin EuropeanSocietyofCardiology.Europace2022;24:165–172.
pulmonaryhypertensionsupportgroupimprovespatient-reportedhealthquality 853. GliksonM,NielsenJC,KronborgMB,MichowitzY,AuricchioA,BarbashIM,etal.
outcomes:apatientandcaregiversurvey.PulmCirc2021;11:20458940211013258. 2021ESCGuidelinesoncardiacpacingandcardiacresynchronizationtherapy.Eur
846.BiganzoliL,CardosoF,BeishonM,CameronD,CataliottiL,ColesCE,etal.The HeartJ2021;42:3427–3520.
requirementsofaspecialistbreastcentre.Breast2020;51:65–84. 854. ColletJP,ThieleH,BarbatoE,BarthelemyO,BauersachsJ,BhattDL,etal.2020
847.AktaaS,BatraG,WallentinL,BaigentC,ErlingeD,JamesS,etal.EuropeanSociety ESCGuidelinesforthemanagementofacutecoronarysyndromesinpatients
ofCardiologymethodologyforthedevelopmentofqualityindicatorsforthequan- presenting without persistent ST-segment elevation. Eur Heart J 2021;42:
tificationofcardiovascularcareandoutcomes.EurHeartJQualCareClinOutcomes 1289–1367.
2022;8:4–13. 855. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, et al.
848.MinchinM,RolandM,RichardsonJ,RowarkS,GuthrieB.QualityofcareintheUK Methodologyforthedevelopmentofinternationalclinicaldatastandardsforcom-
afterremovaloffinancialincentives.NEnglJMed2018;379:948–957. mon cardiovascular conditions: European Unified Registries for Heart Care
849.SongZ,JiY,SafranDG,ChernewME.Healthcarespending,utilization,andquality Evaluation and Randomised Trials (EuroHeart). Eur Heart J Qual Care Clin
8yearsintoglobalpayment.NEnglJMed2019;381:252–263. Outcomes2021.doi:10.1093/ehjqcco/qcab052.Epubaheadofprint.
Downloaded
from
https://academic.oup.com/eurheartj/article/43/38/3618/6673929
by
guest
on
22
January
2026
